{"symbol": "GOOG", "link": "https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html", "title": "Coronavirus Vaccine Progress Accelerates", "keywords": ["data", "progress", "tests", "vaccines", "coronavirus", "phase", "accelerates", "covid19", "vaccine", "patients", "testing", "capacity", "manufacturing"], "summary": "We think widespread availability of a coronavirus vaccine or curative treatment will probably be necessary to completely remove social distancing measures.\nAlso, rather than building manufacturing capacity, the accelerated process requires partnering with contract manufacturers or large pharma firms to buy extra capacity.\nIn addition, if Moderna validates its technology with an initial vaccine, time to availability would be quite short for a new vaccine, with manufacturing capacity already expanded and a much-abbreviated development timeline (like annual flu vaccine changes).\nImmunology drug Actemra could also prove helpful in severely ill patients (data should be available this month).\nTraditional and point-of-care COVID-19 tests support strong molecular diagnostics growth but don\u2019t significantly sway our valuation.", "authors": ["Joanna Kong", "Yahoo Finance Premium"], "publish_date": "2020-05-14T15:51:09+00:00", "top_image": "https://s.yimg.com/uu/api/res/1.2/yfmPmOmwuoMa7svbTToA.g--~B/aD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6", "text": "Mentioned: Alphabet Inc (GOOG), Catalent Inc (CTLT), Translate Bio Inc (TBIO), Moderna Inc (MRNA), Adaptive Biotechnologies Corp (ADPT), BioNTech SE (BNTX), Thermo Fisher Scientific Inc (TMO), Emergent BioSolutions Inc (EBS), Incyte Corp (INCY), Hologic Inc (HOLX), LabCorp (LH), Quest (DGX), Apple (AAPL), Regeneron (REGN), Roche (RHHBY), Sanofi (SNY), Novartis (NVS), Lilly (LLY), Gilead (GILD), Pfizer (PFE), Abbott (ABT), Glaxo (GSK)\n\nEditor\u2019s note: This is the second of two updates to Morningstar's COVID-19 forecast. In the first part, we looked at plans for easing the U.S. lockdown . Read the latest on how the coronavirus is rattling the markets and what investors can do to navigate it.\n\nWe think widespread availability of a coronavirus vaccine or curative treatment will probably be necessary to completely remove social distancing measures. In our base-case U.S. scenario, we expect states to wait for reassurance that the COVID-19 spread has flattened before beginning to reopen businesses, and we assume a 30% reduction in visits to nonessential businesses from baseline by the end of the year. This is a significant improvement from levels at the end of March (65% reduction) and should improve further in 2021 with the availability of a coronavirus vaccine. We assume that less than 10% of the U.S. population is infected by the end of 2020, with a 0.7% death rate, as improving levels of testing help control the spread of the disease.\n\nWhile coronavirus vaccines have yet to produce clinical data, encouraging preclinical data, strong partnerships and funding, and rapid clinical progress all seem to indicate that use in high-risk populations could be possible by the end of 2020, with tens of millions of doses potentially available by that point. If just two of these vaccines succeed, we could have enough supply to protect high-risk populations in late 2020 and for broader vaccination as we enter 2021.\n\nRepurposed drugs could be the next wave of approvals. We expect IL-6 antibodies like Actemra and Kevzara could find a niche among the most severely ill patients by this summer, with data starting to read out on JAK inhibitors like Jakafi and Olumiant this summer, as well.\n\nRemdesivir\u2019s recent emergency use authorization in severely ill COVID-19 patients is a turning point, but efficacy to date does not look strong enough on its own to justify relaxing lockdowns. We project $2 billion in peak sales in 2021, assuming an eventual U.S. price (after donated supplies) of around $500 per treatment.\n\nConsidering the utter importance of diagnostic testing to help the U.S. begin resuming economic activity in a manner that minimizes the prospect of increases in infection, we remain concerned about national testing capacity meeting necessary levels both in terms of volume and accuracy. The United States was already behind the eight ball when SARS-CoV-2 infections began to rise in February and March. Once the Food and Drug Administration began to approve COVID-19 diagnostic tests under the Emergency Use Act in March, we began to see new tests roll out and capacity for diagnostic testing rise. At the start of May, the U.S. was above 300,000 tests per day, which gets us to roughly 2.1 million tests per week.\n\nNevertheless, this remains far lower than the 500,000 to more than 1 million tests per day that we see as the midrange of what epidemiologists and economists have projected is required to keep the COVID-19 infection from overwhelming our finite healthcare provider systems.\n\nU.S. testing czar Adm. Brett Giroir says our testing capabilities are in the right ballpark for reopening in May and that four types of testing are needed: surveillance (testing hundreds of thousands a month to get a radar view, even among asymptomatic), symptomatic (millions of tests per month to get a nearly 10% positive rate, meaning 10% of tests coming back positive ), contact tracing (five people per confirmed case on average), and antibody testing. A 10% positive rate is the maximum recommended by the World Health Organization and a level the U.S. recently reached, based on daily data. Cumulative testing results as of May 7, with more than 8 million tests run, show an overall positive rate around 15%.\n\nIn addition, comparing U.S. testing rates to other countries gives some perspective. This comparison shows the slow start the U.S. made in ramping testing, and while there is a clear improvement over the past couple of months, the extent of the U.S. outbreak should justify even higher testing rates.\n\nAnother way of examining this is from the perspective of positive rates--the percentage of tests coming back positive. While the U.S. is making progress on positive rates, we have just barely reached the 10% threshold as a country, and some states are well above. South Korea was at 2% (roughly 10,000 positive tests out of 600,000), and we are higher than every other developed country outside the United Kingdom, which is at 30%.\n\nStory continues\n\nDiagnostic Testing and Antibody Testing Serve Two Different Strategies\n\nTo open up the economy while minimizing the spread of COVID-19, we need two general types of tests. First, we need diagnostic testing to help identify which patients are in the active phase of infection and, thus, shedding the virus to others. This is the information that is most useful for tamping down the spread of COVID-19 so that infectious patients can be quarantined. Asymptomatic patients could be tested either through surveillance (random sampling) or contact tracing (if disease detectives found the person to be in recent contact with a confirmed patient). Infected patients could be most contagious before becoming symptomatic, making quarantine based on diagnostics rather than symptoms more effective. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has estimated that 25%-50% of patients are asymptomatic. While some asymptomatic infected people go on to develop symptoms, some do not: 18% of infected patients on the Diamond Princess cruise ship in early February remained asymptomatic. In addition, at least 40% of infected patients were asymptomatic in a broad two-stage survey in the town of Vo\u2019, Italy, and in a random sample by DeCODE in Iceland.\n\nSecond, we also need COVID-19 antibody (serology) tests that can provide a better picture of how widely the SARS-CoV-2 virus has spread throughout the larger population, and the proportion of the population that has already cleared the virus from their systems and who may enjoy some lingering immunity to SARS-CoV-2. This test contributes information that helps us more accurately estimate prevalence and how close we might be to reaching herd immunity, generally seen with around 60% of the population.\n\nWe think that at this point, the diagnostic test remains the most important testing mechanism, particularly given how low the SARS-CoV-2 infection rate seems to be. We think prevalence is still probably below 5% based on antibody tests among samples in different geographic markets; two studies in California have put prevalence at 2.8% (Santa Clara County) and 4.1% (Los Angeles County), although these studies (and antibody tests in general) have been widely criticized for their potential to produce artificially high prevalence rates, or false positives. One key area of higher prevalence is New York City, which has been hit hardest by COVID-19 and where a recent analysis pegged seroprevalence at 20% (although infection rates in most of the state beyond NYC are in the low to mid-single digits). This still leaves approximately 95% of the U.S. population vulnerable to infection who will need access to diagnostic testing if they are to resume economic activity.\n\nUnfortunately, diagnostic testing is more labor-intensive, slower to turn around results, and reliant on trained professionals to both acquire the specimen and to run the tests in the lab. As a result, diagnostic testing is more challenging to scale up to required levels. Antibody tests are far easier to scale up because they are blood-based, easier to process, and tap into existing infrastructure and labor that can handle significantly higher throughput. Both LabCorp (LH) and Quest (DGX) have extensive networks of patient service centers where specimens can be collected. These companies may even assemble mobile teams of phlebotomists to do blood draws for antibody tests on site at company locations in the second half of the year, boosting access. By the second half, we assume concerns about false positives with the initial tests will fade, particularly given that newer tests, like Roche\u2019s (RHHBY) serology test, have much higher specificity (99.8%) that should reduce false positives regardless of how low the true prevalence of antibodies is in the population. That said, immunity benefits from the antibody are still unclear. Lower or undetectable antibody levels in some recovered patients may not be protective, or may fade in two to three years, although memory B cells (harder to detect than antibodies) could still protect patients.\n\nAntigen tests are just entering the market, and while they provide potential for higher capacity in the long run, we\u2019re concerned about test accuracy and scale (Quidel can provide 200,000 tests per week, scaling to more than 1 million a week in several weeks).\n\nThere is emerging research on using saliva samples for RT-PCR diagnostic testing, which suggests it is as good as, if not better than, the nasal-pharyngeal swab that currently dominates those tests. If patient data continue to bear this out, we think shifting to saliva specimens could relieve some of the factors that have slowed diagnostic testing. Experts say that the rush for coronavirus tests has led to low sensitivity, with perhaps a third of patients who are infected getting a negative test result, versus over 90% sensitivity for most PCR-based tests, but saliva-based testing could make it easier for healthcare professionals to get good samples and improve sensitivity of the test.\n\nAside from the prospect of testing saliva, the current picture of capacity for RT-PCR tests, based on the largest manufacturers, looks far better in theory than in practice. We have examined U.S. capacity by the base of machines, throughput, and cycle time. Based on that, we have estimated total capacity of U.S. existing lab infrastructure can get us close to 5 million diagnostic tests per day. In other words, if we squeezed out every last bit of efficiency on our collective installed base of lab equipment--running full batches, with consecutive cycles, for 16 hours a day, seven days a week (and eliminating all other non-COVID-19 tests that might otherwise be running on that equipment).\n\nIn addition to the installed base, U.S. capacity to run tests is limited by the number of tests and kits available. The manufacturing of tests has accelerated but still significantly lags the capacity of the installed base to run them. Nonetheless, our estimate of the number of tests available daily gets us to more than 600,000, which could meet the numbers that public health officials have suggested would be adequate for safely reopening the economy.\n\nHowever, these estimates reflect theoretical capacity, which is far more hopeful than de facto utilization, which gets us closer to the peak of 315,000 tests in a day. There are any number of bottlenecks and pain points that prevent us from optimizing existing capacity, and many of these inefficiencies reflect the relatively decentralized lab testing environment in the U.S.\n\nKey Obstacles to Optimizing Diagnostic Testing Capacity\n\nUnlike the diagnostics lab industry in other countries, including Australia and the U.K., the U.S. remains a relatively fragmented and decentralized market. Even Quest and LabCorp--the two largest independent reference labs--have only captured an estimated 22% market share. Approximately half the diagnostic market is still controlled by the smaller, hospital-based labs. Considering that most of the competitive labs operate independently and that the federal government has failed to step in with leadership, it\u2019s not surprising that we haven\u2019t seen a coordinated effort to ramp up efficient use of capacity to handle the new COVID-19 tests. This is the overarching theme, and there are additional specific factors that are causing friction in efforts to scale up. There is no magic bullet to be found. Instead, the current situation is more akin to a rowboat that has sprung multiple leaks.\n\nTests That Are Largely Proprietary to the Equipment\n\nThe razor/razor blade model is standard for diagnostic equipment makers, with the proprietary consumables offering a high-margin stream of ongoing revenue once the main machine is installed. For example, Roche\u2019s COVID-19 RT-PCR tests must be run on its cobas 6800 and 8800 high-throughput machines. This means that individual hospitals and integrated delivery networks that are collecting patient specimens with the Roche test must figure out which labs have those Roche cobas machines. This issue is somewhat mitigated if the hospital or network has contracted with LabCorp or Quest to handle some of its lab testing. According to Roche management, there are 122 cobas machines installed in 60 labs across the U.S. LabCorp and Quest are some of Roche\u2019s largest customers, and each has its own information technology systems that provide information on tests coming in and capacity throughout its network of labs. If the hospital hasn\u2019t contracted with this type of larger independent lab network, it may not have much visibility on where there\u2019s capacity to run those Roche tests it has collected, which could lead to longer turnaround times and inefficient use of the installed base.\n\nWe suspect this proprietary test-to-equipment framework has been particularly cumbersome for Abbott (ABT), which introduced its COVID-19 diagnostic testing fairly early but had not seen its throughput of COVID-19 tests accelerate to the level expected. We think this is because Abbott\u2019s roughly 175 m2000 machines scattered across the U.S. are in smaller labs. The m2000 is not widely installed at Quest\u2019s network of labs, for example. Molecular diagnostic equipment at Quest is dominated by Roche and Hologic (HOLX). We suspect there may be a similar situation at LabCorp. If most of Abbott\u2019s m2000 machines are not linked to a wider network, it won\u2019t benefit from information flow that can identify and match available machine capacity to incoming tests.\n\nNeed for Trained Personnel\n\nThis is an issue on two fronts. First, we need trained medical professionals to obtain the specimen via nasal-pharyngeal swab. Capturing that nasal swab can be risky because it puts the medical professional close to the patient. Additionally, swabbing can make patients sneeze, which could further spread the virus if they\u2019re infectious. Second, we also need trained technicians to run the diagnostic machines. These are the people who transfer and prepare the specimens for PCR testing in the lab and monitor quality controls along the way. The dearth of trained lab professionals has been a chronic problem in the industry, even before the COVID-19 pandemic. The prospect of increasing capacity by installing more machines is likely to be constrained by the limited number of people who know how to operate them.\n\nInadequate Supplies of Personal Protective Equipment for Medical Professionals\n\nThe well-documented PPE insufficiency has also hampered the ability of medical professionals to collect specimens from patients. As discussed earlier, the nasal-pharyngeal swab can result in the patient sneezing on the healthcare worker, which means the medical professionals need substantial protective gear to do their jobs safely. If the saliva-based RT-PCR test offers comparable or superior specimen capture, shifting over could relieve some of the pressure on the healthcare workers, in terms of needing less training and PPE.\n\nInadequate Reagents and Other Supplies for Tests\n\nOn a preliminary basis, we have run across reports of healthcare providers running out of reagents, nasal swabs, and transport media supplies necessary to capture and preserve specimens. Test makers have suggested that they are sending out sufficient supplies with their tests. We remain skeptical that supply has matched demand. The bandwidth for producing those enzymes and primers tailored to the SARS-CoV-2 virus remains somewhat limited. These enzymes are biological molecules that are typically produced and then purified on a small scale. Increasing quantity of production will take time.\n\nRestrictive Conditions on Testing for Patients\n\nSevere test constraints in the early stages of the COVID-19 crisis in January and February meant that healthcare providers tried to limit the tests to symptomatic patients, those who were in contact with COVID-19 patients, and first responders. Now that more tests are available, providers can expand their guidelines for testing. However, the Centers for Disease Control and Prevention has not led the way in setting more liberal testing guidelines. Instead, it is leaving it up to the states, which has resulted in a more disjointed shift in making the tests more widely accessible.\n\nLack of Centralized IT and Logistics Capabilities\n\nWe think this, perhaps, is the most significant factor in the near and mid-term that prevents us from turning our theoretical test capacity into reality. Getting the specimen from the healthcare provider to a lab with the appropriate equipment platform that has space in its overnight batches is difficult without a centralized information system. Then, take hundreds of thousands of specimens, multiplied by thousands of healthcare providers, multiplied by hundreds of labs, and by a handful of major equipment platforms. This quickly turns into a massive matching game to get each specimen to the right lab at the right time. White House coronavirus response coordinator Dr. Deborah Birx noted on April 8 that only 10% of the available 1 million Abbott tests for m2000 machines (175 in the U.S.) had been run, probably because the high-throughput machines are not always in locations where they are most needed, and staff and supplies can run short. Federal testing czar Giroir hopes to triple usage to 60% in May.\n\nBoth LabCorp and Quest have their own proprietary information systems that can provide insight into equipment platforms and testing capacity on a nightly basis across their own network of labs. However, roughly half the diagnostic industry in the U.S. is housed in hospital-based labs, and they are not looped into such a lab network. Same thing applies to the smaller, regional independent labs. As a result, there\u2019s a fair amount of capacity in our system that is going unused. We think addressing this shortfall will take action on the part of the federal government to centralize information flow related to the incoming tests and individual lab capacity. Based on this administration\u2019s propensity to leave diagnostic testing programs to the states, we speculate that any sort of common information system to unlock capacity in our existing lab infrastructure probably won\u2019t happen unless a different administration takes over next year.\n\nSignificantly expanding lab infrastructure will take time. According to the Rockefeller Foundation plan, the U.S. could roughly triple current testing if we efficiently use all labs in U.S. that could do high-throughput testing. According to Rockefeller, it would take about eight months to get to 30 million tests a week, assuming an incredible ramp with strong funding. We could also make more point-of-care tests for rural areas, but building more could run into bottlenecks for China-sourced electronics or reagents. Hologic has been contacted by a range of customers, including departments of public health, hospital systems, and LabCorp and Quest, about buying more Panthers. In the near term, we expect that there will be robust placement of this kind of midsize high-throughput testing equipment. However, production of these machines is not necessarily easy to accelerate three- or four-fold to meet the current demand. Further, it is not clear to us that LabCorp and Quest, as the largest reference labs, are willing to significantly build out and maintain extra capacity that could go unused until another pandemic. Thus, the near- and mid-term expansion of capacity will likely be on the periphery of what we already have. We doubt there will be any tripling or quadrupling of the U.S. installed base of machines.\n\nIn the near and mid-term, we expect most of the usable capacity to come from LabCorp and Quest more efficiently using their existing equipment. This will be enhanced by the addition of Hologic\u2019s newest COVID-19 diagnostic testing capabilities, run on its Panther machines, which are located in a range of small and midsize labs.\n\nPoint-of-Care and At-Home Diagnostic Testing Unlikely to Be Short-Run Fix\n\nWe may see some new innovations to address the testing challenges. Quest management said the current administration has encouraged the firm to think creatively about how to bring on more capacity in different ways. The CARES Act also contains more than $1 billion dedicated to a competition to develop new diagnostics that can get around these pain points that have slowed COVID-19 diagnostic testing so far.\n\nAbbott is ramping up production of its point-of-care diagnostic test, but we still see this topping out at around 2 million tests per month over the summer, translating to 67,000 tests per day. Also, the Abbott machines for POC testing are likely mainly in doctors\u2019 offices, and most of those offices are closed with the machines trapped inside. Abbott management says there are 18,000 ID Now machines in the U.S., but demand for these machines seems unmet, with the mayor of Detroit asking for just five to put in his hospitals. In other words, Abbott\u2019s machines don\u2019t appear to be translating into usable supply. Until ID Now machines are relocated to where most potential COVID-19 patients will be, we\u2019re unlikely to see POC testing significantly increase.\n\nIn addition, POC accuracy will probably continue to trail that of the RT-PCR tests done in the reference lab. Reported 15% rates of false negatives for the Abbott POC test should improve peripherally as medical professionals become more familiar with how to run the test and handle the specimens, but that may not be enough to close the gap with lab tests. The other leap forward for the POC tests is if they can run tests on saliva. If there\u2019s greater and more consistent concentration of the virus in saliva, that could improve accuracy. That said, each machine is severely limited in its capacity; one Abbott ID Now machine can process only 64 tests, if run continuously for 16 hours.\n\nThe first at-home tests are hampered by the need for a prescription and a $119 out-of-pocket payment. LabCorp expects that in a few weeks it will have enough supply of the Pixel test to branch out from the initial target of first responders, aiming for normalized production of 100,000 tests per week. We think it could be easy to remove the obstacle of needing a prescription, but LabCorp can\u2019t distribute tests without collecting money from someone to cover costs. The process of working with payers to collect the money would take time, as patients would then need to send insurance information to LabCorp for the lab to close the loop with the patient\u2019s payer, collect payment, and send out the test. LabCorp could also contract with employers directly to pay for kits in bulk, which could then be distributed to employees, but we haven\u2019t seen evidence that this is part of its strategy. Regardless, getting at-home tests in the hands of noninsured Americans seems challenging.\n\nContact Tracing Offers Incremental Improvement in Fighting Outbreak\n\nContact tracing can help narrow the field of testing to be more precise, but U.S. health departments don\u2019t seem well equipped using traditional methods. The Association of State and Territorial Health Officials recommends 100,000 U.S. contact tracers to get to a 1:1,000 individual/tracer ratio, using a three-tier response of lay contact tracers, disease investigator specialists (professionals) at the state level (currently only 2,200 DIS positions), and healthcare providers or epidemiologists at the CDC (a COVID-19 corps) to support the other two tiers. In Wuhan, China, aggressive contact tracing was done by 1,800 teams of epidemiologists, with at least five members on each team. Scaling up to a level like China\u2019s would require one investigator per 1,200 individuals, or more than 300,000.\n\nTo control outbreaks at an R0 (reproduction number, signifying extent of contagion) of 2.5 (estimate for SARS-CoV-2), we would need to trace more than 70% of contacts of those infected, but the outbreak could be controlled with less than 50% successfully traced, if R0 is less than 1.5. We expect this could mean that if we are using additional measures beyond contact tracing to control the disease, such as social distancing or school closures, we may be able to make some headway even without perfect coverage.\n\nA Boston nonprofit, Partners in Health, is hiring 1,000 people for contact tracing, and New York is launching a massive testing and contact tracing program, particularly in hard-hit, low-income communities, involving tens of thousands of tracers (the state previously had fewer than 1,000), and the state has $1.3 billion in federal funding to support the initiative. San Francisco is also boosting its 40-person contact tracer team to at least 150, or one tracer for every 5,553 residents. However, these are small-scale efforts compared with what we would need for a nationwide program.\n\nTechnology could make this process easier and faster. Manual contact tracing (by disease detectives) may not be good enough to slow transmission, but instantaneous tracing (notifying exposed people the minute someone is diagnosed) could be, as used in South Korea and Singapore. Apps are being built to help with contact tracing, and proximity tracking could allow people to self-isolate if they get a notification that they have been near someone who is now confirmed to be infected. While apps in Asia have led to the disclosure of personal info, in the West, a system that uses Bluetooth signaling to record proximity could be less intrusive. In the U.S., many projects have been announced, like Covid Watch, CoEpi, and NextTrace, and the ability to piece all of their data together could become an issue unless we rally around one provider. Apple (AAPL) and Google (GOOG) announced that they are working together to facilitate contact tracing using Bluetooth functionality. To satisfy privacy concerns, rather than using GPS, their platform will focus on codes created when users are within proximity for a certain amount of time; if one is infected, the voluntary app (to be designed by healthcare agencies) could automatically warn close contacts that they may have been exposed. While they are first planning to unify their wireless protocols to allow others to build apps across platforms, we expect their own app could be more reliable than third-party apps. With any app, the idea is to limit the number of people who need to be tested in order to maintain containment of the virus. However, epidemiologists estimate that we would need to see 60% uptake of these apps for them to be effective, and so far, uptake is less than 20% for TraceTogether in Singapore and 40% for Iceland\u2019s Rakning C-19.\n\nAnother issue is how Americans will react to technology like contact tracing apps. President Donald Trump may be able to sway Republicans to get on board with tracing despite privacy concerns, but preserving freedom is a critical issue. GPS data could work better than Bluetooth technology, for example, as it monitors location (people and surfaces can trigger infection) but is harder to anonymize and harder to use in use in multistory situations. GPS data is helping enforce quarantine of those infected in Taiwan, as well as location-tracking wristbands in Hong Kong and texting proof of being home in Singapore. However, opinions are mixed; a recent survey by a University of Pennsylvania political scientist saw 70% of Republicans and 46% of Democrats strongly opposing the use of cellphones to enforce quarantines, but more than half of Americans back anonymized government smartphone tracking, according to a recent Harris poll.\n\nEven in countries that have successfully used technology for contact tracing, concerns remain. South Korea passed amendments to its Contagious Disease Control and Prevention Act following its 2015 MERS outbreak to allow override of previous privacy laws during a serious infectious disease outbreak, which allowed disclosure of a wide range of personal information to the country\u2019s federal, state, and local governments, including credit card transactions, location, transit history, and medical records. However, criticism of the level of data released to the public could lead to refinement of this strategy in the future, as significant amounts of this data were also released publicly, when aggregated data could have been enough.\n\nProgress With Treatments\n\nFormer FDA commissioner Scott Gottlieb sees a treatment as our best hope for returning to normal this year. We now have two regimens with emergency use authorizations, although safety issues with chloroquine (and recent studies casting more doubt on potential efficacy) put the focus squarely on Gilead\u2019s (GILD) remdesivir.\n\nFollowing strong data released April 29, Gilead received FDA emergency use authorization on May 1. While not at the same threshold as FDA approval, this allows Gilead (with the direction of state governments) to begin distributing remdesivir to severely ill patients at select hospitals in the U.S. Gilead already has 1.5 million doses of remdesivir, enough to treat roughly 300,000 patients, assuming they receive the shorter, five-day dosing regimen that proved similar to the 10-day regimen in the Simple study. Using this dose, Gilead should have enough for 1 million patients by October and 2 million patients by the end of 2020. Gilead has also announced that it plans to license remdesivir to other firms capable of manufacturing it in Europe, Asia, and the developing world through at least 2022.\n\nWe now assume that remdesivir can generate $2 billion in sales in 2021, but sales this year will be significantly lower (due to donations and limited supply), and we only model sales extending to 2023 (as we assume progress with a coronavirus vaccine will make stockpiling and demand less common). Our model assumes a price tag of $500 per treatment, a middle ground between the $5 per five-day course expected to help Gilead recoup manufacturing costs and the $4,500 price ceiling estimated by the Institute for Clinical and Economic Review, using a $50,000 per quality-adjusted life year threshold. We believe this will be more than enough to recoup the $1 billion in remdesivir-related development and manufacturing costs Gilead expects to incur in 2020, but not enough to significantly swing Gilead\u2019s valuation.\n\nRemdesivir\u2019s efficacy so far is impressive and looks likely to reduce mortality rates from COVID-19 (although mortality data so far isn\u2019t statistically significant, it shows a trend to a benefit). However, these improvements fall short of what we see as necessary for our former base-case scenario, which assumed that efficacy would be strong enough to allow wider relaxing of lockdown measures on its own.\n\nSeveral other drug candidates are also moving through testing. Among anti-inflammatories, we expect IL-6 antibodies like Roche\u2019s Actemra and Regeneron (REGN)/Sanofi\u2019s (SNY) Kevzara could find a niche among the most severely ill patients by this summer, although initial data from Kevzara was disappointing (development is now focused on critically ill patients). Data could start to read out on JAK inhibitors like Incyte (INCY)/Novartis\u2019 (NVS) Jakafi and Incyte/Lilly\u2019s (LLY) Olumiant this summer, as well, although we have limited view on their potential efficacy. Targeted antibodies, led by Regeneron\u2019s antibody cocktail, are among the most likely to succeed but are behind this schedule, and we don\u2019t expect them to be available until late this year for high-risk populations. While convalescent serum and hyperimmune globulins from plasma firms could also be quite effective, scale is severely constrained; according to Adaptive Biotechnologies (ADPT), convalescent antibodies can treat only one or two patients for every donation from a recovered patient, and quality can vary.\n\nFuture trials will be more likely to focus on combinations with remdesivir, and a trial adding Olumiant to remdesivir (to enroll 1,000 patients) began May 8. Pfizer\u2019s (PFE) protease inhibitor is also entering studies this summer and could be a good candidate for combination therapy with remdesivir.\n\nCoronavirus Vaccine Advancement Even Faster Than Accelerated Timelines\n\nVaccine development typically takes years--28 years for varicella and FluMist, and 15 years for HPV and rotavirus. We\u2019ve been waiting decades for an effective HIV vaccine, without success. Preparing manufacturing plants to make a new vaccine can cost anywhere from $50 million to $700 million, according to a 2017 paper in the medical journal Vaccine, and the investments are typically made in a stepwise fashion at different scales, based on the available data and probability of eventual approval. However, if a firm is willing to take financial risks, the process can be accelerated.\n\nThe Standard Paradigm for Vaccine Development is Lengthy... More\n\n...But It Can Be Accelerated in a Pandemic More\n\nFor example, rather than waiting for confirmation of efficacy, a firm can move to large-scale production while efficacy is being tested. Groups like the Bill & Melinda Gates Foundation are taking on some of this risk by offering to pay for manufacturing capacity for a handful of promising vaccines. Government entities (the U.S. Biomedical Advanced Research Development Authority) and public-private alliances (Coalition for Epidemic Preparedness Innovations) are also rapidly offering funding.\n\nAlso, rather than building manufacturing capacity, the accelerated process requires partnering with contract manufacturers or large pharma firms to buy extra capacity. This still requires tech transfer for the partner to be able to manufacture the new coronavirus vaccine, but if done early enough, it allows large-scale production to ramp during the second phase of trials. In addition, capital expense is significantly lower for cell-free manufacturing (less than $200 million for nucleic acid vaccines like Moderna\u2019s (MRNA) versus up to $1 billion for more traditional vaccines), which requires smaller reactors and purification tools than recombinant protein vaccines and can be more flexible in switching from one vaccine to another, lowering the risk from investing in manufacturing of any one vaccine in its portfolio. Several of the most advanced programs are nucleic acid (RNA or DNA) vaccines.\n\nFinally, the approval would come in two stages. Broad approval would still be reserved for when a larger phase 3 trial is completed, but the FDA could grant an early, accelerated approval (or emergency use authorization) based on phase 1 and phase 2 safety and efficacy data.\n\nFDA Likely to Accelerate Coronavirus Vaccine Approval if Pandemic Continues This Fall\n\nThe FDA\u2019s perspective on approval of a coronavirus vaccine will probably vary depending on how extensively the pandemic is still spreading in the U.S. by the time we have phase 2 data, which will likely be late this summer. With some circulating virus, firms should be able to conduct larger, controlled phase 2/phase 3 studies that can confirm whether antibodies generated in response to a vaccine actually protect individuals from infection. The FDA can also look at antibody levels generated by the vaccine and try to determine whether this could be a biomarker for protection. The second is what Moderna has referred to as looking at \u201cserological correlates\u201d of protection. This can be done by comparing to preclinical models of the vaccine offering protection, or to antibody levels in convalescent serum (from patients who have recovered from infection). If the virus is widespread--and need for the vaccine is most urgent--then Fauci and FDA officials have noted that an emergency use authorization could be made based on phase 1 and animal model safety data as well as efficacy data from phase 2. Such a decision would need to weigh the safety risks; while data through phase 2 should clarify such risks as viral enhancement, it will not be able to isolate any ultrarare risks, which can only be found by testing several thousand volunteers.\n\nIf there are a limited number of outbreaks by late this summer, when larger phase 3 studies might be starting (a good problem to have), there are also creative ways of potentially accelerating development to stay ahead of a second wave. The most ethically controversial is challenge studies, which offer a faster option than traditional phase 3 studies by deliberately exposing volunteers to the virus to test a vaccine\u2019s efficacy. For example, 1 Day Sooner is working to qualify healthy, low-risk volunteers for a potential challenge study, with more than 14,000 volunteers listed on the website as of May 8. However, there are serious ethical questions about deliberately infecting patients in such studies, even with their permission. Another way to accelerate development and reduce the number of placebo volunteers is to test multiple vaccines in one trial with one shared control arm; normally, drugmakers avoid this sort of trial, as it forces head-to-head comparisons, but this situation may be exceptional.\n\nWe expect initial approval could be reserved for a high-risk population, including the elderly, those with pre-existing conditions, and essential workers (including healthcare workers). We expect that children--who rarely suffer serious consequences from infection and would have the most to lose from theoretical severe but very rare side effects of vaccination--would not be vaccinated until longer-term studies are completed. Vaccination could also be focused on areas with the largest outbreaks if supply is limited.\n\nProbability of Approval Looks Quite High, at Least for a Handful of Coronavirus Vaccines\n\nRecent analysis examining the probability of success of different types of therapeutics, using data from a variety of small- and large-cap drug firms from 2000 to 2015, indicated that vaccines have the highest overall probability of sales, 42% from phase 2 start to approval, and this now stands at 45.8%, using the traditional slow and steady development pathway. In addition, researchers are already familiar with coronaviruses, and particularly familiar with designing vaccines for other serious coronaviruses like SARS and MERS. Key parts of the virus are conserved in SARS-CoV-2 (overall, the viruses are 80% identical), so many vaccines target the spike protein or a portion of it. Researchers see this as unlikely to mutate rapidly, as well, as it is critical for viruses to be able to enter the cell. We think this increases the likelihood of approval. Also, given the sheer number of coronavirus vaccines and the diverse nature of their designs, we would expect some attrition, but some success. Bill Gates recently noted that of the 115 vaccine candidates in the pipeline, 8-10 look \u201cparticularly promising,\u201d noting that 60% efficacy would be able to produce herd immunity if we eventually vaccinate roughly 7 billion people, or most of the world\u2019s population. This estimate is likely based on SARS-CoV-2\u2019s reproduction number of 2.5, which means that if 60% are immune and only 40% are vulnerable, the effective transmission rate would decline to 1, meaning flat levels of transmission.\n\nEven if trials complete, plenty of skeptics point to the fact that manufacturing validation typically takes several months, not to mention the manufacturing ramp. However, we think there have been enough partnerships announced to expand manufacturing capacity, as well as parallel programs at several firms, that the capacity should be there if the vaccines are safe and effective, and we assume the FDA would approve the manufacturing facilities at a breakthrough pace. As long as more than one coronavirus vaccine makes it to emergency authorization, that would also relieve some of the pressure on manufacturing to surpass the 1 billion mark. Newer technologies mean much easier scale-up--mRNA vaccines are easier to produce than antigen-based vaccines and require very small doses. DNA and RNA platforms have the most potential for rapid development, followed by recombinant-subunit vaccines.\n\nVirus Enhancement a Key Safety Risk\n\nUntil we see evidence that vaccinated patients have been challenged with the virus, we won\u2019t know whether the antibodies created in response to the vaccine paradoxically reduce a patient\u2019s ability to fight a virus. Immune enhancement can be due to antibody-dependent enhancement (antibodies help infection spread) or cell-based enhancement (allergic, type 2 helper T-cell-based inflammation). Allergic inflammation was an issue for at least one SARS vaccine in older mice when they were challenged with the virus. With Sanofi\u2019s Dengvaxia, a vaccine against one of dengue fever\u2019s four serotypes, later infection with a different serotype led to much more severe illness than in those who had not received the vaccine. An RSV vaccine tested in the 1960s caused infections to become much more lethal due to allergic inflammation. Fauci has noted that the key concern in phase 1 is enhancement of the virus, and studies are now in progress for several vaccines.\n\nLeading Coronavirus Vaccine Programs Could Offer Significant Capacity by Year-End\n\nWhile vaccines have yet to produce clinical data, encouraging preclinical data, strong partnerships and funding, and rapid progress into large phase 1/phase 2 studies all seem to indicate that use in high-risk populations could be possible by the end of the year, with tens or even hundreds of millions of doses available. While we doubt that all vaccines will see strong enough safety and efficacy to reach approval from the FDA, several stand out with a head start and aggressive plans for supplying the market. If just two or three of these vaccines succeed, we could have enough supply to protect high-risk populations in late 2020 (allowing further relaxing of distancing measures) and for broader vaccination as we enter 2021.\n\nModerna\u2019s mRNA-1273\n\nModerna\u2019s mRNA-based vaccine is a single antigen vaccine targeting the full-length spike protein. Although the firm has no approved therapies, it has data from more than 1,500 patients studied in various vaccine clinical trials attesting to its safety, and patients have developed neutralizing antibodies to virus antigens for all eight of the viruses that Moderna has vaccinated against in trials. We expect rapid acceleration of manufacturing and development timelines (enabled by at-risk manufacturing expansion, government funding, partnerships, and parallel clinical trials) to allow emergency use by late 2020 and approval for wider distribution in 2021.\n\nModerna shipped the first vaccine to the National Institute of Allergy and Infectious Diseases 42 days after sequence selection, a record for vaccines, with the first patient dosed as of March 16. This phase 1 trial involves a two-shot series in healthy volunteers, first in 45 adults age 18-55 at three different doses (now fully enrolled), and then at these three doses for 30 older adults (56-70) and 30 elderly adults (71 and older). Phase 1 data is still expected in the second quarter. Moderna received FDA clearance on May 6 to begin a phase 2 immunogenicity study in 600 patients, with 300 adults age 18-55 and 300 age 55 and up receiving two doses of either placebo, 50 ug, or 250 ug doses, so this study will run in parallel with phase 1. Phase 3 timelines have moved up aggressively, and the first phase 3 trial is now expected to begin in early summer, with design still being finalized (although this NIH-partnered study will likely be conducted in the U.S. and will compare natural infection rates and symptoms with patients who have been vaccinated with mRNA-1273 or placebo). We think this coronavirus vaccine could be available for emergency use (healthcare workers) in fall 2020 based on phase 1 and phase 2 data (comparing immunogenicity to what is seen in the plasma of recovered patients), and for broader commercial use in 2021 (based on a potential interim look at phase 3 data in late 2020 and full data in 2021). The Biomedical Advanced Research and Development Authority has agreed to commit up to $483 million to push the vaccine forward to approval, through development and manufacturing support (moving to 24/7 manufacturing).\n\nModerna is ramping up internal manufacturing to allow millions of doses per month in 2020 and tens of millions per month in 2021, and management\u2019s belief that the 50 ug dose could be selected would help expand the reach of Moderna\u2019s vaccine to more patients (the firm\u2019s Norwood, Massachusetts, facility could supply up to 100 million doses a year at this dosage). An April 30 partnership with Lonza boosts capacity by 10 times, with the goal of producing 1 billion doses a year at the 50 ug expected dose (manufacturing at Lonza suites in the U.S. and Switzerland to begin in July).\n\nJohnson & Johnson\n\nJohnson & Johnson (JNJ) selected an Ad26 vector candidate expressing the SARS-CoV-2 spike protein as of March 30. The firm has steadily accelerated development plans, most recently moving up its estimated phase 1 start from early November to September at the latest, with data available December 2020 and potential launch in emergency use in the first quarter of 2021. J&J has also accelerated supply estimates, from an initial estimate of 300 million doses a year in 8-12 months and ready for emergency use by early 2021 to annual production of 600 million-900 million coronavirus vaccines likely by early 2021 and full supply of 1 billion doses by late 2021. Emergent BioSolutions (EBS) will act as one contract development and manufacturing organization beginning in 2021. Catalent (CTLT) will supply large-scale manufacturing capacity as well, ready for 24/7 manufacturing by January 2021. J&J is aiming for a not-for-profit price around $10.\n\nUniversity of Oxford/Vaccitech/Merck KGaA/AstraZeneca\u2019s ChAdOx1 nCoV-19\n\nThis chimp AAV vaccine for the spike protein started a large (1,100 volunteers) phase 1 COV001 study in April 2020, with data expected in May for the first group of volunteers (age 18-55), followed by 55-70 and 70-plus cohorts. This is part of a partnership between Merck KGaA and the Jenner Institute (part of a joint venture with University of Oxford and Pirbright Institute). Oxford now has a 10-liter scale process for the adenovirus vector vaccine. They expect data by autumn 2020 from the phase 2/phase 3 portion of the study (5,000 volunteers expected to start enrolling in May), which could allow emergency approval in September, when the first few million doses could be available. Data from a rhesus macaque study was positive in April (six challenged monkeys stayed healthy). AstraZeneca (AZN) joined as global development and manufacturing lead on April 30, with a cited goal of 100 million doses by the end of 2020. The collaboration is not-for-profit during the pandemic.\n\nSanofi/Glaxo\n\nSanofi is working with BARDA on a coronavirus vaccine, using proven influenza FluBlok technology (with Glaxo\u2019s adjuvant booster). Sanofi partnered this program with Glaxo (GSK) on April 14 and plans to move a coronavirus vaccine to development in the fourth quarter of 2020, with earliest approval in the second half of 2021. They expect to be able to manufacture a billion doses by April 2021 by sharing their technology (Sanofi\u2019s S-protein antigen using recombinant DNA technology and Glaxo\u2019s adjuvant technology, which can lower the required dose). Sanofi also entered a collaboration with Translate Bio (TBIO) for its mRNA vaccine, which, like the more traditional Sanofi/Glaxo vaccine, could be in a clinical trial by the end of 2020 and be approved by the end of 2021. Translate\u2019s vaccine has been manufactured at a 100-gram scale, and CMO manufacturing of two 250-gram batches per month could add to supply; at Moderna\u2019s midlevel dose, this could vaccinate 3 million people per month initially, but hundreds of millions by the end of 2021 with Sanofi\u2019s help (at kilogram-size batches). Sanofi expects 90 million-360 million doses by the first quarter of 2021.\n\nCureVac\n\nWorking with CEPI, CureVac has two mRNA candidates that do not target the spike protein poised to enter trials by summer. CureVac\u2019s mRNA is self-amplifying, which reduces the amount of vaccine needed for manufacturing. While the three approved manufacturing suites could make 10 million doses per campaign, a fourth suite would push this north of a billion per production run. CureVac received funding from the European Commission in March.\n\nPfizer/BioNTech\n\nBioNTech (BNTX) started a trial in Germany, with the first cohort of 12 volunteers in Germany dosed by April 29, and a U.S. trial (a phase 1/phase 2 trial to enroll 360 adults and elderly volunteers) kicked off on May 5. Fosun has China rights, and BioNTech signed a letter of intent March 17 with Pfizer elsewhere (expanding their flu vaccine partnership to coronavirus). As of early April, Pfizer said it could have tens of millions of doses by the end of 2020 and hundreds of millions in 2021. The first BNT162 study in Germany will test doses between 1ug and 100 ug in 200 volunteers (ages 18-55) for four vaccines (modified mRNA, uRNA, and self-amplifying RNA). SaRNA could have a big dosing advantage, potentially requiring just one dose (others could require prime and boost) and 60 times lower dose versus uRNA vaccine (and perhaps against Moderna\u2019s mRNA vaccine). Pfizer plans to choose the one or two most promising to move forward by June, with the help of data from primates and plasma of vaccinated humans due by late May/early June. Pfizer is aiming for an EUA or accelerated approval in October (with human study and surrogate endpoint), at the start of flu season and a time when the next wave could be building. Pfizer\u2019s Mikael Dolsten said on a call with Stat news that it could focus on the high-risk population, which could be 30%-40% of the broader population.\n\nFading Antibody Levels and Mutation Rates Unlikely to Derail Near-Term Pipelines\n\nWith a new virus, it\u2019s difficult to say how long immunity will last after infection or after treatment with targeted antibodies or a vaccine. We don\u2019t know what antibody level is sufficient to protect a patient, although research on convalescent serum (from recovered patients) is ongoing. For older coronaviruses that trigger common colds, reinfection can occur. However, even if protection is incomplete, experts say antibodies are likely to at least lead to milder infections, and recent research seems to indicate that almost all infected patients produce antibodies. We will very likely need to continue to make new versions of antibodies or vaccines if the virus recurs. However, we think it\u2019s very likely that coronavirus vaccines in development today, if effective in trials, will provide enough immunity to get us through the pandemic.\n\nWhile SARS-CoV-2 could mutate to become resistant to vaccines currently in development (targeting the spike protein), we think the evidence so far indicates that this is unlikely. RNA viruses--which include viruses like HIV, influenza, and coronaviruses--generally have the highest mutation rates among microorganisms, creating concerns about how long a potential treatment or vaccine could be effective before SARS-CoV-2 is able to mutate around it. HIV vaccines have been in development for decades without positive results because HIV\u2019s surface molecules (envelope glycoproteins) mutate so rapidly, even within one patient, that they can learn to evade treatment and vaccines, and we now have multiple versions of the virus circulating in society. For influenza, we have vaccines, but these are only at best 60% effective in preventing the flu. This is because there are multiple strains of flu with different surface markers, or antigens, and with so many different strains circulating, it is difficult to predict which one will become most dangerous in a given season (and only so many can be selected for the vaccine). In addition, the flu can mutate, creating new versions that would require new vaccines. Flu vaccine effectiveness can be as low as 20%-30% if vaccine manufacturers do not select the viral strain that ends up being most common that season.\n\nWhile most RNA viruses have an RNA polymerase that operates without proofreading capabilities--meaning that the viral genetic material mutates rapidly--coronaviruses have such large genomes that they do have proofreading, so their mutation rate is significantly lower. In addition, typically, the most crucial parts of the virus--for example, the spike protein (which allows the virus to infect a cell and is the target of vaccines and antibodies), the polymerase (that copies coronavirus genes, targeted by Gilead\u2019s remdesivir), and the protease (that cut peptides to help form key viral enzymes, targeted by Pfizer\u2019s antiviral)--are not subject to as much variation because of their essential nature. While antivirals like remdesivir could pressure the virus and trigger mutations in the viral polymerase that allow higher mutation rates, changing a viruses\u2019 established mutation rate is more likely to destabilize it and weaken it. A recent hypothesis regarding SARS-CoV-2 mutations and increased transmissibility of a new mutant version (Spike D614G) has been released (a preprint article, not a peer-reviewed publication), but Moderna doesn\u2019t expect mutations seen so far to interfere with the efficacy of its vaccine. In addition, if Moderna validates its technology with an initial vaccine, time to availability would be quite short for a new vaccine, with manufacturing capacity already expanded and a much-abbreviated development timeline (like annual flu vaccine changes).\n\nFinally, drug developers are working on ways to make their products less vulnerable to mutations. Antibody developers like Regeneron are also working on potential cocktails of antibodies to make sure that a potential point mutation doesn\u2019t erode efficacy, and Regeneron says that its cocktails work on all of the spike protein variants it\u2019s tested in vitro (Amgen (AMGN) and Adaptive are hoping for two or three in their cocktail, as well). By the time such point mutations develop (if they do), we should have well-developed infrastructure for producing novel vaccines, allowing for a much faster response. In addition, current antivirals could offer some protection despite mutations that lower coronavirus vaccine efficacy.\n\nIn Our Pharma and Biotech Coverage, Roche, Pfizer, and Sanofi Undervalued\n\nGilead\u2019s remdesivir received emergency use authorization from the FDA on May 1 based on strong data from two clinical studies. Although the initial supply will be donated, we expect a $500 U.S. price tag to allow for $2 billion in sales in 2021. The arrival of coronavirus vaccines is likely to make any profits short term, limiting the upside to Gilead\u2019s valuation, and the shares look fairly valued.\n\nRoche is a leading supplier of SARS-CoV-2 diagnostics and antibody tests, which provides some counterbalance to the decline in routine diagnostic tests due to the pandemic. Immunology drug Actemra could also prove helpful in severely ill patients (data should be available this month). While Roche shares have performed strongly during the downturn, they remain slightly undervalued.\n\nRegeneron and Amgen are both racing to bring targeted antibodies to market, which could serve as treatments or prophylaxis for COVID-19. We think Regeneron is a few months ahead, and greater visibility gives us confidence to include $2 billion in potential sales in our model in 2021, similar to the sales potential of remdesivir. However, without clinical data or guidance on pricing, it\u2019s difficult for this to move the meter substantially on our Regeneron valuation, and the shares look slightly overvalued. Amgen\u2019s partnership with Adaptive is encouraging, but we\u2019re awaiting more details before including this in our model, and Amgen shares look fairly valued.\n\nBig Pharma firms like J&J, Sanofi, Glaxo, Astra, and Pfizer are all rapidly accelerating development and manufacturing timelines to bring a coronavirus vaccine to market. Shares for all these firms have held up well during the pandemic, but we think the shares of Pfizer and Sanofi still look slightly undervalued, and Pfizer\u2019s partnership with BioNTech offers several shots on goal. That said, pandemic sales for most of these coronavirus vaccines will likely be not-for-profit.\n\nMost Diagnostics Names Appear Fairly Valued or Overvalued\n\nWe modestly lowered our fair value estimates for LabCorp and Quest to reflect loss of revenue from non-COVID-19 tests, which will only be partially offset by COVID-19 tests. If the normal volume of surgeries and elective procedures returns sooner than expected, this could offer upside to our valuations. We think LabCorp\u2019s higher proportion of esoteric tests (hit less severely than routine tests) could allow it to fare marginally better, and shares look slightly undervalued.\n\nAbbott remains overvalued, from our perspective, after we incorporated declines in medical devices to reflect procedures crowded out by COVID-19 through the second and third quarters, as well as softness in nutritionals thanks to global recessionary conditions. Traditional and point-of-care COVID-19 tests support strong molecular diagnostics growth but don\u2019t significantly sway our valuation.\n\nHologic shares are fairly valued, in our opinion, after incorporating weakness in the women\u2019s health and surgical segments, which is partially offset by COVID-19-driven growth in molecular diagnostics. Considering Hologic\u2019s extensive installed base of Panthers in the U.S. and their presence in the largest reference labs, increased production of SARS-CoV-2 tests could add upside to our valuation.\n\nWhile Thermo Fisher (TMO) stands to benefit from COVID-19 as one of the developers of diagnostic testing with scale, a pullback in capital spending will modestly affect its instrumentation business. However, Thermo Fisher\u2019s business is less exposed to higher-ticket purchases than many of its analytical instrument peers (and relative to its own business during the last economic pullback), and its strong consumable revenue stream should help the company weather this cycle rather unscathed. The market seems to agree, with the shares trading above prepandemic levels and ahead of our valuation.\n\nThis article was written by Karen Anderson, CFA\u00a9 and Healthcare Strategist at Morningstar, a research partner for Yahoo Finance Premium.\n\nKaren and Preston Caldwell, Equity Analyst at Morningstar, will discuss the long-term economic impact of the global shutdown in a special Yahoo Finance Premium webinar on Tuesday, May 19 at 12pm ET. Register for free today.\n\nKaren Andersen has a position in the following security mentioned above: DGX. Find out about Morningstar\u2019s editorial policies.\n\nAdditional Morningstar research is available in Yahoo Finance Premium. Start your free trial today.*", "html": "<!DOCTYPE html><html id=\"atomic\" class=\"NoJs featurephone\" lang=\"en-US\"><head prefix=\"og: http://ogp.me/ns#\"><script>window.performance && window.performance.mark && window.performance.mark('PageStart');</script><meta charset=\"utf-8\"/><meta name=\"oath:guce:consent-host\" content=\"guce.yahoo.com\"/><meta name=\"msapplication-TileColor\" content=\"#6e329d\"/><meta name=\"msapplication-TileImage\" content=\"https://s.yimg.com/rz/p/yahoo_frontpage_en-US_s_f_w_bestfit_frontpage.png\"/><meta name=\"msvalidate.01\" content=\"A9862C0E6E1BE95BCE0BF3D0298FD58B\"/><meta name=\"referrer\" content=\"unsafe-url\"/><meta name=\"theme-color\" content=\"#400090\"/><meta name=\"twitter:dnt\" content=\"on\"/><meta name=\"twitter:site\" content=\"@YahooFinance\"/><meta name=\"news_keywords\" content=\"diagnostic testing\"/><meta name=\"apple-itunes-app\" content=\"app-id=304158842,app-argument=yahoo://article/view?uuid=ee6c0f80-61d5-3bba-8101-bb8bd4d538c3&amp;src=web\"/><meta name=\"twitter:card\" content=\"summary_large_image\"/><meta name=\"twitter:description\" content=\"Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.\"/><meta name=\"twitter:image\" content=\"https://s.yimg.com/uu/api/res/1.2/yfmPmOmwuoMa7svbTToA.g--~B/aD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"/><meta name=\"twitter:image:src\" content=\"https://s.yimg.com/uu/api/res/1.2/yfmPmOmwuoMa7svbTToA.g--~B/aD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"/><meta name=\"twitter:title\" content=\"Coronavirus Vaccine Progress Accelerates\"/><meta name=\"description\" content=\"Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.\"/><meta property=\"og:type\" content=\"article\"/><meta property=\"al:android:app_name\" content=\"Yahoo\"/><meta property=\"al:android:package\" content=\"com.yahoo.mobile.client.android.yahoo\"/><meta property=\"al:android:url\" content=\"yahoo://article/view?uuid=ee6c0f80-61d5-3bba-8101-bb8bd4d538c3&amp;src=web\"/><meta property=\"al:ios:app_name\" content=\"Yahoo\"/><meta property=\"al:ios:app_store_id\" content=\"304158842\"/><meta property=\"al:ios:url\" content=\"yahoo://article/view?uuid=ee6c0f80-61d5-3bba-8101-bb8bd4d538c3&amp;src=web\"/><meta property=\"og:image:width\" content=\"1672\"/><meta property=\"og:image:height\" content=\"1110\"/><meta property=\"og:description\" content=\"Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.\"/><meta property=\"og:image\" content=\"https://s.yimg.com/uu/api/res/1.2/yfmPmOmwuoMa7svbTToA.g--~B/aD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"/><meta property=\"og:title\" content=\"Coronavirus Vaccine Progress Accelerates\"/><meta property=\"og:url\" content=\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"/><meta http-equiv=\"x-dns-prefetch-control\" content=\"on\"/><link rel=\"canonical\" href=\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"/><link rel=\"alternate\" href=\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"x-default\"/><link rel=\"alternate\" href=\"https://ca.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-CA\"/><link rel=\"alternate\" href=\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-US\"/><link rel=\"alternate\" href=\"https://uk.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-GB\"/><link rel=\"alternate\" href=\"https://in.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-IN\"/><link rel=\"alternate\" href=\"https://nz.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-NZ\"/><link rel=\"alternate\" href=\"https://ie.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-IE\"/><link rel=\"alternate\" href=\"https://au.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-AU\"/><link rel=\"alternate\" href=\"https://sg.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" hreflang=\"en-SG\"/><link rel=\"preconnect\" href=\"//s.yimg.com\"/><link rel=\"preconnect\" href=\"//mbp.yimg.com\"/><link rel=\"preconnect\" href=\"//geo.query.yahoo.com\"/><link rel=\"preconnect\" href=\"//consent.cmp.oath.com\"/><link rel=\"preconnect\" href=\"//csc.beap.bc.yahoo.com\"/><link rel=\"preconnect\" href=\"//beap.gemini.yahoo.com\"/><link rel=\"preconnect\" href=\"//yep.video.yahoo.com\"/><link rel=\"preconnect\" href=\"//video-api.yql.yahoo.com\"/><link rel=\"preconnect\" href=\"//yrtas.btrll.com\"/><link rel=\"preconnect\" href=\"//shim.btrll.com\"/><link rel=\"icon\" sizes=\"any\" href=\"https://s.yimg.com/os/mit/media/p/common/images/favicon_new-7483e38.svg\"/><link rel=\"icon\" type=\"image/x-icon\" href=\"https://s.yimg.com/cv/apiv2/default/fp/20180826/icons/favicon_y19_32x32.ico\"/><link rel=\"amphtml\" href=\"https://finance.yahoo.com/amphtml/news/coronavirus-vaccine-progress-accelerates-155109303.html\"/><title>Coronavirus Vaccine Progress Accelerates</title><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/custom.65019634.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/bundle.ce149847.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/atomic-desktop-ltr-0.7e2ad9b7.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/atomic-desktop-ltr.63053ca8.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/atomic-context.3bb2edfe.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/patch.cd698090.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/theme.2f876e26.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/os/fuji-style/css/fuji-rollup.min.4b1d0681.css\"/><link rel=\"stylesheet\" href=\"https://s.yimg.com/aaq/yc/css/content-canvas.358644ff.css\"/><script src=\"https://www.yahoo.com/polyfill.min.js?features=locale-data-en-us%2Carray.isarray%2Carray.prototype.every%2Carray.prototype.foreach%2Carray.prototype.indexof%2Carray.prototype.map%2Cdate.now%2Cfunction.prototype.bind%2Cobject.keys%2Cstring.prototype.trim%2Cobject.defineproperty%2Cobject.defineproperties%2Cobject.create%2Cobject.freeze%2Carray.prototype.filter%2Carray.prototype.reduce%2Cobject.assign%2Cpromise%2Crequestanimationframe%2Carray.prototype.some%2Cobject.getownpropertynames%2Cintl&amp;version=2.1.23\" defer=\"\"></script><script src=\"https://s.yimg.com/aaq/yc/2.9.0/en.js\"></script><script src=\"https://s.yimg.com/ss/rapid-3.53.3.js\"></script><script src=\"https://s.yimg.com/rq/darla/3-21-0/js/g-r-min.js\"></script><script src=\"https://s.yimg.com/aaq/yc/js/vendor.6f47d6e4941bb9d1ce0d.min.js\" defer=\"\"></script><script src=\"https://s.yimg.com/aaq/yc/js/common.0a9b639f2addfae5fafc.min.js\" defer=\"\"></script><script src=\"https://consent.cmp.oath.com/cmpStub.min.js\"></script><script src=\"https://consent.cmp.oath.com/cmp.js\" async=\"\"></script><script>!function(o,c){var a,t,i,n,e=[],r={passive:!0,capture:!0},p=new Date,f=\"pointerup\",u=\"pointercancel\",d=window;function m(n,e){a||(a=e,t=n,i=new Date,M(c),w())}function w(){0<=t&&t<i-p&&(e.forEach(function(n){n(t,a)}),e=[])}function s(n){if(n.cancelable){var e=(1e12<n.timeStamp?new Date:d.performance.now())-n.timeStamp;\"pointerdown\"===n.type?function(n,e){function a(){m(n,e),i()}function t(){i()}function i(){c(f,a,r),c(u,t,r)}o(f,a,r),o(u,t,r)}(e,n):m(e,n)}}function M(e){[\"click\",\"mousedown\",\"keydown\",\"touchstart\",\"pointerdown\"].forEach(function(n){e(n,s,r)})}d.performance&&d.performance.now&&M(o),n=function(n,e){var a=d.YAHOO&&d.YAHOO.i13n&&d.YAHOO.i13n.rapidInstance||d.YMedia&&d.YMedia.My&&d.YMedia.My.App&&d.YMedia.My.App.getRapidTracker&&d.YMedia.My.App.getRapidTracker()||d.rapidInstance,t=Math.round(n);a&&a.beaconPerformanceData&&0<t&&(t={utm:{yaft_fid:t}},a.beaconPerformanceData({perf_usertime:t}))},e.push(n),w()}(addEventListener,removeEventListener);</script><script>!function(s,f,p){var a=[],e={_version:\"3.6.0\",_config:{classPrefix:\"\",enableClasses:!0,enableJSClass:!0,usePrefixes:!0},_q:[],on:function(e,t){var n=this;setTimeout(function(){t(n[e])},0)},addTest:function(e,t,n){a.push({name:e,fn:t,options:n})},addAsyncTest:function(e){a.push({name:null,fn:e})}},l=function(){};l.prototype=e,l=new l;var c=[];function v(e,t){return typeof e===t}var t=\"Moz O ms Webkit\",u=e._config.usePrefixes?t.split(\" \"):[];e._cssomPrefixes=u;var y=f.documentElement,m=\"svg\"===y.nodeName.toLowerCase();function g(){return\"function\"!=typeof f.createElement?f.createElement(arguments[0]):m?f.createElementNS.call(f,\"http://www.w3.org/2000/svg\",arguments[0]):f.createElement.apply(f,arguments)}var n={elem:g(\"modernizr\")};l._q.push(function(){delete n.elem});var h={style:n.elem.style};function o(e,t,n,r){var o,i,s,a,l,c=\"modernizr\",u=g(\"div\"),d=((l=f.body)||((l=g(m?\"svg\":\"body\")).fake=!0),l);if(parseInt(n,10))for(;n--;)(s=g(\"div\")).id=r?r[n]:c+(n+1),u.appendChild(s);return(o=g(\"style\")).type=\"text/css\",o.id=\"s\"+c,(d.fake?d:u).appendChild(o),d.appendChild(u),o.styleSheet?o.styleSheet.cssText=e:o.appendChild(f.createTextNode(e)),u.id=c,d.fake&&(d.style.background=\"\",d.style.overflow=\"hidden\",a=y.style.overflow,y.style.overflow=\"hidden\",y.appendChild(d)),i=t(u,e),d.fake?(d.parentNode.removeChild(d),y.style.overflow=a,y.offsetHeight):u.parentNode.removeChild(u),!!i}function i(e){return e.replace(/([A-Z])/g,function(e,t){return\"-\"+t.toLowerCase()}).replace(/^ms-/,\"-ms-\")}function S(e,t){var n=e.length;if(\"CSS\"in s&&\"supports\"in s.CSS){for(;n--;)if(s.CSS.supports(i(e[n]),t))return!0;return!1}if(\"CSSSupportsRule\"in s){for(var r=[];n--;)r.push(\"(\"+i(e[n])+\":\"+t+\")\");return o(\"@supports (\"+(r=r.join(\" or \"))+\") { #modernizr { position: absolute; } }\",function(e){return\"absolute\"==function(e,t,n){var r;if(\"getComputedStyle\"in s){r=getComputedStyle.call(s,e,t);var o=s.console;null!==r?n&&(r=r.getPropertyValue(n)):o&&o[o.error?\"error\":\"log\"].call(o,\"getComputedStyle returning null, its possible modernizr test results are inaccurate\")}else r=!t&&e.currentStyle&&e.currentStyle[n];return r}(e,null,\"position\")})}return p}function C(e){return e.replace(/([a-z])-([a-z])/g,function(e,t,n){return t+n.toUpperCase()}).replace(/^-/,\"\")}l._q.unshift(function(){delete h.style});var d=e._config.usePrefixes?t.toLowerCase().split(\" \"):[];function w(e,t){return function(){return e.apply(t,arguments)}}function r(e,t,n,r,o){var i=e.charAt(0).toUpperCase()+e.slice(1),s=(e+\" \"+u.join(i+\" \")+i).split(\" \");return v(t,\"string\")||v(t,\"undefined\")?function(e,t,n,r){if(r=!v(r,\"undefined\")&&r,!v(n,\"undefined\")){var o=S(e,n);if(!v(o,\"undefined\"))return o}for(var i,s,a,l,c,u=[\"modernizr\",\"tspan\",\"samp\"];!h.style&&u.length;)i=!0,h.modElem=g(u.shift()),h.style=h.modElem.style;function d(){i&&(delete h.style,delete h.modElem)}for(a=e.length,s=0;s<a;s++)if(l=e[s],c=h.style[l],~(\"\"+l).indexOf(\"-\")&&(l=C(l)),h.style[l]!==p){if(r||v(n,\"undefined\"))return d(),\"pfx\"!=t||l;try{h.style[l]=n}catch(e){}if(h.style[l]!=c)return d(),\"pfx\"!=t||l}return d(),!1}(s,t,r,o):function(e,t,n){var r;for(var o in e)if(e[o]in t)return!1===n?e[o]:v(r=t[e[o]],\"function\")?w(r,n||t):r;return!1}(s=(e+\" \"+d.join(i+\" \")+i).split(\" \"),t,n)}e._domPrefixes=d,e.testAllProps=r;var x=function(e){var t,n=T.length,r=s.CSSRule;if(void 0===r)return p;if(!e)return!1;if((t=(e=e.replace(/^@/,\"\")).replace(/-/g,\"_\").toUpperCase()+\"_RULE\")in r)return\"@\"+e;for(var o=0;o<n;o++){var i=T[o];if(i.toUpperCase()+\"_\"+t in r)return\"@-\"+i.toLowerCase()+\"-\"+e}return!1};e.atRule=x;e.prefixed=function(e,t,n){return 0===e.indexOf(\"@\")?x(e):(-1!=e.indexOf(\"-\")&&(e=C(e)),t?r(e,t,n):r(e,\"pfx\"))};l.addTest(\"canvas\",function(){var e=g(\"canvas\");return!(!e.getContext||!e.getContext(\"2d\"))});var T=e._config.usePrefixes?\" -webkit- -moz- -o- -ms- \".split(\" \"):[\"\",\"\"];function P(e,t,n){return r(e,p,p,t,n)}e._prefixes=T,l.addTest(\"csspositionsticky\",function(){var e=\"position:\",t=g(\"a\").style;return t.cssText=e+T.join(\"sticky;\"+e).slice(0,-e.length),-1!==t.position.indexOf(\"sticky\")}),e.testAllProps=P;var _=\"CSS\"in s&&\"supports\"in s.CSS,b=\"supportsCSS\"in s;l.addTest(\"supports\",_||b),l.addTest(\"csstransforms3d\",function(){return!!P(\"perspective\",\"1px\",!0)}),l.addTest(\"csstransitions\",P(\"transition\",\"all\",!0)),l.addTest(\"history\",function(){var e=navigator.userAgent;return(-1===e.indexOf(\"Android 2.\")&&-1===e.indexOf(\"Android 4.0\")||-1===e.indexOf(\"Mobile Safari\")||-1!==e.indexOf(\"Chrome\")||-1!==e.indexOf(\"Windows Phone\")||\"file:\"===location.protocol)&&(s.history&&\"pushState\"in s.history)}),l.addTest(\"inlinesvg\",function(){var e=g(\"div\");return e.innerHTML=\"<svg/>\",\"http://www.w3.org/2000/svg\"==(\"undefined\"!=typeof SVGRect&&e.firstChild&&e.firstChild.namespaceURI)}),l.addTest(\"localstorage\",function(){var e=\"modernizr\";try{return localStorage.setItem(e,e),localStorage.removeItem(e),!0}catch(e){return!1}}),l.addTest(\"sessionstorage\",function(){var e=\"modernizr\";try{return sessionStorage.setItem(e,e),sessionStorage.removeItem(e),!0}catch(e){return!1}}),l.addTest(\"svg\",!!f.createElementNS&&!!f.createElementNS(\"http://www.w3.org/2000/svg\",\"svg\").createSVGRect),l.addTest(\"video\",function(){var e=g(\"video\"),t=!1;try{(t=!!e.canPlayType)&&((t=new Boolean(t)).ogg=e.canPlayType('video/ogg; codecs=\"theora\"').replace(/^no$/,\"\"),t.h264=e.canPlayType('video/mp4; codecs=\"avc1.42E01E\"').replace(/^no$/,\"\"),t.webm=e.canPlayType('video/webm; codecs=\"vp8, vorbis\"').replace(/^no$/,\"\"),t.vp9=e.canPlayType('video/webm; codecs=\"vp9\"').replace(/^no$/,\"\"),t.hls=e.canPlayType('application/x-mpegURL; codecs=\"avc1.42E01E\"').replace(/^no$/,\"\"))}catch(e){}return t}),function(){var e,t,n,r,o,i;for(var s in a)if(a.hasOwnProperty(s)){if(e=[],(t=a[s]).name&&(e.push(t.name.toLowerCase()),t.options&&t.options.aliases&&t.options.aliases.length))for(n=0;n<t.options.aliases.length;n++)e.push(t.options.aliases[n].toLowerCase());for(r=v(t.fn,\"function\")?t.fn():t.fn,o=0;o<e.length;o++)1===(i=e[o].split(\".\")).length?l[i[0]]=r:(!l[i[0]]||l[i[0]]instanceof Boolean||(l[i[0]]=new Boolean(l[i[0]])),l[i[0]][i[1]]=r),c.push((r?\"\":\"no-\")+i.join(\"-\"))}}(),delete e.addTest,delete e.addAsyncTest;for(var E=0;E<l._q.length;E++)l._q[E]();s.Modernizr=l}(window,document);</script><script>(function(html){var c = html.className;c += \" JsEnabled\";c = c.replace(\"NoJs\",\"\");html.className = c;})(document.documentElement);</script><script>window.webpackManifest={\"0\":\"common.0a9b639f2addfae5fafc.min.js\",\"2\":\"react-adblock-promo.7be4d4f89e245d1a9263.min.js\",\"3\":\"react-finance.3a315e96e2f4fa971d07.min.js\",\"4\":\"react-finance.ms.c6d4b0fed2017b0484c2.min.js\",\"5\":\"react-finance.rmp.e75b7d237051317b33b3.min.js\",\"6\":\"react-finance.smartphone.176e345c7b4f2e7ffbf5.min.js\",\"7\":\"react-finance.y20.dc2fb83297d7c1f560a7.min.js\",\"8\":\"react-lightbox.9821b6ca2f2cdf8a264d.min.js\",\"9\":\"react-location-widget.318ad38f536e1333333a.min.js\",\"10\":\"react-page-transition.a44ea954aae3795581c5.min.js\",\"11\":\"react-share-buttons.f02b4936037f771b670b.min.js\",\"12\":\"react-sports.c9791b45782656705e62.min.js\",\"13\":\"react-sports.boxscore.ec377684a43b190133f5.min.js\",\"14\":\"react-sports.graphite.fc96362700b9bf71b317.min.js\",\"15\":\"react-sports.leaderboard.a9ca746c4fd711b2d54d.min.js\",\"16\":\"react-sports.nav.2f04e608eac0d1d8998f.min.js\",\"17\":\"react-sports.odds.ca85e3a2cc3d8e3ce183.min.js\",\"18\":\"react-sports.onthisday.5bce7e13f9a21ede1ee2.min.js\",\"19\":\"react-sports.schedule.eb97b7b0134e0ab0e32a.min.js\",\"20\":\"react-sports.tennis.0f0ad1e2d38773e3be2e.min.js\",\"21\":\"react-sports.trivia.fb143e35b65bb76f07ea.min.js\",\"22\":\"react-sports.y20.eef0a209caf683e33ac6.min.js\",\"23\":\"react-tumblr-tile.23ac01c439f8b745dcc6.min.js\",\"24\":\"react-weather.6119b3e57369d62ffcf8.min.js\",\"25\":\"react-weather.simple.2f6b3b82a0d82a63a013.min.js\",\"26\":\"td-ads.976d2cfff2454e54440d.min.js\",\"27\":\"td-app-yahoo.05bb120b03977068a066.min.js\",\"28\":\"td-app-yahoo.cmmts.79cde5eab04b69caf58e.min.js\",\"29\":\"tdv2-applet-abu-chatbox.ae0074edd28f12fe4edf.min.js\",\"30\":\"tdv2-applet-abu-footer.68580d851de266114e3a.min.js\",\"31\":\"tdv2-applet-abu-news.36ee4b35bb815776b4b4.min.js\",\"32\":\"tdv2-applet-abu-news.abunews.fc68020188bf872b01c1.min.js\",\"33\":\"tdv2-applet-abu-news.abustock.39c634a3c8a215f0b544.min.js\",\"34\":\"tdv2-applet-abu-news.hl.5cde99ec827e2eb3e7e4.min.js\",\"35\":\"tdv2-applet-abu-news.y20.b7e768cb2456d06d9297.min.js\",\"36\":\"tdv2-applet-abu-search.1788477e54441377f293.min.js\",\"37\":\"tdv2-applet-account-switch.53c1905459a7aeb32738.min.js\",\"38\":\"tdv2-applet-apac-membership.170067920c358933b305.min.js\",\"39\":\"tdv2-applet-apac-ncp.000e70dce3dc6b69a471.min.js\",\"40\":\"tdv2-applet-apac-web-components.828caa17af622a73c087.min.js\",\"41\":\"tdv2-applet-bubble.d9fccc37dbac1e4972a5.min.js\",\"42\":\"tdv2-applet-canvass.c5d0b272a22808128565.min.js\",\"43\":\"tdv2-applet-cardstrip.346cf14898fe2f906795.min.js\",\"44\":\"tdv2-applet-channels.2850f831a3e9a3948df8.min.js\",\"45\":\"tdv2-applet-content-caas.f59fc2b45d3fa319bdfe.min.js\",\"46\":\"tdv2-applet-content-canvas.1d23a33c9ebc44f6396a.min.js\",\"47\":\"tdv2-applet-content-canvas.CanvasStickyShareButtons.e49834b2903c4f10bf75.min.js\",\"48\":\"tdv2-applet-content-canvas.CommunityBar.58916c49cc55785be53f.min.js\",\"49\":\"tdv2-applet-content-canvas.FauxdalLayout.b31457d15c6d9f10414e.min.js\",\"50\":\"tdv2-applet-content-canvas.MegaModalLayout.c2f8817a2cc345b5879b.min.js\",\"51\":\"tdv2-applet-content-canvas.UnifiedFauxdalLayout.bbabdc74a99c344d8ca5.min.js\",\"52\":\"tdv2-applet-content-canvas.UnifiedModalLayout.902152b110f3adb42f11.min.js\",\"53\":\"tdv2-applet-content-canvas.vibe.3a5a394c293fa4526f84.min.js\",\"54\":\"tdv2-applet-discussion.6d495019434a0351d1e4.min.js\",\"55\":\"tdv2-applet-discussion.flyout.3c27f4188e68a8a4b2a6.min.js\",\"56\":\"tdv2-applet-drop.1b9e25984013588ffb33.min.js\",\"57\":\"tdv2-applet-everything.d76ea43e596b5258cf92.min.js\",\"58\":\"tdv2-applet-featurebar.64e451c2517a64df44b2.min.js\",\"59\":\"tdv2-applet-follow.f9538d01fe7f90adc527.min.js\",\"60\":\"tdv2-applet-followauthor.5a3737e477c1d6f58c8b.min.js\",\"61\":\"tdv2-applet-footer.239b6ddb1c35fe172ea2.min.js\",\"62\":\"tdv2-applet-header.25e31d470b2cd9b3b887.min.js\",\"63\":\"tdv2-applet-header.news.d92cb46b7703687133cc.min.js\",\"64\":\"tdv2-applet-header.sports.8fd8a6e1050caffa851d.min.js\",\"65\":\"tdv2-applet-horoscope.bf7504366ab55324779b.min.js\",\"66\":\"tdv2-applet-livecoverage.d8f6d2208c6193031d02.min.js\",\"67\":\"tdv2-applet-native-ads.5b06f0668d11ae1326d1.min.js\",\"68\":\"tdv2-applet-native-ads.GeminiDeals.da426a8e4bda4289b5e0.min.js\",\"69\":\"tdv2-applet-native-ads.PencilAd.4958c4f19b2e24fee5d1.min.js\",\"70\":\"tdv2-applet-navrail.dffe4abd6486585c1444.min.js\",\"71\":\"tdv2-applet-navrail.smartphone.05e32247d4dede93a8fa.min.js\",\"72\":\"tdv2-applet-navrail.tablet.a3e5829cce8372f6ba92.min.js\",\"73\":\"tdv2-applet-pk.2bd4ae8aab5bf40fc067.min.js\",\"74\":\"tdv2-applet-pk.sports.050bea1f84399a36171a.min.js\",\"75\":\"tdv2-applet-pk.y20.57ddca30f3d1e912daa7.min.js\",\"76\":\"tdv2-applet-poll.a26d3fdc21ee10fb8596.min.js\",\"77\":\"tdv2-applet-profile-dashboard.76aaa58f3ec1bc6510fb.min.js\",\"78\":\"tdv2-applet-rawads.395d477dc4557687ef7f.min.js\",\"79\":\"tdv2-applet-rmp.8381aefe416f53b1f4ec.min.js\",\"80\":\"tdv2-applet-search-input.64d467d38aaac3357900.min.js\",\"81\":\"tdv2-applet-showtimes.838da89dd867223e7847.min.js\",\"82\":\"tdv2-applet-slideshow.ea7352c9f14c43845b0d.min.js\",\"83\":\"tdv2-applet-sponsored-moments.0e0d31eed08174cc190f.min.js\",\"84\":\"tdv2-applet-sponsored-moments.desktop.552bea226a69c0d08874.min.js\",\"85\":\"tdv2-applet-sponsored-moments.streamSponsoredMoments.05b5317c70992db775b4.min.js\",\"86\":\"tdv2-applet-sponsored-moments.wafer.837e0256f3991193caaf.min.js\",\"87\":\"tdv2-applet-sports-bracket.b7a9d8b5af8190a9b825.min.js\",\"88\":\"tdv2-applet-sports-bracket.y20.36fa16420ff225e71a12.min.js\",\"89\":\"tdv2-applet-sports-header.bb2660b38996b42a48dc.min.js\",\"90\":\"tdv2-applet-sports-media.c45a740f724b93d09a8d.min.js\",\"91\":\"tdv2-applet-sports-media.news.89549fad84c219801e44.min.js\",\"92\":\"tdv2-applet-sports-media.podcasts.99eed3bf81074ff64f50.min.js\",\"93\":\"tdv2-applet-sports-promos.df1ff91efc3a9700d10f.min.js\",\"94\":\"tdv2-applet-sports-promos.smartphone.22c97efc6d77040fedc8.min.js\",\"95\":\"tdv2-applet-sports-promos.y20.1d61a6a1d0c59684adb1.min.js\",\"96\":\"tdv2-applet-sports-scores.0e0ffac5e11f345155e7.min.js\",\"97\":\"tdv2-applet-sports-scores.y20.5ee25fae8b43622f070e.min.js\",\"98\":\"tdv2-applet-stream.216b2f95ab6fd3da22cc.min.js\",\"99\":\"tdv2-applet-stream-hero.dc133af65b70edf6e61d.min.js\",\"100\":\"tdv2-applet-stream-hero.carousel.97a947f963a798555c64.min.js\",\"101\":\"tdv2-applet-stream-hero.featuredhero.04acfa8926144322c715.min.js\",\"102\":\"tdv2-applet-stream-hero.widehero.4479c45abab66cc6d828.min.js\",\"103\":\"tdv2-applet-stream.ads.f6e65099c4b103766862.min.js\",\"104\":\"tdv2-applet-stream.authorbio.57d8e42e0576913a1261.min.js\",\"105\":\"tdv2-applet-stream.tiles.4eaa2f2f2b026430999e.min.js\",\"106\":\"tdv2-applet-stream.tools.d935ceb16e9df63ea545.min.js\",\"107\":\"tdv2-applet-style.fda4c3431ab0ec4438c2.min.js\",\"108\":\"tdv2-applet-swisschamp.243ccec132797eb9dde4.min.js\",\"109\":\"tdv2-applet-swisschamp.FunctionButtons.1264e1c51887ae4d7cb7.min.js\",\"110\":\"tdv2-applet-swisschamp.SidekickWrapper.4aa0a6c383fbe1a641b1.min.js\",\"111\":\"tdv2-applet-swisschamp.TwitterTimeline.c6125bc6ff9c3bbf41e5.min.js\",\"112\":\"tdv2-applet-uh.24e017775e6464ae2dc9.min.js\",\"113\":\"tdv2-applet-uh.smartphone.50492ca295a1ff0365be.min.js\",\"114\":\"tdv2-applet-uh.tablet.1e405622b4cdb351f07e.min.js\",\"115\":\"tdv2-applet-userintent.f692e5d84fc3674a0378.min.js\",\"116\":\"tdv2-applet-video-lightbox.31ddbd0eaf1cc5549b67.min.js\",\"117\":\"tdv2-applet-video-modal.423b3a1c7989fae95038.min.js\",\"118\":\"tdv2-applet-videolist.20a6bfc29eeae218f6a9.min.js\",\"119\":\"tdv2-applet-videolist.smartphone.43435305f6a0fffba316.min.js\",\"120\":\"tdv2-applet-videolist.y20.0d86301184eedc6e1a07.min.js\",\"121\":\"tdv2-dev-info.eb8ba238ca1add0586ad.min.js\",\"122\":\"tdv2-service-ccpa.f0e513a64cd4ada55cf3.min.js\",\"123\":\"tdv2-service-mail.43fd6c4ff0b7588fefd6.min.js\",\"124\":\"tdv2-service-profile.cdd0e5dc7ca9d9c40368.min.js\",\"125\":\"tdv2-service-storylines.636e60c23eb3556d3bdb.min.js\",\"126\":\"tdv2-wafer-adfeedback.b4063a96d80e8808a242.min.js\",\"127\":\"tdv2-wafer-adfeedback.smartphone.83d6f23bc08db6e24ce2.min.js\",\"128\":\"tdv2-wafer-gtmpixel.2dd9de7f2be13c78c6f2.min.js\",\"129\":\"tdv2-wafer-header.cad7f847b13d5bf5267a.min.js\",\"130\":\"tdv2-wafer-header.finance.5b40904e5c163f1a5afb.min.js\",\"131\":\"tdv2-wafer-hpsetpromo.aeffc17e5fda89318125.min.js\",\"132\":\"tdv2-wafer-promo.82eca4c1eebb30332001.min.js\",\"133\":\"tdv2-wafer-promo.smartphone.8d84dfade50202d1761e.min.js\",\"134\":\"tdv2-wafer-sitemap.b7682510db08835adf6d.min.js\",\"135\":\"tdv2-wafer-topicmanagement.90b2bd232a5dc0b3e0dc.min.js\",\"136\":\"tdv2-wafer-tv.b6ff5abaceb9f71e1bcb.min.js\",\"137\":\"tdv2-wafer-utils.99864e7993fc469fba75.min.js\",\"138\":\"vendor.6f47d6e4941bb9d1ce0d.min.js\",\"139\":\"yahoodotcom-layout.e56c52fb1a822f940df3.min.js\",\"140\":\"yahoodotcom-layout.AOLLayout.9f6dbd31313e41e19281.min.js\",\"141\":\"yahoodotcom-layout.FlexboxTwoColumnLayout.f7d5ffd0393c681e2d13.min.js\",\"142\":\"yahoodotcom-layout.LightboxLayout.07738850c7fdc2cfcdbb.min.js\",\"143\":\"yahoodotcom-layout.MegaLayout.4481698e81c88a7b49c6.min.js\",\"144\":\"yahoodotcom-layout.MegaModalLayout.ab559a5c7ba2b8c98c5f.min.js\",\"145\":\"yahoodotcom-layout.MobileOneColumnLayout.97a3eaa2ea4a675ad63e.min.js\",\"146\":\"yahoodotcom-layout.RC5ExperimentalLayout.e5971298a6aacf4f3b10.min.js\",\"147\":\"yahoodotcom-layout.RC5Layout.7acae9d5d7966d456291.min.js\",\"148\":\"yahoodotcom-layout.RC5OneColumnLayout.90327f15f59864f0941b.min.js\",\"149\":\"yahoodotcom-layout.RC5TwoColumnLayout.7f2b643001421f962d31.min.js\",\"150\":\"yahoodotcom-layout.SingleColumnLayout.8c2340bcbdd0c8cdb52f.min.js\",\"151\":\"yahoodotcom-layout.TwoColumnLayout.8bf9dec53329c3bf8b8d.min.js\"};</script><style>.tdv2-applet-canvass .action-appear,.tdv2-applet-canvass .action-enter{opacity:.01}.tdv2-applet-canvass .action-leave{opacity:1}.tdv2-applet-canvass .action-appear.action-appear-active,.tdv2-applet-canvass .action-enter.action-enter-active{opacity:1;transition:opacity .5s ease-in}.tdv2-applet-canvass .action-leave.action-leave-active{opacity:.01;transition:opacity 1s ease-in}.tdv2-applet-canvass .arrow_box,.tdv2-applet-canvass .arrow_box_tags{position:relative;background:#fff;border:1px solid #e0e4e9}.tdv2-applet-canvass .arrow_box_tags:after,.tdv2-applet-canvass .arrow_box_tags:before{border:solid transparent;content:\" \";height:0;width:0;position:absolute;pointer-events:none}.tdv2-applet-canvass .arrow_box:after,.tdv2-applet-canvass .arrow_box:before{bottom:100%;left:50%}.tdv2-applet-canvass .arrow_box_tags:after,.tdv2-applet-canvass .arrow_box_tags:before{left:47px;top:100%}.tdv2-applet-canvass .arrow_box:after,.tdv2-applet-canvass .arrow_box_tags:after{border-color:rgba(232,235,234,0);border-width:7px;margin-left:-7px}.tdv2-applet-canvass .arrow_box:after{border-bottom-color:#fff}.tdv2-applet-canvass .arrow_box_tags:after{border-top-color:#fff}.tdv2-applet-canvass .arrow_box:before,.tdv2-applet-canvass .arrow_box_tags:before{border-color:rgba(224,228,233,0);border-width:8px;margin-left:-8px}.tdv2-applet-canvass .arrow_box:before{border-bottom-color:#e0e4e9}.tdv2-applet-canvass .arrow_box_tags:before{border-top-color:#e0e4e9}.Ff\\(YahooSans\\){font-family:\"Yahoo Sans\"!important}button,textarea{font-family:inherit}@font-face{font-family:\"Yahoo Sans\";src:url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Regular.eot);src:url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Regular.eot?#iefix) format(\"embedded-opentype\"),url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Regular.woff2) format(\"woff2\"),url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Regular.woff) format(\"woff\");font-weight:400;font-style:normal}@font-face{font-family:\"Yahoo Sans\";src:url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Semibold.eot);src:url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Semibold.eot?#iefix) format(\"embedded-opentype\"),url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Semibold.woff2) format(\"woff2\"),url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Semibold.woff) format(\"woff\");font-weight:600;font-style:normal}@font-face{font-family:\"Yahoo Sans\";src:url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Bold.eot);src:url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Bold.eot?#iefix) format(\"embedded-opentype\"),url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Bold.woff2) format(\"woff2\"),url(https://s.yimg.com/cv/ae/sports/fonts/2017/Yahoo_Sans-Bold.woff) format(\"woff\");font-weight:700;font-style:normal}</style><style>.jtdTrans-enter{transform:translateY(7px) scale(.9667)}.jtdTrans-enter.jtdTrans-enter-active{transform:translateY(0) scale(1);transition:all 350ms ease-out}.jtdTrans-leave{opacity:1;transform:translateX(0)}.jtdTrans-leave.jtdTrans-leave-active{opacity:.01;transform:translateX(100%);transition:all 350ms ease-in}.jtdBgTrans-enter{opacity:0;transform:translateY(7px) scale(.9667)}.jtdBgTrans-enter.jtdBgTrans-enter-active{opacity:1;transform:translateY(0) scale(1);transition:all 350ms ease-out}.jtdBgTrans-leave{opacity:0}@-webkit-keyframes moveAnimation{25%{transform:rotate(-90deg)}75%{transform:rotate(0)}}@keyframes moveAnimation{25%{transform:rotate(-90deg)}75%{transform:rotate(0)}}</style><style>.tdv2-applet-livecoverage .action-enter{opacity:.01}.tdv2-applet-livecoverage .action-enter.action-enter-active{opacity:1;transition:opacity .5s ease-in}.tdv2-applet-livecoverage .action-leave{opacity:1}.tdv2-applet-livecoverage .action-leave.action-leave-active{opacity:.01;transition:opacity 1s ease-in}.tdv2-applet-livecoverage .action-appear{opacity:.01}.tdv2-applet-livecoverage .action-appear.action-appear-active{opacity:1;transition:opacity .5s ease-in}.tdv2-applet-livecoverage .new-post{animation:transistion-bd-color 10s ease-in}@keyframes transistion-bd-color{0%{border-color:#ff333a}25%{border-color:#ff333a}100%{border-color:#188fff}}.tdv2-applet-livecoverage .twitter-tweet{margin:0!important}.tdv2-applet-livecoverage blockquote{border-left:2px #787d82 solid;padding-left:20px;color:#787d82;font:italic bold 18px Georgia,serif}</style><style>@-webkit-keyframes spin{to{-webkit-transform:rotate(360deg);transform:rotate(360deg)}}@keyframes spin{to{-webkit-transform:rotate(360deg);transform:rotate(360deg)}}@-webkit-keyframes location-spinner{0%{-webkit-transform:scale(0);transform:scale(0)}100%{-webkit-transform:scale(1);transform:scale(1);opacity:0}}@keyframes location-spinner{0%{-webkit-transform:scale(0);transform:scale(0)}100%{-webkit-transform:scale(1);transform:scale(1);opacity:0}}.bgimg-enter{opacity:.01}.bgimg-enter.bgimg-enter-active{opacity:1;-webkit-transition:opacity .5s ease-in;transition:opacity .5s ease-in}.bgimg-leave{opacity:1}.bgimg-leave.bgimg-leave-active{opacity:.01;-webkit-transition:opacity .3s ease-in;transition:opacity .3s ease-in}</style><style>@-webkit-keyframes follow-anim{0%{opacity:1;stroke-width:1px}50%{opacity:.8;stroke-width:4px}100%{opacity:1;stroke-width:1px}}@keyframes follow-anim{0%{opacity:1;stroke-width:1px}50%{opacity:.8;stroke-width:4px}100%{opacity:1;stroke-width:1px}}</style><script>(function () {\nif (!window.YAHOO || !window.YAHOO.i13n || !window.YAHOO.i13n.Rapid) { return; }\nvar rapidConfig = {\"keys\":{\"ver\":\"y20\",\"navtype\":\"server\",\"layout\":\"y20stream\",\"pd\":\"non_modal\",\"pt\":\"content\",\"p_cpos\":1,\"p_hosted\":\"hosted\",\"pct\":\"story\",\"pstaid\":\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\",\"pstcat\":\"finance\",\"p_sec\":\"finance\",\"ss_cid\":\"\",\"mrkt\":\"us\",\"site\":\"finance\",\"lang\":\"en-US\",\"colo\":\"gq1\",\"_yrid\":\"d1fpqmlfc95jj\",\"_rid\":\"d1fpqmlfc95jj\",\"abk\":\"\"},\"compr_type\":\"deflate\",\"tracked_mods_viewability\":[],\"test_id\":\"finance-US-en-US-def\",\"webworker_file\":\"/lib/metro/g/myy/rapidworker_1_2_0.0.2.js\",\"client_only\":1,\"track_right_click\":true,\"pageview_on_init\":true,\"viewability\":true,\"dwell_on\":true,\"spaceid\":\"980771051\"};\n(function (){var val = \"; \" + document.cookie; var parts = val.split(\"; thamba=\"); if (parts.length === 2){var abk = parts.pop().split(\";\").shift(); abk && rapidConfig.keys && (rapidConfig.keys.abk = abk === \"2\"?\"abp\" : \"other\");}})();\nwindow.rapidInstance = new window.YAHOO.i13n.Rapid(rapidConfig);\n})();</script><script>(function(win){win.tdBeaconConfig = {context:{esiVarRid:\"d1fpqmlfc95jj\",esiTemplateRid:\"d1fpqmlfc95jj\"}};})(window)</script></head><body><div id=\"app\"><div data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"216167617\"><div class=\"render-target-active  render-target-default\" id=\"render-target-default\" data-reactid=\"2\"><div class=\"finance US en-US\" data-reactid=\"3\"><div id=\"YDC-MainCanvas\" class=\"YDC-MainCanvas Bgc($bg-body) Bxz(bb) Mih(100%) W(100%) Pos(a) lightweight_Miw(1247px)\" data-reactid=\"4\"><div id=\"YDC-UH\" class=\"YDC-UH\" style=\"height:128px;\" data-reactid=\"5\"><div id=\"YDC-UH-Stack\" class=\"YDC-UH-Stack Z(10) End(0) Start(0) T(0) Pos(f) uh-search-open_Pos(a)\" data-reactid=\"6\"><div id=\"YDC-UH-Stack-Composite\" data-reactid=\"7\"><div data-reactid=\"8\"><div id=\"mrt-node-UH-0-UH\" data-locator=\"subtree-root\"><div id=\"UH-0-UH-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"58589416\"><div data-reactid=\"2\"><div data-reactid=\"3\"><div id=\"masterNav\" class=\"C(#fff) Fz(13px) H(22px)\" data-reactid=\"4\"><ul id=\"eyebrow\" role=\"navigation\" class=\"H(22px) Lh(1.7) M(0) NavLinks P(0) Whs(nw) Z(11) Bgc(#2d1152) Pos(a) Start(0) End(0)\" data-reactid=\"5\"><!-- react-empty: 6 --></ul></div><div id=\"UH-0-UH-0-Header\" class=\"Miw(980px) UH Z(10) Py(14px) Pos(r)\" data-name=\"tdv2-applet-uh\" data-version=\"10.2.13\" data-reactid=\"7\"><div data-reactid=\"8\"><div class=\"Fl(start) Fz(0) M(0) P(0) ie-7_W(190px) Miw(190px) UHMR1D_Py(0)\" style=\"background-color:transparent;\" data-reactid=\"9\"><div data-reactid=\"10\"><style data-reactid=\"11\">#UH-0-UH-0-Header #uh-logo {background-image: url(https://s.yimg.com/rz/d/yahoo_finance_en-US_s_f_pw_351x40_finance.png);} @media  only screen and ( -webkit-min-device-pixel-ratio: 2 ), only screen and ( min--moz-device-pixel-ratio: 2), only screen and ( -o-min-device-pixel-ratio: 2/1), only screen and ( min-device-pixel-ratio: 2), only screen and ( min-resolution: 192dpi), only screen and ( min-resolution: 2dppx), only screen and ( min-aspect-ratio: 2/1 ) { #UH-0-UH-0-Header #uh-logo {background-image: url(https://s.yimg.com/rz/d/yahoo_finance_en-US_s_f_pw_351x40_finance_2x.png);} }</style><a id=\"uh-logo\" class=\"Bgpx(0) Bgr(nr) Cur(p) D(b) H(35px) Bgz(702px) Mx(a)! W(92px)\" href=\"https://finance.yahoo.com/\" data-reactid=\"12\"><b class=\"Hidden\" data-reactid=\"13\">Yahoo</b></a></div></div><div id=\"uh-search\" class=\"Bdrs(3px) D(b) Start(0) W(100%) Z(4)\" data-reactid=\"14\"><form action=\"/quote/\" class=\"M(0) P(0) Whs(nw)\" method=\"get\" name=\"input\" data-reactid=\"15\"><label class=\"Hidden\" for=\"fin-srch-assist\" data-reactid=\"16\">Search</label><div class=\"\" data-reactid=\"17\"><div id=\"fin-srch-assist\" class=\"Z(2) Pos(r) IbBox uh-search-open_W($srchInputTouchDeviceWidth) W(100%)\" data-reactid=\"18\"><input type=\"text\" id=\"yfin-usr-qry\" name=\"yfin-usr-qry\" aria-label=\"Search\" autocomplete=\"off\" autocorrect=\"off\" autocapitalize=\"off\" maxlength=\"4096\" class=\"Pos(r) W(100%) H(35px) M(0) O(0) O(0):f Bgc($lv2BgColor) Z(2) Bxsh(n) Bxsh(n):f Pt(6px) Pb(8px)  Pstart(36px) Pend(20px) Va(t) Bd(0) Bdrs(2px) Fz(16px)\" placeholder=\"Search for news, symbols or companies\" value=\"\" data-reactid=\"19\"/><div class=\"Z(2) Pos(a) Start(8px) T(8px)\" data-reactid=\"20\"><svg class=\"H(20px) W(20px) Va(m)! Fill($finDarkGray)! Stk($finDarkGray) Cur(p)\" width=\"20\" style=\"fill:#000;stroke:#000;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 24 24\" data-icon=\"search\" data-reactid=\"21\"><path d=\"M9 3C5.686 3 3 5.686 3 9c0 3.313 2.686 6 6 6s6-2.687 6-6c0-3.314-2.686-6-6-6m13.713 19.713c-.387.388-1.016.388-1.404 0l-7.404-7.404C12.55 16.364 10.85 17 9 17c-4.418 0-8-3.582-8-8 0-4.42 3.582-8 8-8s8 3.58 8 8c0 1.85-.634 3.55-1.69 4.905l7.403 7.404c.39.386.39 1.015 0 1.403\" data-reactid=\"22\"></path></svg></div><div class=\"Pos(a) Z(2) End(0) T(0)\" data-reactid=\"23\"></div></div><script data-reactid=\"24\">(function () {\n        var inputEl = document.getElementById('yfin-usr-qry');\n        var perf = window.performance;\n        if (inputEl && inputEl.addEventListener && perf && perf.mark && perf.getEntriesByName) {\n            var listener = function (e) {\n                inputEl.removeEventListener('keyup', listener);\n                if (perf.getEntriesByName('Fin.Search first keyup').length === 0) {\n                    perf.mark('Fin.Search first keyup');\n                }\n            };\n            inputEl.addEventListener('keyup', listener);\n        }\n    })();</script><div class=\"Pos(a) Ta(start) Start(0) End(0) Bgc($lv3BgColor) Z(1) Wob(ba) Whs(n) Bxsh($boxShadow) D(n) Mt(8px) Bd(0)\" data-test=\"search-assist-input-sugglst\" data-reactid=\"25\"><div class=\"M(0) Pb(5px) Bxsh($boxShadow) Bdrsbend(3px) Bdrsbstart(3px) \" data-reactid=\"26\"><div class=\"Mb(10px) Pt(40px) Ta(c)\" data-reactid=\"27\"><svg class=\"H(20px) W(20px) Mend(10px) Va(m)! Fill($finDarkGray)! Stk($finDarkGray) Cur(a)! Cur(p)\" width=\"20\" style=\"fill:#000;stroke:#000;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 48 48\" data-icon=\"attention\" data-reactid=\"28\"><path d=\"M24.993 46.424c-12.13 0-22-9.87-22-22s9.87-22 22-22 22 9.87 22 22-9.87 22-22 22zm0-40c-9.925 0-18 8.075-18 18 0 9.926 8.075 18 18 18s18-8.074 18-18c0-9.924-8.075-18-18-18zM24.993 27.424c-1.104 0-2-.895-2-2v-10c0-1.104.896-2 2-2s2 .896 2 2v10c0 1.105-.895 2-2 2zM22.993 33.424a2 2 0 1 0 4 0 2 2 0 1 0-4 0z\" data-reactid=\"29\"></path></svg></div><div class=\"C($finDarkGray) Fw(500) Fz(m) Ta(c) Pb(40px) Px(20px)\" data-reactid=\"30\"><span data-reactid=\"31\">No matching results for &#x27;&#x27;</span></div></div><div class=\"Ta(start) C($finDarkGray) Fz(s) Fz(500) D(b) Py(8px) Pstart(20px)\" data-reactid=\"32\"><span data-reactid=\"33\">Tip: Try a valid symbol or a specific company name for relevant results</span></div></div><button type=\"button\" class=\"C(white) Bd(0) Fw(500) Fz(s) Px(10px) Py(5px) Ta(c) uh-search-open_D(ib) D(n) Va(m) H(35px) Fl(end)\" data-reactid=\"34\"><div class=\"Ell D(ib) Maw(80px)\" data-reactid=\"35\"><span data-reactid=\"36\">Cancel</span></div></button></div><input type=\"hidden\" name=\"fr\" value=\"uh3_finance_vert\" data-reactid=\"37\"/><input type=\"hidden\" name=\"fr2\" value=\"p:finvsrp,m:sb\" data-reactid=\"38\"/><input type=\"hidden\" name=\".tsrc\" value=\"\" data-reactid=\"39\"/></form></div><ul id=\"uh-right\" class=\"End(20px) List(n) Pos(a) T(14px)\" data-reactid=\"40\"><li class=\"Fl(start) Mx(4px) Mend(9px)\" data-reactid=\"41\"><a id=\"uh-signedin\" class=\"Bdrs(5px) Bds(s) Bdw(2px) C(#fff):h D(ib) Ell Fz(14px) Fw(b) Py(2px) Mt(3px) Ta(c) Td(n):h Miw(78px) H(18px) Bdc(signInBtn) Bgc(signInBtn):h C(signInBtn)\" href=\"https://login.yahoo.com/config/login?.intl=us&amp;.lang=en-US&amp;.src=finance&amp;.done=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html\" data-reactid=\"42\">Sign in</a></li><li class=\"D(ib) Mstart(14px) Mt(-1px) ua-ie8_Pb(10px) ua-ie9_Pb(10px)\" data-reactid=\"43\"><a id=\"uh-mail\" class=\"Pos(r) D(ib) Ta(s) Td(n):h\" href=\"https://mail.yahoo.com/?.intl=us&amp;.lang=en-US&amp;.partner=none&amp;.src=finance\" data-reactid=\"44\"><svg class=\"Cur(p)\" width=\"30\" style=\"fill:#400090;stroke:#400090;stroke-width:0;vertical-align:bottom;\" height=\"35\" viewBox=\"0 0 512 512\" data-icon=\"NavMail\" data-reactid=\"45\"><path d=\"M460.586 91.31H51.504c-10.738 0-19.46 8.72-19.46 19.477v40.088l224 104.03 224-104.03v-40.088c0-10.757-8.702-19.478-19.458-19.478M32.046 193.426V402.96c0 10.758 8.72 19.48 19.458 19.48h409.082c10.756 0 19.46-8.722 19.46-19.48V193.428l-224 102.327-224-102.327z\" data-reactid=\"46\"></path></svg><b class=\"Lh(userNavTextLh) D(ib) C($c-fuji-purple-1-c) Fz(14px) Fw(b) Va(t) Mstart(6px)\" data-reactid=\"47\">Mail</b></a></li></ul></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('UH-0-UH');window.performance.measure && window.performance.measure('UH-0-UHDone','PageStart','UH-0-UH');}</script></div><div data-reactid=\"9\"><div id=\"mrt-node-UH-1-DesktopNav\" data-locator=\"subtree-root\"><div id=\"UH-1-DesktopNav-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-757699016\"><div id=\"UH-1-DesktopNav\" class=\"Pos(r) Z(1)\" data-reactid=\"2\"><nav class=\"tdv2-applet-navrail\" data-reactid=\"3\"><div class=\"Ff(navFrontFamily)\" data-reactid=\"4\"><div id=\"UH-1-DesktopNav\" class=\"nr-applet-main-nav Pos(r) Start(0) End(0) Z(8) H(navHeight) Lh(navHeight) Fz(13px) Fw(b) Bdw(1px) Miw(980px) Bdc($c-divider) Bdbs(s) Bdts(s) Bdc(borderColorLight)\" data-reactid=\"5\"><div class=\"Bgc(#f9f9f9) Bgc($bg-header)\" data-reactid=\"6\"><div class=\"nr-applet-title Fl(start) Pend(navPaddings) Bxz(bb) Ov(h) H(navHeight) Mstart(navPaddings) Miw(170px)\" data-reactid=\"7\"><div class=\"\" data-reactid=\"8\"><a class=\"nr-applet-nav-item Td(n) Ell Td(n) D(ib) Lh(itemHeight_uhMagDesign) C(lightTheme)\" href=\"https://finance.yahoo.com\" title=\"Finance\" data-reactid=\"9\"><!-- react-text: 10 -->Finance<!-- /react-text --></a></div></div><div class=\"nr-applet-main-nav-right Bxz(bb) Fl(end) Px(navPaddings) H(navHeight) W(0px)\" data-reactid=\"11\"></div><div class=\"nr-applet-main-nav-left H(navHeight) Mstart(190px) Mend(0px)!\" data-reactid=\"12\"><div class=\"mainNavInnerWrapper D(tb) H(navHeight)\" data-reactid=\"13\"><nav class=\"Lh(itemHeight) D(tbc)\" style=\"width:auto;\" role=\"navigation\" data-reactid=\"14\"><ul class=\"H(navHeight) Ov(h)\" data-reactid=\"15\"><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-1\" data-reactid=\"16\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://news.yahoo.com/coronavirus\" role=\"listitem link\" title=\"Coronavirus\" data-reactid=\"17\"><!-- react-text: 18 -->Coronavirus<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-2\" data-reactid=\"19\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/watchlists\" role=\"listitem link\" title=\"Watchlists\" data-reactid=\"20\"><!-- react-text: 21 -->Watchlists<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-3\" data-reactid=\"22\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/portfolios\" role=\"listitem link\" title=\"My Portfolio\" data-reactid=\"23\"><!-- react-text: 24 -->My Portfolio<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-4\" data-reactid=\"25\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/screener\" role=\"listitem link\" title=\"Screeners\" data-reactid=\"26\"><!-- react-text: 27 -->Screeners<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-5\" data-reactid=\"28\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/premium?ncid=navbarprem_fqbo1nu0ks0\" role=\"listitem link\" title=\"Premium\" data-reactid=\"29\"><!-- react-text: 30 -->Premium<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-6\" data-reactid=\"31\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/calendar\" role=\"listitem link\" title=\"Markets\" data-reactid=\"32\"><!-- react-text: 33 -->Markets<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-7\" data-reactid=\"34\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/news/\" role=\"listitem link\" title=\"News\" data-reactid=\"35\"><!-- react-text: 36 -->News<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-8\" data-reactid=\"37\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://money.yahoo.com\" target=\"_blank\" rel=\"noopener noreferrer\" role=\"listitem link\" title=\"Personal Finance\" data-reactid=\"38\"><!-- react-text: 39 -->Personal Finance<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-9\" data-reactid=\"40\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/videos/\" role=\"listitem link\" title=\"Videos\" data-reactid=\"41\"><!-- react-text: 42 -->Videos<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-10\" data-reactid=\"43\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/industries\" role=\"listitem link\" title=\"Industries\" data-reactid=\"44\"><!-- react-text: 45 -->Industries<!-- /react-text --></a></li><li class=\"nr-applet-main-nav-item Pend(navPaddings) Whs(nw) Fl(start) H(itemHeight) closed-subnav\" data-subnav-type=\"networknav_root-11\" data-reactid=\"46\"><a class=\"nr-applet-nav-item Td(n) nr-list-link Ell Td(n) D(ib) Bdbs(s):h Pos(r) Bdc($fg-header) Lh(cateNavHeight) C(hoverColor):h C($fg-header) Mt(cateNavMargin) C(lightTheme) Bdc(lightTheme) Tt(c) Fz(14px) openSubNav\" href=\"https://finance.yahoo.com/tech\" role=\"listitem link\" title=\"Tech\" data-reactid=\"47\"><!-- react-text: 48 -->Tech<!-- /react-text --></a></li></ul></nav><div class=\"D(tbc) Va(t) Lh(itemHeight)\" data-reactid=\"49\"><div class=\"nr-applet-moreNav Fl(start) Pos(r) H(itemHeight) Mstart(-10px) Pstart(10px) subnav-closed V(h)\" data-subnav-type=\"more-menu\" data-reactid=\"50\"><svg class=\"Cur(p)\" width=\"20\" style=\"vertical-align:middle;cursor:pointer;margin-top:-2px;color:#26282a;fill:#26282a;stroke:#26282a;stroke-width:0;\" height=\"20\" viewBox=\"0 0 96 96\" data-icon=\"StreamShare\" data-reactid=\"51\"><path d=\"M16 38c-5.516 0-10 4.477-10 10 0 5.525 4.484 10 10 10 5.53 0 10-4.475 10-10 0-5.523-4.47-10-10-10zM48 38c-5.516 0-10 4.477-10 10 0 5.525 4.484 10 10 10 5.53 0 10-4.475 10-10 0-5.523-4.47-10-10-10zM80 38c-5.516 0-10 4.477-10 10 0 5.525 4.484 10 10 10 5.53 0 10-4.475 10-10 0-5.523-4.47-10-10-10z\" data-reactid=\"52\"></path></svg></div></div></div></div><div class=\"W(100%) H(0)\" data-reactid=\"53\"></div></div></div></div></nav></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('NavLite');window.performance.measure && window.performance.measure('NavLiteDone','PageStart','NavLite');}</script></div></div></div></div><div class=\"Bgc($bg-content) Cf\" data-reactid=\"10\"><div id=\"YDC-Hero\" class=\"YDC-Hero  \" data-reactid=\"11\"><div id=\"YDC-Hero-Stack\" class=\"YDC-Hero-Stack Pos(r) Z(3)\" data-reactid=\"12\"><div id=\"YDC-Hero-Stack-Composite\" data-reactid=\"13\"><div data-reactid=\"14\"><div id=\"mrt-node-Hero-0-FinanceHeader\" data-locator=\"subtree-root\"><div id=\"Hero-0-FinanceHeader-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"2114570469\"><div class=\"Mx(20px) My(20px)\" data-reactid=\"2\"><div class=\"\" data-reactid=\"3\"><div id=\"\" class=\"D(ib) Fl(end) Pb(6px)\" data-yaft-module=\"tdv2-applet-MarketTime\" data-reactid=\"4\"><div data-id=\"mk-wrapper\" class=\"Fz(xs) Fw(b) D(ib) C($tertiaryColor)\" data-reactid=\"5\"><svg class=\"H(16px) W(16px) Va(m)! Mend(5px) Cur(a)! Fill($tertiaryColor)! Stk($tertiaryColor)! Cur(p)\" width=\"16\" style=\"stroke-width:0;vertical-align:bottom;\" height=\"16\" viewBox=\"0 0 48 48\" data-icon=\"live\" data-reactid=\"6\"><path d=\"M24 20c-2.205 0-4 1.795-4 4s1.795 4 4 4 4-1.795 4-4-1.795-4-4-4M37.12 24.032c0-4.09-1.764-7.896-4.78-10.537-.83-.727-2.094-.644-2.822.187-.727.832-.644 2.095.187 2.823 2.158 1.89 3.416 4.604 3.416 7.527 0 2.932-1.265 5.654-3.434 7.543-.833.726-.92 1.99-.194 2.822.725.833 1.99.92 2.822.194 3.032-2.64 4.807-6.458 4.807-10.558zM45.097 23.982c0-6.996-3.29-13.45-8.77-17.58-.883-.664-2.137-.488-2.802.394-.664.882-.488 2.136.394 2.8 4.487 3.384 7.177 8.66 7.177 14.386 0 5.775-2.736 11.09-7.288 14.468-.89.658-1.074 1.91-.416 2.798.658.887 1.91 1.073 2.797.415 5.56-4.124 8.907-10.625 8.907-17.68zM15 24.032c0-2.923 1.26-5.638 3.416-7.527.83-.728.915-1.99.187-2.823-.727-.83-1.99-.914-2.822-.187-3.015 2.64-4.78 6.448-4.78 10.537 0 4.1 1.776 7.918 4.808 10.56.833.725 2.096.638 2.822-.195.725-.833.638-2.096-.195-2.822-2.17-1.89-3.435-4.61-3.435-7.543zM7 23.982c0-5.726 2.69-11.002 7.178-14.385.882-.665 1.06-1.92.394-2.8-.665-.883-1.92-1.06-2.8-.394C6.29 10.533 3 16.986 3 23.983c0 7.055 3.347 13.556 8.906 17.68.887.658 2.14.472 2.798-.415.658-.887.472-2.14-.415-2.798C9.735 35.073 7 29.757 7 23.982z\" data-reactid=\"7\"></path></svg><span class=\"Va(m)\" data-id=\"mk-msg\" data-reactid=\"8\">U.S. Markets closed</span></div></div></div><div class=\"Whs(nw) D(ib) Bgc($lv2BgColor) W(100%) Bxz(bb)\" id=\"market-summary\" aria-label=\"Market summary containing a list of 15 items\" tabindex=\"0\" data-reactid=\"9\"><div class=\"Pos(r) Bxz(bb) Mstart(a) Mend(a) Ov(h)\" data-reactid=\"10\"><div class=\"D(ib) Fl(start)\" data-yaft-module=\"tdv2-applet-MarketSummary\" data-reactid=\"11\"><div class=\"Carousel-Mask Pos(r) Ov(h) market-summary M(0) Pos(r) Ov(h) D(ib) Va(t)\" style=\"width:980px;\" data-reactid=\"12\"><ul class=\"Carousel-Slider Pos(r) Whs(nw)\" style=\"margin-left:0;margin-right:-2px;\" data-reactid=\"13\"><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px)  BdEnd \" id=\"marketsummary-itm-ES=F\" aria-label=\"S&amp;P Futures\" data-reactid=\"14\"><h3 class=\"Maw(160px)\" data-reactid=\"15\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/ES=F?p=ES=F\" title=\"S&amp;P Futures\" aria-label=\"S&amp;P Futures has increased by 0.57% or 16.75 points to 2,935.50 points\" data-reactid=\"16\">S&amp;P Futures</a><br data-reactid=\"17\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"18\">2,935.50</span><div class=\"Fz(xs) Fw(b)  C($positiveColor)\" data-reactid=\"19\"><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"20\">+16.75</span><span class=\"Mstart(2px)\" data-reactid=\"21\"><!-- react-text: 22 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"23\">+0.57%</span><!-- react-text: 24 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/ES=F\" data-symbol=\"ES=F\" title=\"S&amp;P Futures Chart\" data-reactid=\"25\"><!-- react-empty: 26 --></a></h3></li><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px)  BdEnd \" id=\"marketsummary-itm-YM=F\" aria-label=\"Dow Futures\" data-reactid=\"27\"><h3 class=\"Maw(160px)\" data-reactid=\"28\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/YM=F?p=YM=F\" title=\"Dow Futures\" aria-label=\"Dow Futures has increased by 0.67% or 161.00 points to 24,319.00 points\" data-reactid=\"29\">Dow Futures</a><br data-reactid=\"30\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"31\">24,319.00</span><div class=\"Fz(xs) Fw(b)  C($positiveColor)\" data-reactid=\"32\"><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"33\">+161.00</span><span class=\"Mstart(2px)\" data-reactid=\"34\"><!-- react-text: 35 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"36\">+0.67%</span><!-- react-text: 37 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/YM=F\" data-symbol=\"YM=F\" title=\"Dow Futures Chart\" data-reactid=\"38\"><!-- react-empty: 39 --></a></h3></li><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px)  BdEnd \" id=\"marketsummary-itm-NQ=F\" aria-label=\"Nasdaq Futures\" data-reactid=\"40\"><h3 class=\"Maw(160px)\" data-reactid=\"41\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/NQ=F?p=NQ=F\" title=\"Nasdaq Futures\" aria-label=\"Nasdaq Futures has increased by 0.48% or 45.00 points to 9,345.75 points\" data-reactid=\"42\">Nasdaq Futures</a><br data-reactid=\"43\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"44\">9,345.75</span><div class=\"Fz(xs) Fw(b)  C($positiveColor)\" data-reactid=\"45\"><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"46\">+45.00</span><span class=\"Mstart(2px)\" data-reactid=\"47\"><!-- react-text: 48 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"49\">+0.48%</span><!-- react-text: 50 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/NQ=F\" data-symbol=\"NQ=F\" title=\"Nasdaq Futures Chart\" data-reactid=\"51\"><!-- react-empty: 52 --></a></h3></li><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px)  BdEnd \" id=\"marketsummary-itm-RTY=F\" aria-label=\"Russell 2000 Futures\" data-reactid=\"53\"><h3 class=\"Maw(160px)\" data-reactid=\"54\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/RTY=F?p=RTY=F\" title=\"Russell 2000 Futures\" aria-label=\"Russell 2000 Futures has increased by 1.09% or 14.30 points to 1,321.80 points\" data-reactid=\"55\">Russell 2000 Futures</a><br data-reactid=\"56\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"57\">1,321.80</span><div class=\"Fz(xs) Fw(b)  C($positiveColor)\" data-reactid=\"58\"><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"59\">+14.30</span><span class=\"Mstart(2px)\" data-reactid=\"60\"><!-- react-text: 61 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"62\">+1.09%</span><!-- react-text: 63 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/RTY=F\" data-symbol=\"RTY=F\" title=\"Russell 2000 Futures Chart\" data-reactid=\"64\"><!-- react-empty: 65 --></a></h3></li><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px)  BdEnd \" id=\"marketsummary-itm-CL=F\" aria-label=\"Crude Oil\" data-reactid=\"66\"><h3 class=\"Maw(160px)\" data-reactid=\"67\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/CL=F?p=CL=F\" title=\"Crude Oil\" aria-label=\"Crude Oil has decreased by -0.43% or -0.14 points to 32.36 points\" data-reactid=\"68\">Crude Oil</a><br data-reactid=\"69\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"70\">32.36</span><div class=\"Fz(xs) Fw(b)  C($negativeColor)\" data-reactid=\"71\"><span class=\"Trsdu(0.3s)  C($negativeColor)\" data-reactid=\"72\">-0.14</span><span class=\"Mstart(2px)\" data-reactid=\"73\"><!-- react-text: 74 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($negativeColor)\" data-reactid=\"75\">-0.43%</span><!-- react-text: 76 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/CL=F\" data-symbol=\"CL=F\" title=\"Crude Oil Chart\" data-reactid=\"77\"><!-- react-empty: 78 --></a></h3></li><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px)  BdEnd \" id=\"marketsummary-itm-GC=F\" aria-label=\"Gold\" data-reactid=\"79\"><h3 class=\"Maw(160px)\" data-reactid=\"80\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/GC=F?p=GC=F\" title=\"Gold\" aria-label=\"Gold has increased by 0.49% or 8.60 points to 1,754.20 points\" data-reactid=\"81\">Gold</a><br data-reactid=\"82\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"83\">1,754.20</span><div class=\"Fz(xs) Fw(b)  C($positiveColor)\" data-reactid=\"84\"><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"85\">+8.60</span><span class=\"Mstart(2px)\" data-reactid=\"86\"><!-- react-text: 87 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"88\">+0.49%</span><!-- react-text: 89 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/GC=F\" data-symbol=\"GC=F\" title=\"Gold Chart\" data-reactid=\"90\"><!-- react-empty: 91 --></a></h3></li><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px)  BdEnd \" id=\"marketsummary-itm-SI=F\" aria-label=\"Silver\" data-reactid=\"92\"><h3 class=\"Maw(160px)\" data-reactid=\"93\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/SI=F?p=SI=F\" title=\"Silver\" aria-label=\"Silver has increased by 0.94% or 0.17 points to 18.07 points\" data-reactid=\"94\">Silver</a><br data-reactid=\"95\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"96\">18.07</span><div class=\"Fz(xs) Fw(b)  C($positiveColor)\" data-reactid=\"97\"><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"98\">+0.17</span><span class=\"Mstart(2px)\" data-reactid=\"99\"><!-- react-text: 100 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"101\">+0.94%</span><!-- react-text: 102 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/SI=F\" data-symbol=\"SI=F\" title=\"Silver Chart\" data-reactid=\"103\"><!-- react-empty: 104 --></a></h3></li><li style=\"width:100px;\" class=\" D(ib) Bxz(bb) Bdc($seperatorColor)  Mend(20px) Fl(start) ie-7_H(70px) \" id=\"marketsummary-itm-EURUSD=X\" aria-label=\"EUR/USD\" data-reactid=\"105\"><h3 class=\"Maw(160px)\" data-reactid=\"106\"><a class=\"Fz(s) Ell Fw(600) C($linkColor)\" href=\"https://finance.yahoo.com/quote/EURUSD=X?p=EURUSD=X\" title=\"EUR/USD\" aria-label=\"EUR/USD has increased by 0.1422% or 0.0016 points to 1.0941 points\" data-reactid=\"107\">EUR/USD</a><br data-reactid=\"108\"/><span class=\"Trsdu(0.3s) Fz(s) Mt(4px) Mb(0px) Fw(b) D(ib)\" data-reactid=\"109\">1.0941</span><div class=\"Fz(xs) Fw(b)  C($positiveColor)\" data-reactid=\"110\"><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"111\">+0.0016</span><span class=\"Mstart(2px)\" data-reactid=\"112\"><!-- react-text: 113 -->(<!-- /react-text --><span class=\"Trsdu(0.3s)  C($positiveColor)\" data-reactid=\"114\">+0.1422%</span><!-- react-text: 115 -->)<!-- /react-text --></span></div><a target=\"_blank\" rel=\"noopener noreferrer\" class=\"Fl(end) Mt(-30px)\" href=\"https://finance.yahoo.com/chart/EURUSD=X\" data-symbol=\"EURUSD=X\" title=\"EUR/USD Chart\" data-reactid=\"116\"><!-- react-empty: 117 --></a></h3></li></ul></div></div><div class=\"Cl(b)\" data-reactid=\"118\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Hero-0-FinanceHeader');window.performance.measure && window.performance.measure('Hero-0-FinanceHeaderDone','PageStart','Hero-0-FinanceHeader');}</script></div><div data-reactid=\"15\"><div id=\"mrt-node-Hero-1-FeatureBar\" data-locator=\"subtree-root\"><div id=\"Hero-1-FeatureBar-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"1341530007\"><!-- react-empty: 2 --></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Hero-1-FeatureBar');window.performance.measure && window.performance.measure('Hero-1-FeatureBarDone','PageStart','Hero-1-FeatureBar');}</script></div><div data-reactid=\"16\"><div id=\"mrt-node-Hero-2-Ad\" data-locator=\"subtree-root\"><div id=\"Hero-2-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"1959488410\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultMAST-sizer\" class=\"darla-container D-n D(n)\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultMAST-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestMAST\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Hero-2-Ad');window.performance.measure && window.performance.measure('Hero-2-AdDone','PageStart','Hero-2-Ad');}</script></div><div data-reactid=\"17\"><div id=\"mrt-node-Hero-3-Ad\" data-locator=\"subtree-root\"><div id=\"Hero-3-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"1016493708\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultLDRB-sizer\" class=\"darla-container D-n D(n) lrec-ldrb-ad darla-nonlrec34-ad\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultLDRB-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestLDRB\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Hero-3-Ad');window.performance.measure && window.performance.measure('Hero-3-AdDone','PageStart','Hero-3-Ad');}</script></div><div data-reactid=\"18\"><div id=\"mrt-node-Hero-4-HeroSlideshow\" data-locator=\"subtree-root\"><div id=\"Hero-4-HeroSlideshow-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-791469831\"><!-- react-empty: 2 --></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Hero-4-HeroSlideshow');window.performance.measure && window.performance.measure('Hero-4-HeroSlideshowDone','PageStart','Hero-4-HeroSlideshow');}</script></div><div data-reactid=\"19\"><div id=\"mrt-node-Hero-5-HeadComponentVideo\" data-locator=\"subtree-root\"><div id=\"Hero-5-HeadComponentVideo-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1914101034\"><!-- react-empty: 2 --></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Hero-5-HeadComponentVideo');window.performance.measure && window.performance.measure('Hero-5-HeadComponentVideoDone','PageStart','Hero-5-HeadComponentVideo');}</script></div></div></div></div><div class=\"W(1/1) Pos(r)\" data-reactid=\"20\"><div class=\"W(2/3)--md W(1/1)--sm W(3/4) Bxz(bb)\" data-reactid=\"21\"><div id=\"YDC-Lead\" class=\"YDC-Lead\" data-reactid=\"22\"><div id=\"YDC-Lead-Stack\" class=\"YDC-Lead-Stack Z(1) Pos(r)\" data-reactid=\"23\"><div id=\"YDC-Lead-Stack-Composite\" data-reactid=\"24\"><div data-reactid=\"25\"><div id=\"mrt-node-Lead-0-CommonSlotComposite\" data-locator=\"subtree-root\"><div id=\"Lead-0-CommonSlotComposite-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1077468325\"><!-- react-empty: 2 --></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Lead-0-CommonSlotComposite');window.performance.measure && window.performance.measure('Lead-0-CommonSlotCompositeDone','PageStart','Lead-0-CommonSlotComposite');}</script></div></div></div></div><div id=\"YDC-Side\" class=\"YDC-Side Pos(a) Pos(r)--md Pos(r)--sm W(1/1)--sm W(1/4) W(1/1)--md ie-7_Mstart(-310px)\" data-reactid=\"26\"><div class=\"sticky-outer-wrapper\" data-reactid=\"27\"><div class=\"sticky-inner-wrapper\" style=\"position:relative;top:0px;\" data-reactid=\"28\"><div id=\"YDC-Side-Stack\" class=\"YDC-Side-Stack Z(1) Pos(r) Bxz(bb) Fl(end) Fl(n)--sm Fl(n)--md M(a)--sm M(a)--md Maw(340px) Maw(640px)--sm Maw(640px)--md P(20px) Pb(0)--md Pb(0)--sm W(1/1)\" data-reactid=\"29\"><div class=\"M(a) W(a)--sm W(0) W(a)--md\" data-reactid=\"30\"><div class=\"Pos(r) Start(-150px) Start(a)--sm Start(a)--md W(a)--sm W(300px) W(a)--md\" data-reactid=\"31\"><div id=\"YDC-Side-StackCompositeSideTop\" data-reactid=\"32\"><div data-reactid=\"33\"><div id=\"mrt-node-SideTop-0-HeadComponentTitle\" data-locator=\"subtree-root\"><div id=\"SideTop-0-HeadComponentTitle-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1614369307\"><div data-reactid=\"2\"><header id=\"SideTop-0-HeadComponentTitle\" class=\"canvas-header\" data-yaft-module=\"tdv2-applet-CommonHeader\" data-reactid=\"3\"><h1 class=\"Lh(36px) Fz(25px)--sm Fz(32px) Mb(17px)--sm Mb(20px) Mb(30px)--lg Ff($ff-primary) Lts($lspacing-md) Fw($fweight) Fsm($fsmoothing) Fsmw($fsmoothing) Fsmm($fsmoothing) Wow(bw)\" itemprop=\"headline\" data-reactid=\"4\">Coronavirus Vaccine Progress Accelerates</h1></header></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('SideTop-0-HeadComponentTitle');window.performance.measure && window.performance.measure('SideTop-0-HeadComponentTitleDone','PageStart','SideTop-0-HeadComponentTitle');}</script></div><div data-reactid=\"34\"><div id=\"mrt-node-SideTop-1-HeadComponentAttribution\" data-locator=\"subtree-root\"><div id=\"SideTop-1-HeadComponentAttribution-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1056933017\"><div id=\"SideTop-1-HeadComponentAttribution\" class=\"auth-attr W(100%) Mb(12px) Pos(r)\" data-yaft-module=\"tdv2-applet-CommonAttribution\" data-reactid=\"2\"><div class=\"auth-prov-logos D(tbc) Va(t) \" data-reactid=\"3\"><div class=\"provider-logo Va(m) Pend(10px) D(tbc) Mah(45px) Mah(40px)--sm\" data-reactid=\"4\"><a href=\"http://finance.yahoo.com/\" data-reactid=\"5\"><img width=\"auto\" class=\" H(a) Mah(40px)--sm Maw(40px)--sm Mah(46px) Maw(46px)\" title=\"Yahoo Finance\" src=\"https://s.yimg.com/ny/api/res/1.2/xN76WXOX_mffi8EAWYz2pw--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODQ7aD04NA--/https://s.yimg.com/os/creatr-uploaded-images/2020-01/4cb0aab0-42e2-11ea-bc79-5bef33ee891c\" data-reactid=\"6\"/></a></div></div><div class=\"auth-prov-soc Mend(4px) Va(m) D(tbc) Mah(45px) Mah(40px)--sm Maw(320px) Fz(14px)\" data-reactid=\"7\"><div class=\"author Mb(4px) D(ib) Mend(4px)\" data-reactid=\"8\"><a class=\"author-link Td(u):h Lh(18px) Td(n) Fw(b) Fz(12px) C(#000)\" itemprop=\"name\" href=\"https://www.yahoo.com/author/joanna-kong\" data-reactid=\"9\">Joanna Kong</a><div class=\"author-title D(n)--sm Mt(4px) Fw(b) Fz(12px) C(#999) Mstart(3px)\" itemprop=\"jobTitle\" data-reactid=\"10\">Yahoo Finance Premium</div></div><div class=\"D(tbc)\" data-reactid=\"11\"><span class=\"provider Mb(4px) Pend(5px)\" data-reactid=\"12\"><span class=\"provider-link\" itemprop=\"name\" data-reactid=\"13\"><a class=\"Fz(12px) C(#222) Fw(b)\" itemprop=\"url\" href=\"http://finance.yahoo.com/\" data-reactid=\"14\">Yahoo Finance</a></span><meta itemprop=\"logo\" content=\"https://s.yimg.com/ny/api/res/1.2/xN76WXOX_mffi8EAWYz2pw--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODQ7aD04NA--/https://s.yimg.com/os/creatr-uploaded-images/2020-01/4cb0aab0-42e2-11ea-bc79-5bef33ee891c\" data-reactid=\"15\"/></span><time class=\"date Fz(11px) Mb(4px)  D(ib)\" datetime=\"2020-05-14T15:51:09.000Z\" itemprop=\"datePublished\" data-reactid=\"16\">May 14, 2020</time></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('SideTop-1-HeadComponentAttribution');window.performance.measure && window.performance.measure('SideTop-1-HeadComponentAttributionDone','PageStart','SideTop-1-HeadComponentAttribution');}</script></div></div><div class=\"D(ib) D(n)--md D(n)--sm\" data-reactid=\"35\"><div id=\"Navigation\" role=\"navigation\" tabindex=\"-1\" data-reactid=\"36\"><div data-reactid=\"37\"><div id=\"mrt-node-Side-0-CanvasShareButtons\" data-locator=\"subtree-root\"><div id=\"Side-0-CanvasShareButtons-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1046723201\"><div class=\"canvas-share-buttons csb-ee6c0f80-61d5-3bba-8101-bb8bd4d538c3 Bgc(t) left-share-buttons\" data-reactid=\"2\"><div class=\"share-button-group \" style=\"-webkit-user-select:none;cursor:default;-webkit-tap-highlight-color:rgba(0,0,0,0);z-index:2;text-align:center;width:45px;\" data-reactid=\"3\"><a data-sharetype=\"tumblr\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Tumblr;cpos:1;subsec:side-left;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:www.tumblr.com\" aria-label=\"Tumblr\" style=\"margin-right:0;border-radius:0;border-width:0;width:45px;height:45px;line-height:43px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#3c5a77;color:white;border-color:#3c5a77;\" class=\"tumblr ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(b) rapid-noclick-resp react-button\" href=\"https://www.tumblr.com/widgets/share/tool?posttype=photo&amp;content=https%3A%2F%2Fs.yimg.com%2Fuu%2Fapi%2Fres%2F1.2%2FyfmPmOmwuoMa7svbTToA.g--~B%2FaD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u%2Fhttps%3A%2F%2Fmedia-mbst-pub-ue1.s3.amazonaws.com%2Fcreatr-uploaded-images%2F2020-05%2F7e7a2c40-95fa-11ea-afff-79b6b59e34b6&amp;url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dtu&amp;clickthroughUrl=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dtu&amp;caption=Diagnostic%20testing%2C%20treatment%2C%20and%20a%20coronavirus%20vaccine%20could%20allow%20near-normal%20distancing%20and%20nonessential%20business%20recovery%20by%20mid-2021.&amp;tags=\" target=\"_blank\" data-reactid=\"4\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 24 24\" data-icon=\"LogoTumblr\" data-reactid=\"5\"><path d=\"M15.4 19.1c-1.1 0-2.5-.7-2.5-1.1v-7.8h4.9V6.8h-4.9V1.7H10C9.9 3 9.5 4.1 8.9 5c-.2.5-.5.8-.9 1.1-.6.4-1.2.7-1.9.7h-.5v3.4H8v8.4c0 3.2 2.9 3.7 4.8 3.7h1.3c3 0 3.6-.3 4.3-.6V18c-.9.6-2 1.1-3 1.1z\" data-reactid=\"6\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:0px;left:45px;\" data-reactid=\"7\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#3c5a77;line-height:45px;\" data-reactid=\"8\">Reblog</span></div></a><a data-sharetype=\"facebook\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Facebook;cpos:2;subsec:side-left;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:www.facebook.com\" aria-label=\"Facebook\" style=\"margin-right:0;border-radius:0;border-width:0;width:45px;height:45px;line-height:43px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#4761a6;color:white;border-color:#4761a6;\" class=\"facebook ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(b) rapid-noclick-resp react-button\" href=\"https://www.facebook.com/dialog/feed?app_id=458584288257241&amp;link=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dfb&amp;name=Coronavirus%20Vaccine%20Progress%20Accelerates&amp;description=Diagnostic%20testing%2C%20treatment%2C%20and%20a%20coronavirus%20vaccine%20could%20allow%20near-normal%20distancing%20and%20nonessential%20business%20recovery%20by%20mid-2021.&amp;picture=https%3A%2F%2Fs.yimg.com%2Fuu%2Fapi%2Fres%2F1.2%2FyfmPmOmwuoMa7svbTToA.g--~B%2FaD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u%2Fhttps%3A%2F%2Fmedia-mbst-pub-ue1.s3.amazonaws.com%2Fcreatr-uploaded-images%2F2020-05%2F7e7a2c40-95fa-11ea-afff-79b6b59e34b6&amp;redirect_uri=https%3A%2F%2Fwww.yahoo.com%2Fnews%2Fmediacontentsharebuttons%2Fpostshare%2F&amp;display=popup&amp;show_error=yes\" target=\"_blank\" data-reactid=\"9\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 32 32\" data-icon=\"LogoFacebook\" data-reactid=\"10\"><path d=\"M12.752 30.4V16.888H9.365V12.02h3.387V7.865c0-3.264 2.002-6.264 6.613-6.264 1.866 0 3.248.19 3.248.19l-.11 4.54s-1.404-.013-2.943-.013c-1.66 0-1.93.81-1.93 2.152v3.553h5.008l-.22 4.867h-4.786V30.4h-4.88z\" data-reactid=\"11\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:0px;left:45px;\" data-reactid=\"12\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#4761a6;line-height:45px;\" data-reactid=\"13\">Share</span></div></a><a data-sharetype=\"twitter\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Twitter;cpos:3;subsec:side-left;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:twitter.com\" aria-label=\"Twitter\" style=\"margin-right:0;border-radius:0;border-width:0;width:45px;height:45px;line-height:43px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#00aceb;color:white;border-color:#00aceb;\" class=\"twitter ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(b) rapid-noclick-resp react-button\" href=\"https://twitter.com/intent/tweet?text=Coronavirus%20Vaccine%20Progress%20Accelerates&amp;url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dtw&amp;via=YahooFinance\" target=\"_blank\" data-reactid=\"14\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 32 32\" data-icon=\"LogoTwitter\" data-reactid=\"15\"><path d=\"M30.402 7.094c-1.058.47-2.198.782-3.392.928 1.218-.725 2.154-1.885 2.595-3.256-1.134.674-2.405 1.165-3.75 1.43-1.077-1.148-2.612-1.862-4.31-1.862-3.268 0-5.915 2.635-5.915 5.893 0 .464.056.91.155 1.34-4.915-.244-9.266-2.59-12.18-6.158-.51.87-.806 1.885-.806 2.96 0 2.044 1.045 3.847 2.633 4.905-.974-.032-1.883-.3-2.68-.736v.07c0 2.857 2.034 5.236 4.742 5.773-.498.138-1.022.21-1.56.21-.38 0-.75-.034-1.11-.103.75 2.344 2.93 4.042 5.518 4.09-2.024 1.58-4.57 2.523-7.333 2.523-.478 0-.952-.032-1.41-.085 2.613 1.674 5.72 2.65 9.054 2.65 10.872 0 16.814-8.976 16.814-16.765 0-.254-.008-.507-.018-.762 1.155-.83 2.155-1.868 2.95-3.047z\" data-reactid=\"16\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:0px;left:45px;\" data-reactid=\"17\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#00aceb;line-height:45px;\" data-reactid=\"18\">Tweet</span></div></a><a data-sharetype=\"mail\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Email;cpos:4;subsec:side-left;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:\" aria-label=\"Email\" style=\"margin-right:0;border-radius:0;border-width:0;width:45px;height:45px;line-height:43px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#5601c0;color:white;border-color:#5601c0;\" class=\"mail ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(b) rapid-noclick-resp react-button\" href=\"mailto:?subject=Coronavirus%20Vaccine%20Progress%20Accelerates&amp;body=Coronavirus%20Vaccine%20Progress%20Accelerates%20https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dma\" target=\"_top\" data-reactid=\"19\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"NavMail\" data-reactid=\"20\"><path d=\"M460.586 91.31H51.504c-10.738 0-19.46 8.72-19.46 19.477v40.088l224 104.03 224-104.03v-40.088c0-10.757-8.702-19.478-19.458-19.478M32.046 193.426V402.96c0 10.758 8.72 19.48 19.458 19.48h409.082c10.756 0 19.46-8.722 19.46-19.48V193.428l-224 102.327-224-102.327z\" data-reactid=\"21\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:0px;left:45px;\" data-reactid=\"22\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#5601c0;line-height:45px;\" data-reactid=\"23\">Share</span></div></a></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Side-0-CanvasShareButtons');window.performance.measure && window.performance.measure('Side-0-CanvasShareButtonsDone','PageStart','Side-0-CanvasShareButtons');}</script></div><div data-reactid=\"38\"><div id=\"mrt-node-Side-1-CommonSlotComposite\" data-locator=\"subtree-root\"><div id=\"Side-1-CommonSlotComposite-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-975887509\"><!-- react-empty: 2 --></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Side-1-CommonSlotComposite');window.performance.measure && window.performance.measure('Side-1-CommonSlotCompositeDone','PageStart','Side-1-CommonSlotComposite');}</script></div><div data-reactid=\"39\"><div id=\"mrt-node-Side-2-Empty\" data-locator=\"subtree-root\"><div id=\"Side-2-Empty-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1565909571\"><!-- react-empty: 2 --></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Side-2-Empty');window.performance.measure && window.performance.measure('Side-2-EmptyDone','PageStart','Side-2-Empty');}</script></div></div></div></div></div></div></div></div></div><div id=\"YDC-Col1\" class=\"YDC-Col1 Bxz(bb) Mstart(0)--sm Mstart(0)--md Mstart(33.3%) P(20px) W(1/1)--sm W(1/1)--md ie-7_W(45%)\" data-reactid=\"40\"><div id=\"YDC-Col1-Stack\" class=\"YDC-Col1-Stack Pos(r) M(a) Maw(600px) Maw(800px)--lg Mih(650px) Mih(0)--sm\" data-reactid=\"41\"><div id=\"Main\" role=\"content\" tabindex=\"-1\" data-reactid=\"42\"><div data-reactid=\"43\"><div id=\"mrt-node-Col1-0-ContentCanvas\" data-locator=\"subtree-root\"><div id=\"Col1-0-ContentCanvas-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-828715633\"><div id=\"Col1-0-ContentCanvas\" class=\"content-canvas Bgc(#fff) Pos(r)\" data-reactid=\"2\"><script type=\"application/ld+json\" data-reactid=\"3\">{\"@context\":\"http://schema.org\",\"@type\":\"NewsArticle\",\"datePublished\":\"Thu, 14 May 2020 15:51:09 GMT\",\"dateModified\":\"Thu, 14 May 2020 15:51:09 GMT\",\"headline\":\"Coronavirus Vaccine Progress Accelerates\",\"keywords\":\"diagnostic testing\",\"image\":\"https://s.yimg.com/uu/api/res/1.2/yfmPmOmwuoMa7svbTToA.g--~B/aD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6\",\"url\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"},\"author\":{\"@type\":\"Person\",\"name\":\"Joanna Kong\"},\"provider\":{\"@type\":\"Organization\",\"name\":\"Yahoo Finance\",\"url\":\"http://finance.yahoo.com/\",\"logo\":{\"@type\":\"ImageObject\",\"width\":84,\"height\":84,\"url\":\"https://s.yimg.com/ny/api/res/1.2/xN76WXOX_mffi8EAWYz2pw--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODQ7aD04NA--/https://s.yimg.com/os/creatr-uploaded-images/2020-01/4cb0aab0-42e2-11ea-bc79-5bef33ee891c\"}},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Yahoo Finance\",\"url\":\"https://finance.yahoo.com/\",\"logo\":{\"@type\":\"ImageObject\",\"width\":354,\"height\":50,\"url\":\"https://s.yimg.com/rz/p/yahoo_finance_en-US_h_p_finance_2.png\"}}}</script><meta itemprop=\"description\" content=\"Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.\" data-reactid=\"4\"/><meta itemprop=\"articleSection\" content=\"finance\" data-reactid=\"5\"/><meta itemprop=\"genre\" content=\"finance\" data-reactid=\"6\"/><meta itemprop=\"thumbnailUrl\" content=\"https://s.yimg.com/uu/api/res/1.2/yfmPmOmwuoMa7svbTToA.g--~B/aD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6\" data-reactid=\"7\"/><meta itemprop=\"keywords\" content=\"diagnostic testing\" data-reactid=\"8\"/><link itemprop=\"url\" href=\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\" data-reactid=\"9\"/><article itemprop=\"articleBody\" data-uuid=\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\" data-type=\"story\" data-reactid=\"10\"><div class=\"canvas-body Wow(bw) Cl(start) Mb(20px) Fz(15px) Lh(1.6) C($c-fuji-grey-l) Ff($ff-secondary) D(i)\" data-reactid=\"11\"><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Mentioned:&lt;/strong&gt;&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/GOOG&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Alphabet Inc&amp;nbsp;(GOOG)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/CTLT&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Catalent Inc&amp;nbsp;(CTLT)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/TBIO&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Translate Bio Inc&amp;nbsp;(TBIO)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/MRNA&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Moderna Inc&amp;nbsp;(MRNA)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/ADPT&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Adaptive Biotechnologies Corp&amp;nbsp;(ADPT)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/BNTX&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;BioNTech SE&amp;nbsp;(BNTX)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/TMO&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Thermo Fisher Scientific Inc&amp;nbsp;(TMO)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/EBS&quot;&gt;Emergent BioSolutions Inc&amp;nbsp;(EBS)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/INCY&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Incyte Corp&amp;nbsp;(INCY)&lt;/a&gt;,&amp;nbsp;&lt;a href=&quot;https://finance.yahoo.com/quote/HOLX&quot; class=&quot;mdc-link mds-link mds-link--no-underline&quot;&gt;Hologic Inc&amp;nbsp;(HOLX)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/LH&quot;&gt;LabCorp&amp;nbsp;(LH)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/DGX&quot;&gt;Quest (DGX)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/AAPL&quot;&gt;Apple (AAPL)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/REGN&quot;&gt;Regeneron&amp;nbsp;(REGN)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/RHHBY&quot;&gt;Roche (RHHBY)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/SNY&quot;&gt;Sanofi&amp;nbsp;(SNY)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/NVS&quot;&gt;Novartis&amp;nbsp;(NVS)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/LLY&quot;&gt;Lilly&amp;nbsp;(LLY)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/GILD&quot;&gt;Gilead&amp;nbsp;(GILD)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/PFE&quot;&gt;Pfizer&amp;nbsp;(PFE)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/ABT&quot;&gt;Abbott&amp;nbsp;(ABT)&lt;/a&gt;, &lt;a href=&quot;https://finance.yahoo.com/quote/GSK&quot;&gt;Glaxo&amp;nbsp;(GSK)&lt;/a&gt;\" data-reactid=\"12\"><strong>Mentioned:</strong>&nbsp;<a href=\"https://finance.yahoo.com/quote/GOOG\" class=\"mdc-link mds-link mds-link--no-underline\">Alphabet Inc&nbsp;(GOOG)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/CTLT\" class=\"mdc-link mds-link mds-link--no-underline\">Catalent Inc&nbsp;(CTLT)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/TBIO\" class=\"mdc-link mds-link mds-link--no-underline\">Translate Bio Inc&nbsp;(TBIO)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/MRNA\" class=\"mdc-link mds-link mds-link--no-underline\">Moderna Inc&nbsp;(MRNA)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/ADPT\" class=\"mdc-link mds-link mds-link--no-underline\">Adaptive Biotechnologies Corp&nbsp;(ADPT)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/BNTX\" class=\"mdc-link mds-link mds-link--no-underline\">BioNTech SE&nbsp;(BNTX)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/TMO\" class=\"mdc-link mds-link mds-link--no-underline\">Thermo Fisher Scientific Inc&nbsp;(TMO)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/EBS\">Emergent BioSolutions Inc&nbsp;(EBS)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/INCY\" class=\"mdc-link mds-link mds-link--no-underline\">Incyte Corp&nbsp;(INCY)</a>,&nbsp;<a href=\"https://finance.yahoo.com/quote/HOLX\" class=\"mdc-link mds-link mds-link--no-underline\">Hologic Inc&nbsp;(HOLX)</a>, <a href=\"https://finance.yahoo.com/quote/LH\">LabCorp&nbsp;(LH)</a>, <a href=\"https://finance.yahoo.com/quote/DGX\">Quest (DGX)</a>, <a href=\"https://finance.yahoo.com/quote/AAPL\">Apple (AAPL)</a>, <a href=\"https://finance.yahoo.com/quote/REGN\">Regeneron&nbsp;(REGN)</a>, <a href=\"https://finance.yahoo.com/quote/RHHBY\">Roche (RHHBY)</a>, <a href=\"https://finance.yahoo.com/quote/SNY\">Sanofi&nbsp;(SNY)</a>, <a href=\"https://finance.yahoo.com/quote/NVS\">Novartis&nbsp;(NVS)</a>, <a href=\"https://finance.yahoo.com/quote/LLY\">Lilly&nbsp;(LLY)</a>, <a href=\"https://finance.yahoo.com/quote/GILD\">Gilead&nbsp;(GILD)</a>, <a href=\"https://finance.yahoo.com/quote/PFE\">Pfizer&nbsp;(PFE)</a>, <a href=\"https://finance.yahoo.com/quote/ABT\">Abbott&nbsp;(ABT)</a>, <a href=\"https://finance.yahoo.com/quote/GSK\">Glaxo&nbsp;(GSK)</a></p><div class=\"canvas-table Px(4px) My(1.4em) Ov(a) canvas-atom\" data-type=\"table\" style=\"letter-spacing:.01em;\" data-reactid=\"13\"><table data-reactid=\"14\"><tbody> <tr> <td><p><em><strong>Editor\u2019s note:&nbsp;</strong>This is the second of two updates to Morningstar's&nbsp;COVID-19 forecast. In the first part, we looked at&nbsp;</em><a href=\"https://finance.yahoo.com/news/relaxing-the-lockdown-move-slowly-stay-nimble-151620574.html\" class=\"mdc-link mds-link\"><em>plans for easing the U.S. lockdown</em></a><em>.&nbsp;</em><a href=\"https://www.morningstar.com/market-moments/coronavirus-economic-impact\" class=\"mdc-link mds-link\" rel=\"nofollow noopener\" target=\"_blank\"><em>Read the latest</em></a><em>&nbsp;on how the coronavirus is rattling the markets and what investors can do to navigate it.</em></p></td> </tr> </tbody></table></div><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"We think widespread availability of a coronavirus vaccine or curative treatment will probably be necessary to completely remove social distancing measures. In our&amp;nbsp;&lt;a href=&quot;https://www.morningstar.com/articles/984323/relaxing-the-lockdown-move-slowly-stay-nimble&quot; class=&quot;mdc-link mds-link&quot; rel=&quot;nofollow noopener&quot; target=&quot;_blank&quot;&gt;base-case U.S. scenario&lt;/a&gt;, we expect states to wait for reassurance that the COVID-19 spread has flattened before beginning to reopen businesses, and we assume a 30% reduction in visits to nonessential businesses from baseline by the end of the year. This is a significant improvement from levels at the end of March (65% reduction) and should improve further in 2021 with the availability of a coronavirus vaccine. We assume that less than 10% of the U.S. population is infected by the end of 2020, with a 0.7% death rate, as improving levels of testing help control the spread of the disease.\" data-reactid=\"15\">We think widespread availability of a coronavirus vaccine or curative treatment will probably be necessary to completely remove social distancing measures. In our&nbsp;<a href=\"https://www.morningstar.com/articles/984323/relaxing-the-lockdown-move-slowly-stay-nimble\" class=\"mdc-link mds-link\" rel=\"nofollow noopener\" target=\"_blank\">base-case U.S. scenario</a>, we expect states to wait for reassurance that the COVID-19 spread has flattened before beginning to reopen businesses, and we assume a 30% reduction in visits to nonessential businesses from baseline by the end of the year. This is a significant improvement from levels at the end of March (65% reduction) and should improve further in 2021 with the availability of a coronavirus vaccine. We assume that less than 10% of the U.S. population is infected by the end of 2020, with a 0.7% death rate, as improving levels of testing help control the spread of the disease.</p><ul class=\"canvas-list List(d)\" data-type=\"list\" data-reactid=\"16\"><li data-reactid=\"17\"><p>Remdesivir\u2019s recent emergency use authorization in severely ill COVID-19 patients is a turning point, but efficacy to date does not look strong enough on its own to justify relaxing lockdowns. We project $2 billion in peak sales in 2021, assuming an eventual U.S. price (after donated supplies) of around $500 per treatment.</p></li><li data-reactid=\"18\"><p>Repurposed drugs could be the next wave of approvals. We expect IL-6 antibodies like Actemra and Kevzara could find a niche among the most severely ill patients by this summer, with data starting to read out on JAK inhibitors like Jakafi and Olumiant this summer, as well.</p></li><li data-reactid=\"19\"><p>Novel, targeted antibodies, led by Regeneron\u2019s antibody cocktail, are likely to be effective but are behind this schedule; they could be available late this year for high-risk populations.</p></li><li data-reactid=\"20\"><p>While coronavirus vaccines have yet to produce clinical data, encouraging preclinical data, strong partnerships and funding, and rapid clinical progress all seem to indicate that use in high-risk populations could be possible by the end of 2020, with tens of millions of doses potentially available by that point. If just two of these vaccines succeed, we could have enough supply to protect high-risk populations in late 2020 and for broader vaccination as we enter 2021.</p></li></ul><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Considering the utter importance of diagnostic testing to help the U.S. begin resuming economic activity in a manner that minimizes the prospect of increases in infection, we remain concerned about national testing capacity meeting necessary levels both in terms of volume and accuracy. The United States was already behind the eight ball when SARS-CoV-2 infections began to rise in February and March. Once the Food and Drug Administration began to approve COVID-19 diagnostic tests under the Emergency Use Act in March, we began to see new tests roll out and capacity for diagnostic testing rise. At the start of May, the U.S. was above 300,000 tests per day, which gets us to roughly 2.1 million tests per week.\" data-reactid=\"21\">Considering the utter importance of diagnostic testing to help the U.S. begin resuming economic activity in a manner that minimizes the prospect of increases in infection, we remain concerned about national testing capacity meeting necessary levels both in terms of volume and accuracy. The United States was already behind the eight ball when SARS-CoV-2 infections began to rise in February and March. Once the Food and Drug Administration began to approve COVID-19 diagnostic tests under the Emergency Use Act in March, we began to see new tests roll out and capacity for diagnostic testing rise. At the start of May, the U.S. was above 300,000 tests per day, which gets us to roughly 2.1 million tests per week.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Nevertheless, this remains far lower than the 500,000 to more than 1 million tests per day that we see as the midrange of what epidemiologists and economists have projected is required to keep the COVID-19 infection from overwhelming our finite healthcare provider systems.\" data-reactid=\"22\">Nevertheless, this remains far lower than the 500,000 to more than 1 million tests per day that we see as the midrange of what epidemiologists and economists have projected is required to keep the COVID-19 infection from overwhelming our finite healthcare provider systems.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"U.S. testing czar Adm. Brett Giroir says our testing capabilities are in the right ballpark for reopening in May and that four types of testing are needed: surveillance (testing hundreds of thousands a month to get a radar view, even among asymptomatic), symptomatic (millions of tests per month to get a nearly 10% positive rate, meaning 10% of tests coming back positive ), contact tracing (five people per confirmed case on average), and antibody testing. A 10% positive rate is the maximum recommended by the World Health Organization and a level the U.S. recently reached, based on daily data. Cumulative testing results as of May 7, with more than 8 million tests run, show an overall positive rate around 15%.\" data-reactid=\"23\">U.S. testing czar Adm. Brett Giroir says our testing capabilities are in the right ballpark for reopening in May and that four types of testing are needed: surveillance (testing hundreds of thousands a month to get a radar view, even among asymptomatic), symptomatic (millions of tests per month to get a nearly 10% positive rate, meaning 10% of tests coming back positive ), contact tracing (five people per confirmed case on average), and antibody testing. A 10% positive rate is the maximum recommended by the World Health Organization and a level the U.S. recently reached, based on daily data. Cumulative testing results as of May 7, with more than 8 million tests run, show an overall positive rate around 15%.</p><figure class=\"canvas-image Mx(a) canvas-atom My(24px) My(20px)--sm\" style=\"max-width:100%;\" data-type=\"image\" data-reactid=\"24\"><meta itemprop=\"height\" content=\"531\" data-reactid=\"25\"/><meta itemprop=\"width\" content=\"800\" data-reactid=\"26\"/><div style=\"padding-bottom:66.4%;\" class=\"Maw(100%) Pos(r) H(0)\" data-reactid=\"27\"><img alt=\"Testing Improving and Positive Rate Moving in Right Direction\" class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox W(100%) H(100%) ie-7_H(a)\" itemprop=\"url\" style=\"background-image:url(https://s.yimg.com/ny/api/res/1.2/09jiduDn86KmFnDATBZLFQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6);\" src=\"https://s.yimg.com/g/images/spaceball.gif\" data-reactid=\"28\"/><noscript data-reactid=\"29\"><img alt=\"Testing Improving and Positive Rate Moving in Right Direction\" class=\"StretchedBox W(100%) H(100%) ie-7_H(a)\" src=\"https://s.yimg.com/ny/api/res/1.2/09jiduDn86KmFnDATBZLFQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/7e7a2c40-95fa-11ea-afff-79b6b59e34b6\" itemprop=\"url\"/></noscript></div><div itemprop=\"caption description\" class=\"Ov(h) Pos(r) Ff(ss) Mah(80px)\" data-reactid=\"30\"><figcaption class=\"C($c-fuji-grey-h) Fz(13px) Py(5px) Lh(1.5)\" title=\"Testing Improving and Positive Rate Moving in Right Direction\" data-reactid=\"31\"><div class=\"figure-caption\" data-reactid=\"32\">Testing Improving and Positive Rate Moving in Right Direction</div></figcaption><button class=\"C($c-fuji-blue-1-b) Cur(p) W(100%) T(63px) Bgc(#fff) Ta(start) Fz(13px) P(0) Bd(0) O(0) Lh(1.5) Pos(a)\" data-reactid=\"33\"><span data-reactid=\"34\">More</span></button></div></figure><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"In addition, comparing U.S. testing rates to other countries gives some perspective. This comparison shows the slow start the U.S. made in ramping testing, and while there is a clear improvement over the past couple of months, the extent of the U.S. outbreak should justify even higher testing rates.\" data-reactid=\"35\">In addition, comparing U.S. testing rates to other countries gives some perspective. This comparison shows the slow start the U.S. made in ramping testing, and while there is a clear improvement over the past couple of months, the extent of the U.S. outbreak should justify even higher testing rates.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Another way of examining this is from the perspective of positive rates--the percentage of tests coming back positive. While the U.S. is making progress on positive rates, we have just barely reached the 10% threshold as a country, and some states are well above. South Korea was at 2% (roughly 10,000 positive tests out of 600,000), and we are higher than every other developed country outside the United Kingdom, which is at 30%.\" data-reactid=\"36\">Another way of examining this is from the perspective of positive rates--the percentage of tests coming back positive. While the U.S. is making progress on positive rates, we have just barely reached the 10% threshold as a country, and some states are well above. South Korea was at 2% (roughly 10,000 positive tests out of 600,000), and we are higher than every other developed country outside the United Kingdom, which is at 30%.</p><div class=\"read-more Mt(20px) Ta(start) Ta(c)--sm\" data-reactid=\"37\"><button class=\"read-more-button Td(n) Cur(p) D(ib) Fw(b) Fz(14px) Fz(15px)--lg W(180px)--sm Bdc($c-fuji-blue-1-a) Bdrs(4px) Bds(s) Bdw(2px) Bgc($c-fuji-blue-1-a):h C($c-fuji-blue-1-a)! C(#fff)!:h Lts(.3px) Px(30px) Py(10px) Lh(1)\" data-reactid=\"38\"><span data-reactid=\"39\">Story continues</span></button></div><div class=\"Ov(h) Trs($transition-readmore) Mah(0)\" data-reactid=\"40\"><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Diagnostic Testing and Antibody Testing Serve Two Different Strategies&lt;/strong&gt;&lt;br&gt;To open up the economy while minimizing the spread of COVID-19, we need two general types of tests. First, we need diagnostic testing to help identify which patients are in the active phase of infection and, thus, shedding the virus to others. This is the information that is most useful for tamping down the spread of COVID-19 so that infectious patients can be quarantined. Asymptomatic patients could be tested either through surveillance (random sampling) or contact tracing (if disease detectives found the person to be in recent contact with a confirmed patient). Infected patients could be most contagious before becoming symptomatic, making quarantine based on diagnostics rather than symptoms more effective. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has estimated that 25%-50% of patients are asymptomatic. While some asymptomatic infected people go on to develop symptoms, some do not: 18% of infected patients on the Diamond Princess cruise ship in early February remained asymptomatic. In addition, at least 40% of infected patients were asymptomatic in a broad two-stage survey in the town of Vo\u2019, Italy, and in a random sample by DeCODE in Iceland.\" data-reactid=\"41\"><strong>Diagnostic Testing and Antibody Testing Serve Two Different Strategies</strong><br>To open up the economy while minimizing the spread of COVID-19, we need two general types of tests. First, we need diagnostic testing to help identify which patients are in the active phase of infection and, thus, shedding the virus to others. This is the information that is most useful for tamping down the spread of COVID-19 so that infectious patients can be quarantined. Asymptomatic patients could be tested either through surveillance (random sampling) or contact tracing (if disease detectives found the person to be in recent contact with a confirmed patient). Infected patients could be most contagious before becoming symptomatic, making quarantine based on diagnostics rather than symptoms more effective. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has estimated that 25%-50% of patients are asymptomatic. While some asymptomatic infected people go on to develop symptoms, some do not: 18% of infected patients on the Diamond Princess cruise ship in early February remained asymptomatic. In addition, at least 40% of infected patients were asymptomatic in a broad two-stage survey in the town of Vo\u2019, Italy, and in a random sample by DeCODE in Iceland.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Second, we also need COVID-19 antibody (serology) tests that can provide a better picture of how widely the SARS-CoV-2 virus has spread throughout the larger population, and the proportion of the population that has already cleared the virus from their systems and who may enjoy some lingering immunity to SARS-CoV-2. This test contributes information that helps us more accurately estimate prevalence and how close we might be to reaching herd immunity, generally seen with around 60% of the population.\" data-reactid=\"42\">Second, we also need COVID-19 antibody (serology) tests that can provide a better picture of how widely the SARS-CoV-2 virus has spread throughout the larger population, and the proportion of the population that has already cleared the virus from their systems and who may enjoy some lingering immunity to SARS-CoV-2. This test contributes information that helps us more accurately estimate prevalence and how close we might be to reaching herd immunity, generally seen with around 60% of the population.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"We think that at this point, the diagnostic test remains the most important testing mechanism, particularly given how low the SARS-CoV-2 infection rate seems to be. We think prevalence is still probably below 5% based on antibody tests among samples in different geographic markets; two studies in California have put prevalence at 2.8% (Santa Clara County) and 4.1% (Los Angeles County), although these studies (and antibody tests in general) have been widely criticized for their potential to produce artificially high prevalence rates, or false positives. One key area of higher prevalence is New York City, which has been hit hardest by COVID-19 and where a recent analysis pegged seroprevalence at 20% (although infection rates in most of the state beyond NYC are in the low to mid-single digits). This still leaves approximately 95% of the U.S. population vulnerable to infection who will need access to diagnostic testing if they are to resume economic activity.\" data-reactid=\"43\">We think that at this point, the diagnostic test remains the most important testing mechanism, particularly given how low the SARS-CoV-2 infection rate seems to be. We think prevalence is still probably below 5% based on antibody tests among samples in different geographic markets; two studies in California have put prevalence at 2.8% (Santa Clara County) and 4.1% (Los Angeles County), although these studies (and antibody tests in general) have been widely criticized for their potential to produce artificially high prevalence rates, or false positives. One key area of higher prevalence is New York City, which has been hit hardest by COVID-19 and where a recent analysis pegged seroprevalence at 20% (although infection rates in most of the state beyond NYC are in the low to mid-single digits). This still leaves approximately 95% of the U.S. population vulnerable to infection who will need access to diagnostic testing if they are to resume economic activity.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Unfortunately, diagnostic testing is more labor-intensive, slower to turn around results, and reliant on trained professionals to both acquire the specimen and to run the tests in the lab. As a result, diagnostic testing is more challenging to scale up to required levels. Antibody tests are far easier to scale up because they are blood-based, easier to process, and tap into existing infrastructure and labor that can handle significantly higher throughput. Both LabCorp&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/LH&quot; class=&quot;mdc-link mds-link&quot;&gt;LH&lt;/a&gt;)&amp;nbsp;and Quest&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/DGX&quot; class=&quot;mdc-link mds-link&quot;&gt;DGX&lt;/a&gt;)&amp;nbsp;have extensive networks of patient service centers where specimens can be collected. These companies may even assemble mobile teams of phlebotomists to do blood draws for antibody tests on site at company locations in the second half of the year, boosting access. By the second half, we assume concerns about false positives with the initial tests will fade, particularly given that newer tests, like Roche\u2019s&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/RHHBY&quot; class=&quot;mdc-link mds-link&quot;&gt;RHHBY&lt;/a&gt;)&amp;nbsp;serology test, have much higher specificity (99.8%) that should reduce false positives regardless of how low the true prevalence of antibodies is in the population. That said, immunity benefits from the antibody are still unclear. Lower or undetectable antibody levels in some recovered patients may not be protective, or may fade in two to three years, although memory B cells (harder to detect than antibodies) could still protect patients.\" data-reactid=\"44\">Unfortunately, diagnostic testing is more labor-intensive, slower to turn around results, and reliant on trained professionals to both acquire the specimen and to run the tests in the lab. As a result, diagnostic testing is more challenging to scale up to required levels. Antibody tests are far easier to scale up because they are blood-based, easier to process, and tap into existing infrastructure and labor that can handle significantly higher throughput. Both LabCorp&nbsp;(<a href=\"https://finance.yahoo.com/quote/LH\" class=\"mdc-link mds-link\">LH</a>)&nbsp;and Quest&nbsp;(<a href=\"https://finance.yahoo.com/quote/DGX\" class=\"mdc-link mds-link\">DGX</a>)&nbsp;have extensive networks of patient service centers where specimens can be collected. These companies may even assemble mobile teams of phlebotomists to do blood draws for antibody tests on site at company locations in the second half of the year, boosting access. By the second half, we assume concerns about false positives with the initial tests will fade, particularly given that newer tests, like Roche\u2019s&nbsp;(<a href=\"https://finance.yahoo.com/quote/RHHBY\" class=\"mdc-link mds-link\">RHHBY</a>)&nbsp;serology test, have much higher specificity (99.8%) that should reduce false positives regardless of how low the true prevalence of antibodies is in the population. That said, immunity benefits from the antibody are still unclear. Lower or undetectable antibody levels in some recovered patients may not be protective, or may fade in two to three years, although memory B cells (harder to detect than antibodies) could still protect patients.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Antigen tests are just entering the market, and while they provide potential for higher capacity in the long run, we\u2019re concerned about test accuracy and scale (Quidel can provide 200,000 tests per week, scaling to more than 1 million a week in several weeks).\" data-reactid=\"45\">Antigen tests are just entering the market, and while they provide potential for higher capacity in the long run, we\u2019re concerned about test accuracy and scale (Quidel can provide 200,000 tests per week, scaling to more than 1 million a week in several weeks).</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"There is emerging research on using saliva samples for RT-PCR diagnostic testing, which suggests it is as good as, if not better than, the nasal-pharyngeal swab that currently dominates those tests. If patient data continue to bear this out, we think shifting to saliva specimens could relieve some of the factors that have slowed diagnostic testing. Experts say that the rush for coronavirus tests has led to low sensitivity, with perhaps a third of patients who are infected getting a negative test result, versus over 90% sensitivity for most PCR-based tests, but saliva-based testing could make it easier for healthcare professionals to get good samples and improve sensitivity of the test.\" data-reactid=\"46\">There is emerging research on using saliva samples for RT-PCR diagnostic testing, which suggests it is as good as, if not better than, the nasal-pharyngeal swab that currently dominates those tests. If patient data continue to bear this out, we think shifting to saliva specimens could relieve some of the factors that have slowed diagnostic testing. Experts say that the rush for coronavirus tests has led to low sensitivity, with perhaps a third of patients who are infected getting a negative test result, versus over 90% sensitivity for most PCR-based tests, but saliva-based testing could make it easier for healthcare professionals to get good samples and improve sensitivity of the test.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Aside from the prospect of testing saliva, the current picture of capacity for RT-PCR tests, based on the largest manufacturers, looks far better in theory than in practice. We have examined U.S. capacity by the base of machines, throughput, and cycle time. Based on that, we have estimated total capacity of U.S. existing lab infrastructure can get us close to 5 million diagnostic tests per day. In other words, if we squeezed out every last bit of efficiency on our collective installed base of lab equipment--running full batches, with consecutive cycles, for 16 hours a day, seven days a week (and eliminating all other non-COVID-19 tests that might otherwise be running on that equipment).\" data-reactid=\"47\">Aside from the prospect of testing saliva, the current picture of capacity for RT-PCR tests, based on the largest manufacturers, looks far better in theory than in practice. We have examined U.S. capacity by the base of machines, throughput, and cycle time. Based on that, we have estimated total capacity of U.S. existing lab infrastructure can get us close to 5 million diagnostic tests per day. In other words, if we squeezed out every last bit of efficiency on our collective installed base of lab equipment--running full batches, with consecutive cycles, for 16 hours a day, seven days a week (and eliminating all other non-COVID-19 tests that might otherwise be running on that equipment).</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"In addition to the installed base, U.S. capacity to run tests is limited by the number of tests and kits available. The manufacturing of tests has accelerated but still significantly lags the capacity of the installed base to run them. Nonetheless, our estimate of the number of tests available daily gets us to more than 600,000, which could meet the numbers that public health officials have suggested would be adequate for safely reopening the economy.\" data-reactid=\"48\">In addition to the installed base, U.S. capacity to run tests is limited by the number of tests and kits available. The manufacturing of tests has accelerated but still significantly lags the capacity of the installed base to run them. Nonetheless, our estimate of the number of tests available daily gets us to more than 600,000, which could meet the numbers that public health officials have suggested would be adequate for safely reopening the economy.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"However, these estimates reflect theoretical capacity, which is far more hopeful than de facto utilization, which gets us closer to the peak of 315,000 tests in a day. There are any number of bottlenecks and pain points that prevent us from optimizing existing capacity, and many of these inefficiencies reflect the relatively decentralized lab testing environment in the U.S.\" data-reactid=\"49\">However, these estimates reflect theoretical capacity, which is far more hopeful than de facto utilization, which gets us closer to the peak of 315,000 tests in a day. There are any number of bottlenecks and pain points that prevent us from optimizing existing capacity, and many of these inefficiencies reflect the relatively decentralized lab testing environment in the U.S.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Key Obstacles to Optimizing Diagnostic Testing Capacity&lt;/strong&gt;&lt;br&gt;Unlike the diagnostics lab industry in other countries, including Australia and the U.K., the U.S. remains a relatively fragmented and decentralized market. Even Quest and LabCorp--the two largest independent reference labs--have only captured an estimated 22% market share. Approximately half the diagnostic market is still controlled by the smaller, hospital-based labs. Considering that most of the competitive labs operate independently and that the federal government has failed to step in with leadership, it\u2019s not surprising that we haven\u2019t seen a coordinated effort to ramp up efficient use of capacity to handle the new COVID-19 tests. This is the overarching theme, and there are additional specific factors that are causing friction in efforts to scale up. There is no magic bullet to be found. Instead, the current situation is more akin to a rowboat that has sprung multiple leaks.\" data-reactid=\"50\"><strong>Key Obstacles to Optimizing Diagnostic Testing Capacity</strong><br>Unlike the diagnostics lab industry in other countries, including Australia and the U.K., the U.S. remains a relatively fragmented and decentralized market. Even Quest and LabCorp--the two largest independent reference labs--have only captured an estimated 22% market share. Approximately half the diagnostic market is still controlled by the smaller, hospital-based labs. Considering that most of the competitive labs operate independently and that the federal government has failed to step in with leadership, it\u2019s not surprising that we haven\u2019t seen a coordinated effort to ramp up efficient use of capacity to handle the new COVID-19 tests. This is the overarching theme, and there are additional specific factors that are causing friction in efforts to scale up. There is no magic bullet to be found. Instead, the current situation is more akin to a rowboat that has sprung multiple leaks.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Tests That Are Largely Proprietary to the Equipment&lt;/em&gt;&lt;br&gt;The razor/razor blade model is standard for diagnostic equipment makers, with the proprietary consumables offering a high-margin stream of ongoing revenue once the main machine is installed. For example, Roche\u2019s COVID-19 RT-PCR tests must be run on its cobas 6800 and 8800 high-throughput machines. This means that individual hospitals and integrated delivery networks that are collecting patient specimens with the Roche test must figure out which labs have those Roche cobas machines. This issue is somewhat mitigated if the hospital or network has contracted with LabCorp or Quest to handle some of its lab testing. According to Roche management, there are 122 cobas machines installed in 60 labs across the U.S. LabCorp and Quest are some of Roche\u2019s largest customers, and each has its own information technology systems that provide information on tests coming in and capacity throughout its network of labs. If the hospital hasn\u2019t contracted with this type of larger independent lab network, it may not have much visibility on where there\u2019s capacity to run those Roche tests it has collected, which could lead to longer turnaround times and inefficient use of the installed base.\" data-reactid=\"51\"><em>Tests That Are Largely Proprietary to the Equipment</em><br>The razor/razor blade model is standard for diagnostic equipment makers, with the proprietary consumables offering a high-margin stream of ongoing revenue once the main machine is installed. For example, Roche\u2019s COVID-19 RT-PCR tests must be run on its cobas 6800 and 8800 high-throughput machines. This means that individual hospitals and integrated delivery networks that are collecting patient specimens with the Roche test must figure out which labs have those Roche cobas machines. This issue is somewhat mitigated if the hospital or network has contracted with LabCorp or Quest to handle some of its lab testing. According to Roche management, there are 122 cobas machines installed in 60 labs across the U.S. LabCorp and Quest are some of Roche\u2019s largest customers, and each has its own information technology systems that provide information on tests coming in and capacity throughout its network of labs. If the hospital hasn\u2019t contracted with this type of larger independent lab network, it may not have much visibility on where there\u2019s capacity to run those Roche tests it has collected, which could lead to longer turnaround times and inefficient use of the installed base.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"We suspect this proprietary test-to-equipment framework has been particularly cumbersome for Abbott&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/ABT&quot; class=&quot;mdc-link mds-link&quot;&gt;ABT&lt;/a&gt;), which introduced its COVID-19 diagnostic testing fairly early but had not seen its throughput of COVID-19 tests accelerate to the level expected. We think this is because Abbott\u2019s roughly 175 m2000 machines scattered across the U.S. are in smaller labs. The m2000 is not widely installed at Quest\u2019s network of labs, for example. Molecular diagnostic equipment at Quest is dominated by Roche and Hologic&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/HOLX&quot; class=&quot;mdc-link mds-link&quot;&gt;HOLX&lt;/a&gt;). We suspect there may be a similar situation at LabCorp. If most of Abbott\u2019s m2000 machines are not linked to a wider network, it won\u2019t benefit from information flow that can identify and match available machine capacity to incoming tests.\" data-reactid=\"52\">We suspect this proprietary test-to-equipment framework has been particularly cumbersome for Abbott&nbsp;(<a href=\"https://finance.yahoo.com/quote/ABT\" class=\"mdc-link mds-link\">ABT</a>), which introduced its COVID-19 diagnostic testing fairly early but had not seen its throughput of COVID-19 tests accelerate to the level expected. We think this is because Abbott\u2019s roughly 175 m2000 machines scattered across the U.S. are in smaller labs. The m2000 is not widely installed at Quest\u2019s network of labs, for example. Molecular diagnostic equipment at Quest is dominated by Roche and Hologic&nbsp;(<a href=\"https://finance.yahoo.com/quote/HOLX\" class=\"mdc-link mds-link\">HOLX</a>). We suspect there may be a similar situation at LabCorp. If most of Abbott\u2019s m2000 machines are not linked to a wider network, it won\u2019t benefit from information flow that can identify and match available machine capacity to incoming tests.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Need for Trained Personnel&lt;/em&gt;&lt;br&gt;This is an issue on two fronts. First, we need trained medical professionals to obtain the specimen via nasal-pharyngeal swab. Capturing that nasal swab can be risky because it puts the medical professional close to the patient. Additionally, swabbing can make patients sneeze, which could further spread the virus if they\u2019re infectious. Second, we also need trained technicians to run the diagnostic machines. These are the people who transfer and prepare the specimens for PCR testing in the lab and monitor quality controls along the way. The dearth of trained lab professionals has been a chronic problem in the industry, even before the COVID-19 pandemic. The prospect of increasing capacity by installing more machines is likely to be constrained by the limited number of people who know how to operate them.\" data-reactid=\"53\"><em>Need for Trained Personnel</em><br>This is an issue on two fronts. First, we need trained medical professionals to obtain the specimen via nasal-pharyngeal swab. Capturing that nasal swab can be risky because it puts the medical professional close to the patient. Additionally, swabbing can make patients sneeze, which could further spread the virus if they\u2019re infectious. Second, we also need trained technicians to run the diagnostic machines. These are the people who transfer and prepare the specimens for PCR testing in the lab and monitor quality controls along the way. The dearth of trained lab professionals has been a chronic problem in the industry, even before the COVID-19 pandemic. The prospect of increasing capacity by installing more machines is likely to be constrained by the limited number of people who know how to operate them.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Inadequate Supplies of Personal Protective Equipment for Medical Professionals&lt;/em&gt;&lt;br&gt;The well-documented PPE insufficiency has also hampered the ability of medical professionals to collect specimens from patients. As discussed earlier, the nasal-pharyngeal swab can result in the patient sneezing on the healthcare worker, which means the medical professionals need substantial protective gear to do their jobs safely. If the saliva-based RT-PCR test offers comparable or superior specimen capture, shifting over could relieve some of the pressure on the healthcare workers, in terms of needing less training and PPE.\" data-reactid=\"54\"><em>Inadequate Supplies of Personal Protective Equipment for Medical Professionals</em><br>The well-documented PPE insufficiency has also hampered the ability of medical professionals to collect specimens from patients. As discussed earlier, the nasal-pharyngeal swab can result in the patient sneezing on the healthcare worker, which means the medical professionals need substantial protective gear to do their jobs safely. If the saliva-based RT-PCR test offers comparable or superior specimen capture, shifting over could relieve some of the pressure on the healthcare workers, in terms of needing less training and PPE.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Inadequate Reagents and Other Supplies for Tests&lt;/em&gt;&lt;br&gt;On a preliminary basis, we have run across reports of healthcare providers running out of reagents, nasal swabs, and transport media supplies necessary to capture and preserve specimens. Test makers have suggested that they are sending out sufficient supplies with their tests. We remain skeptical that supply has matched demand. The bandwidth for producing those enzymes and primers tailored to the SARS-CoV-2 virus remains somewhat limited. These enzymes are biological molecules that are typically produced and then purified on a small scale. Increasing quantity of production will take time.\" data-reactid=\"55\"><em>Inadequate Reagents and Other Supplies for Tests</em><br>On a preliminary basis, we have run across reports of healthcare providers running out of reagents, nasal swabs, and transport media supplies necessary to capture and preserve specimens. Test makers have suggested that they are sending out sufficient supplies with their tests. We remain skeptical that supply has matched demand. The bandwidth for producing those enzymes and primers tailored to the SARS-CoV-2 virus remains somewhat limited. These enzymes are biological molecules that are typically produced and then purified on a small scale. Increasing quantity of production will take time.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Restrictive Conditions on Testing for Patients&lt;/em&gt;&lt;br&gt;Severe test constraints in the early stages of the COVID-19 crisis in January and February meant that healthcare providers tried to limit the tests to symptomatic patients, those who were in contact with COVID-19 patients, and first responders. Now that more tests are available, providers can expand their guidelines for testing. However, the Centers for Disease Control and Prevention has not led the way in setting more liberal testing guidelines. Instead, it is leaving it up to the states, which has resulted in a more disjointed shift in making the tests more widely accessible.\" data-reactid=\"56\"><em>Restrictive Conditions on Testing for Patients</em><br>Severe test constraints in the early stages of the COVID-19 crisis in January and February meant that healthcare providers tried to limit the tests to symptomatic patients, those who were in contact with COVID-19 patients, and first responders. Now that more tests are available, providers can expand their guidelines for testing. However, the Centers for Disease Control and Prevention has not led the way in setting more liberal testing guidelines. Instead, it is leaving it up to the states, which has resulted in a more disjointed shift in making the tests more widely accessible.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Lack of Centralized IT and Logistics Capabilities&lt;/em&gt;&lt;br&gt;We think this, perhaps, is the most significant factor in the near and mid-term that prevents us from turning our theoretical test capacity into reality. Getting the specimen from the healthcare provider to a lab with the appropriate equipment platform that has space in its overnight batches is difficult without a centralized information system. Then, take hundreds of thousands of specimens, multiplied by thousands of healthcare providers, multiplied by hundreds of labs, and by a handful of major equipment platforms. This quickly turns into a massive matching game to get each specimen to the right lab at the right time. White House coronavirus response coordinator Dr. Deborah Birx noted on April 8 that only 10% of the available 1 million Abbott tests for m2000 machines (175 in the U.S.) had been run, probably because the high-throughput machines are not always in locations where they are most needed, and staff and supplies can run short. Federal testing czar Giroir hopes to triple usage to 60% in May.\" data-reactid=\"57\"><em>Lack of Centralized IT and Logistics Capabilities</em><br>We think this, perhaps, is the most significant factor in the near and mid-term that prevents us from turning our theoretical test capacity into reality. Getting the specimen from the healthcare provider to a lab with the appropriate equipment platform that has space in its overnight batches is difficult without a centralized information system. Then, take hundreds of thousands of specimens, multiplied by thousands of healthcare providers, multiplied by hundreds of labs, and by a handful of major equipment platforms. This quickly turns into a massive matching game to get each specimen to the right lab at the right time. White House coronavirus response coordinator Dr. Deborah Birx noted on April 8 that only 10% of the available 1 million Abbott tests for m2000 machines (175 in the U.S.) had been run, probably because the high-throughput machines are not always in locations where they are most needed, and staff and supplies can run short. Federal testing czar Giroir hopes to triple usage to 60% in May.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Both LabCorp and Quest have their own proprietary information systems that can provide insight into equipment platforms and testing capacity on a nightly basis across their own network of labs. However, roughly half the diagnostic industry in the U.S. is housed in hospital-based labs, and they are not looped into such a lab network. Same thing applies to the smaller, regional independent labs. As a result, there\u2019s a fair amount of capacity in our system that is going unused. We think addressing this shortfall will take action on the part of the federal government to centralize information flow related to the incoming tests and individual lab capacity. Based on this administration\u2019s propensity to leave diagnostic testing programs to the states, we speculate that any sort of common information system to unlock capacity in our existing lab infrastructure probably won\u2019t happen unless a different administration takes over next year.\" data-reactid=\"58\">Both LabCorp and Quest have their own proprietary information systems that can provide insight into equipment platforms and testing capacity on a nightly basis across their own network of labs. However, roughly half the diagnostic industry in the U.S. is housed in hospital-based labs, and they are not looped into such a lab network. Same thing applies to the smaller, regional independent labs. As a result, there\u2019s a fair amount of capacity in our system that is going unused. We think addressing this shortfall will take action on the part of the federal government to centralize information flow related to the incoming tests and individual lab capacity. Based on this administration\u2019s propensity to leave diagnostic testing programs to the states, we speculate that any sort of common information system to unlock capacity in our existing lab infrastructure probably won\u2019t happen unless a different administration takes over next year.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Significantly expanding lab infrastructure will take time. According to the Rockefeller Foundation plan, the U.S. could roughly triple current testing if we efficiently use all labs in U.S. that could do high-throughput testing. According to Rockefeller, it would take about eight months to get to 30 million tests a week, assuming an incredible ramp with strong funding. We could also make more point-of-care tests for rural areas, but building more could run into bottlenecks for China-sourced electronics or reagents. Hologic has been contacted by a range of customers, including departments of public health, hospital systems, and LabCorp and Quest, about buying more Panthers. In the near term, we expect that there will be robust placement of this kind of midsize high-throughput testing equipment. However, production of these machines is not necessarily easy to accelerate three- or four-fold to meet the current demand. Further, it is not clear to us that LabCorp and Quest, as the largest reference labs, are willing to significantly build out and maintain extra capacity that could go unused until another pandemic. Thus, the near- and mid-term expansion of capacity will likely be on the periphery of what we already have. We doubt there will be any tripling or quadrupling of the U.S. installed base of machines.\" data-reactid=\"59\">Significantly expanding lab infrastructure will take time. According to the Rockefeller Foundation plan, the U.S. could roughly triple current testing if we efficiently use all labs in U.S. that could do high-throughput testing. According to Rockefeller, it would take about eight months to get to 30 million tests a week, assuming an incredible ramp with strong funding. We could also make more point-of-care tests for rural areas, but building more could run into bottlenecks for China-sourced electronics or reagents. Hologic has been contacted by a range of customers, including departments of public health, hospital systems, and LabCorp and Quest, about buying more Panthers. In the near term, we expect that there will be robust placement of this kind of midsize high-throughput testing equipment. However, production of these machines is not necessarily easy to accelerate three- or four-fold to meet the current demand. Further, it is not clear to us that LabCorp and Quest, as the largest reference labs, are willing to significantly build out and maintain extra capacity that could go unused until another pandemic. Thus, the near- and mid-term expansion of capacity will likely be on the periphery of what we already have. We doubt there will be any tripling or quadrupling of the U.S. installed base of machines.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"In the near and mid-term, we expect most of the usable capacity to come from LabCorp and Quest more efficiently using their existing equipment. This will be enhanced by the addition of Hologic\u2019s newest COVID-19 diagnostic testing capabilities, run on its Panther machines, which are located in a range of small and midsize labs.\" data-reactid=\"60\">In the near and mid-term, we expect most of the usable capacity to come from LabCorp and Quest more efficiently using their existing equipment. This will be enhanced by the addition of Hologic\u2019s newest COVID-19 diagnostic testing capabilities, run on its Panther machines, which are located in a range of small and midsize labs.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Point-of-Care and At-Home Diagnostic Testing Unlikely to Be Short-Run Fix&lt;/strong&gt;&lt;br&gt;We may see some new innovations to address the testing challenges. Quest management said the current administration has encouraged the firm to think creatively about how to bring on more capacity in different ways. The CARES Act also contains more than $1 billion dedicated to a competition to develop new diagnostics that can get around these pain points that have slowed COVID-19 diagnostic testing so far.\" data-reactid=\"61\"><strong>Point-of-Care and At-Home Diagnostic Testing Unlikely to Be Short-Run Fix</strong><br>We may see some new innovations to address the testing challenges. Quest management said the current administration has encouraged the firm to think creatively about how to bring on more capacity in different ways. The CARES Act also contains more than $1 billion dedicated to a competition to develop new diagnostics that can get around these pain points that have slowed COVID-19 diagnostic testing so far.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Abbott is ramping up production of its point-of-care diagnostic test, but we still see this topping out at around 2 million tests per month over the summer, translating to 67,000 tests per day. Also, the Abbott machines for POC testing are likely mainly in doctors\u2019 offices, and most of those offices are closed with the machines trapped inside. Abbott management says there are 18,000 ID Now machines in the U.S., but demand for these machines seems unmet, with the mayor of Detroit asking for just five to put in his hospitals. In other words, Abbott\u2019s machines don\u2019t appear to be translating into usable supply. Until ID Now machines are relocated to where most potential COVID-19 patients will be, we\u2019re unlikely to see POC testing significantly increase.\" data-reactid=\"62\">Abbott is ramping up production of its point-of-care diagnostic test, but we still see this topping out at around 2 million tests per month over the summer, translating to 67,000 tests per day. Also, the Abbott machines for POC testing are likely mainly in doctors\u2019 offices, and most of those offices are closed with the machines trapped inside. Abbott management says there are 18,000 ID Now machines in the U.S., but demand for these machines seems unmet, with the mayor of Detroit asking for just five to put in his hospitals. In other words, Abbott\u2019s machines don\u2019t appear to be translating into usable supply. Until ID Now machines are relocated to where most potential COVID-19 patients will be, we\u2019re unlikely to see POC testing significantly increase.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"In addition, POC accuracy will probably continue to trail that of the RT-PCR tests done in the reference lab. Reported 15% rates of false negatives for the Abbott POC test should improve peripherally as medical professionals become more familiar with how to run the test and handle the specimens, but that may not be enough to close the gap with lab tests. The other leap forward for the POC tests is if they can run tests on saliva. If there\u2019s greater and more consistent concentration of the virus in saliva, that could improve accuracy. That said, each machine is severely limited in its capacity; one Abbott ID Now machine can process only 64 tests, if run continuously for 16 hours.\" data-reactid=\"63\">In addition, POC accuracy will probably continue to trail that of the RT-PCR tests done in the reference lab. Reported 15% rates of false negatives for the Abbott POC test should improve peripherally as medical professionals become more familiar with how to run the test and handle the specimens, but that may not be enough to close the gap with lab tests. The other leap forward for the POC tests is if they can run tests on saliva. If there\u2019s greater and more consistent concentration of the virus in saliva, that could improve accuracy. That said, each machine is severely limited in its capacity; one Abbott ID Now machine can process only 64 tests, if run continuously for 16 hours.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"The first at-home tests are hampered by the need for a prescription and a $119 out-of-pocket payment. LabCorp expects that in a few weeks it will have enough supply of the Pixel test to branch out from the initial target of first responders, aiming for normalized production of 100,000 tests per week. We think it could be easy to remove the obstacle of needing a prescription, but LabCorp can\u2019t distribute tests without collecting money from someone to cover costs. The process of working with payers to collect the money would take time, as patients would then need to send insurance information to LabCorp for the lab to close the loop with the patient\u2019s payer, collect payment, and send out the test. LabCorp could also contract with employers directly to pay for kits in bulk, which could then be distributed to employees, but we haven\u2019t seen evidence that this is part of its strategy. Regardless, getting at-home tests in the hands of noninsured Americans seems challenging.\" data-reactid=\"64\">The first at-home tests are hampered by the need for a prescription and a $119 out-of-pocket payment. LabCorp expects that in a few weeks it will have enough supply of the Pixel test to branch out from the initial target of first responders, aiming for normalized production of 100,000 tests per week. We think it could be easy to remove the obstacle of needing a prescription, but LabCorp can\u2019t distribute tests without collecting money from someone to cover costs. The process of working with payers to collect the money would take time, as patients would then need to send insurance information to LabCorp for the lab to close the loop with the patient\u2019s payer, collect payment, and send out the test. LabCorp could also contract with employers directly to pay for kits in bulk, which could then be distributed to employees, but we haven\u2019t seen evidence that this is part of its strategy. Regardless, getting at-home tests in the hands of noninsured Americans seems challenging.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Contact Tracing Offers Incremental Improvement in Fighting Outbreak&lt;/strong&gt;&lt;br&gt;Contact tracing can help narrow the field of testing to be more precise, but U.S. health departments don\u2019t seem well equipped using traditional methods. The Association of State and Territorial Health Officials recommends 100,000 U.S. contact tracers to get to a 1:1,000 individual/tracer ratio, using a three-tier response of lay contact tracers, disease investigator specialists (professionals) at the state level (currently only 2,200 DIS positions), and healthcare providers or epidemiologists at the CDC (a COVID-19 corps) to support the other two tiers. In Wuhan, China, aggressive contact tracing was done by 1,800 teams of epidemiologists, with at least five members on each team. Scaling up to a level like China\u2019s would require one investigator per 1,200 individuals, or more than 300,000.\" data-reactid=\"65\"><strong>Contact Tracing Offers Incremental Improvement in Fighting Outbreak</strong><br>Contact tracing can help narrow the field of testing to be more precise, but U.S. health departments don\u2019t seem well equipped using traditional methods. The Association of State and Territorial Health Officials recommends 100,000 U.S. contact tracers to get to a 1:1,000 individual/tracer ratio, using a three-tier response of lay contact tracers, disease investigator specialists (professionals) at the state level (currently only 2,200 DIS positions), and healthcare providers or epidemiologists at the CDC (a COVID-19 corps) to support the other two tiers. In Wuhan, China, aggressive contact tracing was done by 1,800 teams of epidemiologists, with at least five members on each team. Scaling up to a level like China\u2019s would require one investigator per 1,200 individuals, or more than 300,000.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"To control outbreaks at an R0 (reproduction number, signifying extent of contagion) of 2.5 (estimate for SARS-CoV-2), we would need to trace more than 70% of contacts of those infected, but the outbreak could be controlled with less than 50% successfully traced, if R0 is less than 1.5. We expect this could mean that if we are using additional measures beyond contact tracing to control the disease, such as social distancing or school closures, we may be able to make some headway even without perfect coverage.\" data-reactid=\"66\">To control outbreaks at an R0 (reproduction number, signifying extent of contagion) of 2.5 (estimate for SARS-CoV-2), we would need to trace more than 70% of contacts of those infected, but the outbreak could be controlled with less than 50% successfully traced, if R0 is less than 1.5. We expect this could mean that if we are using additional measures beyond contact tracing to control the disease, such as social distancing or school closures, we may be able to make some headway even without perfect coverage.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"A Boston nonprofit, Partners in Health, is hiring 1,000 people for contact tracing, and New York is launching a massive testing and contact tracing program, particularly in hard-hit, low-income communities, involving tens of thousands of tracers (the state previously had fewer than 1,000), and the state has $1.3 billion in federal funding to support the initiative. San Francisco is also boosting its 40-person contact tracer team to at least 150, or one tracer for every 5,553 residents. However, these are small-scale efforts compared with what we would need for a nationwide program.\" data-reactid=\"67\">A Boston nonprofit, Partners in Health, is hiring 1,000 people for contact tracing, and New York is launching a massive testing and contact tracing program, particularly in hard-hit, low-income communities, involving tens of thousands of tracers (the state previously had fewer than 1,000), and the state has $1.3 billion in federal funding to support the initiative. San Francisco is also boosting its 40-person contact tracer team to at least 150, or one tracer for every 5,553 residents. However, these are small-scale efforts compared with what we would need for a nationwide program.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Technology could make this process easier and faster. Manual contact tracing (by disease detectives) may not be good enough to slow transmission, but instantaneous tracing (notifying exposed people the minute someone is diagnosed) could be, as used in South Korea and Singapore. Apps are being built to help with contact tracing, and proximity tracking could allow people to self-isolate if they get a notification that they have been near someone who is now confirmed to be infected. While apps in Asia have led to the disclosure of personal info, in the West, a system that uses Bluetooth signaling to record proximity could be less intrusive. In the U.S., many projects have been announced, like Covid Watch, CoEpi, and NextTrace, and the ability to piece all of their data together could become an issue unless we rally around one provider. Apple&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/AAPL&quot; class=&quot;mdc-link mds-link&quot;&gt;AAPL&lt;/a&gt;)&amp;nbsp;and Google&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/GOOG&quot; class=&quot;mdc-link mds-link&quot;&gt;GOOG&lt;/a&gt;)&amp;nbsp;announced that they are working together to facilitate contact tracing using Bluetooth functionality. To satisfy privacy concerns, rather than using GPS, their platform will focus on codes created when users are within proximity for a certain amount of time; if one is infected, the voluntary app (to be designed by healthcare agencies) could automatically warn close contacts that they may have been exposed. While they are first planning to unify their wireless protocols to allow others to build apps across platforms, we expect their own app could be more reliable than third-party apps. With any app, the idea is to limit the number of people who need to be tested in order to maintain containment of the virus. However, epidemiologists estimate that we would need to see 60% uptake of these apps for them to be effective, and so far, uptake is less than 20% for TraceTogether in Singapore and 40% for Iceland\u2019s Rakning C-19.\" data-reactid=\"68\">Technology could make this process easier and faster. Manual contact tracing (by disease detectives) may not be good enough to slow transmission, but instantaneous tracing (notifying exposed people the minute someone is diagnosed) could be, as used in South Korea and Singapore. Apps are being built to help with contact tracing, and proximity tracking could allow people to self-isolate if they get a notification that they have been near someone who is now confirmed to be infected. While apps in Asia have led to the disclosure of personal info, in the West, a system that uses Bluetooth signaling to record proximity could be less intrusive. In the U.S., many projects have been announced, like Covid Watch, CoEpi, and NextTrace, and the ability to piece all of their data together could become an issue unless we rally around one provider. Apple&nbsp;(<a href=\"https://finance.yahoo.com/quote/AAPL\" class=\"mdc-link mds-link\">AAPL</a>)&nbsp;and Google&nbsp;(<a href=\"https://finance.yahoo.com/quote/GOOG\" class=\"mdc-link mds-link\">GOOG</a>)&nbsp;announced that they are working together to facilitate contact tracing using Bluetooth functionality. To satisfy privacy concerns, rather than using GPS, their platform will focus on codes created when users are within proximity for a certain amount of time; if one is infected, the voluntary app (to be designed by healthcare agencies) could automatically warn close contacts that they may have been exposed. While they are first planning to unify their wireless protocols to allow others to build apps across platforms, we expect their own app could be more reliable than third-party apps. With any app, the idea is to limit the number of people who need to be tested in order to maintain containment of the virus. However, epidemiologists estimate that we would need to see 60% uptake of these apps for them to be effective, and so far, uptake is less than 20% for TraceTogether in Singapore and 40% for Iceland\u2019s Rakning C-19.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Another issue is how Americans will react to technology like contact tracing apps. President Donald Trump may be able to sway Republicans to get on board with tracing despite privacy concerns, but preserving freedom is a critical issue. GPS data could work better than Bluetooth technology, for example, as it monitors location (people and surfaces can trigger infection) but is harder to anonymize and harder to use in use in multistory situations. GPS data is helping enforce quarantine of those infected in Taiwan, as well as location-tracking wristbands in Hong Kong and texting proof of being home in Singapore. However, opinions are mixed; a recent survey by a University of Pennsylvania political scientist saw 70% of Republicans and 46% of Democrats strongly opposing the use of cellphones to enforce quarantines, but more than half of Americans back anonymized government smartphone tracking, according to a recent Harris poll.\" data-reactid=\"69\">Another issue is how Americans will react to technology like contact tracing apps. President Donald Trump may be able to sway Republicans to get on board with tracing despite privacy concerns, but preserving freedom is a critical issue. GPS data could work better than Bluetooth technology, for example, as it monitors location (people and surfaces can trigger infection) but is harder to anonymize and harder to use in use in multistory situations. GPS data is helping enforce quarantine of those infected in Taiwan, as well as location-tracking wristbands in Hong Kong and texting proof of being home in Singapore. However, opinions are mixed; a recent survey by a University of Pennsylvania political scientist saw 70% of Republicans and 46% of Democrats strongly opposing the use of cellphones to enforce quarantines, but more than half of Americans back anonymized government smartphone tracking, according to a recent Harris poll.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Even in countries that have successfully used technology for contact tracing, concerns remain. South Korea passed amendments to its Contagious Disease Control and Prevention Act following its 2015 MERS outbreak to allow override of previous privacy laws during a serious infectious disease outbreak, which allowed disclosure of a wide range of personal information to the country\u2019s federal, state, and local governments, including credit card transactions, location, transit history, and medical records. However, criticism of the level of data released to the public could lead to refinement of this strategy in the future, as significant amounts of this data were also released publicly, when aggregated data could have been enough.\" data-reactid=\"70\">Even in countries that have successfully used technology for contact tracing, concerns remain. South Korea passed amendments to its Contagious Disease Control and Prevention Act following its 2015 MERS outbreak to allow override of previous privacy laws during a serious infectious disease outbreak, which allowed disclosure of a wide range of personal information to the country\u2019s federal, state, and local governments, including credit card transactions, location, transit history, and medical records. However, criticism of the level of data released to the public could lead to refinement of this strategy in the future, as significant amounts of this data were also released publicly, when aggregated data could have been enough.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Progress With Treatments&lt;/strong&gt;&lt;br&gt;Former FDA commissioner Scott Gottlieb sees a treatment as our best hope for returning to normal this year. We now have two regimens with emergency use authorizations, although safety issues with chloroquine (and recent studies casting more doubt on potential efficacy) put the focus squarely on Gilead\u2019s&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/GILD&quot; class=&quot;mdc-link mds-link&quot;&gt;GILD&lt;/a&gt;)&amp;nbsp;remdesivir.\" data-reactid=\"71\"><strong>Progress With Treatments</strong><br>Former FDA commissioner Scott Gottlieb sees a treatment as our best hope for returning to normal this year. We now have two regimens with emergency use authorizations, although safety issues with chloroquine (and recent studies casting more doubt on potential efficacy) put the focus squarely on Gilead\u2019s&nbsp;(<a href=\"https://finance.yahoo.com/quote/GILD\" class=\"mdc-link mds-link\">GILD</a>)&nbsp;remdesivir.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Following strong data released April 29, Gilead received FDA emergency use authorization on May 1. While not at the same threshold as FDA approval, this allows Gilead (with the direction of state governments) to begin distributing remdesivir to severely ill patients at select hospitals in the U.S. Gilead already has 1.5 million doses of remdesivir, enough to treat roughly 300,000 patients, assuming they receive the shorter, five-day dosing regimen that proved similar to the 10-day regimen in the Simple study. Using this dose, Gilead should have enough for 1 million patients by October and 2 million patients by the end of 2020. Gilead has also announced that it plans to license remdesivir to other firms capable of manufacturing it in Europe, Asia, and the developing world through at least 2022.\" data-reactid=\"72\">Following strong data released April 29, Gilead received FDA emergency use authorization on May 1. While not at the same threshold as FDA approval, this allows Gilead (with the direction of state governments) to begin distributing remdesivir to severely ill patients at select hospitals in the U.S. Gilead already has 1.5 million doses of remdesivir, enough to treat roughly 300,000 patients, assuming they receive the shorter, five-day dosing regimen that proved similar to the 10-day regimen in the Simple study. Using this dose, Gilead should have enough for 1 million patients by October and 2 million patients by the end of 2020. Gilead has also announced that it plans to license remdesivir to other firms capable of manufacturing it in Europe, Asia, and the developing world through at least 2022.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"We now assume that remdesivir can generate $2 billion in sales in 2021, but sales this year will be significantly lower (due to donations and limited supply), and we only model sales extending to 2023 (as we assume progress with a coronavirus vaccine will make stockpiling and demand less common). Our model assumes a price tag of $500 per treatment, a middle ground between the $5 per five-day course expected to help Gilead recoup manufacturing costs and the $4,500 price ceiling estimated by the Institute for Clinical and Economic Review, using a $50,000 per quality-adjusted life year threshold. We believe this will be more than enough to recoup the $1 billion in remdesivir-related development and manufacturing costs Gilead expects to incur in 2020, but not enough to significantly swing Gilead\u2019s valuation.\" data-reactid=\"73\">We now assume that remdesivir can generate $2 billion in sales in 2021, but sales this year will be significantly lower (due to donations and limited supply), and we only model sales extending to 2023 (as we assume progress with a coronavirus vaccine will make stockpiling and demand less common). Our model assumes a price tag of $500 per treatment, a middle ground between the $5 per five-day course expected to help Gilead recoup manufacturing costs and the $4,500 price ceiling estimated by the Institute for Clinical and Economic Review, using a $50,000 per quality-adjusted life year threshold. We believe this will be more than enough to recoup the $1 billion in remdesivir-related development and manufacturing costs Gilead expects to incur in 2020, but not enough to significantly swing Gilead\u2019s valuation.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Remdesivir\u2019s efficacy so far is impressive and looks likely to reduce mortality rates from COVID-19 (although mortality data so far isn\u2019t statistically significant, it shows a trend to a benefit). However, these improvements fall short of what we see as necessary for&amp;nbsp;&lt;a href=&quot;https://www.morningstar.com/articles/976107/coronavirus-update-long-term-economic-impact-forecast-to-be-less-than-2008-recession&quot; class=&quot;mdc-link mds-link&quot; rel=&quot;nofollow noopener&quot; target=&quot;_blank&quot;&gt;our former base-case scenario&lt;/a&gt;, which assumed that efficacy would be strong enough to allow wider relaxing of lockdown measures on its own.\" data-reactid=\"74\">Remdesivir\u2019s efficacy so far is impressive and looks likely to reduce mortality rates from COVID-19 (although mortality data so far isn\u2019t statistically significant, it shows a trend to a benefit). However, these improvements fall short of what we see as necessary for&nbsp;<a href=\"https://www.morningstar.com/articles/976107/coronavirus-update-long-term-economic-impact-forecast-to-be-less-than-2008-recession\" class=\"mdc-link mds-link\" rel=\"nofollow noopener\" target=\"_blank\">our former base-case scenario</a>, which assumed that efficacy would be strong enough to allow wider relaxing of lockdown measures on its own.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Several other drug candidates are also moving through testing. Among anti-inflammatories, we expect IL-6 antibodies like Roche\u2019s Actemra and Regeneron&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/REGN&quot; class=&quot;mdc-link mds-link&quot;&gt;REGN&lt;/a&gt;)/Sanofi\u2019s&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/SNY&quot; class=&quot;mdc-link mds-link&quot;&gt;SNY&lt;/a&gt;)&amp;nbsp;Kevzara could find a niche among the most severely ill patients by this summer, although initial data from Kevzara was disappointing (development is now focused on critically ill patients). Data could start to read out on JAK inhibitors like Incyte&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/INCY&quot; class=&quot;mdc-link mds-link&quot;&gt;INCY&lt;/a&gt;)/Novartis\u2019&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/NVS&quot; class=&quot;mdc-link mds-link&quot;&gt;NVS&lt;/a&gt;)&amp;nbsp;Jakafi and Incyte/Lilly\u2019s&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/LLY&quot; class=&quot;mdc-link mds-link&quot;&gt;LLY&lt;/a&gt;)&amp;nbsp;Olumiant this summer, as well, although we have limited view on their potential efficacy. Targeted antibodies, led by Regeneron\u2019s antibody cocktail, are among the most likely to succeed but are behind this schedule, and we don\u2019t expect them to be available until late this year for high-risk populations. While convalescent serum and hyperimmune globulins from plasma firms could also be quite effective, scale is severely constrained; according to Adaptive Biotechnologies&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/ADPT&quot; class=&quot;mdc-link mds-link&quot;&gt;ADPT&lt;/a&gt;), convalescent antibodies can treat only one or two patients for every donation from a recovered patient, and quality can vary.\" data-reactid=\"75\">Several other drug candidates are also moving through testing. Among anti-inflammatories, we expect IL-6 antibodies like Roche\u2019s Actemra and Regeneron&nbsp;(<a href=\"https://finance.yahoo.com/quote/REGN\" class=\"mdc-link mds-link\">REGN</a>)/Sanofi\u2019s&nbsp;(<a href=\"https://finance.yahoo.com/quote/SNY\" class=\"mdc-link mds-link\">SNY</a>)&nbsp;Kevzara could find a niche among the most severely ill patients by this summer, although initial data from Kevzara was disappointing (development is now focused on critically ill patients). Data could start to read out on JAK inhibitors like Incyte&nbsp;(<a href=\"https://finance.yahoo.com/quote/INCY\" class=\"mdc-link mds-link\">INCY</a>)/Novartis\u2019&nbsp;(<a href=\"https://finance.yahoo.com/quote/NVS\" class=\"mdc-link mds-link\">NVS</a>)&nbsp;Jakafi and Incyte/Lilly\u2019s&nbsp;(<a href=\"https://finance.yahoo.com/quote/LLY\" class=\"mdc-link mds-link\">LLY</a>)&nbsp;Olumiant this summer, as well, although we have limited view on their potential efficacy. Targeted antibodies, led by Regeneron\u2019s antibody cocktail, are among the most likely to succeed but are behind this schedule, and we don\u2019t expect them to be available until late this year for high-risk populations. While convalescent serum and hyperimmune globulins from plasma firms could also be quite effective, scale is severely constrained; according to Adaptive Biotechnologies&nbsp;(<a href=\"https://finance.yahoo.com/quote/ADPT\" class=\"mdc-link mds-link\">ADPT</a>), convalescent antibodies can treat only one or two patients for every donation from a recovered patient, and quality can vary.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Future trials will be more likely to focus on combinations with remdesivir, and a trial adding Olumiant to remdesivir (to enroll 1,000 patients) began May 8. Pfizer\u2019s&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/PFE&quot; class=&quot;mdc-link mds-link&quot;&gt;PFE&lt;/a&gt;)&amp;nbsp;protease inhibitor is also entering studies this summer and could be a good candidate for combination therapy with remdesivir.\" data-reactid=\"76\">Future trials will be more likely to focus on combinations with remdesivir, and a trial adding Olumiant to remdesivir (to enroll 1,000 patients) began May 8. Pfizer\u2019s&nbsp;(<a href=\"https://finance.yahoo.com/quote/PFE\" class=\"mdc-link mds-link\">PFE</a>)&nbsp;protease inhibitor is also entering studies this summer and could be a good candidate for combination therapy with remdesivir.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Coronavirus Vaccine Advancement Even Faster Than Accelerated Timelines&lt;/strong&gt;&lt;br&gt;Vaccine development typically takes years--28 years for varicella and FluMist, and 15 years for HPV and rotavirus. We\u2019ve been waiting decades for an effective HIV vaccine, without success. Preparing manufacturing plants to make a new vaccine can cost anywhere from $50 million to $700 million, according to a 2017 paper in the medical journal Vaccine, and the investments are typically made in a stepwise fashion at different scales, based on the available data and probability of eventual approval. However, if a firm is willing to take financial risks, the process can be accelerated.\" data-reactid=\"77\"><strong>Coronavirus Vaccine Advancement Even Faster Than Accelerated Timelines</strong><br>Vaccine development typically takes years--28 years for varicella and FluMist, and 15 years for HPV and rotavirus. We\u2019ve been waiting decades for an effective HIV vaccine, without success. Preparing manufacturing plants to make a new vaccine can cost anywhere from $50 million to $700 million, according to a 2017 paper in the medical journal Vaccine, and the investments are typically made in a stepwise fashion at different scales, based on the available data and probability of eventual approval. However, if a firm is willing to take financial risks, the process can be accelerated.</p><figure class=\"canvas-image Mx(a) canvas-atom My(24px) My(20px)--sm\" style=\"max-width:100%;\" data-type=\"image\" data-reactid=\"78\"><meta itemprop=\"height\" content=\"431\" data-reactid=\"79\"/><meta itemprop=\"width\" content=\"800\" data-reactid=\"80\"/><div style=\"padding-bottom:53.9%;\" class=\"Maw(100%) Pos(r) H(0)\" data-reactid=\"81\"><img alt=\"The Standard Paradigm for Vaccine Development is Lengthy...\" class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox W(100%) H(100%) ie-7_H(a)\" itemprop=\"url\" style=\"background-image:url(https://s.yimg.com/ny/api/res/1.2/jeeRzgX_TiFWzuxXoCMBng--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/4415e670-95fa-11ea-bdf9-f2bd25ff3f99);\" src=\"https://s.yimg.com/g/images/spaceball.gif\" data-reactid=\"82\"/><noscript data-reactid=\"83\"><img alt=\"The Standard Paradigm for Vaccine Development is Lengthy...\" class=\"StretchedBox W(100%) H(100%) ie-7_H(a)\" src=\"https://s.yimg.com/ny/api/res/1.2/jeeRzgX_TiFWzuxXoCMBng--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/4415e670-95fa-11ea-bdf9-f2bd25ff3f99\" itemprop=\"url\"/></noscript></div><div itemprop=\"caption description\" class=\"Ov(h) Pos(r) Ff(ss) Mah(80px)\" data-reactid=\"84\"><figcaption class=\"C($c-fuji-grey-h) Fz(13px) Py(5px) Lh(1.5)\" title=\"The Standard Paradigm for Vaccine Development is Lengthy...\" data-reactid=\"85\"><div class=\"figure-caption\" data-reactid=\"86\">The Standard Paradigm for Vaccine Development is Lengthy...</div></figcaption><button class=\"C($c-fuji-blue-1-b) Cur(p) W(100%) T(63px) Bgc(#fff) Ta(start) Fz(13px) P(0) Bd(0) O(0) Lh(1.5) Pos(a)\" data-reactid=\"87\"><span data-reactid=\"88\">More</span></button></div></figure><figure class=\"canvas-image Mx(a) canvas-atom My(24px) My(20px)--sm\" style=\"max-width:100%;\" data-type=\"image\" data-reactid=\"89\"><meta itemprop=\"height\" content=\"431\" data-reactid=\"90\"/><meta itemprop=\"width\" content=\"800\" data-reactid=\"91\"/><div style=\"padding-bottom:53.9%;\" class=\"Maw(100%) Pos(r) H(0)\" data-reactid=\"92\"><img alt=\"...But It Can Be Accelerated in a Pandemic\" class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox W(100%) H(100%) ie-7_H(a)\" itemprop=\"url\" style=\"background-image:url(https://s.yimg.com/ny/api/res/1.2/Wm2eWaxHqJy39umPmcY8RQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/5dff3370-95fa-11ea-bebf-39dd74820101);\" src=\"https://s.yimg.com/g/images/spaceball.gif\" data-reactid=\"93\"/><noscript data-reactid=\"94\"><img alt=\"...But It Can Be Accelerated in a Pandemic\" class=\"StretchedBox W(100%) H(100%) ie-7_H(a)\" src=\"https://s.yimg.com/ny/api/res/1.2/Wm2eWaxHqJy39umPmcY8RQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-05/5dff3370-95fa-11ea-bebf-39dd74820101\" itemprop=\"url\"/></noscript></div><div itemprop=\"caption description\" class=\"Ov(h) Pos(r) Ff(ss) Mah(80px)\" data-reactid=\"95\"><figcaption class=\"C($c-fuji-grey-h) Fz(13px) Py(5px) Lh(1.5)\" title=\"...But It Can Be Accelerated in a Pandemic\" data-reactid=\"96\"><div class=\"figure-caption\" data-reactid=\"97\">...But It Can Be Accelerated in a Pandemic</div></figcaption><button class=\"C($c-fuji-blue-1-b) Cur(p) W(100%) T(63px) Bgc(#fff) Ta(start) Fz(13px) P(0) Bd(0) O(0) Lh(1.5) Pos(a)\" data-reactid=\"98\"><span data-reactid=\"99\">More</span></button></div></figure><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"For example, rather than waiting for confirmation of efficacy, a firm can move to large-scale production while efficacy is being tested. Groups like the Bill &amp;amp; Melinda Gates Foundation are taking on some of this risk by offering to pay for manufacturing capacity for a handful of promising vaccines. Government entities (the U.S. Biomedical Advanced Research Development Authority) and public-private alliances (Coalition for Epidemic Preparedness Innovations) are also rapidly offering funding.\" data-reactid=\"100\">For example, rather than waiting for confirmation of efficacy, a firm can move to large-scale production while efficacy is being tested. Groups like the Bill &amp; Melinda Gates Foundation are taking on some of this risk by offering to pay for manufacturing capacity for a handful of promising vaccines. Government entities (the U.S. Biomedical Advanced Research Development Authority) and public-private alliances (Coalition for Epidemic Preparedness Innovations) are also rapidly offering funding.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Also, rather than building manufacturing capacity, the accelerated process requires partnering with contract manufacturers or large pharma firms to buy extra capacity. This still requires tech transfer for the partner to be able to manufacture the new coronavirus vaccine, but if done early enough, it allows large-scale production to ramp during the second phase of trials. In addition, capital expense is significantly lower for cell-free manufacturing (less than $200 million for nucleic acid vaccines like Moderna\u2019s&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/MRNA&quot; class=&quot;mdc-link mds-link&quot;&gt;MRNA&lt;/a&gt;)&amp;nbsp;versus up to $1 billion for more traditional vaccines), which requires smaller reactors and purification tools than recombinant protein vaccines and can be more flexible in switching from one vaccine to another, lowering the risk from investing in manufacturing of any one vaccine in its portfolio. Several of the most advanced programs are nucleic acid (RNA or DNA) vaccines.\" data-reactid=\"101\">Also, rather than building manufacturing capacity, the accelerated process requires partnering with contract manufacturers or large pharma firms to buy extra capacity. This still requires tech transfer for the partner to be able to manufacture the new coronavirus vaccine, but if done early enough, it allows large-scale production to ramp during the second phase of trials. In addition, capital expense is significantly lower for cell-free manufacturing (less than $200 million for nucleic acid vaccines like Moderna\u2019s&nbsp;(<a href=\"https://finance.yahoo.com/quote/MRNA\" class=\"mdc-link mds-link\">MRNA</a>)&nbsp;versus up to $1 billion for more traditional vaccines), which requires smaller reactors and purification tools than recombinant protein vaccines and can be more flexible in switching from one vaccine to another, lowering the risk from investing in manufacturing of any one vaccine in its portfolio. Several of the most advanced programs are nucleic acid (RNA or DNA) vaccines.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Finally, the approval would come in two stages. Broad approval would still be reserved for when a larger phase 3 trial is completed, but the FDA could grant an early, accelerated approval (or emergency use authorization) based on phase 1 and phase 2 safety and efficacy data.\" data-reactid=\"102\">Finally, the approval would come in two stages. Broad approval would still be reserved for when a larger phase 3 trial is completed, but the FDA could grant an early, accelerated approval (or emergency use authorization) based on phase 1 and phase 2 safety and efficacy data.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;FDA Likely to Accelerate Coronavirus Vaccine Approval if Pandemic Continues This Fall&lt;/strong&gt;&lt;br&gt;The FDA\u2019s perspective on approval of a coronavirus vaccine will probably vary depending on how extensively the pandemic is still spreading in the U.S. by the time we have phase 2 data, which will likely be late this summer. With some circulating virus, firms should be able to conduct larger, controlled phase 2/phase 3 studies that can confirm whether antibodies generated in response to a vaccine actually protect individuals from infection. The FDA can also look at antibody levels generated by the vaccine and try to determine whether this could be a biomarker for protection. The second is what Moderna has referred to as looking at \u201cserological correlates\u201d of protection. This can be done by comparing to preclinical models of the vaccine offering protection, or to antibody levels in convalescent serum (from patients who have recovered from infection). If the virus is widespread--and need for the vaccine is most urgent--then Fauci and FDA officials have noted that an emergency use authorization could be made based on phase 1 and animal model safety data as well as efficacy data from phase 2. Such a decision would need to weigh the safety risks; while data through phase 2 should clarify such risks as viral enhancement, it will not be able to isolate any ultrarare risks, which can only be found by testing several thousand volunteers.\" data-reactid=\"103\"><strong>FDA Likely to Accelerate Coronavirus Vaccine Approval if Pandemic Continues This Fall</strong><br>The FDA\u2019s perspective on approval of a coronavirus vaccine will probably vary depending on how extensively the pandemic is still spreading in the U.S. by the time we have phase 2 data, which will likely be late this summer. With some circulating virus, firms should be able to conduct larger, controlled phase 2/phase 3 studies that can confirm whether antibodies generated in response to a vaccine actually protect individuals from infection. The FDA can also look at antibody levels generated by the vaccine and try to determine whether this could be a biomarker for protection. The second is what Moderna has referred to as looking at \u201cserological correlates\u201d of protection. This can be done by comparing to preclinical models of the vaccine offering protection, or to antibody levels in convalescent serum (from patients who have recovered from infection). If the virus is widespread--and need for the vaccine is most urgent--then Fauci and FDA officials have noted that an emergency use authorization could be made based on phase 1 and animal model safety data as well as efficacy data from phase 2. Such a decision would need to weigh the safety risks; while data through phase 2 should clarify such risks as viral enhancement, it will not be able to isolate any ultrarare risks, which can only be found by testing several thousand volunteers.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"If there are a limited number of outbreaks by late this summer, when larger phase 3 studies might be starting (a good problem to have), there are also creative ways of potentially accelerating development to stay ahead of a second wave. The most ethically controversial is challenge studies, which offer a faster option than traditional phase 3 studies by deliberately exposing volunteers to the virus to test a vaccine\u2019s efficacy. For example, 1 Day Sooner is working to qualify healthy, low-risk volunteers for a potential challenge study, with more than 14,000 volunteers listed on the website as of May 8. However, there are serious ethical questions about deliberately infecting patients in such studies, even with their permission. Another way to accelerate development and reduce the number of placebo volunteers is to test multiple vaccines in one trial with one shared control arm; normally, drugmakers avoid this sort of trial, as it forces head-to-head comparisons, but this situation may be exceptional.\" data-reactid=\"104\">If there are a limited number of outbreaks by late this summer, when larger phase 3 studies might be starting (a good problem to have), there are also creative ways of potentially accelerating development to stay ahead of a second wave. The most ethically controversial is challenge studies, which offer a faster option than traditional phase 3 studies by deliberately exposing volunteers to the virus to test a vaccine\u2019s efficacy. For example, 1 Day Sooner is working to qualify healthy, low-risk volunteers for a potential challenge study, with more than 14,000 volunteers listed on the website as of May 8. However, there are serious ethical questions about deliberately infecting patients in such studies, even with their permission. Another way to accelerate development and reduce the number of placebo volunteers is to test multiple vaccines in one trial with one shared control arm; normally, drugmakers avoid this sort of trial, as it forces head-to-head comparisons, but this situation may be exceptional.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"We expect initial approval could be reserved for a high-risk population, including the elderly, those with pre-existing conditions, and essential workers (including healthcare workers). We expect that children--who rarely suffer serious consequences from infection and would have the most to lose from theoretical severe but very rare side effects of vaccination--would not be vaccinated until longer-term studies are completed. Vaccination could also be focused on areas with the largest outbreaks if supply is limited.\" data-reactid=\"105\">We expect initial approval could be reserved for a high-risk population, including the elderly, those with pre-existing conditions, and essential workers (including healthcare workers). We expect that children--who rarely suffer serious consequences from infection and would have the most to lose from theoretical severe but very rare side effects of vaccination--would not be vaccinated until longer-term studies are completed. Vaccination could also be focused on areas with the largest outbreaks if supply is limited.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Probability of Approval Looks Quite High, at Least for a Handful of Coronavirus Vaccines&lt;/strong&gt;&lt;br&gt;Recent analysis examining the probability of success of different types of therapeutics, using data from a variety of small- and large-cap drug firms from 2000 to 2015, indicated that vaccines have the highest overall probability of sales, 42% from phase 2 start to approval, and this now stands at 45.8%, using the traditional slow and steady development pathway. In addition, researchers are already familiar with coronaviruses, and particularly familiar with designing vaccines for other serious coronaviruses like SARS and MERS. Key parts of the virus are conserved in SARS-CoV-2 (overall, the viruses are 80% identical), so many vaccines target the spike protein or a portion of it. Researchers see this as unlikely to mutate rapidly, as well, as it is critical for viruses to be able to enter the cell. We think this increases the likelihood of approval. Also, given the sheer number of coronavirus vaccines and the diverse nature of their designs, we would expect some attrition, but some success. Bill Gates recently noted that of the 115 vaccine candidates in the pipeline, 8-10 look \u201cparticularly promising,\u201d noting that 60% efficacy would be able to produce herd immunity if we eventually vaccinate roughly 7 billion people, or most of the world\u2019s population. This estimate is likely based on SARS-CoV-2\u2019s reproduction number of 2.5, which means that if 60% are immune and only 40% are vulnerable, the effective transmission rate would decline to 1, meaning flat levels of transmission.\" data-reactid=\"106\"><strong>Probability of Approval Looks Quite High, at Least for a Handful of Coronavirus Vaccines</strong><br>Recent analysis examining the probability of success of different types of therapeutics, using data from a variety of small- and large-cap drug firms from 2000 to 2015, indicated that vaccines have the highest overall probability of sales, 42% from phase 2 start to approval, and this now stands at 45.8%, using the traditional slow and steady development pathway. In addition, researchers are already familiar with coronaviruses, and particularly familiar with designing vaccines for other serious coronaviruses like SARS and MERS. Key parts of the virus are conserved in SARS-CoV-2 (overall, the viruses are 80% identical), so many vaccines target the spike protein or a portion of it. Researchers see this as unlikely to mutate rapidly, as well, as it is critical for viruses to be able to enter the cell. We think this increases the likelihood of approval. Also, given the sheer number of coronavirus vaccines and the diverse nature of their designs, we would expect some attrition, but some success. Bill Gates recently noted that of the 115 vaccine candidates in the pipeline, 8-10 look \u201cparticularly promising,\u201d noting that 60% efficacy would be able to produce herd immunity if we eventually vaccinate roughly 7 billion people, or most of the world\u2019s population. This estimate is likely based on SARS-CoV-2\u2019s reproduction number of 2.5, which means that if 60% are immune and only 40% are vulnerable, the effective transmission rate would decline to 1, meaning flat levels of transmission.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Even if trials complete, plenty of skeptics point to the fact that manufacturing validation typically takes several months, not to mention the manufacturing ramp. However, we think there have been enough partnerships announced to expand manufacturing capacity, as well as parallel programs at several firms, that the capacity should be there if the vaccines are safe and effective, and we assume the FDA would approve the manufacturing facilities at a breakthrough pace. As long as more than one coronavirus vaccine makes it to emergency authorization, that would also relieve some of the pressure on manufacturing to surpass the 1 billion mark. Newer technologies mean much easier scale-up--mRNA vaccines are easier to produce than antigen-based vaccines and require very small doses. DNA and RNA platforms have the most potential for rapid development, followed by recombinant-subunit vaccines.\" data-reactid=\"107\">Even if trials complete, plenty of skeptics point to the fact that manufacturing validation typically takes several months, not to mention the manufacturing ramp. However, we think there have been enough partnerships announced to expand manufacturing capacity, as well as parallel programs at several firms, that the capacity should be there if the vaccines are safe and effective, and we assume the FDA would approve the manufacturing facilities at a breakthrough pace. As long as more than one coronavirus vaccine makes it to emergency authorization, that would also relieve some of the pressure on manufacturing to surpass the 1 billion mark. Newer technologies mean much easier scale-up--mRNA vaccines are easier to produce than antigen-based vaccines and require very small doses. DNA and RNA platforms have the most potential for rapid development, followed by recombinant-subunit vaccines.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Virus Enhancement a Key Safety Risk&lt;/strong&gt;&lt;br&gt;Until we see evidence that vaccinated patients have been challenged with the virus, we won\u2019t know whether the antibodies created in response to the vaccine paradoxically reduce a patient\u2019s ability to fight a virus. Immune enhancement can be due to antibody-dependent enhancement (antibodies help infection spread) or cell-based enhancement (allergic, type 2 helper T-cell-based inflammation). Allergic inflammation was an issue for at least one SARS vaccine in older mice when they were challenged with the virus. With Sanofi\u2019s Dengvaxia, a vaccine against one of dengue fever\u2019s four serotypes, later infection with a different serotype led to much more severe illness than in those who had not received the vaccine. An RSV vaccine tested in the 1960s caused infections to become much more lethal due to allergic inflammation. Fauci has noted that the key concern in phase 1 is enhancement of the virus, and studies are now in progress for several vaccines.\" data-reactid=\"108\"><strong>Virus Enhancement a Key Safety Risk</strong><br>Until we see evidence that vaccinated patients have been challenged with the virus, we won\u2019t know whether the antibodies created in response to the vaccine paradoxically reduce a patient\u2019s ability to fight a virus. Immune enhancement can be due to antibody-dependent enhancement (antibodies help infection spread) or cell-based enhancement (allergic, type 2 helper T-cell-based inflammation). Allergic inflammation was an issue for at least one SARS vaccine in older mice when they were challenged with the virus. With Sanofi\u2019s Dengvaxia, a vaccine against one of dengue fever\u2019s four serotypes, later infection with a different serotype led to much more severe illness than in those who had not received the vaccine. An RSV vaccine tested in the 1960s caused infections to become much more lethal due to allergic inflammation. Fauci has noted that the key concern in phase 1 is enhancement of the virus, and studies are now in progress for several vaccines.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Leading Coronavirus Vaccine Programs Could Offer Significant Capacity by Year-End&lt;/strong&gt;&lt;br&gt;While vaccines have yet to produce clinical data, encouraging preclinical data, strong partnerships and funding, and rapid progress into large phase 1/phase 2 studies all seem to indicate that use in high-risk populations could be possible by the end of the year, with tens or even hundreds of millions of doses available. While we doubt that all vaccines will see strong enough safety and efficacy to reach approval from the FDA, several stand out with a head start and aggressive plans for supplying the market. If just two or three of these vaccines succeed, we could have enough supply to protect high-risk populations in late 2020 (allowing further relaxing of distancing measures) and for broader vaccination as we enter 2021.\" data-reactid=\"109\"><strong>Leading Coronavirus Vaccine Programs Could Offer Significant Capacity by Year-End</strong><br>While vaccines have yet to produce clinical data, encouraging preclinical data, strong partnerships and funding, and rapid progress into large phase 1/phase 2 studies all seem to indicate that use in high-risk populations could be possible by the end of the year, with tens or even hundreds of millions of doses available. While we doubt that all vaccines will see strong enough safety and efficacy to reach approval from the FDA, several stand out with a head start and aggressive plans for supplying the market. If just two or three of these vaccines succeed, we could have enough supply to protect high-risk populations in late 2020 (allowing further relaxing of distancing measures) and for broader vaccination as we enter 2021.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Moderna\u2019s mRNA-1273&lt;/em&gt;&lt;br&gt;Moderna\u2019s mRNA-based vaccine is a single antigen vaccine targeting the full-length spike protein. Although the firm has no approved therapies, it has data from more than 1,500 patients studied in various vaccine clinical trials attesting to its safety, and patients have developed neutralizing antibodies to virus antigens for all eight of the viruses that Moderna has vaccinated against in trials. We expect rapid acceleration of manufacturing and development timelines (enabled by at-risk manufacturing expansion, government funding, partnerships, and parallel clinical trials) to allow emergency use by late 2020 and approval for wider distribution in 2021.\" data-reactid=\"110\"><em>Moderna\u2019s mRNA-1273</em><br>Moderna\u2019s mRNA-based vaccine is a single antigen vaccine targeting the full-length spike protein. Although the firm has no approved therapies, it has data from more than 1,500 patients studied in various vaccine clinical trials attesting to its safety, and patients have developed neutralizing antibodies to virus antigens for all eight of the viruses that Moderna has vaccinated against in trials. We expect rapid acceleration of manufacturing and development timelines (enabled by at-risk manufacturing expansion, government funding, partnerships, and parallel clinical trials) to allow emergency use by late 2020 and approval for wider distribution in 2021.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Moderna shipped the first vaccine to the National Institute of Allergy and Infectious Diseases 42 days after sequence selection, a record for vaccines, with the first patient dosed as of March 16. This phase 1 trial involves a two-shot series in healthy volunteers, first in 45 adults age 18-55 at three different doses (now fully enrolled), and then at these three doses for 30 older adults (56-70) and 30 elderly adults (71 and older). Phase 1 data is still expected in the second quarter. Moderna received FDA clearance on May 6 to begin a phase 2 immunogenicity study in 600 patients, with 300 adults age 18-55 and 300 age 55 and up receiving two doses of either placebo, 50 ug, or 250 ug doses, so this study will run in parallel with phase 1. Phase 3 timelines have moved up aggressively, and the first phase 3 trial is now expected to begin in early summer, with design still being finalized (although this NIH-partnered study will likely be conducted in the U.S. and will compare natural infection rates and symptoms with patients who have been vaccinated with mRNA-1273 or placebo). We think this coronavirus vaccine could be available for emergency use (healthcare workers) in fall 2020 based on phase 1 and phase 2 data (comparing immunogenicity to what is seen in the plasma of recovered patients), and for broader commercial use in 2021 (based on a potential interim look at phase 3 data in late 2020 and full data in 2021). The Biomedical Advanced Research and Development Authority has agreed to commit up to $483 million to push the vaccine forward to approval, through development and manufacturing support (moving to 24/7 manufacturing).\" data-reactid=\"111\">Moderna shipped the first vaccine to the National Institute of Allergy and Infectious Diseases 42 days after sequence selection, a record for vaccines, with the first patient dosed as of March 16. This phase 1 trial involves a two-shot series in healthy volunteers, first in 45 adults age 18-55 at three different doses (now fully enrolled), and then at these three doses for 30 older adults (56-70) and 30 elderly adults (71 and older). Phase 1 data is still expected in the second quarter. Moderna received FDA clearance on May 6 to begin a phase 2 immunogenicity study in 600 patients, with 300 adults age 18-55 and 300 age 55 and up receiving two doses of either placebo, 50 ug, or 250 ug doses, so this study will run in parallel with phase 1. Phase 3 timelines have moved up aggressively, and the first phase 3 trial is now expected to begin in early summer, with design still being finalized (although this NIH-partnered study will likely be conducted in the U.S. and will compare natural infection rates and symptoms with patients who have been vaccinated with mRNA-1273 or placebo). We think this coronavirus vaccine could be available for emergency use (healthcare workers) in fall 2020 based on phase 1 and phase 2 data (comparing immunogenicity to what is seen in the plasma of recovered patients), and for broader commercial use in 2021 (based on a potential interim look at phase 3 data in late 2020 and full data in 2021). The Biomedical Advanced Research and Development Authority has agreed to commit up to $483 million to push the vaccine forward to approval, through development and manufacturing support (moving to 24/7 manufacturing).</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Moderna is ramping up internal manufacturing to allow millions of doses per month in 2020 and tens of millions per month in 2021, and management\u2019s belief that the 50 ug dose could be selected would help expand the reach of Moderna\u2019s vaccine to more patients (the firm\u2019s Norwood, Massachusetts, facility could supply up to 100 million doses a year at this dosage). An April 30 partnership with Lonza boosts capacity by 10 times, with the goal of producing 1 billion doses a year at the 50 ug expected dose (manufacturing at Lonza suites in the U.S. and Switzerland to begin in July).\" data-reactid=\"112\">Moderna is ramping up internal manufacturing to allow millions of doses per month in 2020 and tens of millions per month in 2021, and management\u2019s belief that the 50 ug dose could be selected would help expand the reach of Moderna\u2019s vaccine to more patients (the firm\u2019s Norwood, Massachusetts, facility could supply up to 100 million doses a year at this dosage). An April 30 partnership with Lonza boosts capacity by 10 times, with the goal of producing 1 billion doses a year at the 50 ug expected dose (manufacturing at Lonza suites in the U.S. and Switzerland to begin in July).</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Johnson &amp;amp; Johnson&lt;/em&gt;&lt;br&gt;Johnson &amp;amp; Johnson&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/JNJ&quot; class=&quot;mdc-link mds-link&quot;&gt;JNJ&lt;/a&gt;)&amp;nbsp;selected an Ad26 vector candidate expressing the SARS-CoV-2 spike protein as of March 30. The firm has steadily accelerated development plans, most recently moving up its estimated phase 1 start from early November to September at the latest, with data available December 2020 and potential launch in emergency use in the first quarter of 2021. J&amp;amp;J has also accelerated supply estimates, from an initial estimate of 300 million doses a year in 8-12 months and ready for emergency use by early 2021 to annual production of 600 million-900 million coronavirus vaccines likely by early 2021 and full supply of 1 billion doses by late 2021. Emergent BioSolutions&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/EBS&quot; class=&quot;mdc-link mds-link&quot;&gt;EBS&lt;/a&gt;)&amp;nbsp;will act as one contract development and manufacturing organization beginning in 2021. Catalent&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/CTLT&quot; class=&quot;mdc-link mds-link&quot;&gt;CTLT&lt;/a&gt;)&amp;nbsp;will supply large-scale manufacturing capacity as well, ready for 24/7 manufacturing by January 2021. J&amp;amp;J is aiming for a not-for-profit price around $10.\" data-reactid=\"113\"><em>Johnson &amp; Johnson</em><br>Johnson &amp; Johnson&nbsp;(<a href=\"https://finance.yahoo.com/quote/JNJ\" class=\"mdc-link mds-link\">JNJ</a>)&nbsp;selected an Ad26 vector candidate expressing the SARS-CoV-2 spike protein as of March 30. The firm has steadily accelerated development plans, most recently moving up its estimated phase 1 start from early November to September at the latest, with data available December 2020 and potential launch in emergency use in the first quarter of 2021. J&amp;J has also accelerated supply estimates, from an initial estimate of 300 million doses a year in 8-12 months and ready for emergency use by early 2021 to annual production of 600 million-900 million coronavirus vaccines likely by early 2021 and full supply of 1 billion doses by late 2021. Emergent BioSolutions&nbsp;(<a href=\"https://finance.yahoo.com/quote/EBS\" class=\"mdc-link mds-link\">EBS</a>)&nbsp;will act as one contract development and manufacturing organization beginning in 2021. Catalent&nbsp;(<a href=\"https://finance.yahoo.com/quote/CTLT\" class=\"mdc-link mds-link\">CTLT</a>)&nbsp;will supply large-scale manufacturing capacity as well, ready for 24/7 manufacturing by January 2021. J&amp;J is aiming for a not-for-profit price around $10.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;University of Oxford/Vaccitech/Merck KGaA/AstraZeneca\u2019s ChAdOx1 nCoV-19&lt;/em&gt;&lt;br&gt;This chimp AAV vaccine for the spike protein started a large (1,100 volunteers) phase 1 COV001 study in April 2020, with data expected in May for the first group of volunteers (age 18-55), followed by 55-70 and 70-plus cohorts. This is part of a partnership between Merck KGaA and the Jenner Institute (part of a joint venture with University of Oxford and Pirbright Institute). Oxford now has a 10-liter scale process for the adenovirus vector vaccine. They expect data by autumn 2020 from the phase 2/phase 3 portion of the study (5,000 volunteers expected to start enrolling in May), which could allow emergency approval in September, when the first few million doses could be available. Data from a rhesus macaque study was positive in April (six challenged monkeys stayed healthy). AstraZeneca&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/AZN&quot; class=&quot;mdc-link mds-link&quot;&gt;AZN&lt;/a&gt;)&amp;nbsp;joined as global development and manufacturing lead on April 30, with a cited goal of 100 million doses by the end of 2020. The collaboration is not-for-profit during the pandemic.\" data-reactid=\"114\"><em>University of Oxford/Vaccitech/Merck KGaA/AstraZeneca\u2019s ChAdOx1 nCoV-19</em><br>This chimp AAV vaccine for the spike protein started a large (1,100 volunteers) phase 1 COV001 study in April 2020, with data expected in May for the first group of volunteers (age 18-55), followed by 55-70 and 70-plus cohorts. This is part of a partnership between Merck KGaA and the Jenner Institute (part of a joint venture with University of Oxford and Pirbright Institute). Oxford now has a 10-liter scale process for the adenovirus vector vaccine. They expect data by autumn 2020 from the phase 2/phase 3 portion of the study (5,000 volunteers expected to start enrolling in May), which could allow emergency approval in September, when the first few million doses could be available. Data from a rhesus macaque study was positive in April (six challenged monkeys stayed healthy). AstraZeneca&nbsp;(<a href=\"https://finance.yahoo.com/quote/AZN\" class=\"mdc-link mds-link\">AZN</a>)&nbsp;joined as global development and manufacturing lead on April 30, with a cited goal of 100 million doses by the end of 2020. The collaboration is not-for-profit during the pandemic.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Sanofi/Glaxo&lt;/em&gt;&lt;br&gt;Sanofi is working with BARDA on a coronavirus vaccine, using proven influenza FluBlok technology (with Glaxo\u2019s adjuvant booster). Sanofi partnered this program with Glaxo&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/GSK&quot; class=&quot;mdc-link mds-link&quot;&gt;GSK&lt;/a&gt;)&amp;nbsp;on April 14 and plans to move a coronavirus vaccine to development in the fourth quarter of 2020, with earliest approval in the second half of 2021. They expect to be able to manufacture a billion doses by April 2021 by sharing their technology (Sanofi\u2019s S-protein antigen using recombinant DNA technology and Glaxo\u2019s adjuvant technology, which can lower the required dose). Sanofi also entered a collaboration with Translate Bio&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/TBIO&quot; class=&quot;mdc-link mds-link&quot;&gt;TBIO&lt;/a&gt;)&amp;nbsp;for its mRNA vaccine, which, like the more traditional Sanofi/Glaxo vaccine, could be in a clinical trial by the end of 2020 and be approved by the end of 2021. Translate\u2019s vaccine has been manufactured at a 100-gram scale, and CMO manufacturing of two 250-gram batches per month could add to supply; at Moderna\u2019s midlevel dose, this could vaccinate 3 million people per month initially, but hundreds of millions by the end of 2021 with Sanofi\u2019s help (at kilogram-size batches). Sanofi expects 90 million-360 million doses by the first quarter of 2021.\" data-reactid=\"115\"><em>Sanofi/Glaxo</em><br>Sanofi is working with BARDA on a coronavirus vaccine, using proven influenza FluBlok technology (with Glaxo\u2019s adjuvant booster). Sanofi partnered this program with Glaxo&nbsp;(<a href=\"https://finance.yahoo.com/quote/GSK\" class=\"mdc-link mds-link\">GSK</a>)&nbsp;on April 14 and plans to move a coronavirus vaccine to development in the fourth quarter of 2020, with earliest approval in the second half of 2021. They expect to be able to manufacture a billion doses by April 2021 by sharing their technology (Sanofi\u2019s S-protein antigen using recombinant DNA technology and Glaxo\u2019s adjuvant technology, which can lower the required dose). Sanofi also entered a collaboration with Translate Bio&nbsp;(<a href=\"https://finance.yahoo.com/quote/TBIO\" class=\"mdc-link mds-link\">TBIO</a>)&nbsp;for its mRNA vaccine, which, like the more traditional Sanofi/Glaxo vaccine, could be in a clinical trial by the end of 2020 and be approved by the end of 2021. Translate\u2019s vaccine has been manufactured at a 100-gram scale, and CMO manufacturing of two 250-gram batches per month could add to supply; at Moderna\u2019s midlevel dose, this could vaccinate 3 million people per month initially, but hundreds of millions by the end of 2021 with Sanofi\u2019s help (at kilogram-size batches). Sanofi expects 90 million-360 million doses by the first quarter of 2021.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;CureVac&lt;/em&gt;&lt;br&gt;Working with CEPI, CureVac has two mRNA candidates that do not target the spike protein poised to enter trials by summer. CureVac\u2019s mRNA is self-amplifying, which reduces the amount of vaccine needed for manufacturing. While the three approved manufacturing suites could make 10 million doses per campaign, a fourth suite would push this north of a billion per production run. CureVac received funding from the European Commission in March.\" data-reactid=\"116\"><em>CureVac</em><br>Working with CEPI, CureVac has two mRNA candidates that do not target the spike protein poised to enter trials by summer. CureVac\u2019s mRNA is self-amplifying, which reduces the amount of vaccine needed for manufacturing. While the three approved manufacturing suites could make 10 million doses per campaign, a fourth suite would push this north of a billion per production run. CureVac received funding from the European Commission in March.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;em&gt;Pfizer/BioNTech&lt;/em&gt;&lt;br&gt;BioNTech&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/BNTX&quot; class=&quot;mdc-link mds-link&quot;&gt;BNTX&lt;/a&gt;)&amp;nbsp;started a trial in Germany, with the first cohort of 12 volunteers in Germany dosed by April 29, and a U.S. trial (a phase 1/phase 2 trial to enroll 360 adults and elderly volunteers) kicked off on May 5. Fosun has China rights, and BioNTech signed a letter of intent March 17 with Pfizer elsewhere (expanding their flu vaccine partnership to coronavirus). As of early April, Pfizer said it could have tens of millions of doses by the end of 2020 and hundreds of millions in 2021. The first BNT162 study in Germany will test doses between 1ug and 100 ug in 200 volunteers (ages 18-55) for four vaccines (modified mRNA, uRNA, and self-amplifying RNA). SaRNA could have a big dosing advantage, potentially requiring just one dose (others could require prime and boost) and 60 times lower dose versus uRNA vaccine (and perhaps against Moderna\u2019s mRNA vaccine). Pfizer plans to choose the one or two most promising to move forward by June, with the help of data from primates and plasma of vaccinated humans due by late May/early June. Pfizer is aiming for an EUA or accelerated approval in October (with human study and surrogate endpoint), at the start of flu season and a time when the next wave could be building. Pfizer\u2019s Mikael Dolsten said on a call with Stat news that it could focus on the high-risk population, which could be 30%-40% of the broader population.\" data-reactid=\"117\"><em>Pfizer/BioNTech</em><br>BioNTech&nbsp;(<a href=\"https://finance.yahoo.com/quote/BNTX\" class=\"mdc-link mds-link\">BNTX</a>)&nbsp;started a trial in Germany, with the first cohort of 12 volunteers in Germany dosed by April 29, and a U.S. trial (a phase 1/phase 2 trial to enroll 360 adults and elderly volunteers) kicked off on May 5. Fosun has China rights, and BioNTech signed a letter of intent March 17 with Pfizer elsewhere (expanding their flu vaccine partnership to coronavirus). As of early April, Pfizer said it could have tens of millions of doses by the end of 2020 and hundreds of millions in 2021. The first BNT162 study in Germany will test doses between 1ug and 100 ug in 200 volunteers (ages 18-55) for four vaccines (modified mRNA, uRNA, and self-amplifying RNA). SaRNA could have a big dosing advantage, potentially requiring just one dose (others could require prime and boost) and 60 times lower dose versus uRNA vaccine (and perhaps against Moderna\u2019s mRNA vaccine). Pfizer plans to choose the one or two most promising to move forward by June, with the help of data from primates and plasma of vaccinated humans due by late May/early June. Pfizer is aiming for an EUA or accelerated approval in October (with human study and surrogate endpoint), at the start of flu season and a time when the next wave could be building. Pfizer\u2019s Mikael Dolsten said on a call with Stat news that it could focus on the high-risk population, which could be 30%-40% of the broader population.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Fading Antibody Levels and Mutation Rates Unlikely to Derail Near-Term Pipelines&lt;/strong&gt;&lt;br&gt;With a new virus, it\u2019s difficult to say how long immunity will last after infection or after treatment with targeted antibodies or a vaccine. We don\u2019t know what antibody level is sufficient to protect a patient, although research on convalescent serum (from recovered patients) is ongoing. For older coronaviruses that trigger common colds, reinfection can occur. However, even if protection is incomplete, experts say antibodies are likely to at least lead to milder infections, and recent research seems to indicate that almost all infected patients produce antibodies. We will very likely need to continue to make new versions of antibodies or vaccines if the virus recurs. However, we think it\u2019s very likely that coronavirus vaccines in development today, if effective in trials, will provide enough immunity to get us through the pandemic.\" data-reactid=\"118\"><strong>Fading Antibody Levels and Mutation Rates Unlikely to Derail Near-Term Pipelines</strong><br>With a new virus, it\u2019s difficult to say how long immunity will last after infection or after treatment with targeted antibodies or a vaccine. We don\u2019t know what antibody level is sufficient to protect a patient, although research on convalescent serum (from recovered patients) is ongoing. For older coronaviruses that trigger common colds, reinfection can occur. However, even if protection is incomplete, experts say antibodies are likely to at least lead to milder infections, and recent research seems to indicate that almost all infected patients produce antibodies. We will very likely need to continue to make new versions of antibodies or vaccines if the virus recurs. However, we think it\u2019s very likely that coronavirus vaccines in development today, if effective in trials, will provide enough immunity to get us through the pandemic.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"While SARS-CoV-2 could mutate to become resistant to vaccines currently in development (targeting the spike protein), we think the evidence so far indicates that this is unlikely. RNA viruses--which include viruses like HIV, influenza, and coronaviruses--generally have the highest mutation rates among microorganisms, creating concerns about how long a potential treatment or vaccine could be effective before SARS-CoV-2 is able to mutate around it. HIV vaccines have been in development for decades without positive results because HIV\u2019s surface molecules (envelope glycoproteins) mutate so rapidly, even within one patient, that they can learn to evade treatment and vaccines, and we now have multiple versions of the virus circulating in society. For influenza, we have vaccines, but these are only at best 60% effective in preventing the flu. This is because there are multiple strains of flu with different surface markers, or antigens, and with so many different strains circulating, it is difficult to predict which one will become most dangerous in a given season (and only so many can be selected for the vaccine). In addition, the flu can mutate, creating new versions that would require new vaccines. Flu vaccine effectiveness can be as low as 20%-30% if vaccine manufacturers do not select the viral strain that ends up being most common that season.\" data-reactid=\"119\">While SARS-CoV-2 could mutate to become resistant to vaccines currently in development (targeting the spike protein), we think the evidence so far indicates that this is unlikely. RNA viruses--which include viruses like HIV, influenza, and coronaviruses--generally have the highest mutation rates among microorganisms, creating concerns about how long a potential treatment or vaccine could be effective before SARS-CoV-2 is able to mutate around it. HIV vaccines have been in development for decades without positive results because HIV\u2019s surface molecules (envelope glycoproteins) mutate so rapidly, even within one patient, that they can learn to evade treatment and vaccines, and we now have multiple versions of the virus circulating in society. For influenza, we have vaccines, but these are only at best 60% effective in preventing the flu. This is because there are multiple strains of flu with different surface markers, or antigens, and with so many different strains circulating, it is difficult to predict which one will become most dangerous in a given season (and only so many can be selected for the vaccine). In addition, the flu can mutate, creating new versions that would require new vaccines. Flu vaccine effectiveness can be as low as 20%-30% if vaccine manufacturers do not select the viral strain that ends up being most common that season.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"While most RNA viruses have an RNA polymerase that operates without proofreading capabilities--meaning that the viral genetic material mutates rapidly--coronaviruses have such large genomes that they do have proofreading, so their mutation rate is significantly lower. In addition, typically, the most crucial parts of the virus--for example, the spike protein (which allows the virus to infect a cell and is the target of vaccines and antibodies), the polymerase (that copies coronavirus genes, targeted by Gilead\u2019s remdesivir), and the protease (that cut peptides to help form key viral enzymes, targeted by Pfizer\u2019s antiviral)--are not subject to as much variation because of their essential nature. While antivirals like remdesivir could pressure the virus and trigger mutations in the viral polymerase that allow higher mutation rates, changing a viruses\u2019 established mutation rate is more likely to destabilize it and weaken it. A recent hypothesis regarding SARS-CoV-2 mutations and increased transmissibility of a new mutant version (Spike D614G) has been released (a preprint article, not a peer-reviewed publication), but Moderna doesn\u2019t expect mutations seen so far to interfere with the efficacy of its vaccine. In addition, if Moderna validates its technology with an initial vaccine, time to availability would be quite short for a new vaccine, with manufacturing capacity already expanded and a much-abbreviated development timeline (like annual flu vaccine changes).\" data-reactid=\"120\">While most RNA viruses have an RNA polymerase that operates without proofreading capabilities--meaning that the viral genetic material mutates rapidly--coronaviruses have such large genomes that they do have proofreading, so their mutation rate is significantly lower. In addition, typically, the most crucial parts of the virus--for example, the spike protein (which allows the virus to infect a cell and is the target of vaccines and antibodies), the polymerase (that copies coronavirus genes, targeted by Gilead\u2019s remdesivir), and the protease (that cut peptides to help form key viral enzymes, targeted by Pfizer\u2019s antiviral)--are not subject to as much variation because of their essential nature. While antivirals like remdesivir could pressure the virus and trigger mutations in the viral polymerase that allow higher mutation rates, changing a viruses\u2019 established mutation rate is more likely to destabilize it and weaken it. A recent hypothesis regarding SARS-CoV-2 mutations and increased transmissibility of a new mutant version (Spike D614G) has been released (a preprint article, not a peer-reviewed publication), but Moderna doesn\u2019t expect mutations seen so far to interfere with the efficacy of its vaccine. In addition, if Moderna validates its technology with an initial vaccine, time to availability would be quite short for a new vaccine, with manufacturing capacity already expanded and a much-abbreviated development timeline (like annual flu vaccine changes).</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Finally, drug developers are working on ways to make their products less vulnerable to mutations. Antibody developers like Regeneron are also working on potential cocktails of antibodies to make sure that a potential point mutation doesn\u2019t erode efficacy, and Regeneron says that its cocktails work on all of the spike protein variants it\u2019s tested in vitro (Amgen&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/AMGN&quot; class=&quot;mdc-link mds-link&quot;&gt;AMGN&lt;/a&gt;)&amp;nbsp;and Adaptive are hoping for two or three in their cocktail, as well). By the time such point mutations develop (if they do), we should have well-developed infrastructure for producing novel vaccines, allowing for a much faster response. In addition, current antivirals could offer some protection despite mutations that lower coronavirus vaccine efficacy.\" data-reactid=\"121\">Finally, drug developers are working on ways to make their products less vulnerable to mutations. Antibody developers like Regeneron are also working on potential cocktails of antibodies to make sure that a potential point mutation doesn\u2019t erode efficacy, and Regeneron says that its cocktails work on all of the spike protein variants it\u2019s tested in vitro (Amgen&nbsp;(<a href=\"https://finance.yahoo.com/quote/AMGN\" class=\"mdc-link mds-link\">AMGN</a>)&nbsp;and Adaptive are hoping for two or three in their cocktail, as well). By the time such point mutations develop (if they do), we should have well-developed infrastructure for producing novel vaccines, allowing for a much faster response. In addition, current antivirals could offer some protection despite mutations that lower coronavirus vaccine efficacy.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;In Our Pharma and Biotech Coverage, Roche, Pfizer, and Sanofi Undervalued&lt;/strong&gt;&lt;br&gt;Gilead\u2019s remdesivir received emergency use authorization from the FDA on May 1 based on strong data from two clinical studies. Although the initial supply will be donated, we expect a $500 U.S. price tag to allow for $2 billion in sales in 2021. The arrival of coronavirus vaccines is likely to make any profits short term, limiting the upside to Gilead\u2019s valuation, and the shares look fairly valued.\" data-reactid=\"122\"><strong>In Our Pharma and Biotech Coverage, Roche, Pfizer, and Sanofi Undervalued</strong><br>Gilead\u2019s remdesivir received emergency use authorization from the FDA on May 1 based on strong data from two clinical studies. Although the initial supply will be donated, we expect a $500 U.S. price tag to allow for $2 billion in sales in 2021. The arrival of coronavirus vaccines is likely to make any profits short term, limiting the upside to Gilead\u2019s valuation, and the shares look fairly valued.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Roche is a leading supplier of SARS-CoV-2 diagnostics and antibody tests, which provides some counterbalance to the decline in routine diagnostic tests due to the pandemic. Immunology drug Actemra could also prove helpful in severely ill patients (data should be available this month). While Roche shares have performed strongly during the downturn, they remain slightly undervalued.\" data-reactid=\"123\">Roche is a leading supplier of SARS-CoV-2 diagnostics and antibody tests, which provides some counterbalance to the decline in routine diagnostic tests due to the pandemic. Immunology drug Actemra could also prove helpful in severely ill patients (data should be available this month). While Roche shares have performed strongly during the downturn, they remain slightly undervalued.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Regeneron and Amgen are both racing to bring targeted antibodies to market, which could serve as treatments or prophylaxis for COVID-19. We think Regeneron is a few months ahead, and greater visibility gives us confidence to include $2 billion in potential sales in our model in 2021, similar to the sales potential of remdesivir. However, without clinical data or guidance on pricing, it\u2019s difficult for this to move the meter substantially on our Regeneron valuation, and the shares look slightly overvalued. Amgen\u2019s partnership with Adaptive is encouraging, but we\u2019re awaiting more details before including this in our model, and Amgen shares look fairly valued.\" data-reactid=\"124\">Regeneron and Amgen are both racing to bring targeted antibodies to market, which could serve as treatments or prophylaxis for COVID-19. We think Regeneron is a few months ahead, and greater visibility gives us confidence to include $2 billion in potential sales in our model in 2021, similar to the sales potential of remdesivir. However, without clinical data or guidance on pricing, it\u2019s difficult for this to move the meter substantially on our Regeneron valuation, and the shares look slightly overvalued. Amgen\u2019s partnership with Adaptive is encouraging, but we\u2019re awaiting more details before including this in our model, and Amgen shares look fairly valued.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Big Pharma firms like J&amp;amp;J, Sanofi, Glaxo, Astra, and Pfizer are all rapidly accelerating development and manufacturing timelines to bring a coronavirus vaccine to market. Shares for all these firms have held up well during the pandemic, but we think the shares of Pfizer and Sanofi still look slightly undervalued, and Pfizer\u2019s partnership with BioNTech offers several shots on goal. That said, pandemic sales for most of these coronavirus vaccines will likely be not-for-profit.\" data-reactid=\"125\">Big Pharma firms like J&amp;J, Sanofi, Glaxo, Astra, and Pfizer are all rapidly accelerating development and manufacturing timelines to bring a coronavirus vaccine to market. Shares for all these firms have held up well during the pandemic, but we think the shares of Pfizer and Sanofi still look slightly undervalued, and Pfizer\u2019s partnership with BioNTech offers several shots on goal. That said, pandemic sales for most of these coronavirus vaccines will likely be not-for-profit.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Most Diagnostics Names Appear Fairly Valued or Overvalued&lt;/strong&gt;&lt;br&gt;We modestly lowered our fair value estimates for LabCorp and Quest to reflect loss of revenue from non-COVID-19 tests, which will only be partially offset by COVID-19 tests. If the normal volume of surgeries and elective procedures returns sooner than expected, this could offer upside to our valuations. We think LabCorp\u2019s higher proportion of esoteric tests (hit less severely than routine tests) could allow it to fare marginally better, and shares look slightly undervalued.\" data-reactid=\"126\"><strong>Most Diagnostics Names Appear Fairly Valued or Overvalued</strong><br>We modestly lowered our fair value estimates for LabCorp and Quest to reflect loss of revenue from non-COVID-19 tests, which will only be partially offset by COVID-19 tests. If the normal volume of surgeries and elective procedures returns sooner than expected, this could offer upside to our valuations. We think LabCorp\u2019s higher proportion of esoteric tests (hit less severely than routine tests) could allow it to fare marginally better, and shares look slightly undervalued.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Abbott remains overvalued, from our perspective, after we incorporated declines in medical devices to reflect procedures crowded out by COVID-19 through the second and third quarters, as well as softness in nutritionals thanks to global recessionary conditions. Traditional and point-of-care COVID-19 tests support strong molecular diagnostics growth but don\u2019t significantly sway our valuation.\" data-reactid=\"127\">Abbott remains overvalued, from our perspective, after we incorporated declines in medical devices to reflect procedures crowded out by COVID-19 through the second and third quarters, as well as softness in nutritionals thanks to global recessionary conditions. Traditional and point-of-care COVID-19 tests support strong molecular diagnostics growth but don\u2019t significantly sway our valuation.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"Hologic shares are fairly valued, in our opinion, after incorporating weakness in the women\u2019s health and surgical segments, which is partially offset by COVID-19-driven growth in molecular diagnostics. Considering Hologic\u2019s extensive installed base of Panthers in the U.S. and their presence in the largest reference labs, increased production of SARS-CoV-2 tests could add upside to our valuation.\" data-reactid=\"128\">Hologic shares are fairly valued, in our opinion, after incorporating weakness in the women\u2019s health and surgical segments, which is partially offset by COVID-19-driven growth in molecular diagnostics. Considering Hologic\u2019s extensive installed base of Panthers in the U.S. and their presence in the largest reference labs, increased production of SARS-CoV-2 tests could add upside to our valuation.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"While Thermo Fisher&amp;nbsp;(&lt;a href=&quot;https://finance.yahoo.com/quote/TMO&quot; class=&quot;mdc-link mds-link&quot;&gt;TMO&lt;/a&gt;)&amp;nbsp;stands to benefit from COVID-19 as one of the developers of diagnostic testing with scale, a pullback in capital spending will modestly affect its instrumentation business. However, Thermo Fisher\u2019s business is less exposed to higher-ticket purchases than many of its analytical instrument peers (and relative to its own business during the last economic pullback), and its strong consumable revenue stream should help the company weather this cycle rather unscathed. The market seems to agree, with the shares trading above prepandemic levels and ahead of our valuation.\" data-reactid=\"129\">While Thermo Fisher&nbsp;(<a href=\"https://finance.yahoo.com/quote/TMO\" class=\"mdc-link mds-link\">TMO</a>)&nbsp;stands to benefit from COVID-19 as one of the developers of diagnostic testing with scale, a pullback in capital spending will modestly affect its instrumentation business. However, Thermo Fisher\u2019s business is less exposed to higher-ticket purchases than many of its analytical instrument peers (and relative to its own business during the last economic pullback), and its strong consumable revenue stream should help the company weather this cycle rather unscathed. The market seems to agree, with the shares trading above prepandemic levels and ahead of our valuation.</p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;This article was written by Karen Anderson, CFA\u00a9 and Healthcare Strategist at Morningstar, a research partner for&amp;nbsp;Yahoo Finance Premium.&lt;/strong&gt;\" data-reactid=\"130\"><strong>This article was written by Karen Anderson, CFA\u00a9 and Healthcare Strategist at Morningstar, a research partner for&nbsp;Yahoo Finance Premium.</strong></p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Karen and Preston Caldwell, Equity Analyst at Morningstar, will discuss the long-term economic impact of the global shutdown in a special Yahoo Finance Premium webinar on Tuesday, May 19 at 12pm ET.&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;https://go.morningstar.com/Long-Term-Impact&quot; rel=&quot;nofollow noopener&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;Register for free today.&lt;/strong&gt;&lt;/a&gt;\" data-reactid=\"131\"><strong>Karen and Preston Caldwell, Equity Analyst at Morningstar, will discuss the long-term economic impact of the global shutdown in a special Yahoo Finance Premium webinar on Tuesday, May 19 at 12pm ET.&nbsp;</strong><a href=\"https://go.morningstar.com/Long-Term-Impact\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Register for free today.</strong></a></p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Karen Andersen has a position in the following security mentioned above: DGX. Find out about Morningstar\u2019s&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;https://www.morningstar.com/editorial-policy&quot; class=&quot;mdc-link mds-link&quot; rel=&quot;nofollow noopener&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;editorial policies&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;.&lt;/strong&gt;\" data-reactid=\"132\"><strong>Karen Andersen has a position in the following security mentioned above: DGX. Find out about Morningstar\u2019s&nbsp;</strong><a href=\"https://www.morningstar.com/editorial-policy\" class=\"mdc-link mds-link\" rel=\"nofollow noopener\" target=\"_blank\"><strong>editorial policies</strong></a><strong>.</strong></p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;strong&gt;Additional Morningstar research is available in Yahoo Finance Premium.&amp;nbsp;&lt;/strong&gt;&lt;a href=&quot;http://finance.yahoo.com/premium-marketing?ncid=editoriald_yhm5ec0oo8o&quot;&gt;&lt;strong&gt;Start your free trial today.*&lt;/strong&gt;&lt;/a&gt;\" data-reactid=\"133\"><strong>Additional Morningstar research is available in Yahoo Finance Premium.&nbsp;</strong><a href=\"http://finance.yahoo.com/premium-marketing?ncid=editoriald_yhm5ec0oo8o\"><strong>Start your free trial today.*</strong></a></p><p class=\"canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm\" type=\"text\" content=\"&lt;a href=&quot;http://finance.yahoo.com/premium-marketing?ncid=editoriald_yhm5ec0oo8o&quot;&gt;  &lt;/a&gt;\" data-reactid=\"134\"><a href=\"http://finance.yahoo.com/premium-marketing?ncid=editoriald_yhm5ec0oo8o\">  </a></p><a href=\"http://finance.yahoo.com/premium-marketing?ncid=editoriald_yhm5ec0oo8o\" data-reactid=\"135\"><figure class=\"canvas-image Mx(a) canvas-atom My(24px) My(20px)--sm Op(.9):h Trsdu(.2s)\" style=\"max-width:100%;\" data-type=\"image\" data-reactid=\"136\"><meta itemprop=\"height\" content=\"177\" data-reactid=\"137\"/><meta itemprop=\"width\" content=\"720\" data-reactid=\"138\"/><div style=\"padding-bottom:24.6%;\" class=\"Maw(100%) Pos(r) H(0)\" data-reactid=\"139\"><img alt=\"Try Yahoo Finance Premium for free today.\" class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox W(100%) H(100%) ie-7_H(a)\" itemprop=\"url\" style=\"background-image:url(https://s.yimg.com/ny/api/res/1.2/iUajoTdoIOKpImXTWIey6g--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9NzIwO2g9MTc3/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-04/81f62ba0-7424-11ea-a97b-dc69225e0d0c);\" src=\"https://s.yimg.com/g/images/spaceball.gif\" data-reactid=\"140\"/><noscript data-reactid=\"141\"><img alt=\"Try Yahoo Finance Premium for free today.\" class=\"StretchedBox W(100%) H(100%) ie-7_H(a)\" src=\"https://s.yimg.com/ny/api/res/1.2/iUajoTdoIOKpImXTWIey6g--~A/YXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9NzIwO2g9MTc3/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-uploaded-images/2020-04/81f62ba0-7424-11ea-a97b-dc69225e0d0c\" itemprop=\"url\"/></noscript></div><div itemprop=\"caption description\" class=\"Ov(h) Pos(r) Ff(ss) Mah(80px)\" data-reactid=\"142\"><figcaption class=\"C($c-fuji-grey-h) Fz(13px) Py(5px) Lh(1.5)\" title=\"Try Yahoo Finance Premium for free today.\" data-reactid=\"143\"><div class=\"figure-caption\" data-reactid=\"144\">Try Yahoo Finance Premium for free today.</div></figcaption><button class=\"C($c-fuji-blue-1-b) Cur(p) W(100%) T(63px) Bgc(#fff) Ta(start) Fz(13px) P(0) Bd(0) O(0) Lh(1.5) Pos(a)\" data-reactid=\"145\"><span data-reactid=\"146\">More</span></button></div></figure></a></div></div></article></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('ContentCanvas');window.performance.measure && window.performance.measure('ContentCanvasDone','PageStart','ContentCanvas');}</script></div><div data-reactid=\"44\"><div id=\"mrt-node-Col1-1-ContentIFrame\" data-locator=\"subtree-root\"><div id=\"Col1-1-ContentIFrame-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1410457466\"><!-- react-empty: 2 --></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col1-1-ContentIFrame');window.performance.measure && window.performance.measure('Col1-1-ContentIFrameDone','PageStart','Col1-1-ContentIFrame');}</script></div><div data-reactid=\"45\"><div id=\"mrt-node-Col1-2-CanvasShareButtons\" data-locator=\"subtree-root\"><div id=\"Col1-2-CanvasShareButtons-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"328218451\"><div class=\"canvas-share-buttons csb-ee6c0f80-61d5-3bba-8101-bb8bd4d538c3 Bgc(t) bottom-share-buttons Pb(35px) Pt(20px)\" data-reactid=\"2\"><div class=\"share-button-group \" style=\"-webkit-user-select:none;cursor:default;-webkit-tap-highlight-color:rgba(0,0,0,0);z-index:2;text-align:center;white-space:nowrap;\" data-reactid=\"3\"><a data-sharetype=\"tumblr\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Tumblr;cpos:1;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:www.tumblr.com\" aria-label=\"Tumblr\" style=\"margin-right:0;border-radius:0;border-width:0;width:58px;height:58px;line-height:56px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#3c5a77;color:white;border-color:#3c5a77;\" class=\"tumblr ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(ib) rapid-noclick-resp react-button\" href=\"https://www.tumblr.com/widgets/share/tool?posttype=photo&amp;content=https%3A%2F%2Fs.yimg.com%2Fuu%2Fapi%2Fres%2F1.2%2FyfmPmOmwuoMa7svbTToA.g--~B%2FaD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u%2Fhttps%3A%2F%2Fmedia-mbst-pub-ue1.s3.amazonaws.com%2Fcreatr-uploaded-images%2F2020-05%2F7e7a2c40-95fa-11ea-afff-79b6b59e34b6&amp;url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dtu&amp;clickthroughUrl=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dtu&amp;caption=Diagnostic%20testing%2C%20treatment%2C%20and%20a%20coronavirus%20vaccine%20could%20allow%20near-normal%20distancing%20and%20nonessential%20business%20recovery%20by%20mid-2021.&amp;tags=\" target=\"_blank\" data-reactid=\"4\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 24 24\" data-icon=\"LogoTumblr\" data-reactid=\"5\"><path d=\"M15.4 19.1c-1.1 0-2.5-.7-2.5-1.1v-7.8h4.9V6.8h-4.9V1.7H10C9.9 3 9.5 4.1 8.9 5c-.2.5-.5.8-.9 1.1-.6.4-1.2.7-1.9.7h-.5v3.4H8v8.4c0 3.2 2.9 3.7 4.8 3.7h1.3c3 0 3.6-.3 4.3-.6V18c-.9.6-2 1.1-3 1.1z\" data-reactid=\"6\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:-45px;left:0px;\" data-reactid=\"7\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#3c5a77;line-height:45px;\" data-reactid=\"8\">Reblog</span></div></a><a data-sharetype=\"facebook\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Facebook;cpos:2;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:www.facebook.com\" aria-label=\"Facebook\" style=\"margin-right:0;border-radius:0;border-width:0;width:58px;height:58px;line-height:56px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#4761a6;color:white;border-color:#4761a6;\" class=\"facebook ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(ib) rapid-noclick-resp react-button\" href=\"https://www.facebook.com/dialog/feed?app_id=458584288257241&amp;link=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dfb&amp;name=Coronavirus%20Vaccine%20Progress%20Accelerates&amp;description=Diagnostic%20testing%2C%20treatment%2C%20and%20a%20coronavirus%20vaccine%20could%20allow%20near-normal%20distancing%20and%20nonessential%20business%20recovery%20by%20mid-2021.&amp;picture=https%3A%2F%2Fs.yimg.com%2Fuu%2Fapi%2Fres%2F1.2%2FyfmPmOmwuoMa7svbTToA.g--~B%2FaD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u%2Fhttps%3A%2F%2Fmedia-mbst-pub-ue1.s3.amazonaws.com%2Fcreatr-uploaded-images%2F2020-05%2F7e7a2c40-95fa-11ea-afff-79b6b59e34b6&amp;redirect_uri=https%3A%2F%2Fwww.yahoo.com%2Fnews%2Fmediacontentsharebuttons%2Fpostshare%2F&amp;display=popup&amp;show_error=yes\" target=\"_blank\" data-reactid=\"9\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 32 32\" data-icon=\"LogoFacebook\" data-reactid=\"10\"><path d=\"M12.752 30.4V16.888H9.365V12.02h3.387V7.865c0-3.264 2.002-6.264 6.613-6.264 1.866 0 3.248.19 3.248.19l-.11 4.54s-1.404-.013-2.943-.013c-1.66 0-1.93.81-1.93 2.152v3.553h5.008l-.22 4.867h-4.786V30.4h-4.88z\" data-reactid=\"11\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:-45px;left:0px;\" data-reactid=\"12\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#4761a6;line-height:45px;\" data-reactid=\"13\">Share</span></div></a><a data-sharetype=\"twitter\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Twitter;cpos:3;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:twitter.com\" aria-label=\"Twitter\" style=\"margin-right:0;border-radius:0;border-width:0;width:58px;height:58px;line-height:56px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#00aceb;color:white;border-color:#00aceb;\" class=\"twitter ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(ib) rapid-noclick-resp react-button\" href=\"https://twitter.com/intent/tweet?text=Coronavirus%20Vaccine%20Progress%20Accelerates&amp;url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dtw&amp;via=YahooFinance\" target=\"_blank\" data-reactid=\"14\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 32 32\" data-icon=\"LogoTwitter\" data-reactid=\"15\"><path d=\"M30.402 7.094c-1.058.47-2.198.782-3.392.928 1.218-.725 2.154-1.885 2.595-3.256-1.134.674-2.405 1.165-3.75 1.43-1.077-1.148-2.612-1.862-4.31-1.862-3.268 0-5.915 2.635-5.915 5.893 0 .464.056.91.155 1.34-4.915-.244-9.266-2.59-12.18-6.158-.51.87-.806 1.885-.806 2.96 0 2.044 1.045 3.847 2.633 4.905-.974-.032-1.883-.3-2.68-.736v.07c0 2.857 2.034 5.236 4.742 5.773-.498.138-1.022.21-1.56.21-.38 0-.75-.034-1.11-.103.75 2.344 2.93 4.042 5.518 4.09-2.024 1.58-4.57 2.523-7.333 2.523-.478 0-.952-.032-1.41-.085 2.613 1.674 5.72 2.65 9.054 2.65 10.872 0 16.814-8.976 16.814-16.765 0-.254-.008-.507-.018-.762 1.155-.83 2.155-1.868 2.95-3.047z\" data-reactid=\"16\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:-45px;left:0px;\" data-reactid=\"17\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#00aceb;line-height:45px;\" data-reactid=\"18\">Tweet</span></div></a><a data-sharetype=\"mail\" data-ylk=\"elm:share;itc:0;sec:social-sh;outcm:share;rspns:op;slk:Email;cpos:4;g:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;tar:\" aria-label=\"Email\" style=\"margin-right:0;border-radius:0;border-width:0;width:58px;height:58px;line-height:56px;max-width:58px;min-width:45px;max-height:58px;min-height:45px;background-color:#5601c0;color:white;border-color:#5601c0;\" class=\"mail ButtonNaked My(0) nofollow Ov(v) P(0) Pos(r) Va(b) D(ib) rapid-noclick-resp react-button\" href=\"mailto:?subject=Coronavirus%20Vaccine%20Progress%20Accelerates&amp;body=Coronavirus%20Vaccine%20Progress%20Accelerates%20https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoronavirus-vaccine-progress-accelerates-155109303.html%3Fsoc_src%3Dsocial-sh%26soc_trk%3Dma\" target=\"_top\" data-reactid=\"19\"><svg class=\"D(ib) Cur(p)\" width=\"20\" style=\"vertical-align:middle;fill:white;stroke:white;stroke-width:0;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"NavMail\" data-reactid=\"20\"><path d=\"M460.586 91.31H51.504c-10.738 0-19.46 8.72-19.46 19.477v40.088l224 104.03 224-104.03v-40.088c0-10.757-8.702-19.478-19.458-19.478M32.046 193.426V402.96c0 10.758 8.72 19.48 19.458 19.48h409.082c10.756 0 19.46-8.722 19.46-19.48V193.428l-224 102.327-224-102.327z\" data-reactid=\"21\"></path></svg><div class=\"share-info-wrapper Pos(a) W(a) Py(0) Whs(nw) Cur(p) Lh(1) D(n) Px(4px)\" style=\"background:#f2f2f2;height:45px;min-width:50px;top:-45px;left:0px;\" data-reactid=\"22\"><span class=\"Pos(r) Fw(b) Ff(ss) Lts(.02em) Fw(n) Fz(14px) Fz(12px)! C($c-fuji-blue-1-a)!:h\" style=\"color:#5601c0;line-height:45px;\" data-reactid=\"23\">Share</span></div></a></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col1-2-CanvasShareButtons');window.performance.measure && window.performance.measure('Col1-2-CanvasShareButtonsDone','PageStart','Col1-2-CanvasShareButtons');}</script></div><div data-reactid=\"46\"><div id=\"mrt-node-Col1-3-CanvassComments\" data-locator=\"subtree-root\"><div id=\"Col1-3-CanvassComments-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"2133939503\"><div class=\"canvas-canvass-comments\" data-reactid=\"2\"><span class=\"canvas-bottom-anchor-ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\" aria-hidden=\"true\" data-reactid=\"3\"></span></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('CanvassComments');window.performance.measure && window.performance.measure('CanvassCommentsDone','PageStart','CanvassComments');}</script></div><div data-reactid=\"47\"><div id=\"mrt-node-Col1-4-Ad\" data-locator=\"subtree-root\"><div id=\"Col1-4-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"396528690\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultFOOT-sizer\" class=\"darla-container Pos-r Z-0 Pos(r) Ov(a) Z(0)\" style=\"height:0;width:0;\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultFOOT-wrapper\" class=\"Pos-a T-0 B-0 Start-0 End-0 Ov-h Pos(a) T(0) B(0) Start(0) End(0) Ov(h)\" data-reactid=\"5\"><div id=\"defaultdestFOOT\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col1-4-Ad');window.performance.measure && window.performance.measure('Col1-4-AdDone','PageStart','Col1-4-Ad');}</script></div><div data-reactid=\"48\"><div id=\"mrt-node-Col1-5-Ad\" data-locator=\"subtree-root\"><div id=\"Col1-5-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-358445735\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultFSRVY-sizer\" class=\"darla-container Pos-r Z-0 Pos(r) Ov(a) Z(0)\" style=\"height:0;width:0;\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultFSRVY-wrapper\" class=\"Pos-a T-0 B-0 Start-0 End-0 Ov-h Pos(a) T(0) B(0) Start(0) End(0) Ov(h)\" data-reactid=\"5\"><div id=\"defaultdestFSRVY\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col1-5-Ad');window.performance.measure && window.performance.measure('Col1-5-AdDone','PageStart','Col1-5-Ad');}</script></div></div></div></div></div><div id=\"YDC-Col2\" class=\"YDC-Col2 Pos(a) T(0) End(0) W(1/3)--md W(1/4) D(n)--sm Z(2)\" data-reactid=\"49\"><div class=\"sticky-outer-wrapper\" data-reactid=\"50\"><div class=\"sticky-inner-wrapper\" style=\"position:relative;top:0px;\" data-reactid=\"51\"><div id=\"YDC-Col2-Stack\" class=\"YDC-Col2-Stack Pos(r) Bxz(bb) Maw(340px) P(20px) W(100%)\" data-reactid=\"52\"><div class=\"M(a) W(0)\" data-reactid=\"53\"><div class=\"Pos(r) Start(-150px) W(300px)\" data-reactid=\"54\"><div id=\"Aside\" role=\"complementary\" tabindex=\"-1\" data-reactid=\"55\"><div data-reactid=\"56\"><div id=\"mrt-node-Col2-0-SymbolLookup\" data-locator=\"subtree-root\"><div id=\"Col2-0-SymbolLookup-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-521927237\"><div class=\"Pos(r) D(ib) Mend(10px) Va(m) W(100%)\" data-test=\"add-symbol-overlay\" data-yaft-module=\"tdv2-applet-SymbolLookup\" data-reactid=\"2\"><div class=\"clear-button-inside Pos(r) react-autocomplete-box\" data-reactid=\"3\"><div class=\"Cf\" data-reactid=\"4\"><fieldset class=\"Pos(r) D(ib) W(100%)\" data-reactid=\"5\"><input type=\"text\" class=\" Bdrs(0) Bxsh(n)! Fz(s) Bxz(bb) D(ib) Bg(n) Pend(5px) Px(8px) Py(0) H(30px) Lh(30px) Bd O(n):f O(n):h Bdc($seperatorColor) Bdc($linkColor):f Bdc($c-fuji-punch-a):inv C($negativeColor):in M(0) Pstart(10px) Bxz(bb) Bgc(white) W(100%) H(32px)! Lh(32px)!\" name=\"s\" tabindex=\"1\" aria-label=\"Quote Lookup\" placeholder=\"Quote Lookup\" autocomplete=\"off\" autocorrect=\"off\" autocapitalize=\"off\" spellcheck=\"false\" data-reactid=\"6\"/></fieldset><button class=\" Bdrs(2px) Td(n) Fz(s) D(ib) Bxz(bb) Py(0) Px(10px) H(30px) Lh(30px) Bd  Bgc($linkColor) Bgc($linkActiveColor):h C(white) C(#aaa):di Bdc($linkColor) Bdc($seperatorColor):di Bg($seperatorColor):di H(32px)! Lh(n)! Va(m) Pos(a) Fl(end) End(1px)\" type=\"submit\" data-reactid=\"7\"><svg class=\"Fill(white)! Stroke(white)! Cur(p)\" width=\"20\" style=\"fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 24 24\" data-icon=\"search\" data-reactid=\"8\"><path d=\"M9 3C5.686 3 3 5.686 3 9c0 3.313 2.686 6 6 6s6-2.687 6-6c0-3.314-2.686-6-6-6m13.713 19.713c-.387.388-1.016.388-1.404 0l-7.404-7.404C12.55 16.364 10.85 17 9 17c-4.418 0-8-3.582-8-8 0-4.42 3.582-8 8-8s8 3.58 8 8c0 1.85-.634 3.55-1.69 4.905l7.403 7.404c.39.386.39 1.015 0 1.403\" data-reactid=\"9\"></path></svg></button></div><!-- react-text: 10 --><!-- /react-text --></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2-0-SymbolLookup');window.performance.measure && window.performance.measure('Col2-0-SymbolLookupDone','PageStart','Col2-0-SymbolLookup');}</script></div><div data-reactid=\"57\"><div id=\"mrt-node-Col2-1-RecentQuotes\" data-locator=\"subtree-root\"><div id=\"Col2-1-RecentQuotes-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1575077004\"><div class=\"My(20px)\" data-yaft-module=\"tdv2-applet-RecentQuotes\" data-reactid=\"2\"><span class=\"Py(10px) Pos(r) D(b)\" data-reactid=\"3\"><a href=\"/recent-quotes\" title=\"Recently Viewed\" class=\"Va(m) Fw(b) Fz(s) C($primaryColor) Wow(bw) Us(n)\" data-test=\"list-name\" data-reactid=\"4\"><span data-reactid=\"5\">Recently Viewed</span><svg class=\"Px(2px) Pt(3px) Cur(p)\" width=\"14\" style=\"fill:#000;stroke:#000;stroke-width:0;vertical-align:bottom;\" height=\"14\" viewBox=\"0 0 48 48\" data-icon=\"caret-right-finance\" data-reactid=\"6\"><path d=\"M20.95 9.774c-.966-1.025-2.694-1.023-3.67 0-.98 1.032-.98 2.71 0 3.74l8.95 9.412-8.946 9.404c-.983 1.036-.98 2.716 0 3.74.49.514 1.14.796 1.837.796.698 0 1.35-.28 1.834-.795l12.5-13.145L20.95 9.775z\" data-reactid=\"7\"></path></svg></a></span><div class=\"Bdrs(2px) Bdc($seperatorColor) Bds(s) Bdw(1px) P(20px)\" data-reactid=\"8\"><div class=\"Fz(s) Ta(c)\" data-reactid=\"9\"><span data-reactid=\"10\">Your list is empty.</span></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2-1-RecentQuotes');window.performance.measure && window.performance.measure('Col2-1-RecentQuotesDone','PageStart','Col2-1-RecentQuotes');}</script></div><div data-reactid=\"58\"><div id=\"mrt-node-Col2-2-Ad\" data-locator=\"subtree-root\"><div id=\"Col2-2-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"263023509\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultMON-1-sizer\" class=\"darla-container D-n D(n)\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultMON-1-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestMON-1\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2-2-Ad');window.performance.measure && window.performance.measure('Col2-2-AdDone','PageStart','Col2-2-Ad');}</script></div><div data-reactid=\"59\"><div id=\"mrt-node-Col2-3-Ad\" data-locator=\"subtree-root\"><div id=\"Col2-3-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"114590588\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultLREC-sizer\" class=\"darla-container D-n D(n) lrec-ldrb-ad darla-nonlrec34-ad darla-nonlrec34ldrb-ad darla-lrec-ad\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultLREC-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestLREC\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2-3-Ad');window.performance.measure && window.performance.measure('Col2-3-AdDone','PageStart','Col2-3-Ad');}</script></div><div data-reactid=\"60\"><div id=\"mrt-node-Col2-4-CommonSlotComposite\" data-locator=\"subtree-root\"><div id=\"Col2-4-CommonSlotComposite-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-731765072\"><span data-reactid=\"2\"></span></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2-4-CommonSlotComposite');window.performance.measure && window.performance.measure('Col2-4-CommonSlotCompositeDone','PageStart','Col2-4-CommonSlotComposite');}</script></div><div data-reactid=\"61\"><div id=\"mrt-node-Col2-5-HeightContainer\" data-locator=\"subtree-root\"><div id=\"Col2-5-HeightContainer-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"626666717\"><div id=\"Col2-5-HeightContainer\" class=\"YDC-Height-Container Ov(h) Trsp(max-height) Trsdu(.42s)\" data-reactid=\"2\"><div data-reactid=\"3\"><div id=\"Col2-5-HeightContainer-0-Stream\" class=\"tdv2-applet-stream Bdc(#e2e2e6)\" style=\"max-width:900px;\" data-reactid=\"4\"><h2 class=\"C($c-fuji-grey-l) Fw(500) Fz(16px) Lh(23px)\" data-reactid=\"5\">What to Read Next</h2><ul class=\"My(0) Ov(h) P(0) Wow(bw)\" data-reactid=\"6\"><li class=\"js-stream-content\" data-reactid=\"7\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"8\"><div class=\"Pos(r)\" data-reactid=\"9\"><div class=\"Pos(r)\" data-reactid=\"10\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"11\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/SXuXhvzdMw9L0GtRM3nIHA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/LiU4S51BhwfWSADmf67XoA--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/N6sY2RZdEHtTfPop68vpyw--~B/aD01MTE7dz03Njg7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en_us/News/afp.com/d915f50e11a5f6fd6833266d4bb4907388f7b895.jpg);\" data-reactid=\"12\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"13\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/six-positive-tests-coronavirus-premier-league-clubs-154903031--sow.html\" data-reactid=\"14\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"15\">Burnley&#x27;s Woan among six positive COVID-19 tests at Premier League clubs</span><u class=\"StretchedBox Z(1)\" data-reactid=\"16\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"17\"><div class=\"C(#959595)\" data-reactid=\"18\">AFP</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"19\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"20\"><div class=\"Pos(r)\" data-reactid=\"21\"><div class=\"Pos(r)\" data-reactid=\"22\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"23\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/J7PDKlb4OTdOBrPPJyUNZg--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/qLwtGu.ZNKpLmQThtOGkmw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/vC6Ojrz_FBdVlYwRMVnttw--~B/aD0xNTYyO3c9MjQ5OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en-GB/the_telegraph_818/41453ebd77899a3bab51d74828e2a88e);\" data-reactid=\"24\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"25\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/burnley-assistant-manager-ian-woan-195813582.html\" data-reactid=\"26\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"27\">Burnley assistant manager Ian Woan tests positive for coronavirus</span><u class=\"StretchedBox Z(1)\" data-reactid=\"28\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"29\"><div class=\"C(#959595)\" data-reactid=\"30\">The Telegraph</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"31\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"32\"><div class=\"Pos(r)\" data-reactid=\"33\"><div class=\"Pos(r)\" data-reactid=\"34\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"35\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/1cWdpP.qS2Sbw_RFu9zzdg--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/1q7MXuiEwvCI8REqIaDXAw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/u6P1v2y3Mp.F.yoMn57vEg--~B/aD01MDg7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en-US/reuters.com/8815090ce898708e1294b944b784cd2d);\" data-reactid=\"36\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"37\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/premier-league-confirms-six-positive-173225730.html\" data-reactid=\"38\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"39\">Premier League confirms six positive COVID-19 cases after testing</span><u class=\"StretchedBox Z(1)\" data-reactid=\"40\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"41\"><div class=\"C(#959595)\" data-reactid=\"42\">Reuters</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"43\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"44\"><div class=\"Pos(r)\" data-reactid=\"45\"><div class=\"Pos(r)\" data-reactid=\"46\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"47\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/MqXYc9RHUzE252roUFR8hw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/L3FSlkIvMoWL3Gd3aygchA--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/H_pCXLAh4G58cFYeQlCMcQ--~B/aD0zNjk7dz01NTM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en-us/wsj.com/db8c8359b18753110e5e0f223133fc2f);\" data-reactid=\"48\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"49\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"http://finance.yahoo.com/m/8b688be8-2f23-3204-b24b-82424c0a20bd/a-political-assault-on.html\" data-reactid=\"50\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"51\">A Political Assault on Antibody Tests</span><u class=\"StretchedBox Z(1)\" data-reactid=\"52\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"53\"><div class=\"C(#959595)\" data-reactid=\"54\">The Wall Street Journal</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"55\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"56\"><div class=\"Pos(r)\" data-reactid=\"57\"><div class=\"Pos(r)\" data-reactid=\"58\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"59\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/4TBgZyMzlP_Z6NTfO7uGqA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/5g7e7EJaa0B4yERObaZLdQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/hmNduLI1xnjP4NIBiHxT4w--~B/aD05NDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/usnewswire.com/c2dda8e27e5f933c46e1a6b84da4057a);\" data-reactid=\"60\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"61\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/coronavirus-covid-19-daily-roundup-225500817.html\" data-reactid=\"62\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"63\">Coronavirus (COVID-19) Update: Daily Roundup</span><u class=\"StretchedBox Z(1)\" data-reactid=\"64\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"65\"><div class=\"C(#959595)\" data-reactid=\"66\">PR Newswire</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"67\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"68\"><div class=\"Pos(r)\" data-reactid=\"69\"><div class=\"Pos(r)\" data-reactid=\"70\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"71\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/IhwrnyEmRBEOgIdxRvMyGw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l2.yimg.com/uu/api/res/1.2/6DzPvDU12cFoTykDF3XDqw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-images/2020-05/6527ef00-99f3-11ea-ac7f-1c379e02683a);\" data-reactid=\"72\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"73\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/over-4-million-will-contract-coronavirus-as-states-reopen-wharton-model-172015472.html\" data-reactid=\"74\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"75\">Over 4 million in US will contract coronavirus if states fully reopen: Wharton model</span><u class=\"StretchedBox Z(1)\" data-reactid=\"76\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"77\"><div class=\"C(#959595)\" data-reactid=\"78\">Yahoo Finance</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"79\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"80\"><div class=\"Pos(r)\" data-reactid=\"81\"><div class=\"Pos(r)\" data-reactid=\"82\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"83\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/AfnohJtu1d64hngRBYtPMA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/_E89ILYev5uULaqVFI6FWQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/npulMz9I82Yc6sddJPOS_w--~B/dz03NjkxO2g9NDMyMTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/19/5ec4591e6ca6be051a981d10/5ec4591e6ca6be051a981d11_o_U_v2.jpg);\" data-reactid=\"84\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"85\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"86\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"87\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"88\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/tesla-raise-full-self-driving-220933356.html\" data-reactid=\"89\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"90\">Tesla to raise &#x27;full self-driving&#x27; option price to $8k </span><u class=\"StretchedBox Z(1)\" data-reactid=\"91\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"92\"><div class=\"C(#959595)\" data-reactid=\"93\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"94\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"95\"><div class=\"Pos(r)\" data-reactid=\"96\"><div class=\"Pos(r)\" data-reactid=\"97\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"98\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/qwE8bpBe6Wqt3pDG_KFOUw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l2.yimg.com/uu/api/res/1.2/MX3dOsE1w.b0gDVtinh5bA--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-images/2020-05/59046d70-99ee-11ea-bf7a-ab7390ed652d);\" data-reactid=\"99\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"100\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/democrats-president-trump-coronavirus-163824935.html\" data-reactid=\"101\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"102\">Democrats slam President Trump for &#x27;lazy, four-page copy and paste project&#x27; on coronavirus</span><u class=\"StretchedBox Z(1)\" data-reactid=\"103\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"104\"><div class=\"C(#959595)\" data-reactid=\"105\">Yahoo Finance</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"106\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"107\"><div class=\"Pos(r)\" data-reactid=\"108\"><div class=\"Pos(r)\" data-reactid=\"109\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"110\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/QajlWA2PbX0WdlemsQ2upA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/49i.CQuZUXlAJDCdfdRJiw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/os/creatr-images/2020-05/4522ae50-99e6-11ea-aff1-ae5f8f285b7a);\" data-reactid=\"111\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"112\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/fomc-minutes-lowes-target-report-earnings-what-to-know-in-markets-wednesday-222436084.html\" data-reactid=\"113\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"114\">FOMC minutes, plus Lowe&#x27;s and Target report earnings: What to know in markets Wednesday</span><u class=\"StretchedBox Z(1)\" data-reactid=\"115\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"116\"><div class=\"C(#959595)\" data-reactid=\"117\">Yahoo Finance</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"118\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"119\"><div class=\"Pos(r)\" data-reactid=\"120\"><div class=\"Pos(r)\" data-reactid=\"121\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"122\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/Co8_a4gdxvZ_fhh_ksUaLQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/tmPFrPuBYONfxy_902TnWA--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/.prWYPDYsYwessgDU3rieA--~B/dz0xOTIwO2g9MTA4MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/19/5ec456ceb43fec69be44026c/5ec456ceb43fec69be44026d_o_U_v2.png);\" data-reactid=\"123\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"124\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"125\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"126\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"127\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/inside-michael-jordans-14-800-215937324.html\" data-reactid=\"128\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"129\">Inside Michael Jordan&#x27;s $14,800,000 Chicago-area estate</span><u class=\"StretchedBox Z(1)\" data-reactid=\"130\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"131\"><div class=\"C(#959595)\" data-reactid=\"132\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"133\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"134\"><div class=\"Pos(r)\" data-reactid=\"135\"><div class=\"Pos(r)\" data-reactid=\"136\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"137\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/L9MSWrpffVzCEVpRvHLO_w--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/xTc6wna1TALjfcfTsddAUw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/4wve76Fjr17sUZGlQCJCvg--~B/aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en-us/insidermonkey.com/229af667ee872155899465db4c5b62bb);\" data-reactid=\"138\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"139\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/moderna-stock-volatile-amid-coronavirus-021933804.html\" data-reactid=\"140\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"141\">Moderna Stock Volatile Amid Work on Coronavirus Vaccine</span><u class=\"StretchedBox Z(1)\" data-reactid=\"142\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"143\"><div class=\"C(#959595)\" data-reactid=\"144\">Insider Monkey</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"145\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"146\"><div class=\"Pos(r)\" data-reactid=\"147\"><div class=\"Pos(r)\" data-reactid=\"148\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"149\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/HynScfXg4_z.WT9QN4HWfw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l2.yimg.com/uu/api/res/1.2/Sdi328B8IUIkYAHvUV4U9w--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://media.zenfs.com/en-US/geekwire_312/940126ab26fe83c13d2920445001f085);\" data-reactid=\"150\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"151\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/nasa-head-human-spaceflight-bows-225246383.html\" data-reactid=\"152\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"153\">Days before landmark launch, NASA\u2019s head of human spaceflight quits due to \u2018mistake\u2019</span><u class=\"StretchedBox Z(1)\" data-reactid=\"154\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"155\"><div class=\"C(#959595)\" data-reactid=\"156\">GeekWire</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"157\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"158\"><div class=\"Pos(r)\" data-reactid=\"159\"><div class=\"Pos(r)\" data-reactid=\"160\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"161\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/fm3tpayguiLfqGAUg0a7Jw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/p1djcEFxezwOCQI5z9FYSw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/14/5ebd7ec190a80d675a63bfe9/5ebd7ec190a80d675a63bfea_o_U_v2.jpg);\" data-reactid=\"162\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"163\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"164\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"165\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"166\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/nvidia-unveils-ai-fight-coronavirus-172414034.html\" data-reactid=\"167\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"168\">Nvidia unveils new AI to fight coronavirus</span><u class=\"StretchedBox Z(1)\" data-reactid=\"169\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"170\"><div class=\"C(#959595)\" data-reactid=\"171\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"172\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"173\"><div class=\"Pos(r)\" data-reactid=\"174\"><div class=\"Pos(r)\" data-reactid=\"175\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"176\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/EeYaH.xG_RjzMCFFlx3k5A--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/_aSwMmyHFNsSMTYl.BO_aQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/08/5eb56c5a5f6f656335c2c0cd/5eb5856384a08c74cced1681_o_U_v4.jpg);\" data-reactid=\"177\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"178\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"179\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"180\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"181\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/most-volume-trading-around-rate-142737826.html\" data-reactid=\"182\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"183\">The &#x27;most volume of trading has been around the rate sector&#x27; amid COVID-19 crisis: Tradeweb CEO</span><u class=\"StretchedBox Z(1)\" data-reactid=\"184\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"185\"><div class=\"C(#959595)\" data-reactid=\"186\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"187\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"188\"><div class=\"Pos(r)\" data-reactid=\"189\"><div class=\"Pos(r)\" data-reactid=\"190\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"191\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/O.Dj.OoPJUcyQTCouqCMxA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l2.yimg.com/uu/api/res/1.2/mVaWKQnw_KguzbibptoKKw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/os/creatr-images/2020-05/bebd1710-9a17-11ea-bfdf-32ef011721b1);\" data-reactid=\"192\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"193\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/stock-market-news-live-may-20-2020-221852318.html\" data-reactid=\"194\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"195\">Stock market news live updates: Stock futures fall, extending declines</span><u class=\"StretchedBox Z(1)\" data-reactid=\"196\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"197\"><div class=\"C(#959595)\" data-reactid=\"198\">Yahoo Finance</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"199\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"200\"><div class=\"Pos(r)\" data-reactid=\"201\"><div class=\"Pos(r)\" data-reactid=\"202\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"203\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/aHphuBvYiBr.H4ZRk7HllA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/U76ZKLDX7Qc8jhqabSXhhg--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/ZKT_30nT6M_MeiWluuvVyQ--~B/dz03MzY7aD00MTQ7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/19/5ec4507a84a08c74cced3df2/5ec4507a84a08c74cced3df3_o_U_v2.png);\" data-reactid=\"204\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"205\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"206\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"207\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"208\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/jacqueline-novogratz-talks-her-book-213240384.html\" data-reactid=\"209\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"210\">Jacqueline Novogratz talks her new book &#x27;Manifesto for a Moral Revolution&#x27;</span><u class=\"StretchedBox Z(1)\" data-reactid=\"211\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"212\"><div class=\"C(#959595)\" data-reactid=\"213\">Yahoo Finance Video</div></div></div></div></div></li></ul></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2-5-HeightContainer');window.performance.measure && window.performance.measure('Col2-5-HeightContainerDone','PageStart','Col2-5-HeightContainer');}</script></div><div data-reactid=\"62\"><div id=\"mrt-node-Col2-6-Ad\" data-locator=\"subtree-root\"><div id=\"Col2-6-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"1586070549\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultLREC2-sizer\" class=\"darla-container D-n D(n) lrec-ldrb-ad darla-nonlrec34-ad darla-nonlrec34ldrb-ad darla-lrec-ad\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultLREC2-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestLREC2\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2-6-Ad');window.performance.measure && window.performance.measure('Col2-6-AdDone','PageStart','Col2-6-Ad');}</script></div></div></div></div></div></div></div></div></div></div><div id=\"YDC-Bottom\" class=\"YDC-Bottom Cl(b) W(100%) \" data-reactid=\"63\"><div id=\"YDC-Bottom-Stack\" class=\"YDC-Bottom-Stack Pos(r) Z(1)\" data-reactid=\"64\"><div id=\"YDC-Bottom-Stack-Composite\" data-reactid=\"65\"><div data-reactid=\"66\"><div id=\"mrt-node-Bottom-0-Ad\" data-locator=\"subtree-root\"><div id=\"Bottom-0-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-764242847\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultSPL-sizer\" class=\"darla-container Pos-r Z-0 Pos(r) Ov(a) Z(0) Bg-n Bg(n)\" style=\"height:0;padding-top:0;width:0;\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultSPL-wrapper\" class=\"Pos-a T-0 B-0 Start-0 End-0 Ov-h Pos(a) T(0) B(0) Start(0) End(0) Ov(h)\" data-reactid=\"5\"><div id=\"defaultdestSPL\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Bottom-0-Ad');window.performance.measure && window.performance.measure('Bottom-0-AdDone','PageStart','Bottom-0-Ad');}</script></div></div></div></div><div class=\"Bgc($bg-content) Cf Pos(r)\" data-reactid=\"67\"><div class=\"W(2/3)--md W(1/1)--sm W(3/4) Bxz(bb)\" data-reactid=\"68\"><div id=\"YDC-Col1Ext\" class=\"YDC-Col1Ext Bxz(bb) Mstart(0)--sm Mstart(0)--md Mstart(33.3%) P(20px) W(1/1)--sm W(1/1)--md ie-7_W(45%)\" data-reactid=\"69\"><div id=\"YDC-Col1Ext-Stack\" class=\"YDC-Col1Ext-Stack Pos(r) M(a) Maw(600px) Maw(800px)--lg Mih(650px) Mih(0)--sm\" data-reactid=\"70\"><div id=\"Main\" role=\"content\" tabindex=\"-1\" data-reactid=\"71\"><div data-reactid=\"72\"><div id=\"mrt-node-YDC-Stream\" data-locator=\"subtree-root\"><div id=\"YDC-Stream-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"1551966349\"><span data-reactid=\"2\"></span></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Stream');window.performance.measure && window.performance.measure('StreamDone','PageStart','Stream');}</script></div></div></div></div></div><div id=\"YDC-Col2Ext\" class=\"YDC-Col2Ext Pos(a) T(0) End(0) W(1/3)--md W(1/4) D(n)--sm Z(2)\" data-reactid=\"73\"><div class=\"sticky-outer-wrapper\" data-reactid=\"74\"><div class=\"sticky-inner-wrapper\" style=\"position:relative;top:0px;\" data-reactid=\"75\"><div id=\"YDC-Col2Ext-Stack\" class=\"YDC-Col2Ext-Stack Pos(r) Bxz(bb) Maw(340px) P(20px) W(100%)\" data-reactid=\"76\"><div class=\"M(a) W(0)\" data-reactid=\"77\"><div class=\"Pos(r) Start(-150px) W(300px)\" data-reactid=\"78\"><div id=\"Aside\" role=\"complementary\" tabindex=\"-1\" data-reactid=\"79\"><div data-reactid=\"80\"><div id=\"mrt-node-Col2Ext-0-Stream\" data-locator=\"subtree-root\"><div id=\"Col2Ext-0-Stream-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"1389189107\"><div id=\"Col2Ext-0-Stream\" class=\"tdv2-applet-stream Bdc(#e2e2e6)\" style=\"max-width:900px;\" data-reactid=\"2\"><ul class=\"My(0) Ov(h) P(0) Wow(bw)\" data-reactid=\"3\"><li class=\"js-stream-content\" data-reactid=\"4\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"5\"><div class=\"Pos(r)\" data-reactid=\"6\"><div class=\"Pos(r)\" data-reactid=\"7\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"8\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/gwmyTin6.BJcffM0B6xR.A--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/OPDLMkkg5._n9UcI_YS_Yg--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/Zu44EF6PwBpOWycwOj9FxA--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en_us/News/afp.com/066faa7db98d63c7ebf819da8a71e09c259d3cfc.jpg);\" data-reactid=\"9\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"10\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/europe-slowly-exits-lockdown-sweden-hunkers-down-long-021756299.html\" data-reactid=\"11\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"12\">As Europe slowly exits lockdown, Sweden hunkers down for long haul</span><u class=\"StretchedBox Z(1)\" data-reactid=\"13\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"14\"><div class=\"C(#959595)\" data-reactid=\"15\">AFP</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"16\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"17\"><div class=\"Pos(r)\" data-reactid=\"18\"><div class=\"Pos(r)\" data-reactid=\"19\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"20\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/ylNGaDu_LIFV9E9x4FzxZA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/l1F0FRFh4MXsxdPTMTmyuQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/11/5eb9bb909bb2c071712dc3e8/5eb9bb909bb2c071712dc3e9_o_U_v2.jpg);\" data-reactid=\"21\"></div><span class=\" StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"22\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"23\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"24\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"25\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/trump-u-pass-10m-testing-205427089.html\" data-reactid=\"26\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"27\">Trump: U.S. will pass 10M testing conducted this week</span><u class=\"StretchedBox Z(1)\" data-reactid=\"28\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"29\"><div class=\"C(#959595)\" data-reactid=\"30\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"31\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"32\"><div class=\"Pos(r)\" data-reactid=\"33\"><div class=\"Pos(r)\" data-reactid=\"34\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"35\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/6TTt34DeWExUdmCHCdKRTA--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/VVwBotKyBuYbSLoGZkU3WA--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/12/5ebaf8a790a80d675a63b88f/5ebb157b9bb2c071712dc884_o_U_v5.jpg);\" data-reactid=\"36\"></div><span class=\" StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"37\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"38\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"39\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"40\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/unemployment-pay-drama-rages-residents-192734345.html\" data-reactid=\"41\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"42\">Some renters are set to face evictions amid coronavirus crisis</span><u class=\"StretchedBox Z(1)\" data-reactid=\"43\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"44\"><div class=\"C(#959595)\" data-reactid=\"45\">Yahoo Finance Video</div></div></div></div></div></li></ul></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2Ext-0-Stream');window.performance.measure && window.performance.measure('Col2Ext-0-StreamDone','PageStart','Col2Ext-0-Stream');}</script></div><div data-reactid=\"81\"><div id=\"mrt-node-Col2Ext-1-Ad\" data-locator=\"subtree-root\"><div id=\"Col2Ext-1-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"637565882\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultLREC3-sizer\" class=\"darla-container D-n D(n) lrec-ldrb-ad darla-lrec34-ad darla-lrec-ad\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultLREC3-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestLREC3\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2Ext-1-Ad');window.performance.measure && window.performance.measure('Col2Ext-1-AdDone','PageStart','Col2Ext-1-Ad');}</script></div><div data-reactid=\"82\"><div id=\"mrt-node-Col2Ext-2-Stream\" data-locator=\"subtree-root\"><div id=\"Col2Ext-2-Stream-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"1802020728\"><div id=\"Col2Ext-2-Stream\" class=\"tdv2-applet-stream Bdc(#e2e2e6)\" style=\"max-width:900px;\" data-reactid=\"2\"><ul class=\"My(0) Ov(h) P(0) Wow(bw)\" data-reactid=\"3\"><li class=\"js-stream-content\" data-reactid=\"4\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"5\"><div class=\"Pos(r)\" data-reactid=\"6\"><div class=\"Pos(r)\" data-reactid=\"7\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"8\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/TAWONlivEV6QlX7VVYoKCQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l2.yimg.com/uu/api/res/1.2/DdFM9KtVvWqSAymfruHSsQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://media-mbst-pub-ue1.s3.amazonaws.com/creatr-images/2020-05/7ff19b80-8f1f-11ea-adff-c55fa4077628);\" data-reactid=\"9\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"10\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/stock-market-news-live-may-6-2020-222531890.html\" data-reactid=\"11\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"12\">Stock market news live updates: Wall Street ends mixed, weighing grim data against states reopening</span><u class=\"StretchedBox Z(1)\" data-reactid=\"13\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"14\"><div class=\"C(#959595)\" data-reactid=\"15\">Yahoo Finance</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"16\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"17\"><div class=\"Pos(r)\" data-reactid=\"18\"><div class=\"Pos(r)\" data-reactid=\"19\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"20\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/Uy8hnuOlBPDqlopQITn7Fw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/Qli0aPFupqgrfkJaPoaYIQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/os/creatr-images/2020-05/5c8ee540-9955-11ea-bfe5-f210f064c7dc);\" data-reactid=\"21\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"22\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/stock-market-news-live-may-19-2020-221634424.html\" data-reactid=\"23\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"24\">Stock market news live updates: Wall St. ends lower, snap 3 day rally as investors pause for breath</span><u class=\"StretchedBox Z(1)\" data-reactid=\"25\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"26\"><div class=\"C(#959595)\" data-reactid=\"27\">Yahoo Finance</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"28\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"29\"><div class=\"Pos(r)\" data-reactid=\"30\"><div class=\"Pos(r)\" data-reactid=\"31\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"32\"><div class=\" Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/AYPpTxeh_asd4KhR79CEEQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/xZHg07e2Ugg5vWvTstDI5Q--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/TA4rD.vGBrh60ttNjXVoWg--~B/dz02MzE1O2g9MzU1OTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/19/5ec44a3290fe357a07b58f9b/5ec44a3290fe357a07b58f9c_o_U_v2.jpg);\" data-reactid=\"33\"></div><span class=\" StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"34\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"35\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"36\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"37\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/restaurateur-nick-kokonas-covid-19-210553528.html\" data-reactid=\"38\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"39\">Restaurateur Nick Kokonas on COVID-19 impact</span><u class=\"StretchedBox Z(1)\" data-reactid=\"40\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"41\"><div class=\"C(#959595)\" data-reactid=\"42\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"43\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"44\"><div class=\"Pos(r)\" data-reactid=\"45\"><div class=\"Pos(r)\" data-reactid=\"46\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"47\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/bShplGtC6dz9hAb0f7w03w--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/hj_UVbfkTPQYEW0.47.lvQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/_.QO.9_aak_VuB67hW4naw--~B/aD0zMjQwO3c9NTc2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/pa_viral_news_704/0391383035e88337e4c063b3e00731a3);\" data-reactid=\"48\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"49\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/mexico-city-virus-deaths-could-020408995.html\" data-reactid=\"50\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"51\">Mexico City virus deaths could be more than triple official toll</span><u class=\"StretchedBox Z(1)\" data-reactid=\"52\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"53\"><div class=\"C(#959595)\" data-reactid=\"54\">PA Media: World News</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"55\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"56\"><div class=\"Pos(r)\" data-reactid=\"57\"><div class=\"Pos(r)\" data-reactid=\"58\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"59\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/Uhv_RynGNRYaQfcoEaClyQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/zmj_1NnMMb1UAHjR734Qtw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/14/5ebd7dd992fc2805e470c674/5ebd80195f6f656335c2d6d2_o_U_v3.jpg);\" data-reactid=\"60\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"61\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"62\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"63\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"64\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/more-consumers-show-interest-traveling-172024841.html\" data-reactid=\"65\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"66\">More consumers show interest in traveling on cruises in the near term: Analyst</span><u class=\"StretchedBox Z(1)\" data-reactid=\"67\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"68\"><div class=\"C(#959595)\" data-reactid=\"69\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"70\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"71\"><div class=\"Pos(r)\" data-reactid=\"72\"><div class=\"Pos(r)\" data-reactid=\"73\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"74\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/97FEwvka1cAlOTpbOp7i7Q--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l2.yimg.com/uu/api/res/1.2/O.L9dA8oAHqGgnUM_iJVOQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/13/5ebbff9e90fe357a07b57985/5ebbff9e90fe357a07b57986_o_U_v2.jpg);\" data-reactid=\"75\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"76\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"77\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"78\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"79\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/stocks-fall-powell-pledges-full-140928993.html\" data-reactid=\"80\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"81\">Stocks fall after Powell pledges full Fed support</span><u class=\"StretchedBox Z(1)\" data-reactid=\"82\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"83\"><div class=\"C(#959595)\" data-reactid=\"84\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"85\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"86\"><div class=\"Pos(r)\" data-reactid=\"87\"><div class=\"Pos(r)\" data-reactid=\"88\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"89\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/qH6hBXCcUiW0tT6mcvjoMg--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/rXQuARcUaxZYO0jcT4DzbA--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/19/5ec3e92c90fe357a07b58e37/5ec3e92c90fe357a07b58e38_o_U_v2.jpg);\" data-reactid=\"90\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"91\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"92\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"93\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"94\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/home-depot-sales-soar-housing-141155942.html\" data-reactid=\"95\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"96\">Home Depot sales soar, Housing starts plunge 30% in April</span><u class=\"StretchedBox Z(1)\" data-reactid=\"97\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"98\"><div class=\"C(#959595)\" data-reactid=\"99\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"100\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"101\"><div class=\"Pos(r)\" data-reactid=\"102\"><div class=\"Pos(r)\" data-reactid=\"103\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"104\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/VK_.ceKy6.M3XhF9CRzDaw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l2.yimg.com/uu/api/res/1.2/NkBQk0xnOdISVfjTNgFqBQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/os/creatr-images/2020-05/b1eb1f60-9949-11ea-bda7-a31b4643b142);\" data-reactid=\"105\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"106\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/carson-block-shorts-chinese-k-12-company-gsx-fraud-201001809.html\" data-reactid=\"107\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"108\">Short seller Carson Block: This Chinese K-12 company is &#x27;a near-total fraud&#x27;</span><u class=\"StretchedBox Z(1)\" data-reactid=\"109\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"110\"><div class=\"C(#959595)\" data-reactid=\"111\">Yahoo Finance</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"112\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"113\"><div class=\"Pos(r)\" data-reactid=\"114\"><div class=\"Pos(r)\" data-reactid=\"115\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"116\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/qfsyTRNPKqHU0ItyYP_yCg--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/dwvZkhNgslbwPENQRnMPtg--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/lgWQNFdTCeM_qjlxG5UOBQ--~B/dz01Njk1O2g9MzIxMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/19/5ec446a690fe357a07b58f82/5ec446a690fe357a07b58f83_o_U_v2.jpg);\" data-reactid=\"117\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"118\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"119\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"120\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"121\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/cant-wrong-midstream-oil-gas-205046626.html\" data-reactid=\"122\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"123\">You can&#x27;t go wrong with midstream oil, gas stocks: Annandale Capital CEO</span><u class=\"StretchedBox Z(1)\" data-reactid=\"124\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"125\"><div class=\"C(#959595)\" data-reactid=\"126\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"127\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"128\"><div class=\"Pos(r)\" data-reactid=\"129\"><div class=\"Pos(r)\" data-reactid=\"130\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"131\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/BXvpFq_F7gyrpE_R5VgDsw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/f.imYthSE6i41YYihzPPVQ--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/uu/api/res/1.2/thBM3Z1k62lpB1StkJ5mgQ--~B/aD03ODQ7dz0xMjk2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_opinion_268/5d65ccf8372b4d492ce7934512817e14);\" data-reactid=\"132\"></div></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"133\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/news/putins-russia-bungled-coronavirus-053003286.html\" data-reactid=\"134\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"135\">How Putin&#x27;s Russia Bungled the Pandemic</span><u class=\"StretchedBox Z(1)\" data-reactid=\"136\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"137\"><div class=\"C(#959595)\" data-reactid=\"138\">Bloomberg</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"139\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"140\"><div class=\"Pos(r)\" data-reactid=\"141\"><div class=\"Pos(r)\" data-reactid=\"142\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"143\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/Sl9IN4SL5xdWbd3GsUGRvQ--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l1.yimg.com/uu/api/res/1.2/rYilMQDZ9ELi915wItIBgg--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/19/5ec41f3a90a80d675a63d16e/5ec447fc92fc2805e470d801_o_U_v5.jpg);\" data-reactid=\"144\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"145\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"146\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"147\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"148\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/curaleaf-ceo-company-earnings-cannabis-180232242.html\" data-reactid=\"149\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"150\">Curaleaf CEO: cannabis is one of the best-performing industries in the country right now</span><u class=\"StretchedBox Z(1)\" data-reactid=\"151\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"152\"><div class=\"C(#959595)\" data-reactid=\"153\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"154\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"155\"><div class=\"Pos(r)\" data-reactid=\"156\"><div class=\"Pos(r)\" data-reactid=\"157\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"158\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/OeWFPZx2Mo4wTSHirw8Pfw--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/.Ey6JoBKmg_oxCaTR3vNpw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/01/5eac23fd6ca6be051a97dc7c/5eac23fd6ca6be051a97dc7d_o_U_v2.jpg);\" data-reactid=\"159\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"160\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"161\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"162\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"163\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/trump-administration-looks-punish-china-132827976.html\" data-reactid=\"164\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"165\">Trump administration looks to punish China over virus: RPT</span><u class=\"StretchedBox Z(1)\" data-reactid=\"166\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"167\"><div class=\"C(#959595)\" data-reactid=\"168\">Yahoo Finance Video</div></div></div></div></div></li><li class=\"js-stream-content\" data-reactid=\"169\"><div class=\"Py(14px) smartphone_Px(20px) smartphone_Bxsh(streamBoxShadow) Cf\" data-test-locator=\"featured\" data-reactid=\"170\"><div class=\"Pos(r)\" data-reactid=\"171\"><div class=\"Pos(r)\" data-reactid=\"172\"><div class=\"Pos(r) smartphone_Mx(a) smartphone_Mb(12px) Maw(500px)\" data-reactid=\"173\"><div class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) Mb(6px) Bdrs(2px) Bgz(cv) Trsdu(0s)!\" style=\"padding-bottom:52%;background-image:url(https://s.yimg.com/ny/api/res/1.2/bwLhZtczs8TVa8t4IqynEg--~A/YXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt/http://l.yimg.com/uu/api/res/1.2/Gf_XfTOFbzvfbH7RdICnWw--/YXBwaWQ9eXRhY2h5b247cT03NTs-/https://s.yimg.com/hd/cp-video-transcode/prod/2020-05/04/5eb04f1c9bb2c071712daa34/5eb04f1c9bb2c071712daa35_o_U_v2.jpg);\" data-reactid=\"174\"></div><span class=\"JsEnabled_Op(0) JsEnabled_Bg(n) Trsdu(.42s) Bgr(nr) Bgz(cv) StretchedBox M(a) lightweight_D(n) Trsdu(0s)!\" dir=\"ltr\" style=\"height:50px;width:50px;background-size:50px;background-image:url(https://s.yimg.com/dh/ap/default/150604/orb.png);\" data-reactid=\"175\"><svg class=\"D(b) Pos(r) Mstart(2px) Cur(p)\" width=\"20\" style=\"left:15px;top:15px;fill:#fff;stroke:#fff;stroke-width:0;vertical-align:bottom;\" height=\"20\" viewBox=\"0 0 512 512\" data-icon=\"CorePlay\" data-reactid=\"176\"><path d=\"M82.294 490.295c-20.327 11.736-36.952 2.14-36.952-21.332V42.295c0-23.472 16.632-33.055 36.952-21.332L451.67 234.295c20.318 11.75 20.318 30.945 0 42.682L82.294 490.295z\" data-reactid=\"177\"></path></svg></span></div><h3 class=\"M(0) Py(1px)\" data-reactid=\"178\"><a class=\"Fz(13px) LineClamp(4,96px) C(#0078ff):h Td(n) C($c-fuji-blue-4-b) smartphone_C(#000) smartphone_Fz(19px)\" href=\"https://finance.yahoo.com/video/pompeo-says-evidence-ties-covid-172129983.html\" data-reactid=\"179\"><span class=\"Fw(600) smartphone_Fw(500)\" data-reactid=\"180\">Pompeo says evidence ties COVID-19 to China lab</span><u class=\"StretchedBox Z(1)\" data-reactid=\"181\"></u></a></h3><div class=\"Lh(1.2) Fz(11px) smartphone_Fz(13px) Pos(r) Z(1) Mt(4px) C(#96989f)\" data-reactid=\"182\"><div class=\"C(#959595)\" data-reactid=\"183\">Yahoo Finance Video</div></div></div></div></div></li></ul></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2Ext-2-Stream');window.performance.measure && window.performance.measure('Col2Ext-2-StreamDone','PageStart','Col2Ext-2-Stream');}</script></div><div data-reactid=\"83\"><div id=\"mrt-node-Col2Ext-3-Ad\" data-locator=\"subtree-root\"><div id=\"Col2Ext-3-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"712407999\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultLREC4-sizer\" class=\"darla-container D-n D(n) lrec-ldrb-ad darla-lrec34-ad darla-lrec-ad\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultLREC4-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestLREC4\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2Ext-3-Ad');window.performance.measure && window.performance.measure('Col2Ext-3-AdDone','PageStart','Col2Ext-3-Ad');}</script></div><div data-reactid=\"84\"><div id=\"mrt-node-Col2Ext-4-Ad\" data-locator=\"subtree-root\"><div id=\"Col2Ext-4-Ad-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1847104444\"><div class=\"\" data-reactid=\"2\"><div id=\"defaultMON2-sizer\" class=\"darla-container D-n D(n)\" data-reactid=\"3\"><!-- react-text: 4 --><!-- /react-text --><div id=\"defaultMON2-wrapper\" class=\"\" data-reactid=\"5\"><div id=\"defaultdestMON2\" style=\"\"></div></div></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2Ext-4-Ad');window.performance.measure && window.performance.measure('Col2Ext-4-AdDone','PageStart','Col2Ext-4-Ad');}</script></div><div data-reactid=\"85\"><div id=\"mrt-node-Col2Ext-5-Footer\" data-locator=\"subtree-root\"><div id=\"Col2Ext-5-Footer-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"676274835\"><span data-reactid=\"2\"></span></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Col2Ext-5-Footer');window.performance.measure && window.performance.measure('Col2Ext-5-FooterDone','PageStart','Col2Ext-5-Footer');}</script></div></div></div></div></div></div></div></div></div><div id=\"YDC-Overlay\" class=\"YDC-Overlay\" data-reactid=\"86\"><div id=\"YDC-Overlay-Stack\" class=\"YDC-Overlay-Stack Z(11) End(0) Pos(f) Start(0) lw-nav-open_Pos(r) lw-nav-open_Z(10) T(0)\" data-reactid=\"87\"><div id=\"YDC-Overlay-Stack-Composite\" data-reactid=\"88\"><div data-reactid=\"89\"><div id=\"mrt-node-Overlay-0-Lightbox\" data-locator=\"subtree-root\"><div id=\"Overlay-0-Lightbox-Proxy\" data-reactroot=\"\" data-reactid=\"1\" data-react-checksum=\"-1142446977\"><div id=\"Overlay-0-Lightbox\" class=\"lightbox\" data-reactid=\"2\"><div tabindex=\"-1\" class=\"lightbox-wrapper Ta(c) Pos(f) T(0) Start(0) H(100%) W(100%)  D(n)! Op(0)\" data-reactid=\"3\"><div id=\"myLightboxContainer\" class=\"Ta(start) Pos(r) Z(1) T(0) Maw(100%) P(0)  D(n)!\" aria-describedby=\"lightbox-container\" role=\"alertdialog\" data-reactid=\"4\"></div><b class=\"ModalShim\" data-reactid=\"5\"></b><b class=\"IEShim\" data-reactid=\"6\"></b></div></div></div></div><script>if (window.performance) {window.performance.mark && window.performance.mark('Overlay-0-Lightbox');window.performance.measure && window.performance.measure('Overlay-0-LightboxDone','PageStart','Overlay-0-Lightbox');}</script></div></div></div></div></div></div></div></div></div><script>\n(function (root) {\n/* -- Data -- */\nroot.App || (root.App = {});\nroot.App.now = 1589941876206;\nroot.App.main = {\"context\":{\"dispatcher\":{\"stores\":{\"PageStore\":{\"currentPageName\":\"content\",\"currentRenderTargetId\":\"default\",\"pagesConfigRaw\":{\"base\":{\"content\":{\"layout\":{\"bundleName\":\"yahoodotcom-layout.RC5TwoColumnLayout\",\"name\":\"RC5TwoColumnLayout\",\"config\":{\"Side\":{\"isSticky\":false},\"UH\":{\"height\":128,\"slotHeight\":128,\"isFixed\":true},\"enableCanvassInit\":true,\"enablePrefetchResource\":false,\"Col2\":{\"sticky\":{\"bottomBoundary\":\"{renderTargetId} .YDC-Col1\"}},\"Col2Ext\":{\"sticky\":{}},\"fetchNewAttribution\":true,\"enableLiveCoverageInit\":true},\"image\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fcv\\u002Fapiv2\\u002Fsocial\\u002Fimages\\u002Fyahoo_default_logo.png\",\"faviconIco\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fcv\\u002Fapiv2\\u002Fdefault\\u002Ffp\\u002F20180826\\u002Ficons\\u002Ffavicon_y19_32x32.ico\",\"meta\":{\"name\":{\"msapplication-TileColor\":\"#6e329d\",\"msapplication-TileImage\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fp\\u002Fyahoo_frontpage_en-US_s_f_w_bestfit_frontpage.png\",\"msvalidate.01\":\"A9862C0E6E1BE95BCE0BF3D0298FD58B\",\"referrer\":\"unsafe-url\",\"theme-color\":\"#400090\",\"twitter:dnt\":\"on\",\"twitter:site\":\"@YahooFinance\"},\"property\":{\"og:type\":\"website\"}},\"enableCtopid\":true,\"favicon\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fcv\\u002Fapiv2\\u002Fdefault\\u002Ficons\\u002Ffavicon_y19_32x32_custom.svg\",\"title\":\"Yahoo Finance\"},\"regions\":{\"UH\":[{\"bundleName\":\"react-finance.y20\",\"name\":\"UH\",\"props\":{\"urlPrefix\":\"https:\\u002F\\u002Ffinance.yahoo.com\",\"key\":\"UH-0-UH\",\"id\":\"UH-0-UH\"},\"config\":{\"disablePortfolioNavUpdate\":false,\"pfUrlType\":\"portfolio\",\"urlPrefix\":\"https:\\u002F\\u002Ffinance.yahoo.com\",\"mrt\":{\"cache\":true,\"skipAlertOnChecksumMismatch\":true},\"compositeConfig\":{\"uh\":{\"search\":{\"placeholderText\":\"FINANCE_UH_SEARCH_WEB\"},\"ui\":{\"follow\":false}}}},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-navrail\",\"name\":\"DesktopNav\",\"perfLabel\":\"NavLite\",\"config\":{\"featureSwitches\":{\"useSubnavTitleSlk\":true},\"renderVersion\":\"rc5\",\"linkMeta\":{\"sports_myteams\":{\"bundles\":{\"props\":{\"urlPrefix\":\"https:\\u002F\\u002Fsports.yahoo.com\"}}}},\"ui\":{\"disableFollowPopouts\":true,\"enableCCPAFooter\":true,\"navCache\":true,\"remoteAdapter\":true,\"makeSticky\":false},\"components\":{\"finance\":{\"title\":\"Finance\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\",\"collapse\":true,\"type\":\"finance\",\"linkWidth\":250,\"i13n\":{},\"links\":true,\"propertyColor\":\"#efefef\"}}},\"props\":{\"className\":\"\",\"key\":\"UH-1-DesktopNav\",\"id\":\"UH-1-DesktopNav\"},\"isPageComposite\":true}],\"Overlay\":[{\"bundleName\":\"react-lightbox\",\"name\":\"Lightbox\",\"props\":{\"key\":\"Overlay-0-Lightbox\",\"id\":\"Overlay-0-Lightbox\"},\"isPageComposite\":true}],\"Hero\":[{\"bundleName\":\"react-finance.y20\",\"name\":\"FinanceHeader\",\"props\":{\"adsConfig\":{\"fetchAds\":false,\"positions\":[\"BTNA\",\"BTNB\",\"BTNC\",\"BTND\"]},\"className\":\"Mx(20px) My(20px)\",\"showAds\":true,\"chartPrefixUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"quotePrefixUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"key\":\"Hero-0-FinanceHeader\",\"id\":\"Hero-0-FinanceHeader\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-featurebar\",\"name\":\"FeatureBar\",\"config\":{\"linkRenderTarget\":\"default\",\"useNCP\":true,\"mrt\":{\"cache\":true,\"skipAlertOnChecksumMismatch\":true},\"site\":\"finance\"},\"props\":{\"key\":\"Hero-1-FeatureBar\",\"id\":\"Hero-1-FeatureBar\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"MAST\",\"style\":{\"marginBottom\":\"8px\",\"marginTop\":\"8px\",\"marginLeft\":\"20px\",\"marginRight\":\"20px\",\"position\":\"relative\",\"textAlign\":\"center\",\"zIndex\":9},\"key\":\"Hero-2-Ad\",\"id\":\"Hero-2-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"LDRB\",\"style\":{\"marginBottom\":\"8px\",\"marginTop\":\"8px\",\"marginLeft\":\"auto\",\"marginRight\":\"auto\",\"position\":\"relative\",\"textAlign\":\"center\",\"lineHeight\":\"0px\",\"zIndex\":9},\"key\":\"Hero-3-Ad\",\"id\":\"Hero-3-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-slideshow\",\"name\":\"HeroSlideshow\",\"config\":{\"animate\":false,\"enableInterstitialAd\":true},\"props\":{\"adRefreshPositions\":[\"LREC2\",\"LREC-2\"],\"key\":\"Hero-4-HeroSlideshow\",\"id\":\"Hero-4-HeroSlideshow\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"HeadComponentVideo\",\"config\":{\"enableVideoMicrodata\":true,\"enableServerSideVRM\":false,\"enableVRMMetrics\":true,\"videoFallbackChannel\":\"finance-videotron\"},\"props\":{\"key\":\"Hero-5-HeadComponentVideo\",\"id\":\"Hero-5-HeadComponentVideo\"},\"isPageComposite\":true}],\"Lead\":[{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"CommonSlotComposite\",\"props\":{\"slotPosition\":\"north\",\"className\":\"Pt(20px) Pstart(20px) Pend(20px)\",\"key\":\"Lead-0-CommonSlotComposite\",\"id\":\"Lead-0-CommonSlotComposite\"},\"isPageComposite\":true}],\"SideTop\":[{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"HeadComponentTitle\",\"props\":{\"key\":\"SideTop-0-HeadComponentTitle\",\"id\":\"SideTop-0-HeadComponentTitle\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"HeadComponentAttribution\",\"config\":{\"attribution\":{\"enableCanvassComments\":true,\"enableCommentsButtonOffnet\":true,\"forceEnableProvider\":true,\"enableNewAttribution\":true}},\"props\":{\"key\":\"SideTop-1-HeadComponentAttribution\",\"id\":\"SideTop-1-HeadComponentAttribution\"},\"isPageComposite\":true}],\"Side\":[{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"CanvasShareButtons\",\"config\":{\"shareButtons\":{\"enableCanvassComments\":true,\"styles\":{\"commentsClasses\":\"Ta(c) W(40px) H(28px) Mb(4px) Lh(20px)\",\"likeClasses\":\"canvas-modal-like-button W(40px) H(28px) Ta(c) Pt(8px) D(ib) lightweight_D(n)\"}}},\"props\":{\"className\":\"left-share-buttons\",\"enableCommentsButtonOffnet\":true,\"orientation\":\"VERTICAL\",\"ylkData\":{\"subsec\":\"side-left\"},\"key\":\"Side-0-CanvasShareButtons\",\"id\":\"Side-0-CanvasShareButtons\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"CommonSlotComposite\",\"props\":{\"slotPosition\":\"west\",\"key\":\"Side-1-CommonSlotComposite\",\"id\":\"Side-1-CommonSlotComposite\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-swisschamp\",\"name\":\"Empty\",\"props\":{\"key\":\"Side-2-Empty\",\"id\":\"Side-2-Empty\"},\"isPageComposite\":true}],\"Col1\":[{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"ContentCanvas\",\"perfLabel\":\"ContentCanvas\",\"config\":{\"ads\":{\"enableInterstitialAd\":false},\"attribution\":{\"forceEnableProvider\":true,\"enableNewAttribution\":true},\"enableCanvassComments\":true,\"enableVideoManager\":true,\"enableVideoMicrodata\":true,\"enableLiveCoverage\":true,\"structuredData\":{\"publisher\":{\"@type\":\"Organization\",\"name\":\"Yahoo Finance\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"logo\":{\"@type\":\"ImageObject\",\"width\":354,\"height\":50,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fp\\u002Fyahoo_finance_en-US_h_p_finance_2.png\"}}}},\"critical\":true,\"props\":{\"key\":\"Col1-0-ContentCanvas\",\"id\":\"Col1-0-ContentCanvas\"},\"isPageComposite\":true},{\"bundleName\":\"react-finance.y20\",\"name\":\"ContentIFrame\",\"props\":{\"allowtransparency\":true,\"scrolling\":\"no\",\"src\":[{\"data-src\":\"smartasset\",\"data-frameid\":\"h0f6d1wq\",\"className\":\"H(500px) W(100%) Bd(0) Pb(10px)\"},{\"data-src\":\"smartasset\",\"data-frameid\":\"hflo8bez\",\"className\":\"H(600px) W(100%) Bd(0) Pb(10px)\"},{\"data-src\":\"smartasset\",\"data-frameid\":\"s7zeux7i\",\"className\":\"H(600px) W(100%) Bd(0) Pb(10px)\"},{\"src\":\"\\u002F\\u002Fwww.bankrate.com\\u002Fwidgets\\u002Fyho\\u002Frate-table-story.aspx\",\"className\":\"H(440px) W(100%) Bd(0)\"}],\"key\":\"Col1-1-ContentIFrame\",\"id\":\"Col1-1-ContentIFrame\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"CanvasShareButtons\",\"config\":{\"shareButtons\":{\"enableCanvassComments\":true,\"styles\":{\"commentsClasses\":\"Ta(c) W(40px) H(28px) Mb(4px) Lh(20px)\",\"likeClasses\":\"canvas-modal-like-button W(40px) H(28px) Ta(c) Pt(8px) D(ib) lightweight_D(n)\"}}},\"props\":{\"className\":\"bottom-share-buttons Pb(35px) Pt(20px)\",\"enableCommentsButtonOffnet\":true,\"key\":\"Col1-2-CanvasShareButtons\",\"id\":\"Col1-2-CanvasShareButtons\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"CanvassComments\",\"perfLabel\":\"CanvassComments\",\"skipRenderWhenLcp\":false,\"initMode\":{\"deferRender\":false,\"deferInitializeAction\":true},\"config\":{\"enableCommentsOffnet\":true,\"ui\":{\"containerExtraClasses\":\"BdT Bdtc(#222) Bdtw(2px) T(20px)\",\"showContextDisplayText\":false},\"enable\":false},\"props\":{\"oauthConsumerKey\":\"finance.oauth.client.canvass.prod.consumerKey\",\"oauthConsumerSecret\":\"finance.oauth.client.canvass.prod.consumerSecret\",\"key\":\"Col1-3-CanvassComments\",\"id\":\"Col1-3-CanvassComments\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"FOOT\",\"key\":\"Col1-4-Ad\",\"id\":\"Col1-4-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"FSRVY\",\"key\":\"Col1-5-Ad\",\"id\":\"Col1-5-Ad\"},\"isPageComposite\":true}],\"Col2\":[{\"bundleName\":\"react-finance.y20\",\"name\":\"SymbolLookup\",\"props\":{\"allowedContentTypes\":[\"story\",\"preview\"],\"resultClassNames\":\"W(100%) Bxz(bb) Z(10)\",\"urlPrefix\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"key\":\"Col2-0-SymbolLookup\",\"id\":\"Col2-0-SymbolLookup\"},\"isPageComposite\":true},{\"bundleName\":\"react-finance.y20\",\"name\":\"RecentQuotes\",\"props\":{\"containerClassNames\":\"My(20px)\",\"allowedContentTypes\":[\"story\",\"preview\"],\"quotePrefixUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"newsPrefixUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"chartPrefixUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"watchlistPrefixUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"key\":\"Col2-1-RecentQuotes\",\"id\":\"Col2-1-RecentQuotes\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"MON-1\",\"style\":{\"marginBottom\":\"8px\"},\"key\":\"Col2-2-Ad\",\"id\":\"Col2-2-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"LREC\",\"style\":{\"marginBottom\":\"20px\"},\"key\":\"Col2-3-Ad\",\"id\":\"Col2-3-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-content-canvas\",\"name\":\"CommonSlotComposite\",\"props\":{\"slotPosition\":\"east\",\"className\":\"Pt(20px) Pstart(20px) Pend(20px)\",\"key\":\"Col2-4-CommonSlotComposite\",\"id\":\"Col2-4-CommonSlotComposite\"},\"initMode\":{\"deferRender\":true,\"deferInitializeAction\":true},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-swisschamp\",\"name\":\"HeightContainer\",\"props\":{\"adjustTop\":{\"subtrahend\":\"#YDC-Col2\",\"minuend\":\"#YDC-Col1\",\"target\":\"#YDC-Col2Ext\"},\"childComponentConfig\":{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Stream\",\"perfLabel\":\"Sidekick\",\"config\":{\"ads\":{\"useHqImg\":true,\"enableGeminiAdFeedback\":true,\"frequency\":3,\"generic_viewability\":true,\"partial_viewability\":true,\"ctx_signals_enabled\":true},\"batches\":{\"pagination\":false,\"size\":32,\"start_index\":0,\"end_index\":15},\"blending_enabled\":true,\"category\":\"SIDEKICK:TOPSTORIES\",\"i13n\":{\"sec\":\"sdkick\"},\"max_exclude\":10,\"ui\":{\"attribution_pos\":\"bottom\",\"featured_summary\":false,\"follow_content\":false,\"inline_filters_max\":0,\"magazine_icon\":false,\"relative_links\":false,\"smart_crop\":true,\"smush_images\":true,\"summary\":false,\"view\":\"sidekick\"},\"video\":{\"use_inline_video\":false},\"use_prefetch\":false,\"use_content_id\":true,\"offnet\":{\"url_scheme\":\"domain\"}},\"initMode\":{\"deferRender\":false,\"deferInitializeAction\":false},\"props\":{\"key\":\"Col2-5-HeightContainer-0-Stream\",\"id\":\"Col2-5-HeightContainer-0-Stream\"}},\"itemsToTruncate\":\".js-stream-content\",\"itemsThatIncreaseHeight\":[\".YDC-Col1 .content-canvas\",\".YDC-Col1 .canvas-share-buttons\",\".YDC-Lead\"],\"itemsThatDecreaseHeight\":[\"#ad-LREC-sizer\",\"#ad-LREC2-sizer\",\"#ad-UBALREC-sizer\",\"#ad-UBALREC2-sizer\",\"#ad-MON-1-sizer\",\".YDC-Col1 .tdv2-applet-canvass\",\"#Col2-0-SymbolLookup-Proxy\",\"#Col2-1-RecentQuotes-Proxy\"],\"key\":\"Col2-5-HeightContainer\",\"id\":\"Col2-5-HeightContainer\"},\"initMode\":{\"deferRender\":false,\"deferInitializeAction\":false},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"LREC2\",\"style\":{\"marginTop\":\"8px\",\"marginBottom\":\"8px\"},\"key\":\"Col2-6-Ad\",\"id\":\"Col2-6-Ad\"},\"isPageComposite\":true}],\"Bottom\":[{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"SPL\",\"key\":\"Bottom-0-Ad\",\"id\":\"Bottom-0-Ad\"},\"isPageComposite\":true}],\"Col1Ext\":[{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Stream\",\"id\":\"YDC-Stream\",\"perfLabel\":\"Stream\",\"config\":{\"ads\":{\"enableGeminiAdFeedback\":false,\"frequency\":3,\"generic_viewability\":true,\"partial_viewability\":true,\"se\":4492794},\"cache_ttl\":300,\"components\":{\"StreamHeroCarousel\":{\"ui\":{\"follow_content\":false}},\"WideHero\":{\"ui\":{\"follow_content\":false}}},\"offnet\":{\"use_preview\":true,\"include_lcp\":true,\"url_scheme\":\"domain\"},\"persist_category\":true,\"service\":{\"specRetry\":{\"enabled\":true,\"triggerDelayPct\":50,\"throttleRate\":300}},\"ui\":{\"comments_offnet\":true,\"enable_canvass_comments\":true,\"follow_content\":false,\"inline_filters_max\":0,\"ntk_bypassA3c\":true,\"related_enabled\":true,\"smart_crop\":true,\"tumblr_reblog\":false,\"breaking_news\":false,\"relative_links\":false,\"button_pos\":\"right\",\"image_classes\":\"W(26.5%) Maw(220px)\",\"share_buttons\":{\"enable\":false},\"show_label\":true,\"view\":\"mega\",\"featured_count\":1,\"tiles\":{\"resizeImages\":true},\"comments\":false,\"follow_cluster\":false,\"show_summary\":true},\"use_mags_nydc\":true,\"use_prefetch\":false,\"pageload_image_count\":60,\"use_content_id\":true,\"use_page_category\":true,\"video\":{\"enable_video_enrichment\":true},\"use_content_site\":true,\"category\":\"YPROP:FINANCE\",\"ss_endpoint\":\"ga-hr.slingstone.yahoo.com@score\\u002Fv9\\u002Ffinance\\u002Fen-US\\u002Funified\\u002Fmega\",\"batches\":{\"pagination\":false,\"size\":25,\"timeout\":500,\"total\":25},\"pageload_item_count\":60,\"ss_timeout\":400},\"critical\":false,\"initMode\":{\"deferRender\":true,\"deferInitializeAction\":true},\"props\":{\"key\":\"YDC-Stream\",\"id\":\"YDC-Stream\"},\"isPageComposite\":true}],\"Col2Ext\":[{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Stream\",\"config\":{\"ads\":{\"useHqImg\":true,\"enableGeminiAdFeedback\":true,\"frequency\":3,\"generic_viewability\":true,\"partial_viewability\":true,\"ctx_signals_enabled\":true},\"batches\":{\"pagination\":false,\"size\":32,\"start_index\":16,\"end_index\":18},\"blending_enabled\":true,\"extended_sidekick\":true,\"category\":\"SIDEKICK:TOPSTORIES\",\"i13n\":{\"sec\":\"sdkick\"},\"max_exclude\":10,\"ui\":{\"attribution_pos\":\"bottom\",\"featured_summary\":false,\"follow_content\":false,\"inline_filters_max\":0,\"magazine_icon\":false,\"summary\":false,\"view\":\"sidekick\",\"title\":\"disabled\"},\"video\":{\"use_inline_video\":false},\"use_prefetch\":false,\"offnet\":{\"url_scheme\":\"domain\"}},\"initMode\":{\"deferRender\":false,\"deferInitializeAction\":false},\"props\":{\"key\":\"Col2Ext-0-Stream\",\"id\":\"Col2Ext-0-Stream\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"LREC3\",\"style\":{\"marginTop\":\"8px\",\"marginBottom\":\"8px\"},\"key\":\"Col2Ext-1-Ad\",\"id\":\"Col2Ext-1-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Stream\",\"config\":{\"ads\":{\"useHqImg\":true,\"enableGeminiAdFeedback\":true,\"frequency\":3,\"generic_viewability\":true,\"partial_viewability\":true,\"ctx_signals_enabled\":true},\"batches\":{\"pagination\":false,\"size\":32,\"start_index\":19,\"end_index\":31},\"blending_enabled\":true,\"extended_sidekick\":true,\"category\":\"SIDEKICK:TOPSTORIES\",\"i13n\":{\"sec\":\"sdkick\"},\"max_exclude\":10,\"ui\":{\"attribution_pos\":\"bottom\",\"featured_summary\":false,\"follow_content\":false,\"inline_filters_max\":0,\"magazine_icon\":false,\"summary\":false,\"view\":\"sidekick\",\"title\":\"disabled\"},\"video\":{\"use_inline_video\":false},\"use_prefetch\":false,\"offnet\":{\"url_scheme\":\"domain\"}},\"initMode\":{\"deferRender\":false,\"deferInitializeAction\":false},\"props\":{\"key\":\"Col2Ext-2-Stream\",\"id\":\"Col2Ext-2-Stream\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"LREC4\",\"style\":{\"marginTop\":\"20px\"},\"key\":\"Col2Ext-3-Ad\",\"id\":\"Col2Ext-3-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"td-ads\",\"name\":\"Ad\",\"props\":{\"pos\":\"MON2\",\"style\":{\"marginBottom\":\"8px\"},\"key\":\"Col2Ext-4-Ad\",\"id\":\"Col2Ext-4-Ad\"},\"isPageComposite\":true},{\"bundleName\":\"tdv2-applet-footer\",\"name\":\"Footer\",\"initMode\":{\"deferRender\":true,\"deferInitializeAction\":true},\"config\":{\"links\":[\"disclaimer\",\"help\",\"suggestions\",\"sitemap\"],\"wrapperClassName\":\"yvpDocked_Mt(260px)\",\"linkMeta\":{\"privacy\":{\"title\":\"PRIVACYUPDATED\"},\"terms\":{\"title\":\"TERMSUPDATED\"},\"disclaimer\":{\"title\":\"DISCLAIMER\",\"href\":\"https:\\u002F\\u002Fhelp.yahoo.com\\u002Fkb\\u002Ffinance\\u002FSLN2310.html?impressions=true\"},\"help\":{\"title\":\"HELP\",\"href\":\"https:\\u002F\\u002Fhelp.yahoo.com\\u002Fl\\u002Fus\\u002Fyahoo\\u002Ffinance\\u002F\"},\"suggestions\":{\"title\":\"SUGGESTIONS\",\"href\":\"https:\\u002F\\u002Fyahoo.uservoice.com\\u002Fforums\\u002F382977\"},\"sitemap\":{\"title\":\"SITEMAP\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsitemap\\u002F\"}},\"enableCCPAFooter\":true,\"isCCPAEnabled\":true},\"props\":{\"key\":\"Col2Ext-5-Footer\",\"id\":\"Col2Ext-5-Footer\"},\"isPageComposite\":true}]},\"title\":\"Yahoo\",\"videoPlayerConfig\":{\"CMS\":{\"env\":\"prod\"}},\"yvapid\":\"193\",\"ads\":{\"events\":{\"adFetch\":{\"ps\":\"BTNA,BTNB,BTNC,BTND,MAST,LDRB,SPL,LREC,LREC2,LREC3,LREC4,FOOT,FSRVY\",\"dynamic\":true,\"addsa\":\"megamodal=true\",\"firstRender\":\"BTNA,BTNB,BTNC,BTND,LREC\"}},\"contentTypeAdPosModifier\":{\"slideshow\":[\"-LREC\",\"LREC-2\",\"LREC2\"],\"inlineSlideshow\":[]},\"deferRender\":true},\"i13n\":{\"enablePartnerPixel\":true,\"rapid\":{\"keys\":{\"layout\":\"y20stream\",\"pd\":\"non_modal\",\"pt\":\"content\"}}},\"initializeAction\":\"initializeContentPage\",\"_context\":{\"site\":\"finance\",\"pageType\":\"content\",\"renderTarget\":\"default\",\"financeSubscribed\":\"\"}}},\"headerOverride\":{},\"queryOverride\":{}},\"compositeConfig\":{\"Lead-0-CommonSlotComposite\":{\"name\":\"Lead-0-CommonSlotComposite\",\"components\":[]},\"Side-1-CommonSlotComposite\":{\"name\":\"Side-1-CommonSlotComposite\",\"components\":[]},\"Col2-5-HeightContainer\":{\"parentComponent\":{\"bundleName\":\"tdv2-applet-swisschamp\",\"name\":\"HeightContainer\"},\"name\":\"Col2-5-HeightContainer\",\"components\":[{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Stream\",\"perfLabel\":\"Sidekick\",\"config\":{\"ads\":{\"useHqImg\":true,\"enableGeminiAdFeedback\":true,\"frequency\":3,\"generic_viewability\":true,\"partial_viewability\":true,\"ctx_signals_enabled\":true},\"batches\":{\"pagination\":false,\"size\":32,\"start_index\":0,\"end_index\":15},\"blending_enabled\":true,\"category\":\"SIDEKICK:TOPSTORIES\",\"i13n\":{\"sec\":\"sdkick\"},\"max_exclude\":10,\"ui\":{\"attribution_pos\":\"bottom\",\"featured_summary\":false,\"follow_content\":false,\"inline_filters_max\":0,\"magazine_icon\":false,\"relative_links\":false,\"smart_crop\":true,\"smush_images\":true,\"summary\":false,\"view\":\"sidekick\"},\"video\":{\"use_inline_video\":false},\"use_prefetch\":false,\"use_content_id\":true,\"offnet\":{\"url_scheme\":\"domain\"}},\"initMode\":{\"deferRender\":false,\"deferInitializeAction\":false},\"props\":{\"key\":\"Col2-5-HeightContainer-0-Stream\",\"id\":\"Col2-5-HeightContainer-0-Stream\"}}]},\"UH-0-UH\":{\"name\":\"UH-0-UH\",\"components\":[{\"bundleName\":\"tdv2-applet-uh\",\"name\":\"Header\",\"config\":{\"mrt\":{\"flush\":false,\"cache\":true,\"skipAlertOnChecksumMismatch\":true,\"prioritize\":false},\"uh\":{\"search\":{\"queries\":{\"fr\":\"uh3_finance_vert\"},\"placeholderText\":\"FINANCE_UH_SEARCH_WEB\",\"instantSearch\":false,\"autofocus\":false,\"action\":\"\\u002Fquote\\u002F\",\"enableFuzzyQuery\":false,\"newsCount\":4,\"quotesCount\":6,\"listCount\":4,\"quotesQueryId\":\"tss_match_phrase_query\",\"multiQuoteQueryId\":\"multi_quote_single_token_query\",\"newsQueryId\":\"news_ss_symbols\",\"enableCb\":true,\"enableNavLinks\":true,\"feedback\":{\"enabled\":false,\"href\":\"https:\\u002F\\u002Fyahoo.uservoice.com\\u002Fforums\\u002F439018\"},\"style\":{\"container\":{\"wrapper\":\"Mend(375px) Mstart(194px) Maw(595px) H(35px) Trstf(eo) Trsde(0s) Trsdu(0.14s) Trsp(a) ie-7_H(100%)\"},\"input\":{\"content\":\"Bdrs(2px)! ie-7_Lh(18px) ie-8_Lh(18px) ie-7_W(88%) ie-7_Mt(2px) ie-7_H(100%)\"},\"search_button\":{\"content_1\":\"C(white) Fz(16px) two-btn_Fz(s) H(35px) ie-7_Lh(18px) ie-8_Lh(18px) ie-7_W(140px) ie-7_H(41px) Mend(0)! ie-8_W(140px) Mstart(5px) W(140px)\"}}},\"ui\":{\"back\":false,\"follow\":false,\"mail\":true,\"notifications\":false,\"profile\":true,\"search\":true,\"share\":false,\"topbar\":true,\"skip_nav\":true},\"skip_nav\":{\"data\":{\"items\":{\"item_1\":{\"name\":\"Skip to Navigation\",\"link\":\"#Navigation\",\"order\":1},\"item_2\":{\"name\":\"Skip to Market Summary\",\"link\":\"#market-summary\",\"order\":2},\"item_3\":{\"name\":\"Skip to Main Content\",\"link\":\"#Main\",\"order\":3},\"item_4\":{\"name\":\"Skip to Related Content\",\"link\":\"#Aside\",\"order\":4}}}},\"useTopicTitle\":false,\"style\":{\"container\":{\"wrapper\":\"Miw(980px) UH Z(10) Py(14px) Pos(r)\"}},\"profile\":{\"mode\":\"server\"}}},\"props\":{\"ref\":\"UHApplet\",\"key\":\"UH-0-UH-0-Header\",\"id\":\"UH-0-UH-0-Header\"}}]},\"UH-1-DesktopNav-acct-switch\":{\"name\":\"UH-1-DesktopNav-acct-switch\",\"components\":[{\"bundleName\":\"tdv2-applet-account-switch\",\"name\":\"AccountSwitch\",\"config\":{\"isEnabled\":true},\"props\":{\"key\":\"UH-1-DesktopNav-acct-switch-0-AccountSwitch\",\"id\":\"UH-1-DesktopNav-acct-switch-0-AccountSwitch\"}}]},\"account-switch-uh\":{\"name\":\"account-switch-uh\",\"components\":[{\"bundleName\":\"tdv2-applet-account-switch\",\"name\":\"AccountSwitch\",\"config\":{\"isEnabled\":true,\"styles\":{\"avatar\":{},\"secondary_accounts\":{}}},\"props\":{\"key\":\"account-switch-uh-0-AccountSwitch\",\"id\":\"account-switch-uh-0-AccountSwitch\"}}]}},\"compositeStatus\":{\"Lead-0-CommonSlotComposite\":1,\"Side-1-CommonSlotComposite\":1,\"Col2-5-HeightContainer\":1,\"UH-0-UH\":1,\"UH-1-DesktopNav-acct-switch\":1,\"account-switch-uh\":1},\"pageData\":{\"meta\":{\"name\":{\"oath:guce:consent-host\":\"guce.yahoo.com\",\"msapplication-TileColor\":\"#6e329d\",\"msapplication-TileImage\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fp\\u002Fyahoo_frontpage_en-US_s_f_w_bestfit_frontpage.png\",\"msvalidate.01\":\"A9862C0E6E1BE95BCE0BF3D0298FD58B\",\"referrer\":\"unsafe-url\",\"theme-color\":\"#400090\",\"twitter:dnt\":\"on\",\"twitter:site\":\"@YahooFinance\",\"news_keywords\":\"diagnostic testing\",\"googlebot\":\"\",\"bingbot\":\"\",\"robots\":\"\",\"apple-itunes-app\":\"app-id=304158842,app-argument=yahoo:\\u002F\\u002Farticle\\u002Fview?uuid=ee6c0f80-61d5-3bba-8101-bb8bd4d538c3&src=web\",\"twitter:card\":\"summary_large_image\"},\"property\":{\"og:type\":\"article\",\"al:android:app_name\":\"Yahoo\",\"al:android:package\":\"com.yahoo.mobile.client.android.yahoo\",\"al:android:url\":\"yahoo:\\u002F\\u002Farticle\\u002Fview?uuid=ee6c0f80-61d5-3bba-8101-bb8bd4d538c3&src=web\",\"al:ios:app_name\":\"Yahoo\",\"al:ios:app_store_id\":\"304158842\",\"al:ios:url\":\"yahoo:\\u002F\\u002Farticle\\u002Fview?uuid=ee6c0f80-61d5-3bba-8101-bb8bd4d538c3&src=web\",\"og:image:width\":\"1672\",\"og:image:height\":\"1110\"},\"httpEquiv\":{\"x-dns-prefetch-control\":\"on\"}},\"amp\":{\"enabled\":true,\"enableFor3pCanonical\":true,\"useFpRoute\":false},\"title\":\"Coronavirus Vaccine Progress Accelerates\",\"dimensions\":{\"authed\":\"0\",\"ynet\":\"0\",\"ssl\":\"1\",\"spdy\":\"0\",\"ytee\":\"0\",\"mode\":\"normal\",\"site\":\"finance\",\"region\":\"US\",\"lang\":\"en-US\",\"bucket\":\"finance-US-en-US-def\",\"colo\":\"gq1\",\"device\":\"featurephone\",\"bot\":\"1\",\"ecma\":\"default\",\"environment\":\"prod\",\"intl\":\"us\",\"partner\":\"none\",\"tz\":\"America\\u002FLos_Angeles\",\"feature\":[\"enableCMP\",\"enableConsentData\",\"enableCCPAFooter\",\"enableGDPRFooter\",\"enableGuceJs\",\"enableGuceJsOverlay\",\"videoDocking\",\"newContentAttribution\",\"newLogo\",\"livecoverage\"],\"nps\":{}},\"description\":\"Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.\",\"links\":[{\"rel\":\"canonical\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"x-default\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Fca.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-CA\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-US\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Fuk.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-GB\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Fin.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-IN\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Fnz.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-NZ\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Fie.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-IE\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Fau.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-AU\"},{\"rel\":\"alternate\",\"href\":\"https:\\u002F\\u002Fsg.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"hrefLang\":\"en-SG\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fs.yimg.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fmbp.yimg.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fgeo.query.yahoo.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fconsent.cmp.oath.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fcsc.beap.bc.yahoo.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fbeap.gemini.yahoo.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fyep.video.yahoo.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fvideo-api.yql.yahoo.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fyrtas.btrll.com\"},{\"rel\":\"preconnect\",\"href\":\"\\u002F\\u002Fshim.btrll.com\"},{\"rel\":\"icon\",\"sizes\":\"any\",\"href\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fmit\\u002Fmedia\\u002Fp\\u002Fcommon\\u002Fimages\\u002Ffavicon_new-7483e38.svg\"},{\"rel\":\"icon\",\"type\":\"image\\u002Fx-icon\",\"href\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fcv\\u002Fapiv2\\u002Fdefault\\u002Ffp\\u002F20180826\\u002Ficons\\u002Ffavicon_y19_32x32.ico\"},{\"rel\":\"amphtml\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Famphtml\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}],\"entities\":[{\"term\":\"WIKIID:Medical_test\",\"label\":\"diagnostic testing\",\"capAbtScore\":\"0.884\"},{\"term\":\"YCT:001000532\",\"score\":\"1.0\",\"label\":\"Pharmaceuticals & Drug Trials\"},{\"term\":\"YCT:001000225\",\"score\":\"0.989295\",\"label\":\"Health Care Industry\"},{\"term\":\"YCT:001000395\",\"score\":\"0.937158\",\"label\":\"Health\"},{\"term\":\"YCT:001000742\",\"score\":\"0.581633\",\"label\":\"Science\"},{\"term\":\"YCT:001000469\",\"score\":\"0.525253\",\"label\":\"Infectious Diseases\"},{\"term\":\"YCT:001000532\",\"score\":\"1.0\",\"label\":\"Pharmaceuticals & Drug Trials\"},{\"term\":\"YMEDIA:CATEGORY=FIN_WHITELISTEDPROVIDERS\",\"score\":\"1.0\",\"label\":\"\"},{\"term\":\"YMEDIA:CATEGORY=100000000\",\"score\":\"1.0\",\"label\":\"Yahoo Originals\"},{\"term\":\"YMEDIA:CATEGORY=100000002\",\"score\":\"1.0\",\"label\":\"\"},{\"term\":\"YCT:001000225\",\"score\":\"0.989295\",\"label\":\"Health Care Industry\"},{\"term\":\"YCT:001000395\",\"score\":\"0.937158\",\"label\":\"Health\"},{\"term\":\"YCT:001000742\",\"score\":\"0.581633\",\"label\":\"Science\"},{\"term\":\"YCT:001000469\",\"score\":\"0.525253\",\"label\":\"Infectious Diseases\"}],\"ctopic\":\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\",\"image\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FyfmPmOmwuoMa7svbTToA.g--~B\\u002FaD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\",\"titleTag\":\"Coronavirus Vaccine Progress Accelerates\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"uuid\":\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\",\"author\":\"Joanna Kong\",\"category\":\"Pharmaceuticals & Drug Trials\"},\"spaceid\":\"980771051\",\"status\":{\"code\":200,\"headers\":null,\"redirect\":null,\"responseBody\":null,\"responseHTML\":null},\"appConfig\":{\"timeouts\":{\"page\":3000,\"xhr\":3000,\"navigate\":6000},\"spaceid\":2023538075,\"renderTargets\":null},\"routeConfig\":{},\"renderTargets\":{\"default\":{\"id\":\"default\",\"guid\":0,\"classNames\":\"render-target-default\",\"owner\":\"app\",\"elementId\":\"render-target-default\",\"url\":\"\"}},\"renderTargetsInited\":false},\"MRTStore\":{\"mrtConfigRaw\":{\"app\":{\"enable\":true},\"page\":{},\"route\":{}},\"originRenderTargetId\":\"default\",\"originUrl\":\"\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"staticComponents\":{}},\"DaggrStore\":{\"config\":{},\"forceEnabled\":true,\"shouldSkipExecute\":false},\"RouteStore\":{\"currentNavigate\":{\"transactionId\":6142894128432896,\"url\":\"\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"method\":\"GET\",\"body\":{},\"externalUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"route\":{\"path\":\"\\u002F:contentPath\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"contentSite\":\"finance\",\"name\":\"storyExtra\",\"url\":\"\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"params\":{\"contentPath\":\"news\",\"alias\":\"coronavirus-vaccine-progress-accelerates-155109303\"},\"query\":{}},\"error\":null,\"isComplete\":true},\"routes\":{\"home\":{\"path\":\"\\u002F\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"finance\",\"pageType\":\"index\",\"renderTarget\":\"default\",\"spaceid\":1183300002},\"appstate\":{\"path\":\"\\u002F_appstate\",\"action\":\"loadConfigAndPage\",\"i13n\":{\"rapid\":{\"pageview_on_init\":false}},\"method\":\"get\",\"page\":\"appstate\"},\"comments\":{\"path\":\"\\u002Fcomments\",\"action\":\"loadConfigAndPage\",\"i13n\":{\"rapid\":{\"pageview_on_init\":false}},\"method\":\"get\",\"page\":\"comments\",\"pageType\":\"comments\"},\"author\":{\"path\":\"\\u002Fauthor\\u002F:author\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"author\",\"pageType\":\"author\",\"renderTarget\":\"default\",\"enableContentRedirect\":true},\"perfHome\":{\"path\":\"\\u002Fperf\\u002Fhome\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"perfHome\",\"pageType\":\"perfhome\"},\"section\":{\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\",\"path\":\"\\u002F:contentSite(news)\\u002F:section(abc-news|dear-abby|odd|science|world)\"},\"topicmanagement\":{\"path\":\"\\u002F:contentSite(managetopics)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"topics\",\"pageType\":\"topics\",\"renderTarget\":\"default\",\"spaceid\":1197808708},\"topicmanagementfrontpage\":{\"path\":\"\\u002F:contentSite(managetopic)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"topics\",\"pageType\":\"topicsfrontpage\",\"renderTarget\":\"default\",\"spaceid\":1197808708},\"blogpost\":{\"path\":\"\\u002Fblogs\\u002F:contentBlog\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"blogpost\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"cavideo\":{\"path\":\"\\u002F:type(v|video)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"cavideo\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"preview\":{\"path\":\"(\\u002Fm)?\\u002F:uuid([a-fA-F0-9]{8}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{12})\\u002F:alias\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"method\":\"get\",\"page\":\"content\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"slideshow\":{\"path\":\"\\u002F:type(photos|ss)\\u002F:alias\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"slideshow\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"slideshowPhoto\":{\"path\":\"\\u002F:type(photos|ss)\\u002F:alias\\u002F:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"slideshow\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"story\":{\"path\":\"\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"magazinesSlideshowPhoto\":{\"path\":\"\\u002Fnews\\u002F:alias\\u002Fphoto-:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"slideshow\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"storyExtra\":{\"path\":\"\\u002F:contentPath\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"contentSite\":\"finance\"},\"everything\":{\"path\":\"\\u002F:contentSite(everything)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"everything\",\"pageType\":\"index\"},\"world\":{\"path\":\"\\u002F:contentSite(everything)\\u002Fworld\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"world\",\"pageType\":\"world\"},\"news\":{\"path\":\"\\u002F:contentSite(news)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"news\",\"pageType\":\"index\",\"renderTarget\":\"default\",\"spaceid\":1197800621},\"eolStory\":{\"path\":\"\\u002F:section(politics|realestate|style|movies|celebrity|beauty)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentSite\":\"news\",\"contentType\":\"story\",\"pageType\":\"content\"},\"sectionUS\":{\"customTitleTag\":\"US\",\"path\":\"\\u002F:contentSite(news)\\u002F:section(us)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"sectionweed\":{\"path\":\"\\u002F:contentSite(news)\\u002F:section(weed)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"magName\":\"news\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"sectionnowigetit\":{\"path\":\"\\u002F:contentSite(news)\\u002F:section(now-i-get-it)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"magName\":\"news\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"sectionpolitics\":{\"path\":\"\\u002F:contentSite(news)\\u002F:section(politics|originals)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"sectionelections\":{\"path\":\"\\u002F:contentSite(news)\\u002F:section(elections)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"elections\",\"renderTarget\":\"default\"},\"sectiongovernor\":{\"path\":\"\\u002F:contentSite(news)\\u002F:section(elections)\\u002Fgovernor\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"governor\",\"renderTarget\":\"default\"},\"sectionhouse\":{\"path\":\"\\u002F:contentSite(news)\\u002F:section(elections)\\u002Fhouse\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"house\",\"renderTarget\":\"default\"},\"sectionsenate\":{\"path\":\"\\u002F:contentSite(news)\\u002F:section(elections)\\u002Fsenate\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"senate\",\"renderTarget\":\"default\"},\"sectionTag\":{\"path\":\"\\u002F:contentSite(news)\\u002Ftagged\\u002F:tag\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"magName\":\"news\",\"page\":\"magtag\",\"pageType\":\"magtag\",\"renderTarget\":\"default\",\"useYqlCTopic\":true,\"enableContentRedirect\":true},\"financeSitemap\":{\"contentSite\":\"finance\",\"path\":\"\\u002Fsitemap\\u002F\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"finance\",\"pageType\":\"sitemapindex\",\"renderTarget\":\"default\"},\"financeSitemapCnt\":{\"contentSite\":\"finance\",\"path\":\"\\u002Fsitemap\\u002F:sitemapalias\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"finance\",\"pageType\":\"sitemapcontent\",\"renderTarget\":\"default\"},\"magazineTag\":{\"path\":\"\\u002Ftagged\\u002F:alias\",\"action\":\"loadConfigAndPage\",\"contentSite\":\"finance\",\"method\":\"get\",\"page\":\"magtag\",\"pageType\":\"magtag\",\"useYqlCTopic\":true},\"autosStory\":{\"contentSite\":\"autos\",\"path\":\"\\u002F:contentSite(autos)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"spaceid\":1197809032},\"autosSlideshow\":{\"path\":\"\\u002F:contentSite(autos)\\u002F:type(photos|ss)\\u002F:alias\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\",\"spaceid\":1197809032},\"autosSlideshowPhoto\":{\"path\":\"\\u002F:contentSite(autos)\\u002Fphotos\\u002F:alias\\u002F:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\",\"spaceid\":1197809032},\"autosVideo\":{\"path\":\"\\u002F:contentSite(autos)\\u002F:type(v|video)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"cavideo\",\"pageType\":\"content\",\"spaceid\":1197809032},\"autosStoryPhotos\":{\"path\":\"\\u002F:contentSite(autos)(\\u002Fss)?\\u002F:alias\\u002Fphoto-:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"spaceid\":1197809032},\"autosStoryExtra\":{\"path\":\"\\u002F:contentSite(autos)\\u002F:contentPath\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"spaceid\":1197809032},\"autosBlogpost\":{\"path\":\"\\u002F:contentSite(autos)\\u002Fblogs\\u002F:contentBlog\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"blogpost\",\"pageType\":\"content\",\"spaceid\":1197809032},\"buildSeries\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fbuildseries\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"buildseries\",\"pageType\":\"buildseries\"},\"buildSeriesCampConfesion\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fbuildseries\\u002Fcamp-confessions\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"buildseries\",\"pageType\":\"camp-confessions\"},\"buildSeriesXChangeRate\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fbuildseries\\u002Fthe-xchange-rate\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"buildseries\",\"pageType\":\"the-xchange-rate\"},\"buildSeriesBuildLondon\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fbuildseries\\u002Fuk\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"buildseries\",\"pageType\":\"build-london\"},\"buildSeriesBuildSydney\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fbuildseries\\u002Fau\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"buildseries\",\"pageType\":\"build-sydney\"},\"entshowtimes\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fshowtimes\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"showtimes\",\"pageType\":\"showtimes\",\"spaceid\":1197803686},\"entertainmentHome\":{\"path\":\"\\u002F:contentSite(entertainment)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"entertainment\",\"pageType\":\"index\",\"renderTarget\":\"default\",\"spaceid\":1197809029},\"entertainmentSitemap\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fsitemap\\u002F\",\"action\":\"loadConfigAndPage\",\"enableContentRedirect\":true,\"method\":\"get\",\"page\":\"index\",\"pageType\":\"sitemapindex\",\"renderTarget\":\"default\"},\"entertainmentSitemapCnt\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fsitemap\\u002F:sitemapalias\",\"action\":\"loadConfigAndPage\",\"enableContentRedirect\":true,\"method\":\"get\",\"page\":\"sitemap\",\"pageType\":\"sitemapcontent\"},\"entertainmentpreview\":{\"path\":\"\\u002F:contentSite(entertainment)(\\u002Fm)?\\u002F:uuid([a-fA-F0-9]{8}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{12})\\u002F:alias\",\"action\":\"loadConfigAndPage\",\"contentSite\":\"entertainment\",\"contentType\":\"story\",\"method\":\"get\",\"page\":\"content\",\"pageType\":\"content\"},\"sectionEnt\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002F:section(celebrity|movies|panorama|firefly)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"sectionEntTV\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002F:section(tv)\",\"action\":\"loadConfigAndPage\",\"customTitleTag\":\"TV\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"sectionEntMusic\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002F:section(music)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"section\",\"overrideSectionName\":\"entertainmentmusic\",\"renderTarget\":\"default\"},\"sectionEntTag\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Ftagged\\u002F:tag\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"magName\":\"entertainment\",\"page\":\"magtag\",\"pageType\":\"magtag\",\"renderTarget\":\"default\",\"useYqlCTopic\":true,\"enableContentRedirect\":true,\"spaceid\":1197800334},\"EntSlideshow\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002F:type(photos|ss)\\u002F:alias\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\"},\"EntSlideshowPhoto\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fphotos\\u002F:alias\\u002F:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\"},\"EntVideo\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002F:type(v|video)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"cavideo\",\"pageType\":\"content\"},\"EntStory\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"EntStoryPhotos\":{\"path\":\"\\u002F:contentSite(entertainment)(\\u002Fss)?\\u002F:alias\\u002Fphoto-:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"EntStoryExtra\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002F:contentPath\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"EntBlogpost\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fblogs\\u002F:contentBlog\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"blogpost\",\"pageType\":\"content\"},\"EntTagmovie\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Ffilm\\u002F:alias\",\"method\":\"get\",\"page\":\"moviesTag\",\"action\":\"loadConfigAndPage\",\"pageType\":\"magtag\",\"renderTarget\":\"default\",\"spaceid\":1197800334,\"tagType\":\"movie\",\"useYqlCTopic\":true,\"enableContentRedirect\":true},\"EntTagperson\":{\"path\":\"\\u002F:contentSite(entertainment)\\u002Fperson\\u002F:alias\",\"method\":\"get\",\"page\":\"moviesTag\",\"action\":\"loadConfigAndPage\",\"pageType\":\"magtag\",\"renderTarget\":\"default\",\"spaceid\":1197800334,\"tagType\":\"person\",\"useYqlCTopic\":true,\"enableContentRedirect\":true},\"lifestylesHome\":{\"path\":\"\\u002F:contentSite(lifestyle)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"index\",\"pageType\":\"index\",\"renderTarget\":\"default\",\"spaceid\":980751902},\"sectionLifeStyle\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:section(style|beauty|well-being|wellness|food|style-beauty|trending|news)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"sectionLifeStylePop\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:section(pop-culture)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"customTitleTag\":\"Pop Culture\",\"page\":\"section\",\"pageType\":\"section\",\"renderTarget\":\"default\"},\"lifestyleSitemap\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002Fsitemap\\u002F\",\"action\":\"loadConfigAndPage\",\"enableContentRedirect\":true,\"method\":\"get\",\"page\":\"index\",\"pageType\":\"sitemapindex\",\"renderTarget\":\"default\"},\"lifestyleSitemapCnt\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002Fsitemap\\u002F:sitemapalias\",\"action\":\"loadConfigAndPage\",\"enableContentRedirect\":true,\"method\":\"get\",\"page\":\"sitemap\",\"pageType\":\"sitemapcontent\"},\"sectionMakers\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:section(makers)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"magName\":\"makersus\",\"page\":\"makers\",\"pageType\":\"makers\",\"renderTarget\":\"default\",\"customDescription\":\"MAKERS is a media brand that accelerates the women's movement, through stories of real life experiences that ignite passion and action.\",\"customTitleTag\":\"Women's empowerment content and conference - MAKERS\"},\"sectionMakersArticles\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:section(makers)\\u002Farticles\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"overrideSectionName\":\"makersArticles\",\"page\":\"makersArticles\",\"pageType\":\"makersArticles\",\"renderTarget\":\"default\",\"customDescription\":\"MAKERS is a media brand that accelerates the women's movement, through stories of real life experiences that ignite passion and action.\",\"customTitleTag\":\"Women's empowerment content and conference - MAKERS\"},\"sectionMakersConference\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:section(makers)\\u002Fvideos\\u002Fconference\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"overrideSectionName\":\"makersVideosConference\",\"page\":\"makers\",\"pageType\":\"makersVideosConference\",\"renderTarget\":\"default\",\"customDescription\":\"MAKERS is a media brand that accelerates the women's movement, through stories of real life experiences that ignite passion and action.\",\"customTitleTag\":\"Women's empowerment content and conference - MAKERS\"},\"sectionMakersVideos\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:section(makers)\\u002Fvideos\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"overrideSectionName\":\"makersVideos\",\"page\":\"makersVideos\",\"pageType\":\"makersVideos\",\"renderTarget\":\"default\",\"customDescription\":\"MAKERS is a media brand that accelerates the women's movement, through stories of real life experiences that ignite passion and action.\",\"customTitleTag\":\"Women's empowerment content and conference - MAKERS\"},\"sectionLifeTag\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002Ftagged\\u002F:tag\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"magtag\",\"pageType\":\"magtag\",\"renderTarget\":\"default\",\"useYqlCTopic\":true,\"enableContentRedirect\":true,\"spaceid\":980751755},\"lifestylepreview\":{\"path\":\"\\u002F:contentSite(lifestyle)(\\u002Fm)?\\u002F:uuid([a-fA-F0-9]{8}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{12})\\u002F:alias\",\"action\":\"loadConfigAndPage\",\"contentSite\":\"lifestyle\",\"contentType\":\"story\",\"method\":\"get\",\"page\":\"content\",\"pageType\":\"content\"},\"LifeSlideshow\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:type(photos|ss)\\u002F:alias\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\"},\"LifeSlideshowPhoto\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002Fphotos\\u002F:alias\\u002F:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\"},\"LifeVideo\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:type(v|video)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"cavideo\",\"pageType\":\"content\"},\"LifeStory\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"LifeStoryPhotos\":{\"path\":\"\\u002F:contentSite(lifestyle)(\\u002Fss)?\\u002F:alias\\u002Fphoto-:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"LifeStoryExtra\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002F:contentPath\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"LifeBlogpost\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002Fblogs\\u002F:contentBlog\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"blogpost\",\"pageType\":\"content\"},\"horoscopes\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002Fhoroscope\\u002F:sign\\u002F:frequency-:frequencyValue.html\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"horoscope\",\"pageType\":\"horoscope\",\"spaceid\":980751755},\"horoscopesHome\":{\"path\":\"\\u002F:contentSite(lifestyle)\\u002Fhoroscope\\u002F\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"horoscopes\",\"pageType\":\"horoscopes\",\"spaceid\":980751755},\"now\":{\"path\":\"\\u002F:contentSite(now)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"index\",\"pageType\":\"index\",\"renderTarget\":\"default\",\"spaceid\":1197806873},\"nowPreview\":{\"path\":\"\\u002F:contentSite(now)(\\u002Fm)?\\u002F:uuid([a-fA-F0-9]{8}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{4}-[a-fA-F0-9]{12})\\u002F:alias\",\"action\":\"loadConfigAndPage\",\"contentSite\":\"now\",\"contentType\":\"story\",\"method\":\"get\",\"page\":\"content\",\"pageType\":\"content\"},\"sectionNowMorning\":{\"path\":\"\\u002F:contentSite(now)\\u002F:section(morning-brief)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"customTitleTag\":\"Morning Brief\",\"page\":\"morning-brief\",\"pageType\":\"morning-brief\",\"renderTarget\":\"default\"},\"sectionCorona\":{\"path\":\"\\u002F:contentSite(now)\\u002F:section(coronavirus)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"customTitleTag\":\"Coronavirus Updates\",\"page\":\"morning-brief\",\"pageType\":\"morning-brief\",\"renderTarget\":\"default\"},\"sectionLiveVideo\":{\"path\":\"\\u002F:contentSite(now)\\u002F:section(live)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"customTitleTag\":\"Live video\",\"page\":\"livevideo\",\"pageType\":\"livevideo\",\"renderTarget\":\"default\"},\"nowSlideshow\":{\"path\":\"\\u002F:contentSite(now)\\u002F:type(photos|ss)\\u002F:alias\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\"},\"nowSlideshowPhoto\":{\"path\":\"\\u002F:contentSite(now)\\u002Fphotos\\u002F:alias\\u002F:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"pageType\":\"content\"},\"nowVideo\":{\"path\":\"\\u002F:contentSite(now)\\u002F:type(v|video)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"cavideo\",\"pageType\":\"content\"},\"nowStory\":{\"path\":\"\\u002F:contentSite(now)\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"nowStoryPhotos\":{\"path\":\"\\u002F:contentSite(now)(\\u002Fss)?\\u002F:alias\\u002Fphoto-:photoAlias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\"},\"video\":{\"path\":\"\\u002F:contentSite(video)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"index\",\"pageType\":\"index\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoOnboarding\":{\"path\":\"\\u002F:contentSite(video)\\u002Fonboarding\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"videoOnboarding\",\"pageType\":\"videoOnboarding\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoContent\":{\"path\":\"\\u002F:contentSite(video)\\u002F:alias.html\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"method\":\"get\",\"page\":\"content\",\"pageType\":\"content\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoContentSuperx\":{\"path\":\"\\u002F:contentSite(video)\\u002Fentertainment\\u002F:alias.html\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"entContent\",\"pageType\":\"entContent\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoContentintheknowSuper\":{\"path\":\"\\u002F:contentSite(video)\\u002Fintheknow\\u002F:alias.html\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"knowContent\",\"pageType\":\"knowContent\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoChannelITK\":{\"path\":\"\\u002F:contentSite(video)\\u002Fintheknow\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"knowChannel\",\"pageType\":\"knowChannel\",\"renderTarget\":\"default\",\"spaceid\":1197808822},\"videoContentfinanceSuper\":{\"path\":\"\\u002F:contentSite(video)\\u002Ffinance\\u002F:alias.html\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"financeContent\",\"pageType\":\"financeContent\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoContentsportSuper\":{\"path\":\"\\u002F:contentSite(video)\\u002Fsports\\u002F:alias.html\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"sportsContent\",\"pageType\":\"sportsContent\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoContentnewsSuper\":{\"path\":\"\\u002F:contentSite(video)\\u002Fnews\\u002F:alias.html\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"newsContent\",\"pageType\":\"newsContent\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoContentLifeSuper\":{\"path\":\"\\u002F:contentSite(video)\\u002Flifestyle\\u002F:alias.html\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"lifeContent\",\"pageType\":\"lifeContent\",\"renderTarget\":\"default\",\"spaceid\":1197808613},\"videoShow\":{\"path\":\"\\u002F:contentSite(videos)\\u002F:pageType(pay-it-forward|reset-your-mindset|together-at-home|we-keep-playing)\",\"action\":\"loadConfigAndPage\",\"method\":\"get\",\"page\":\"videoShow\"}}},\"I13nStore\":{\"appConfig\":{\"base\":{\"initComscore\":true,\"initRapid\":true,\"enablePartnerPixel\":false,\"enablePartneradobeBeacon\":false,\"adobeProp53\":\"\",\"enableNielsenBeacon\":false,\"partnerAdobeJSFile\":\"\",\"rapid\":{\"keys\":{\"ver\":\"y20\",\"navtype\":\"server\"},\"compr_type\":\"deflate\",\"tracked_mods_viewability\":[],\"test_id\":\"\",\"webworker_file\":\"\\u002Flib\\u002Fmetro\\u002Fg\\u002Fmyy\\u002Frapidworker_1_2_0.0.2.js\",\"client_only\":1,\"track_right_click\":true,\"pageview_on_init\":true,\"viewability\":true,\"dwell_on\":true},\"rootModelData\":{},\"navigationPageview\":{\"enable\":true},\"serverPageview\":{\"enable\":true,\"type\":\"nonClassified\"},\"enableConsentData\":true}},\"comscoreC7Keyword\":\"\",\"currentUrl\":\"\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"i13nConfig\":{\"initComscore\":true,\"initRapid\":true,\"enablePartnerPixel\":true,\"enablePartneradobeBeacon\":false,\"adobeProp53\":\"\",\"enableNielsenBeacon\":false,\"partnerAdobeJSFile\":\"\",\"rapid\":{\"keys\":{\"ver\":\"y20\",\"navtype\":\"server\",\"layout\":\"y20stream\",\"pd\":\"non_modal\",\"pt\":\"content\",\"p_cpos\":1,\"p_hosted\":\"hosted\",\"pct\":\"story\",\"pstaid\":\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\",\"pstcat\":\"finance\",\"p_sec\":\"finance\",\"ss_cid\":\"\",\"mrkt\":\"us\",\"site\":\"finance\",\"lang\":\"en-US\",\"colo\":\"gq1\",\"_yrid\":\"d1fpqmlfc95jj\",\"_rid\":\"d1fpqmlfc95jj\",\"abk\":\"\"},\"compr_type\":\"deflate\",\"tracked_mods_viewability\":[],\"test_id\":\"finance-US-en-US-def\",\"webworker_file\":\"\\u002Flib\\u002Fmetro\\u002Fg\\u002Fmyy\\u002Frapidworker_1_2_0.0.2.js\",\"client_only\":1,\"track_right_click\":true,\"pageview_on_init\":true,\"viewability\":true,\"dwell_on\":true,\"spaceid\":\"980771051\"},\"rootModelData\":{},\"navigationPageview\":{\"enable\":true},\"serverPageview\":{\"enable\":true,\"type\":\"nonClassified\"},\"enableConsentData\":true},\"pageConfig\":{\"base\":{\"enablePartnerPixel\":true,\"rapid\":{\"keys\":{\"layout\":\"y20stream\",\"pd\":\"non_modal\",\"pt\":\"content\"}}},\"headerOverride\":null},\"routeConfig\":{},\"runtimeConfig\":{\"rapid\":{\"keys\":{\"p_cpos\":1,\"p_hosted\":\"hosted\",\"pct\":\"story\",\"pstaid\":\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\",\"pstcat\":\"finance\",\"p_sec\":\"finance\",\"ss_cid\":\"\"}}}},\"ClientStore\":{\"currentRoute\":{\"path\":\"\\u002F:contentPath\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"contentSite\":\"finance\",\"name\":\"storyExtra\",\"url\":\"\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"params\":{\"contentPath\":\"news\",\"alias\":\"coronavirus-vaccine-progress-accelerates-155109303\"},\"query\":{}}},\"QuoteAutoCompleteStore\":{\"clear\":true},\"PageTransitionStore\":{\"_appConfig\":{\"pageTransition\":{\"enabled\":true,\"enableHandlerCallback\":true}},\"_currentRoute\":{\"path\":\"\\u002F:contentPath\\u002F:alias.html\",\"method\":\"get\",\"page\":\"content\",\"action\":\"loadConfigAndPage\",\"contentType\":\"story\",\"pageType\":\"content\",\"contentSite\":\"finance\",\"name\":\"storyExtra\",\"url\":\"\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"params\":{\"contentPath\":\"news\",\"alias\":\"coronavirus-vaccine-progress-accelerates-155109303\"},\"query\":{}},\"_currentRenderTarget\":{\"referrer\":{\"route\":{}},\"id\":\"default\",\"guid\":0,\"classNames\":\"render-target-default\",\"owner\":\"app\",\"elementId\":\"render-target-default\",\"url\":\"\"},\"_renderTargets\":{\"default\":{\"referrer\":{\"route\":{}},\"id\":\"default\",\"guid\":0,\"classNames\":\"render-target-default\",\"owner\":\"app\",\"elementId\":\"render-target-default\",\"url\":\"\"}}},\"ApacMembershipChallengesStore\":{\"challenges\":{\"read_article\":{}}},\"VideoPlayerStore\":{\"_config\":{\"docking\":false,\"enableRestoreOnNavigate\":true,\"enableUndockOnNavigate\":true,\"refreshDockingOnNavigate\":true,\"totalInactivePlayers\":10,\"videoClickSrc\":[\"video-click\",\"startScreen\"]},\"_playerConfig\":{\"CMS\":{\"env\":\"prod\"}},\"_playerUrls\":{\"url\":\"https:\\u002F\\u002Fyep.video.yahoo.com\\u002Fjs\\u002F3\\u002Fvideoplayer-min.js?r=nextgen&lang=en-US&ypv=prod\"}},\"FlyoutStore\":{},\"NavrailStore\":{\"showNavrail\":false,\"navTitle\":\"finance\",\"navSections\":\"coronavirus-vaccine-progress-accelerates-155109303\",\"currentUrl\":\"\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"pageType\":\"content\",\"navSectionsDisplayTitle\":{},\"site\":\"finance\"},\"AppConfigStore\":{\"config\":{\"clientEligible\":{\"index\":[\"entertainment\",\"gma\",\"hkstylemen\",\"hktravelnow\",\"lifestyle\",\"news\",\"now\",\"saludbucal\",\"saudebucal\",\"weather\"],\"content\":[\"finance\"],\"home\":[\"entertainment\",\"gma\",\"hkstylemen\",\"hktravelnow\",\"lifestyle\",\"news\",\"now\",\"saludbucal\",\"saudebucal\",\"weather\"]},\"enableScrollRestoration\":false,\"enableVideoManager\":true,\"pageTransition\":{\"enabled\":true,\"enableHandlerCallback\":true},\"prefetch\":{\"enableOnPageStoreChange\":false,\"prerenderDelay\":1000,\"pageTypes\":{\"home\":[\"content\"],\"index\":[\"content\"],\"intlMagazine\":[\"intlMagazineContent\"],\"maghome\":[\"magcontent\",\"magpreview\"],\"magtag\":[\"magcontent\",\"magpreview\"]}},\"timeouts\":{\"page\":3000,\"xhr\":3000,\"navigate\":6000},\"renderTargets\":null,\"videoPlayer\":{\"docking\":false,\"enableRestoreOnNavigate\":true,\"enableOathPlayer\":false,\"refreshDockingOnNavigate\":true,\"version\":null,\"videoPlayerJSUrl\":\"\",\"videoPlayerJSTop\":false,\"videoPlayerJSAsync\":false}}},\"LangStore\":{\"defaultBundle\":\"td-app-yahoo\",\"baseLangs\":{\"td-app-yahoo\":{\"TITLE\":\"Articles\",\"DEFAULT_TITLE\":\"Yahoo\",\"REDIRECT_404_MSG\":\"Hmmm... the page you're looking for isn't here. Try searching above.\",\"RSS_TITLE\":\"RSS feed for {page}\",\"ACCOUNT_INFO\":\"Account Info\",\"ADD_MANAGE_ACCOUNTS\":\"Add or Manage accounts\",\"AUTHOR_TITLE\":\"{name} on Yahoo\",\"AUTHOR_BYLINE_TITLE\":\"{name}, {byline} for Yahoo\",\"FOLLOW_MODULE_TITLE\":\"Follow {property}\",\"FOLLOW_PROPERTY_TITLE_NEWS\":\"Yahoo News\",\"FOLLOW_PROPERTY_TITLE_MAKERS\":\"MAKERS\",\"FINANCE_UH_SEARCH_WEB\":\"Search for news, symbols or companies\",\"GOTO_TEXT\":\"Go to {text}\",\"MANAGE_SUBSCRIPTION\":\"Manage Subscription\",\"MORE_SYMBOLS\":\"More symbols\",\"MSG_NO_NEWS\":\"no news found\",\"MSG_NO_SEARCH_RESULTS\":\"No matching results for '{query}'\",\"MSG_NO_SYMBOLS\":\"no symbols found\",\"NEWS\":\"News\",\"PRIVATE\":\"PRIVATE\",\"SCREENER\":\"Screener\",\"SEARCH\":\"Search\",\"SEARCH_FEEDBACK_MSG\":\"Give feedback on the new search experience\",\"SEARCH_PRIVATE_COMPANIES_PROMOTION\":\"Now you can search stock related news and private companies such as Airbnb.\",\"SEARCH_SCREENER_LINK\":\"Screener for stocks & more\",\"SEARCH_TIP\":\"Tip: Try a valid symbol or a specific company name for relevant results\",\"SHOW_LESS\":\"Show less\",\"SIGN_OUT_ALL\":\"Sign out all\",\"SYMBOLS\":\"Symbols\",\"TRENDING_TODAY\":\"Trending Today\",\"UH_SEARCH_MOBILE_WEB_V2\":\"Search for news or symbols\",\"UH_SEARCH_WEB\":\"Search for news, symbols or companies\",\"VIDEO_TITLE\":\" [Video]\",\"YAHOO_COMPANY_NAME\":\"Yahoo\"},\"react-finance\":{\"200_DAY_MOVING_AVG\":\"200-Day Moving Average\",\"AD\":\"Ad\",\"ADD_SYMBOL\":\"Add Symbol\",\"ADD_TO_WATCHLIST\":\"Add to Watchlist\",\"ADVERTISEMENT\":\"Advertisement\",\"AERONAUTICS_TITLE\":\"Aeronautics\",\"ALGO_WATCHLIST\":\"Watchlist\",\"APP_PROMO_OPEN_APP\":\"Open in App\",\"AUDIOVISUAL_MEDIA_TITLE\":\"Audiovisual and Media\",\"AUTO_TITLE\":\"Auto\",\"AUTOCOMPLETE_PLACEHOLDER\":\"VZ, AAPL, TSLA\",\"AUTOS_TITLE\":\"Autos\",\"AUTOS_TRANSPORTATION_TITLE\":\"Autos & Transportation\",\"AVG_VOL_10_DAY\":\"Avg Vol (10 day)\",\"AVG_VOL_3_MONTH\":\"Avg Vol (3 month)\",\"BANKING_INSURANCE_TITLE\":\"Banking & Insurance\",\"BASIC_MATERIALS_TITLE\":\"Basic Materials\",\"BETA\":\"Beta\",\"BONDS_TITLE\":\"US Treasury Bonds Rates\",\"BREXIT_TITLE\":\"Brexit\",\"BUSINESS_SERVICES_TITLE\":\"Business Services\",\"CALENDARS_TITLE\":\"Calendars\",\"CANCEL\":\"Cancel\",\"CAREERS_TITLE\":\"Careers\",\"CHART\":\"Chart\",\"CHEMICAL_BASIC_MATERIALS_TITLE\":\"Chemical and Basic Materials\",\"CHEMIE_TITLE\":\"Chemie\",\"CLOSE\":\"Close\",\"COMMODITIES\":\"Futures\",\"COMPARE_PRODUCTS_TITLE\":\"Compare Products\",\"COMPONENTS\":\"Components\",\"CONFIRM_DELETE\":\"Confirm Delete\",\"CONFIRM_DELETE_MSG\":\"Are you sure you want to delete {pfName} watchlist?\",\"CONFIRM_DELETE_TICKER\":\"Are you sure you want to remove {symbol}?\",\"CONFIRM_NO\":\"No\",\"CONFIRM_YES\":\"Yes\",\"CONFIRMED_CASES\":\"Confirmed Cases\",\"CONSTRUCTION_TITLE\":\"Construction\",\"CONSUMER_DURABLES_TITLE\":\"Consumer Durables\",\"CONSUMER_GOODS_TITLE\":\"Consumer Goods\",\"CONSUMER_PRODUCTS_MEDIA_TITLE\":\"Consumer Products & Media\",\"CONTRIBUTORS_TITLE\":\"Contributors\",\"COVID_19\":\"COVID-19\",\"CREATE_NEW_LIST\":\"Create a new list\",\"CURRENCIES\":\"Currencies\",\"CURRENCIES_TITLE\":\"Currencies\",\"CURRENCY_CONVERTER_TITLE\":\"Currency Converter\",\"DELAYED\":\"Delayed Price\",\"DELETE_BTN\":\"Delete\",\"DELETE_TICKER_INFO\":\"Delete symbol from watchlist\",\"DELETE_WATCHLIST\":\"Delete Watchlist\",\"DIVERSIFIED_BUSINESS_TITLE\":\"Diversified Business\",\"DIVIDEND\":\"Dividend\",\"EARNINGS_REPORT\":\"Earnings Report\",\"EDIT\":\"Edit\",\"END\":\"End\",\"ENERGY_TITLE\":\"Energy\",\"ENTER_LIST_NAME\":\"Enter List name\",\"ETFS_TITLE\":\"Top ETFs\",\"EX_DIVIDEND\":\"Ex-Dividend\",\"EX_DIVIDEND_DATE\":\"Ex-Dividend Date\",\"FAILSAFE_CACHE_MESSAGE\":\"We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.\",\"FEEDBACK_TITLE\":\"Feedback\",\"FINAL_ROUND_TITLE\":\"The Final Round\",\"FINANCIAL_TITLE\":\"Financial\",\"FMCG_TITLE\":\"FMCG\",\"FOODS_TITLE\":\"Foods\",\"FOOTER_ABOUT_TEXT\":\"About Our Ads\",\"FOOTER_COMPANY_TEXT\":\"{copyright}. All rights reserved.\",\"FOOTER_DISCLAIMER_TEXT\":\"Data Disclaimer\",\"FOOTER_FB_FOLLOW_TEXT\":\"Follow on Facebook\",\"FOOTER_HELP_TEXT\":\"Help\",\"FOOTER_PRIVACY_TEXT\":\"Privacy\",\"FOOTER_PRIVACY_TEXT_UPDATED\":\"Privacy (Updated)\",\"FOOTER_SITEMAP_TEXT\":\"Sitemap\",\"FOOTER_SUGGEST_TEXT\":\"Suggestions\",\"FOOTER_TERMS_TEXT\":\"Terms (Updated)\",\"FOOTER_TU_FOLLOW_TEXT\":\"Follow on Tumblr\",\"FOOTER_TW_FOLLOW_TEXT\":\"Follow on Twitter\",\"FORWARD_PE\":\"Forward P\\u002FE\",\"FREE_REALTIME\":\"Real Time Price\",\"GAINERS_TITLE\":\"Stocks: Gainers\",\"GENERAL\":\"Breaking News\",\"GLOBAL\":\"Global\",\"GOOD_LIFE_NAV_TITLE\":\"The Good Life\",\"GOTO_TEXT\":\"Go to {text}\",\"HARDWARE_ELECTRONICS_TITLE\":\"Computer Hardware & Electronics\",\"HEALTHCARE_TITLE\":\"Healthcare\",\"HIGH\":\"High\",\"IN_WATCHLIST\":\"In Watchlist\",\"INDUSTRIALS_TITLE\":\"Industrials\",\"INDUSTRY_NAV_TITLE\":\"Industry News\",\"INTERNET_TITLE\":\"Internet\",\"LAST_MONTH\":\"Last Mo.\",\"LEISURE_INDUSTRIES_TITLE\":\"Leisure Industries\",\"LIFESTYLE_TITLE\":\"Lifestyle\",\"LISTS\":\"Lists\",\"LIVE_VIDEO\":\"Live Video\",\"LOADING\":\"Loading...\",\"LOOKUP_FOOTER_TIP\":\"Tip: Use comma to separate multiple quotes\",\"LOSERS_TITLE\":\"Stocks: Losers\",\"LOW\":\"Low\",\"MAIL\":\"Mail\",\"MANAGE_SUBSCRIPTION\":\"Manage Subscription\",\"MANUFACTURING_MATERIALS_TITLE\":\"Manufacturing & Materials\",\"MARKET_BLOGS_TITLE\":\"Market Blogs\",\"MARKET_MOVERS_TITLE\":\"Market Movers\",\"MARKET_SUMMARY\":\"Market Summary\",\"MARKET_SUMMARY_CAROUSEL\":\"Market summary containing a list of {size} items\",\"MARKET_SUMMARY_CAROUSEL_ITEM_DECREASED\":\"{name} has decreased by {changePercent} or {change} points to {price} points\",\"MARKET_SUMMARY_CAROUSEL_ITEM_INCREASED\":\"{name} has increased by {changePercent} or {change} points to {price} points\",\"MARKET_SUMMARY_CAROUSEL_ITEM_UNCHANGED\":\"{name} is unchanged at {price}\",\"MONEY_GUIDES_TITLE\":\"Money Guides\",\"MORE_SYMBOLS\":\"More symbols\",\"MORNING_BRIEF\":\"Morning Brief\",\"MOST_ACTIVE_TITLE\":\"Stocks: Most Actives\",\"MSG_EMPTY_LIST\":\"Your list is empty.\",\"MSG_EMPTY_PF\":\"You don't have any symbols in this list.\",\"MSG_EMPTY_RQ\":\"Your Recently Viewed list is empty.\",\"MSG_EMPTY_YFINLIST\":\"We're sorry, but we were unable to retrieve this data. Please try again.\",\"MSG_NO_LISTS\":\"No lists found\",\"MSG_NO_NEWS\":\"No news found\",\"MSG_NO_SEARCH_RESULTS\":\"No matching results for '{query}'\",\"MSG_NO_SYMBOLS\":\"No symbols found\",\"MUTUALFUNDS_TITLE\":\"Top Mutual Funds\",\"MY_PORTFOLIO_NAV_TITLE\":\"My Portfolio\",\"MY_WATCHLIST\":\"My Watchlist\",\"NA\":\"N\\u002FA\",\"NAME_NEW_WATCHLIST\":\"Name your new watchlist\",\"NASDAQ_REALTIME_PRICE\":\"Nasdaq Realtime Price\",\"NEWS_NAV_TITLE\":\"News\",\"NEWS\":\"News\",\"NEW_HIGH\":\"Price Alert\",\"NEW_LOW\":\"Price Alert\",\"NOTIFICATIONS\":\"Notifications\",\"NO_NOTIFICATION_DATA\":\"Notification data is not available\",\"OIL_NATURAL_GAS_TITLE\":\"Oil and Natural Gas\",\"YAHOO_FINANCE_APP\":\"Yahoo Finance App\",\"OLDER\":\"Older\",\"OPTIONS\":\"Options\",\"OPTIONS_TITLE\":\"Most Traded Options by Volume\",\"ORIGINALS_TITLE\":\"Yahoo Originals\",\"PEG_RATIO_5_YR\":\"PEG Ratio (5 yr expected)\",\"PERSONAL_FINANCE_NAV_TITLE\":\"Personal Finance\",\"PHARMACEUTICAL_TITLE\":\"Pharmaceutical\",\"POST_MARKET_NOTICE\":\"Post-Market:\",\"POWER_TITLE\":\"Power\",\"PREDEFINED_SCREENER\":\"Screener\",\"PREMIUM\":\"Premium\",\"PRESS_RELEASE\":\"Press Releases\",\"PRICE_TO_BOOK\":\"Price\\u002FBook\",\"PRICE_ALERT_UP\":\"Price Alert\",\"PRICE_ALERT_DOWN\":\"Price Alert\",\"PRIVATE\":\"PRIVATE\",\"PROFILE\":\"Profile\",\"PROPERTIES_TITLE\":\"Properties\",\"PROPERTY_TITLE\":\"Property\",\"PUBLIC_SERVICES_TITLE\":\"Public Services\",\"PORTFOLIO_DAILY_SUMMARY\":\"Portfolio Summary\",\"QUICK_VIDEO\":\"Quick Video\",\"QUOTE_LOOKUP\":\"Quote Lookup\",\"RATES\":\"Rates\",\"RAW_MATERIALS_TITLE\":\"Raw Materials\",\"REAL_ESTATE_TITLE\":\"Real Estate\",\"REALTY_TITLE\":\"Realty\",\"RESEARCH_REPORTS\":\"Research Reports\",\"RESEARCH_REPORT\":\"Premium Research Report\",\"RECOMMEND_STOCKS\":\"Recommended Stocks\",\"RENAME\":\"Rename\",\"RENAME_MODAL_ERROR_MESSAGE\":\"Please enter a valid watchlist name.\",\"RENAME_MODAL_MESSAGE\":\"Enter a new name for {pfName}.\",\"RENAME_MODAL_TITLE\":\"Rename your watchlist\",\"RETAILING_HOSPITALITY_TITLE\":\"Retailing & Hospitality\",\"RETIREMENT_TITLE\":\"Retirement\",\"RQ_TITLE\":\"Recently Viewed\",\"RELATED_QUOTES\":\"Related Quotes\",\"SAVE\":\"Save\",\"SAVING_SPENDING_TITLE\":\"Saving & Spending\",\"SCREENER\":\"Screener\",\"SEARCH\":\"Search\",\"SEARCH_FEEDBACK_MSG\":\"Give feedback on the new search experience\",\"SEARCH_FEEDBACK_CURRENT_MSG\":\"Give feedback on the search experience\",\"SEARCH_PRIVATE_COMPANIES_PROMOTION\":\"Now you can search stock related news and private companies such as Airbnb.\",\"SEARCH_SCREENER_LINK\":\"Screener for stocks & more\",\"SEARCH_TIP\":\"Tip: Try a valid symbol or a specific company name for relevant results\",\"SHARE\":\"Share\",\"SHARES_FLOAT\":\"Float\",\"SHORT_RATIO\":\"Short Ratio\",\"SHOW_ALL_RESULTS_FOR\":\"Show all results for {query}\",\"SHOW_LESS\":\"Show less\",\"SIGN_IN\":\"Sign In\",\"SIGN_IN_TO_ADD_WATCHLIST\":\"Sign in to add to watchlist\",\"SIGNIFICANT_DEVELOPMENT\":\"Premium Significant Development\",\"SIGNIFICANT_DEVELOPMENTS\":\"Significant Developments\",\"SMALL_BUSINESS_TITLE\":\"Small Business\",\"SOFTWARE_SERVICES_TITLE\":\"Computer Software & Services\",\"SPLIT\":\"Split\",\"SPORTSBOOK_TITLE\":\"Sportsbook\",\"START\":\"Start\",\"SUGGESTIONS\":\"Suggestions\",\"SUMMARY\":\"Summary\",\"SYMBOLS\":\"Symbols\",\"TAXES_TITLE\":\"Taxes\",\"TD_52_WK_HIGH\":\"52 Week High\",\"TD_52_WK_LOW\":\"52 Week Low\",\"TD_52_WK_RANGE\":\"52 Week Range\",\"TD_ALERTS\":\"Alerts\",\"TD_ASK\":\"Ask\",\"TD_ASK_SIZE\":\"Ask Size\",\"TD_BID\":\"Bid\",\"TD_BID_SIZE\":\"Bid Size\",\"TD_BOOK_VALUE\":\"Book Val\",\"TD_CASH_AMOUNT\":\"Amount\",\"TD_CHANGE\":\"Change\",\"TD_COST_BASIS\":\"Cost Basis\",\"TD_CURRENCY\":\"Currency\",\"TD_DAY_GAIN\":\"Day Gain $\",\"TD_DAY_GAIN_PERCENT\":\"Day Gain %\",\"TD_DAY_HIGH\":\"Day High\",\"TD_DAY_LOW\":\"Day Low\",\"TD_DAY_RANGE\":\"Intraday High\\u002FLow\",\"TD_DIVIDEND_PAYMENT_DATE\":\"Dividend Payment Date\",\"TD_DIVIDEND_YIELD\":\"Dividend Yield\",\"TD_EBITDA\":\"EBITDA\",\"TD_EPS\":\"EPS\",\"TD_EXCHANGE\":\"Exchange\",\"TD_FIVE_YEAR\":\"5-Yr Return\",\"TD_FUND_CATEGORY\":\"Category\",\"TD_HIGH_LIMIT\":\"High Limit\",\"TD_LAST_MONTH\":\"Last Month\",\"TD_LAST_NAV\":\"Last NAV\",\"TD_LAST_WEEK\":\"Last Week\",\"TD_LOT_VALUE\":\"Lot Value\",\"TD_LOW_LIMIT\":\"Low Limit\",\"TD_MARKET\":\"Intraday Return\",\"TD_MARKET_CAP\":\"Market Cap\",\"TD_MARKET_TIME\":\"Market Time\",\"TD_MARKET_VALUE\":\"Market Value\",\"TD_MATURITY\":\"Maturity\",\"TD_NAV_CHANGE\":\"NAV $ Change\",\"TD_NAV_PERCENT_CHANGE\":\"NAV % Change\",\"TD_NOTES\":\"Notes\",\"TD_OPEN\":\"Open\",\"TD_OPEN_INTEREST\":\"Open Interest\",\"TD_OPTION_NAME\":\"Option\",\"TD_PE_RATIO\":\"PE Ratio\",\"TD_PERCENT_CHANGE\":\"% Change\",\"TD_PREV_CLOSE\":\"Prev Close\",\"TD_PRICE\":\"Last Price\",\"TD_PRICE_PAID_PER_SHARE\":\"Price Paid\",\"TD_SHARES\":\"Shares\",\"TD_SHARES_OUTSTANDING\":\"Shares Out\",\"TD_SPARKLINE\":\"Day Chart\",\"TD_SYMBOL\":\"Symbol\",\"TD_THREE_MONTH\":\"3-Mo Return\",\"TD_THREE_YEAR\":\"3-Yr Return\",\"TD_TOTAL_GAIN\":\"Total Gain $\",\"TD_TOTAL_GAIN_PERCENT\":\"Total Gain %\",\"TD_TRADE_DATE\":\"Trade Date\",\"TD_VOLUME\":\"Volume\",\"TD_YEAR_TO_DATE\":\"YTD Return\",\"TD_YESTERDAY\":\"Yesterday\",\"TD_YIELD\":\"Yield\",\"TDG_BASIC\":\"Basic Columns\",\"TDG_DETAILS\":\"Details Columns\",\"TDG_FUNDAMENTALS\":\"Fundamentals Columns\",\"TDG_MARKET\":\"Share Statistics\",\"TDG_MOVERS\":\"Moving Averages Columns\",\"TDG_PORTFOLIOS\":\"Portfolios Columns\",\"TDG_SHARE_STATS\":\"Share Statistics\",\"TECH_NAV_TITLE\":\"Tech\",\"TECHNOLOGY_TITLE\":\"Technology\",\"TELECOM_UTILITIES_TITLE\":\"Telecom & Utilities\",\"TEXTILES_TITLE\":\"Textiles\",\"TOP_STORIES_TITLE\":\"Top Stories\",\"TOURISM_SERVICES_TITLE\":\"Tourism and Services\",\"TRADE_IDEAS\":\"Investment Ideas\",\"TRADE_IDEA\":\"Premium Investment Idea\",\"TRAILING_PE\":\"Trailing P\\u002FE\",\"TRAVEL_TITLE\":\"Travel\",\"TRENDING_TICKERS_TITLE\":\"Trending Tickers\",\"TRENDING_TODAY\":\"Trending Today\",\"TRIGGER_ALERT\":\"Price Alert\",\"TODAY\":\"Today\",\"UH_SEARCH_MOBILE_WEB\":\"Quote Lookup\",\"UH_SEARCH_MOBILE_WEB_V2\":\"Search for news or symbols\",\"UH_SEARCH_WEB\":\"Search for news, symbols or companies\",\"UNDO\":\"Undo\",\"UNITED_STATES\":\"United States\",\"VIDEO_TITLE\":\"Video\",\"VIEW_CHART\":\"View Chart\",\"WATCHLISTS_NAV_TITLE\":\"Watchlists\",\"WEEK_AHEAD\":\"Earnings This Week\",\"WORLD_INDICES\":\"World Indices\",\"WORLD_TITLE\":\"World\",\"YF_TITLE\":\"Yahoo Finance Lists\"},\"tdv2-applet-navrail\":{\"ABOUT\":\"About\",\"ACCOUNT_INFO\":\"Account Info\",\"APPS\":\"Apps\",\"APPS_ATT\":\"AT&T Apps\",\"BACK\":\"Back\",\"FOLLOW\":\"Follow\",\"FOLLOW_US\":\"Follow Us\",\"MORE\":\"More\",\"MORE_NAVLINKS\":\"More Navlinks\",\"MORE_SITES\":\"More Sites\",\"PROFILE\":\"Profile\",\"PROPERTY_HOME\":\"{property} Home\",\"SERVICES_ATT\":\"AT&T Services\",\"SETTINGS\":\"Settings\",\"SHOW_LESS\":\"Show less\",\"SHOW_MORE\":\"Show More\",\"SHOW_X_MORE\":\"Show {number} More\",\"SIGNIN\":\"Sign in\",\"SIGNOUT\":\"Sign out\",\"SIGNOUT_ALL\":\"Sign out all\",\"STORYLINES\":\"Storylines\",\"TOOLS\":\"Tools\",\"WEATHER_FORECAST\":\"Weather Forecast\",\"WELCOME_BACK\":\"Welcome back\",\"VIEW_ON_INSTAGRAM\":\"View on Instagram\",\"YAHOO\":\"Yahoo\",\"YAHOO_SITES\":\"Yahoo Sites\"},\"tdv2-applet-featurebar\":{\"BREAKING_NEWS\":\"Breaking News\",\"HIGH_LIGHT\":\"Highlight\"},\"td-ads\":{\"AD\":\"AD\",\"ADVERTISEMENT\":\"Advertisement\",\"SCROLL_TO_CONTINUE\":\"Scroll to continue with content\"},\"tdv2-applet-slideshow\":{\"NEXT\":\"Next\",\"PREV\":\"Previous\",\"SPONSORED\":\"Sponsored\",\"MORE\":\"More\",\"LESS\":\"Less\"},\"tdv2-applet-content-canvas\":{\"SOURCE\":\"Source: {source}\",\"READ_MORE\":\"Read more\",\"CONTINUE_READING\":\"Continue reading\",\"READ_FULL_ARTICLE\":\"Read full article\",\"STORY_CONTINUES\":\"Story continues\",\"SPONSORED\":\"Sponsored\",\"ADFB_DONE\":\"Done\",\"ADFB_FDB1\":\"It's offensive to me\",\"ADFB_FDB2\":\"I keep seeing this\",\"ADFB_FDB3\":\"It's not relevant to me\",\"ADFB_FDB4\":\"Something else\",\"ADFB_HEADING\":\"Why don't you like this ad?\",\"ADFB_REVIEW\":\"We'll review and make changes needed.\",\"ADFB_THANKYOU\":\"Thanks for your feedback!\",\"ADFB_TOOLTIP\":\"I don't like this ad\",\"ADFB_UNDO\":\"Undo\",\"ADFB_CLOSE\":\"Close\",\"TUMBLR_SHARE\":\"Reblog\",\"FACEBOOK_SHARE\":\"Share\",\"TWITTER_SHARE\":\"Tweet\",\"PINTEREST_SHARE\":\"Pin it\",\"POSTED_IN\":\"posted in\",\"REPOSTED_IN\":\"reposted in\",\"MAIL_SHARE\":\"Send\",\"COPY_LINK_SHARE\":\"Copy\",\"SHARE\":\"Share\",\"CLOSE\":\"Close\",\"COMMENT\":\"Comment\",\"RELATED_SEARCH_RESULT\":\"Related Search Result\",\"VIEW_PHOTOS\":\"View photos\",\"MORE\":\"More\",\"LESS\":\"Less\",\"COMMENT_COUNT\":\"{count, number} {count, plural, one {Comment} other {Comments}}\",\"LIKE_THIS_TOPIC\":\"Like\",\"SIGN_IN_TO_LIKE\":\"Like\",\"UNDO\":\"Undo\",\"ENTER_MODAL_MSG\":\"Beginning of a Modal Window. You are entering a Modal, Escape will cancel and close the window.\",\"DOWNLOAD_APP\":\"Join the conversation in the {appName} app\",\"BE_THE_FIRST\":\"Start the conversation\",\"VIEW_REACTIONS\":\"View Reactions ({count, number})\",\"REACTION_COUNT\":\"{count, number} {count, plural, one {Reaction} other {Reactions}}\",\"DOWNLOAD_APP_PROMPT\":\"Download {appName} app\",\"EXPAND_COMMENTS\":\"Expand user comments\",\"CLOSE_COMMENTS\":\"Close user comments\",\"SIGN_IN_POST_COMMENT\":\"Sign in to post a message.\",\"SHARE_YOUR_REACTION\":\"Share your reaction\",\"CATEGORY_LABEL_AUTOS\":\"Autos\",\"CATEGORY_LABEL_BUSINESS\":\"Business\",\"CATEGORY_LABEL_BEAUTY\":\"Beauty\",\"CATEGORY_LABEL_CELEBRITY\":\"Celebrity\",\"CATEGORY_LABEL_DIY\":\"DIY\",\"CATEGORY_LABEL_ENTERTAINMENT\":\"Entertainment\",\"CATEGORY_LABEL_FINANCE\":\"Finance\",\"CATEGORY_LABEL_FOOD\":\"Food\",\"CATEGORY_LABEL_GAMES\":\"Games\",\"CATEGORY_LABEL_GMA\":\"News\",\"CATEGORY_LABEL_HEALTH\":\"Health\",\"CATEGORY_LABEL_HKFOOD\":\"Food\",\"CATEGORY_LABEL_HKSTYLEMEN\":\"StyleMEN\",\"CATEGORY_LABEL_HKTRAVELNOW\":\"Travel\",\"CATEGORY_LABEL_HOMES\":\"Homes\",\"CATEGORY_LABEL_IVY\":\"Screen\",\"CATEGORY_LABEL_LIFESTYLE\":\"Lifestyle\",\"CATEGORY_LABEL_MAKERS\":\"Projects\",\"CATEGORY_LABEL_MOVIES\":\"Movies\",\"CATEGORY_LABEL_MUSIC\":\"Music\",\"CATEGORY_LABEL_NEWS\":\"News\",\"CATEGORY_LABEL_NEWSORIGINALSSTREAM\":\"Yahoo News Originals\",\"CATEGORY_LABEL_OMG\":\"Celebrity\",\"CATEGORY_LABEL_POLITICS\":\"Politics\",\"CATEGORY_LABEL_POPCULTURE\":\"Pop Culture\",\"CATEGORY_LABEL_SCIENCE\":\"Science\",\"CATEGORY_LABEL_SHOPPING\":\"Shopping\",\"CATEGORY_LABEL_SPORTS\":\"Sports\",\"CATEGORY_LABEL_STYLE\":\"Style\",\"CATEGORY_LABEL_TECH\":\"Tech\",\"CATEGORY_LABEL_TECHNOLOGY\":\"Technology\",\"CATEGORY_LABEL_TRAVEL\":\"Travel\",\"CATEGORY_LABEL_TRENDING\":\"Trending\",\"CATEGORY_LABEL_TV\":\"TV\",\"CATEGORY_LABEL_US\":\"U.S.\",\"CATEGORY_LABEL_WELLNESS\":\"Wellness\",\"CATEGORY_LABEL_WORLD\":\"World\"},\"tdv2-applet-swisschamp\":{\"BROWSER_UPGRADE\":\"Some parts of this page is not supported on your current browser version. Please upgrade the browser to the latest.\",\"CLOSE\":\"Close\"},\"tdv2-applet-stream\":{\"AD\":\"Ad\",\"AD_EXPIRED\":\"Ad has expired\",\"AD_FEEDBACK\":\"Ad Feedback\",\"AD_TERMS\":\"Why this ad?\",\"AD_LIKE\":\"I like this ad\",\"AD_LIKE_DETAIL\":\"Show more ads like this\",\"AD_DISLIKE\":\"I don't like this ad\",\"AD_DISLIKE_DETAIL\":\"Show fewer ads like this\",\"ADFB_DONE\":\"Done\",\"ADFB_FDB1\":\"It's offensive to me\",\"ADFB_FDB2\":\"I keep seeing this\",\"ADFB_FDB3\":\"It's not relevant to me\",\"ADFB_FDB4\":\"Something else\",\"ADFB_HEADING\":\"Why don't you like this ad?\",\"ADFB_REVIEW\":\"We'll review and make changes needed\",\"ADFB_THANKYOU\":\"Thanks for your feedback!\",\"ADFB_THANKYOU_DISLIKE\":\"Thanks for your feedback! We'll review and make changes needed.\",\"ADFB_TOOLTIP\":\"I don't like this ad\",\"ADFB_DISLIKE_AD_HIDDEN\":\"This ad has been hidden\",\"ADFB_DISLIKE_AD_HIDDEN_DETAIL\":\"Improve your future experience.\",\"ADFB_UNDO\":\"Undo\",\"ADFB_CLOSE\":\"Close\",\"ADFB_SEND_FEEDBACK\":\"Send Feedback\",\"AD_GIVE_FEEDBACK\":\"Give feedback\",\"ADVERTISE_WITH_US\":\"Advertise with us\",\"LEARN_MORE\":\"Learn More\",\"DAYS\":\"days\",\"EDITORS_PICK\":\"Editor's Pick\",\"FEATURED\":\"Featured\",\"FLASHSALE_DAYS\":\"d\",\"FREE_SHIPPING\":\"Free Shipping\",\"HIDE_SOURCES\":\"Hide Sources\",\"HIDE_STORIES\":\"Hide Stories\",\"OFF\":\"{off} off\",\"PROMOTIONS_DAYS\":\"days\",\"PROMOTIONS_OFF\":\"{off} off\",\"SALE_ENDS_IN\":\"Sale ends in\",\"SHARE_MENU\":\"Share Menu\",\"SHOW_SOURCES\":\"More Sources\",\"SHOW_STORIES\":\"More Stories\",\"THE_ROUNDUP\":\"Need To Know\",\"YOU_MIGHT_ALSO_LIKE\":\"You might also like\",\"STREAM_CATEGORY_AUTOS\":\"Autos\",\"STREAM_CATEGORY_BUSINESS\":\"Business\",\"STREAM_CATEGORY_BEAUTY\":\"Beauty\",\"STREAM_CATEGORY_CELEBRITY\":\"Celebrity\",\"STREAM_CATEGORY_DIY\":\"DIY\",\"STREAM_CATEGORY_ENTERTAINMENT\":\"Entertainment\",\"STREAM_CATEGORY_FINANCE\":\"Finance\",\"STREAM_CATEGORY_FOOD\":\"Food\",\"STREAM_CATEGORY_GAMES\":\"Games\",\"STREAM_CATEGORY_GMA\":\"News\",\"STREAM_CATEGORY_HEALTH\":\"Health\",\"STREAM_CATEGORY_HKFOOD\":\"Food\",\"STREAM_CATEGORY_HKSTYLEMEN\":\"StyleMEN\",\"STREAM_CATEGORY_HKTRAVELNOW\":\"Travel\",\"STREAM_CATEGORY_HOMES\":\"Homes\",\"STREAM_CATEGORY_IVY\":\"Screen\",\"STREAM_CATEGORY_LIFESTYLE\":\"Lifestyle\",\"STREAM_CATEGORY_MAKERS\":\"Projects\",\"STREAM_CATEGORY_MOVIES\":\"Movies\",\"STREAM_CATEGORY_MUSIC\":\"Music\",\"STREAM_CATEGORY_NEWS\":\"News\",\"STREAM_CATEGORY_OMG\":\"Celebrity\",\"STREAM_CATEGORY_POLITICS\":\"Politics\",\"STREAM_CATEGORY_POPCULTURE\":\"Pop Culture\",\"STREAM_CATEGORY_SCIENCE\":\"Science\",\"STREAM_CATEGORY_SHOPPING\":\"Shopping\",\"STREAM_CATEGORY_SPORTS\":\"Sports\",\"STREAM_CATEGORY_STYLE\":\"Style\",\"STREAM_CATEGORY_TECH\":\"Tech\",\"STREAM_CATEGORY_TECHNOLOGY\":\"Technology\",\"STREAM_CATEGORY_TRAVEL\":\"Travel\",\"STREAM_CATEGORY_TRENDING\":\"Trending\",\"STREAM_CATEGORY_TV\":\"TV\",\"STREAM_CATEGORY_US\":\"U.S.\",\"STREAM_CATEGORY_WELLNESS\":\"Wellness\",\"STREAM_CATEGORY_WORLD\":\"World\",\"APPLET_COMMENT_ARIA_VIEW_COMMENTS\":\"Reactions. Click to view reactions\",\"APPLET_COMMENT_COMMENTS\":\"Reactions\",\"APPLET_COMMENT_START_CONVERSATION\":\"Start the conversation\",\"APPLET_COMMENT_COUNT_DESCRIPTION\":\"{count, plural, one {reaction} other {reactions}}\",\"FACEBOOK\":\"Facebook\",\"EMAIL\":\"Email\",\"SEND\":\"Send\",\"PINTEREST\":\"Pinterest\",\"TUMBLR\":\"Tumblr\",\"TWITTER\":\"Twitter\",\"WHATSAPP\":\"Whatsapp\",\"CLOSE\":\"Close\",\"CONTENT_ERROR\":\"{hasItems, select, true {We're sorry this is all we were able to find about this topic.} false {We're sorry we weren't able to find anything about this topic.}}\",\"JOIN_THE_CONVERSATION\":\"Join the Conversation\",\"MORE\":\"More\",\"MORE_ON\":\"More on {category}\",\"SIDEKICK_TITLE\":\"What to Read Next\",\"SIDEPIC_TITLE\":\"Popular in the Community\",\"SPONSORED\":\"Sponsored\",\"PROMO_ARIA_RATINGS\":\"Average user rating for the app is {ratings}\",\"CALL_TO_ACTION\":\"Get the app\"},\"tdv2-applet-footer\":{\"ABOUT_OUR_ADS\":\"About our Ads\",\"ADVERTISE\":\"Advertise\",\"ATTRIBUTION_AUTOS\":\"Yahoo Autos\",\"ATTRIBUTION_CELEBRITY\":\"Yahoo-ABC News Network\",\"ATTRIBUTION_CELEBRITY_UK\":\"Yahoo Celebrity UK\",\"ATTRIBUTION_DECOR\":\"Yahoo Decor and Real Estate Network\",\"ATTRIBUTION_GMA\":\"Yahoo - ABC News Network\",\"ATTRIBUTION_HOMES\":\"Yahoo Homes\",\"ATTRIBUTION_LETSSOLVEIT\":\"Yahoo Finance\",\"ATTRIBUTION_LIFESTYLE\":\"Yahoo Lifestyle Network\",\"ATTRIBUTION_MOVIES\":\"Yahoo-ABC News Network\",\"ATTRIBUTION_MUSIC\":\"Yahoo-ABC News Network\",\"ATTRIBUTION_NEWS\":\"Yahoo-ABC News Network\",\"ATTRIBUTION_REALESTATE\":\"Yahoo Decor and Real Estate Network\",\"ATTRIBUTION_STYLE\":\"Yahoo Style and Beauty Network\",\"ATTRIBUTION_STYLE_BEAUTY\":\"Yahoo Style and Beauty Network\",\"ATTRIBUTION_TRAVEL\":\"Yahoo Travel Network\",\"ATTRIBUTION_TV\":\"Yahoo-ABC News Network\",\"ATTRIBUTION_WEATHER\":\"Yahoo News\",\"ATTRIBUTION_YAHOO\":\"Yahoo\",\"CAREERS\":\"Careers\",\"DISCLAIMER\":\"Data Disclaimer\",\"FEEDBACK\":\"Feedback\",\"HELP\":\"Help\",\"LEGAL_ATTRIBUTION\":\"Brought to you by {attribution}\",\"PRIVACY\":\"Privacy\",\"SUGGESTIONS\":\"Suggestions\",\"TERMS\":\"Terms\",\"TERMSUPDATED\":\"Terms (Updated)\",\"PRIVACYUPDATED\":\"Privacy (Updated)\",\"SITEMAP\":\"Sitemap\"},\"tdv2-applet-uh\":{\"ABOUT_THIS_PAGE\":\"About this Page\",\"ACCOUNT_INFO\":\"Account Info\",\"ADVANCED_SEARCH\":\"Advanced Search\",\"ADVERTISING_PROGRAMS\":\"Advertising Programs\",\"ALL\":\"ALL\",\"BACK\":\"Back\",\"CANCEL\":\"Cancel\",\"COMPOSE\":\"Compose\",\"CORPMAIL\":\"Corp Mail\",\"GO_TO_HELP\":\"Go\",\"GO_TO_MAIL\":\"Go to Mail\",\"HAVE_NO_NEW_MESSAGES\":\"You have no new messages.\",\"HELP\":\"Help\",\"HOME\":\"Home\",\"LOADING\":\"Loading\",\"MAIL\":\"Mail\",\"MENU\":\"Menu\",\"MORE\":\"More\",\"NAV_HOME\":\"Home\",\"NAV_MAIL\":\"Mail\",\"NOTIFICATIONS\":\"Notifications\",\"NOTIFICATION_CENTER_NAV_MSG\":\"View all {newCount} notifications\",\"NO_NEW_NOTIFICATIONS\":\"You have no new notifications.\",\"PLEASE_CHECK_BACK_LATER\":\"Please check back later.\",\"PREFERENCES\":\"Preferences\",\"PROFILE\":\"Profile\",\"PROPERTY_NAME_ANSWERS\":\"Answers\",\"PROPERTY_NAME_AUTOS\":\"Autos\",\"PROPERTY_NAME_BEAUTY\":\"Beauty\",\"PROPERTY_NAME_CELEBRITY\":\"Celebrity\",\"PROPERTY_NAME_DAILYFANTASY\":\"Fantasy\",\"PROPERTY_NAME_DECOR\":\"Decor\",\"PROPERTY_NAME_ENTERTAINMENT\":\"Entertainment\",\"PROPERTY_NAME_ESPORTS\":\"Esports\",\"PROPERTY_NAME_FANTASY\":\"Fantasy\",\"PROPERTY_NAME_FINANCE\":\"Finance\",\"PROPERTY_NAME_FLICKR\":\"Flickr\",\"PROPERTY_NAME_FOOD\":\"Food\",\"PROPERTY_NAME_GAMES\":\"Games\",\"PROPERTY_NAME_GMA\":\"News\",\"PROPERTY_NAME_HUFFPOST\":\"News\",\"PROPERTY_NAME_GROUPS\":\"Groups\",\"PROPERTY_NAME_HEALTH\":\"Health\",\"PROPERTY_NAME_HOMES\":\"Homes\",\"PROPERTY_NAME_HOROSCOPES\":\"Horoscopes\",\"PROPERTY_NAME_KATIECOURIC\":\"News\",\"PROPERTY_NAME_LIFESTYLE\":\"Lifestyle\",\"PROPERTY_NAME_LIFESTYLES\":\"Lifestyle\",\"PROPERTY_NAME_LIVENATIONPRESENTS\":\"Music\",\"PROPERTY_NAME_MAIL\":\"Mail\",\"PROPERTY_NAME_MAKERS\":\"Makers\",\"PROPERTY_NAME_MOBILE\":\"Mobile\",\"PROPERTY_NAME_MONEY\":\"Money\",\"PROPERTY_NAME_MOVIES\":\"Movies\",\"PROPERTY_NAME_MUSIC\":\"Music\",\"PROPERTY_NAME_BACKSTAGE\":\"Music\",\"PROPERTY_NAME_NEWS\":\"News\",\"PROPERTY_NAME_OMG\":\"omg!\",\"PROPERTY_NAME_PARENTING\":\"Parenting\",\"PROPERTY_NAME_PEOPLE\":\"People\",\"PROPERTY_NAME_POLITICS\":\"Politics\",\"PROPERTY_NAME_POPEVISIT\":\"In-Depth\",\"PROPERTY_NAME_CUBA\":\"In-Depth\",\"PROPERTY_NAME_REALESTATE\":\"Real Estate\",\"PROPERTY_NAME_RISING\":\"Music\",\"PROPERTY_NAME_SCREEN\":\"Screen\",\"PROPERTY_NAME_SETTINGS\":\"Settings\",\"PROPERTY_NAME_SHINE\":\"Shine\",\"PROPERTY_NAME_SHOPPING\":\"Shopping\",\"PROPERTY_NAME_SPORTS\":\"Sports\",\"PROPERTY_NAME_STYLE\":\"Style\",\"PROPERTY_NAME_TECH\":\"Tech\",\"PROPERTY_NAME_TRAVEL\":\"Travel\",\"PROPERTY_NAME_TV\":\"TV\",\"PROPERTY_NAME_WEATHER\":\"Weather\",\"SEARCH\":\"Search\",\"SEARCH_EMPTY\":\" \",\"SEARCH_HISTORY\":\"Search History\",\"SEARCH_VERT_NEWS\":\"Search News\",\"SEARCH_WEB\":\"Search web\",\"SETTINGS\":\"Settings\",\"SHARE\":\"Share\",\"SIGNIN\":\"Sign in\",\"SIGNOUT\":\"Sign out\",\"START_TYPING\":\"Start typing...\",\"SUGGESTIONS\":\"Suggestions\",\"TO_VIEW_MAIL\":\" to view your mail\",\"UNABLE_TO_PREVIEW_MAIL\":\"We are unable to preview your mail.\",\"WELCOME_BACK\":\"Welcome back\",\"YAHOO\":\"Yahoo\"},\"tdv2-applet-account-switch\":{\"ACCOUNT_INFO\":\"Account Info\",\"MANAGE_PUBLISHERS_SHORT\":\"Manage Publishers\",\"ACCOUNT_MANAGEMENT\":\"Add or Manage accounts\",\"ADD_ACCOUNT\":\"Add account\",\"BACKYARD\":\"Backyard\",\"SIGNOUT\":\"Sign Out\",\"SIGNOUT_ALL\":\"Sign out all\",\"WELCOME\":\"Welcome back\"}},\"intlConfig\":{}},\"BeaconStore\":{\"beaconConfig\":{\"defaultSrc\":\"td-app-yahoo\",\"beaconUncaughtJSError\":true,\"enableBatch\":false,\"pathPrefix\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002F_td_api\\u002Fbeacon\",\"sampleSize\":1,\"sampleSizeUncaughtJSError\":100,\"context\":{\"prid\":\"d1fpqmlfc95jj\",\"authed\":\"0\",\"ynet\":\"0\",\"ssl\":\"1\",\"spdy\":\"0\",\"ytee\":\"0\",\"mode\":\"normal\",\"site\":\"finance\",\"region\":\"US\",\"lang\":\"en-US\",\"bucket\":\"finance-US-en-US-def\",\"colo\":\"gq1\",\"device\":\"featurephone\",\"bot\":\"1\",\"ecma\":\"default\",\"environment\":\"prod\",\"intl\":\"us\",\"partner\":\"none\",\"tz\":\"America\\u002FLos_Angeles\",\"feature\":[\"enableCMP\",\"enableConsentData\",\"enableCCPAFooter\",\"enableGDPRFooter\",\"enableGuceJs\",\"enableGuceJsOverlay\",\"videoDocking\",\"newContentAttribution\",\"newLogo\",\"livecoverage\"],\"nps\":{}}}},\"AdStore\":{\"appConfig\":{\"base\":{\"aboveFoldPositions\":\"MAST,LDRB,SPRZ,SPL,SPL-2,LREC,MON-1\",\"autoRotation\":10000,\"autoadrender\":true,\"allowHostUrlAsReferrer\":true,\"darlaJsAtTop\":true,\"darlaVersion\":\"3-21-0\",\"darlaAssetFetch\":false,\"cacheDarlaAsset\":false,\"darlaConfigFetch\":true,\"cacheDarlaConfig\":true,\"events\":{\"AUTO\":{\"name\":\"AUTO\",\"autoStart\":1,\"autoMax\":25,\"autoRT\":10000,\"autoIV\":1,\"autoDDG\":1,\"ps\":{\"BTNA\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTNB\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTNC\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTND\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB2-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB2-2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC2-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-5\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-6\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-7\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-8\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC3\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC3-4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-5\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-6\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-7\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-8\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"MAST\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"MAST-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"MON-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"SPL\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"SPL-2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"SPL2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"WIDGET\":{\"autoIV\":0,\"autoMax\":0,\"autoRT\":3600000}}},\"DEFAULT\":{\"clw\":{\"LREC\":{\"blocked_by\":\"MON-1\"},\"MON-1\":{\"blocked_by\":\"LREC\"},\"MAST-9\":{\"blocked_by\":\"SPL,LDRB-9\"},\"MAST\":{\"blocked_by\":\"SPL,LDRB\"},\"LDRB\":{\"blocked_by\":\"MAST,SPL\"},\"LDRB-9\":{\"blocked_by\":\"MAST-9,SPL\"},\"SPL\":{\"blocked_by\":\"MAST,LDRB\"}}}},\"multipleRenderTargets\":true,\"positions\":{\"DEFAULT\":{\"meta\":{\"stack\":\"ydc\"}},\"BTNA\":{\"w\":120,\"h\":60,\"autoFetch\":false},\"BTNB\":{\"w\":120,\"h\":60,\"autoFetch\":false},\"BTNC\":{\"w\":120,\"h\":60,\"autoFetch\":false},\"BTND\":{\"w\":120,\"h\":60,\"autoFetch\":false},\"FOOT\":{\"id\":\"FOOT\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1}},\"FOOT9\":{\"id\":\"FOOT9\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1}},\"FSRVY\":{\"id\":\"FSRVY\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1}},\"LREC\":{\"id\":\"LREC\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"LREC-1\":{\"id\":\"LREC-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC-2\":{\"id\":\"LREC-2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC-9\":{\"id\":\"LREC-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-1\":{\"id\":\"LREC2-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-2\":{\"id\":\"LREC2-2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-4\":{\"id\":\"LREC2-4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-5\":{\"id\":\"LREC2-5\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-6\":{\"id\":\"LREC2-6\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-7\":{\"id\":\"LREC2-7\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-8\":{\"id\":\"LREC2-8\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2-9\":{\"id\":\"LREC2-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC2\":{\"id\":\"LREC2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3\":{\"id\":\"LREC3\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3-1\":{\"id\":\"LREC3-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3-4\":{\"id\":\"LREC3-4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3-5\":{\"id\":\"LREC3-5\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3-6\":{\"id\":\"LREC3-6\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3-7\":{\"id\":\"LREC3-7\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3-8\":{\"id\":\"LREC3-8\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC3-9\":{\"id\":\"LREC3-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LREC4\":{\"id\":\"LREC4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"metaSize\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"LDRB\":{\"id\":\"LDRB\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"LDRB-1\":{\"id\":\"LDRB-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"LDRB-9\":{\"id\":\"LDRB-9\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"LDRB2-1\":{\"id\":\"LDRB2-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"LDRB2-2\":{\"id\":\"LDRB2-2\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"LDRP\":{\"id\":\"LDRP\",\"w\":320,\"h\":50,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1},\"enable\":true,\"metaSize\":true,\"staticLayout\":true,\"fdb\":true},\"MAST\":{\"id\":\"MAST\",\"w\":970,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"closeBtn\":{\"adc\":0,\"mode\":2,\"useShow\":1},\"metaSize\":true},\"MAST-9\":{\"id\":\"MAST-9\",\"w\":970,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"closeBtn\":{\"adc\":0,\"mode\":2,\"useShow\":1},\"metaSize\":true},\"MFPAD\":{\"id\":\"MFPAD\",\"w\":720,\"h\":90,\"autoFetch\":false,\"enable\":true,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"metaSize\":true,\"staticLayout\":false,\"fdb\":false},\"MON\":{\"id\":\"MON\",\"w\":300,\"h\":600,\"dest\":\"defaultdestMON\",\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"MON-1\":{\"id\":\"MON-1\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"MON2\":{\"id\":\"MON2\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"MON-9\":{\"id\":\"MON-9\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"MOMENTS\":{\"id\":\"MOMENTS\",\"w\":375,\"h\":667,\"flex\":{\"ratio\":\"1x1.78\",\"w\":{\"min\":320},\"h\":{\"min\":568}},\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"NE1\":{\"id\":\"NE1\",\"w\":970,\"h\":60,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1},\"enable\":true,\"staticLayout\":true,\"metaSize\":true,\"z\":2000},\"SCREC\":{\"id\":\"SCREC\",\"w\":300,\"h\":65,\"pos\":\"SCREC\",\"autoFetch\":false,\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"SPL\":{\"id\":\"SPL\",\"flex\":\"both\",\"enable\":true,\"autoFetch\":false,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"type\":\"stream\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\"},\"SPL-2\":{\"id\":\"SPL-2\",\"flex\":\"both\",\"enable\":true,\"autoFetch\":false,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"type\":\"stream\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\"},\"SPL2\":{\"id\":\"SPL2\",\"autoFetch\":false,\"flex\":\"both\",\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"stack\":\"ydc\",\"type\":\"stream\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\"},\"SPRZ\":{\"id\":\"SPRZ\",\"autoFetch\":false,\"flex\":\"both\",\"enable\":true,\"staticLayout\":false,\"fdb\":false,\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\"},\"SPON\":{\"pos\":\"SPON\",\"h\":1,\"id\":\"SPON\",\"w\":1,\"autoFetch\":false},\"TXTL\":{\"id\":\"TXTL\",\"w\":120,\"h\":170,\"css\":\".ad-tl2b{overflow:hidden;text-align:left}p{margin:0}a{color:#020e65}a:hover{color:#0078ff}.y-fp-pg-controls{margin-top:5px;margin-bottom:5px}#tl1_slug{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-size:11px;color:#999}#fc_align a{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-size:11px}a:link{text-decoration:none}\",\"autoFetch\":false},\"WFPAD\":{\"id\":\"WFPAD\",\"w\":320,\"h\":50,\"autoFetch\":false,\"enable\":true,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1,\"resize-to\":1},\"metaSize\":true,\"staticLayout\":false,\"fdb\":false},\"UBALDRB\":{\"id\":\"UBALDRB\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"UBALDRB-9\":{\"id\":\"UBALDRB-9\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"UBALDRB2-1\":{\"id\":\"UBALDRB2-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"UBALDRB2-2\":{\"id\":\"UBALDRB2-2\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true},\"UBALREC\":{\"id\":\"UBALREC\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"UBALREC-1\":{\"id\":\"UBALREC-1\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"UBALREC-9\":{\"id\":\"UBALREC-9\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3},\"UBALREC2-9\":{\"id\":\"UBALREC2-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"UBALREC2\":{\"id\":\"UBALREC2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"UBALREC3\":{\"id\":\"UBALREC3\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"UBALREC3-9\":{\"id\":\"UBALREC3-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"UBALREC4\":{\"id\":\"UBALREC4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9},\"INARTICLE\":{\"id\":\"INARTICLE\",\"w\":375,\"h\":211,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"flex\":{\"ratio\":\"1.78x1\",\"w\":{\"min\":10},\"h\":{\"min\":5}},\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"z\":9},\"AS6\":{\"id\":\"AS6\",\"w\":850,\"h\":173,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":false,\"metaSize\":false,\"z\":9},\"WIDGET\":{\"id\":\"WIDGET\",\"clean\":\"cleanWIDGET\",\"dest\":\"destWIDGET\",\"metaSize\":false,\"w\":600,\"h\":635,\"flex\":{\"w\":{\"min\":600,\"max\":800}}}},\"rotationTimingDisabled\":false,\"nukeAds\":\"LREC,LREC2,LREC3,LREC-9,LREC2-9,LREC3-9,MAST,LDRB,LDRB2-1,LDRB2-2,MON-1,SPL\"}},\"pageConfig\":{\"base\":{\"events\":{\"adFetch\":{\"ps\":\"BTNA,BTNB,BTNC,BTND,MAST,LDRB,SPL,LREC,LREC2,LREC3,LREC4,FOOT,FSRVY\",\"dynamic\":true,\"addsa\":\"megamodal=true\",\"firstRender\":\"BTNA,BTNB,BTNC,BTND,LREC\"}},\"contentTypeAdPosModifier\":{\"slideshow\":[\"-LREC\",\"LREC-2\",\"LREC2\"],\"inlineSlideshow\":[]},\"deferRender\":true},\"header\":null},\"routeConfig\":{},\"failedPositions\":{\"positions\":{\"BTNA\":{\"failed\":true},\"BTNB\":{\"failed\":true},\"BTNC\":{\"failed\":true},\"BTND\":{\"failed\":true},\"MAST\":{\"failed\":true},\"LDRB\":{\"failed\":true},\"SPL\":{\"failed\":true},\"LREC2\":{\"failed\":true},\"LREC3\":{\"failed\":true},\"LREC4\":{\"failed\":true},\"FOOT\":{\"failed\":true},\"FSRVY\":{\"failed\":true}}},\"darlaConfig\":{\"aboveFoldPositions\":\"MAST,LDRB,SPRZ,SPL,SPL-2,LREC,MON-1\",\"autoRotation\":10000,\"darlaAssetFetch\":false,\"cacheDarlaAsset\":false,\"events\":{\"AUTO\":{\"name\":\"AUTO\",\"autoStart\":1,\"autoMax\":25,\"autoRT\":10000,\"autoIV\":1,\"autoDDG\":1,\"ps\":{\"BTNA\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTNB\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTNC\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTND\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB2-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB2-2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC2-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-5\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-6\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-7\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-8\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC3\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC3-4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-5\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-6\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-7\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-8\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"MAST\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"MAST-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"MON-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"SPL\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"SPL-2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"SPL2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"WIDGET\":{\"autoIV\":0,\"autoMax\":0,\"autoRT\":3600000}}},\"DEFAULT\":{\"clw\":{\"LREC\":{\"blocked_by\":\"MON-1\"},\"MON-1\":{\"blocked_by\":\"LREC\"},\"MAST-9\":{\"blocked_by\":\"SPL,LDRB-9\"},\"MAST\":{\"blocked_by\":\"SPL,LDRB\"},\"LDRB\":{\"blocked_by\":\"MAST,SPL\"},\"LDRB-9\":{\"blocked_by\":\"MAST-9,SPL\"},\"SPL\":{\"blocked_by\":\"MAST,LDRB\"}}},\"adFetch\":{\"ps\":\"BTNA,BTNB,BTNC,BTND,MAST,LDRB,SPL,LREC,LREC2,LREC3,LREC4,FOOT,FSRVY\",\"dynamic\":true,\"addsa\":\"megamodal=true\",\"firstRender\":\"BTNA,BTNB,BTNC,BTND,LREC\"}},\"positions\":{\"DEFAULT\":{\"meta\":{\"stack\":\"ydc\",\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},\"clean\":\"cleanDEFAULT\",\"dest\":\"destDEFAULT\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"DEFAULT\",\"staticLayout\":false},\"BTNA\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"cleanBTNA\",\"dest\":\"destBTNA\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTNA\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"BTNB\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"cleanBTNB\",\"dest\":\"destBTNB\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTNB\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"BTNC\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"cleanBTNC\",\"dest\":\"destBTNC\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTNC\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"BTND\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"cleanBTND\",\"dest\":\"destBTND\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTND\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"FOOT\":{\"id\":\"FOOT\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1},\"failed\":true,\"clean\":\"cleanFOOT\",\"dest\":\"destFOOT\",\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"FOOT9\":{\"id\":\"FOOT9\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1},\"clean\":\"cleanFOOT9\",\"dest\":\"destFOOT9\",\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"FSRVY\":{\"id\":\"FSRVY\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1},\"failed\":true,\"clean\":\"cleanFSRVY\",\"dest\":\"destFSRVY\",\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC\":{\"id\":\"LREC\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanLREC\",\"dest\":\"destLREC\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC-1\":{\"id\":\"LREC-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC-1\",\"dest\":\"destLREC-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC-2\":{\"id\":\"LREC-2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC-2\",\"dest\":\"destLREC-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC-9\":{\"id\":\"LREC-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC-9\",\"dest\":\"destLREC-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-1\":{\"id\":\"LREC2-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-1\",\"dest\":\"destLREC2-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-2\":{\"id\":\"LREC2-2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-2\",\"dest\":\"destLREC2-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-4\":{\"id\":\"LREC2-4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-4\",\"dest\":\"destLREC2-4\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-5\":{\"id\":\"LREC2-5\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-5\",\"dest\":\"destLREC2-5\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-6\":{\"id\":\"LREC2-6\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-6\",\"dest\":\"destLREC2-6\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-7\":{\"id\":\"LREC2-7\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-7\",\"dest\":\"destLREC2-7\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-8\":{\"id\":\"LREC2-8\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-8\",\"dest\":\"destLREC2-8\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-9\":{\"id\":\"LREC2-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC2-9\",\"dest\":\"destLREC2-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2\":{\"id\":\"LREC2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"failed\":true,\"clean\":\"cleanLREC2\",\"dest\":\"destLREC2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3\":{\"id\":\"LREC3\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"failed\":true,\"clean\":\"cleanLREC3\",\"dest\":\"destLREC3\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-1\":{\"id\":\"LREC3-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC3-1\",\"dest\":\"destLREC3-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-4\":{\"id\":\"LREC3-4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC3-4\",\"dest\":\"destLREC3-4\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-5\":{\"id\":\"LREC3-5\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC3-5\",\"dest\":\"destLREC3-5\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-6\":{\"id\":\"LREC3-6\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC3-6\",\"dest\":\"destLREC3-6\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-7\":{\"id\":\"LREC3-7\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC3-7\",\"dest\":\"destLREC3-7\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-8\":{\"id\":\"LREC3-8\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC3-8\",\"dest\":\"destLREC3-8\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-9\":{\"id\":\"LREC3-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanLREC3-9\",\"dest\":\"destLREC3-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC4\":{\"id\":\"LREC4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"metaSize\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"failed\":true,\"clean\":\"cleanLREC4\",\"dest\":\"destLREC4\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB\":{\"id\":\"LDRB\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"failed\":true,\"clean\":\"cleanLDRB\",\"dest\":\"destLDRB\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB-1\":{\"id\":\"LDRB-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanLDRB-1\",\"dest\":\"destLDRB-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB-9\":{\"id\":\"LDRB-9\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanLDRB-9\",\"dest\":\"destLDRB-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB2-1\":{\"id\":\"LDRB2-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanLDRB2-1\",\"dest\":\"destLDRB2-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB2-2\":{\"id\":\"LDRB2-2\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanLDRB2-2\",\"dest\":\"destLDRB2-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRP\":{\"id\":\"LDRP\",\"w\":320,\"h\":50,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1},\"enable\":true,\"metaSize\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanLDRP\",\"dest\":\"destLDRP\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MAST\":{\"id\":\"MAST\",\"w\":970,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"closeBtn\":{\"adc\":0,\"mode\":2,\"useShow\":1},\"metaSize\":true,\"failed\":true,\"clean\":\"cleanMAST\",\"dest\":\"destMAST\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MAST-9\":{\"id\":\"MAST-9\",\"w\":970,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"closeBtn\":{\"adc\":0,\"mode\":2,\"useShow\":1},\"metaSize\":true,\"clean\":\"cleanMAST-9\",\"dest\":\"destMAST-9\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MFPAD\":{\"id\":\"MFPAD\",\"w\":720,\"h\":90,\"autoFetch\":false,\"enable\":true,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"metaSize\":true,\"staticLayout\":false,\"fdb\":false,\"clean\":\"cleanMFPAD\",\"dest\":\"destMFPAD\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON\":{\"id\":\"MON\",\"w\":300,\"h\":600,\"dest\":\"defaultdestMON\",\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanMON\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON-1\":{\"id\":\"MON-1\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanMON-1\",\"dest\":\"destMON-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON2\":{\"id\":\"MON2\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanMON2\",\"dest\":\"destMON2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON-9\":{\"id\":\"MON-9\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanMON-9\",\"dest\":\"destMON-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MOMENTS\":{\"id\":\"MOMENTS\",\"w\":375,\"h\":667,\"flex\":{\"ratio\":\"1x1.78\",\"w\":{\"min\":320},\"h\":{\"min\":568}},\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanMOMENTS\",\"dest\":\"destMOMENTS\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"NE1\":{\"id\":\"NE1\",\"w\":970,\"h\":60,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1},\"enable\":true,\"staticLayout\":true,\"metaSize\":true,\"z\":2000,\"clean\":\"cleanNE1\",\"dest\":\"destNE1\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"SCREC\":{\"id\":\"SCREC\",\"w\":300,\"h\":65,\"pos\":\"SCREC\",\"autoFetch\":false,\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanSCREC\",\"dest\":\"destSCREC\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"SPL\":{\"id\":\"SPL\",\"flex\":\"both\",\"enable\":true,\"autoFetch\":false,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"type\":\"stream\",\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\",\"failed\":true,\"clean\":\"cleanSPL\",\"dest\":\"destSPL\",\"fallback\":null,\"metaSize\":false},\"SPL-2\":{\"id\":\"SPL-2\",\"flex\":\"both\",\"enable\":true,\"autoFetch\":false,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"type\":\"stream\",\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\",\"clean\":\"cleanSPL-2\",\"dest\":\"destSPL-2\",\"fallback\":null,\"metaSize\":false},\"SPL2\":{\"id\":\"SPL2\",\"autoFetch\":false,\"flex\":\"both\",\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"stack\":\"ydc\",\"type\":\"stream\",\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\",\"clean\":\"cleanSPL2\",\"dest\":\"destSPL2\",\"fallback\":null,\"metaSize\":false},\"SPRZ\":{\"id\":\"SPRZ\",\"autoFetch\":false,\"flex\":\"both\",\"enable\":true,\"staticLayout\":false,\"fdb\":false,\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"clean\":\"cleanSPRZ\",\"dest\":\"destSPRZ\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"SPON\":{\"pos\":\"SPON\",\"h\":1,\"id\":\"SPON\",\"w\":1,\"autoFetch\":false,\"clean\":\"cleanSPON\",\"dest\":\"destSPON\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"TXTL\":{\"id\":\"TXTL\",\"w\":120,\"h\":170,\"css\":\".ad-tl2b{overflow:hidden;text-align:left}p{margin:0}a{color:#020e65}a:hover{color:#0078ff}.y-fp-pg-controls{margin-top:5px;margin-bottom:5px}#tl1_slug{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-size:11px;color:#999}#fc_align a{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-size:11px}a:link{text-decoration:none}\",\"autoFetch\":false,\"clean\":\"cleanTXTL\",\"dest\":\"destTXTL\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"WFPAD\":{\"id\":\"WFPAD\",\"w\":320,\"h\":50,\"autoFetch\":false,\"enable\":true,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1,\"resize-to\":1},\"metaSize\":true,\"staticLayout\":false,\"fdb\":false,\"clean\":\"cleanWFPAD\",\"dest\":\"destWFPAD\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB\":{\"id\":\"UBALDRB\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanUBALDRB\",\"dest\":\"destUBALDRB\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB-9\":{\"id\":\"UBALDRB-9\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanUBALDRB-9\",\"dest\":\"destUBALDRB-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB2-1\":{\"id\":\"UBALDRB2-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanUBALDRB2-1\",\"dest\":\"destUBALDRB2-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB2-2\":{\"id\":\"UBALDRB2-2\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"cleanUBALDRB2-2\",\"dest\":\"destUBALDRB2-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC\":{\"id\":\"UBALREC\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanUBALREC\",\"dest\":\"destUBALREC\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC-1\":{\"id\":\"UBALREC-1\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanUBALREC-1\",\"dest\":\"destUBALREC-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC-9\":{\"id\":\"UBALREC-9\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"cleanUBALREC-9\",\"dest\":\"destUBALREC-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC2-9\":{\"id\":\"UBALREC2-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanUBALREC2-9\",\"dest\":\"destUBALREC2-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC2\":{\"id\":\"UBALREC2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanUBALREC2\",\"dest\":\"destUBALREC2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC3\":{\"id\":\"UBALREC3\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanUBALREC3\",\"dest\":\"destUBALREC3\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC3-9\":{\"id\":\"UBALREC3-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanUBALREC3-9\",\"dest\":\"destUBALREC3-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC4\":{\"id\":\"UBALREC4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"cleanUBALREC4\",\"dest\":\"destUBALREC4\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"INARTICLE\":{\"id\":\"INARTICLE\",\"w\":375,\"h\":211,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"flex\":{\"ratio\":\"1.78x1\",\"w\":{\"min\":10},\"h\":{\"min\":5}},\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"z\":9,\"clean\":\"cleanINARTICLE\",\"dest\":\"destINARTICLE\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"AS6\":{\"id\":\"AS6\",\"w\":850,\"h\":173,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":false,\"metaSize\":false,\"z\":9,\"clean\":\"cleanAS6\",\"dest\":\"destAS6\",\"fallback\":null,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}},\"WIDGET\":{\"id\":\"WIDGET\",\"clean\":\"cleanWIDGET\",\"dest\":\"destWIDGET\",\"metaSize\":false,\"w\":600,\"h\":635,\"flex\":{\"w\":{\"min\":600,\"max\":800}},\"enable\":true,\"fallback\":null,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}}},\"rotationTimingDisabled\":false,\"contentTypeAdPosModifier\":{\"slideshow\":[\"-LREC\",\"LREC-2\",\"LREC2\"],\"inlineSlideshow\":[]}},\"adFetchEvent\":{\"ps\":\"BTNA,BTNB,BTNC,BTND,MAST,LDRB,SPL,LREC,LREC2,LREC3,LREC4,FOOT,FSRVY\",\"sp\":\"980771051\",\"sa\":\"ticker=\\\"DGX;GOOG;GOOGL;CTLT;TBIO;MRNA;ADPT;BNTX;TMO;EBS;INCY;HOLX;LH;AAPL;REGN;RHHBF;RHHBY;RHHVF;SNY;SNYNF;NVS;NVSEF;LLY;DIOD;GILD;PFE;ABT;GLAXF;GSK\\\" wiki_topics=\\\"Medical_test;COVID-19_vaccine;Health_care_provider;LabCorp;Emergency_Use_Authorization;Contact_tracing;Vaccine;United_States\\\" ctopid=\\\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" hashtag=\\\"%24sanofi;%24incy;%24quest-diagnostics-incorporated;%24nvs;%24aapl;%24rhhvf;%24goog;%24nvsef;%24roche-holding-ag;%24lly;%24gild;%24lh;%24regn;%24glaxf;%24googl;%24tmo;%24mrna;%24adpt;%24laboratory-corporation-of-america-holdings;yfipremium;%24snynf;%24rhhbf;%24abt;%24pfe;%24biontech-se;%24tbio;%24sny;%24bntx;%24holx;%24diod;%24dgx;%24ebs;%24ctlt;%24rhhby;%24gsk;1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" megamodal=true rs=\\\"lmsid:a077000000BAh3wAAD;revsp:yahoofinance.com;lpstaid:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;pct:story;pt:content;site:finance;ver:y20;pd:non_modal\\\" Y-BUCKET=\\\"finance-US-en-US-def\\\"\",\"optionalps\":\"\",\"launchViewportAdPos\":\"\",\"site\":\"finance\"},\"siteAttrs\":\"ticker=\\\"DGX;GOOG;GOOGL;CTLT;TBIO;MRNA;ADPT;BNTX;TMO;EBS;INCY;HOLX;LH;AAPL;REGN;RHHBF;RHHBY;RHHVF;SNY;SNYNF;NVS;NVSEF;LLY;DIOD;GILD;PFE;ABT;GLAXF;GSK\\\" wiki_topics=\\\"Medical_test;COVID-19_vaccine;Health_care_provider;LabCorp;Emergency_Use_Authorization;Contact_tracing;Vaccine;United_States\\\" ctopid=\\\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" hashtag=\\\"%24sanofi;%24incy;%24quest-diagnostics-incorporated;%24nvs;%24aapl;%24rhhvf;%24goog;%24nvsef;%24roche-holding-ag;%24lly;%24gild;%24lh;%24regn;%24glaxf;%24googl;%24tmo;%24mrna;%24adpt;%24laboratory-corporation-of-america-holdings;yfipremium;%24snynf;%24rhhbf;%24abt;%24pfe;%24biontech-se;%24tbio;%24sny;%24bntx;%24holx;%24diod;%24dgx;%24ebs;%24ctlt;%24rhhby;%24gsk;1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" megamodal=true rs=\\\"lmsid:a077000000BAh3wAAD;revsp:yahoofinance.com;lpstaid:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;pct:story;pt:content;site:finance;ver:y20;pd:non_modal\\\" Y-BUCKET=\\\"finance-US-en-US-def\\\"\",\"autoAdRender\":true,\"supportMultipleRenderTargets\":true,\"darlaJsAtTop\":true,\"delayedRender\":false,\"darlaVersion\":\"3-21-0\",\"disableDarla\":false,\"detectAdblock\":false,\"inarticleTextEnable\":false,\"adblockPos\":false,\"disableDocDomain\":true,\"enableAdboost\":false,\"adBoostGroupConf\":{},\"tabswitchRotateTime\":3000,\"deferRender\":true,\"keepPerfEntries\":false,\"darlaAssetFetch\":false,\"cacheDarlaAsset\":false,\"darlaConfigFetch\":true,\"cacheDarlaConfig\":true,\"prefetchedPositions\":{\"BTNA\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"BTNB\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"BTNC\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"BTND\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"MAST\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"LDRB\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"SPL\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"LREC\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"LREC2\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"LREC3\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"LREC4\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"FOOT\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null},\"FSRVY\":{\"hasError\":true,\"error\":\"robot\",\"size\":\"unknown\",\"slotData\":null,\"serveType\":null}},\"_newPageRendered\":false,\"checkForModalClose\":false,\"nukeAds\":[\"LREC\",\"LREC2\",\"LREC3\",\"LREC-9\",\"LREC2-9\",\"LREC3-9\",\"MAST\",\"LDRB\",\"LDRB2-1\",\"LDRB2-2\",\"MON-1\",\"SPL\"],\"adfetchTimeout\":null,\"forceSsl\":false,\"customPositionEnabled\":false,\"customPositionConf\":{},\"reactjsDisabled\":false,\"prefetchDisabled\":false,\"displayMomentsScroller\":false,\"adsMeta\":null,\"nonNativeBillboardConf\":{\"positions\":{}},\"nativeBillboardConf\":{\"positions\":{}},\"allowHostUrlAsReferrer\":true,\"detectExpandEvent\":false,\"launchViewportFetch\":false,\"_childCompositeReady\":{}},\"VideoStore\":{\"videos\":{},\"microdata\":{},\"_cdnBase\":\"https:\\u002F\\u002Fs.yimg.com\"},\"ContentStore\":{\"currentContentIds\":{\"default\":\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\"},\"uuidMap\":{\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\":{\"trackingPixelUrl\":null,\"ad_meta\":{\"spaceid\":\"980771051\",\"site_attribute\":\"ticker=\\\"DGX;GOOG;GOOGL;CTLT;TBIO;MRNA;ADPT;BNTX;TMO;EBS;INCY;HOLX;LH;AAPL;REGN;RHHBF;RHHBY;RHHVF;SNY;SNYNF;NVS;NVSEF;LLY;DIOD;GILD;PFE;ABT;GLAXF;GSK\\\" wiki_topics=\\\"Medical_test;COVID-19_vaccine;Health_care_provider;LabCorp;Emergency_Use_Authorization;Contact_tracing;Vaccine;United_States\\\" ctopid=\\\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" hashtag=\\\"%24sanofi;%24incy;%24quest-diagnostics-incorporated;%24nvs;%24aapl;%24rhhvf;%24goog;%24nvsef;%24roche-holding-ag;%24lly;%24gild;%24lh;%24regn;%24glaxf;%24googl;%24tmo;%24mrna;%24adpt;%24laboratory-corporation-of-america-holdings;yfipremium;%24snynf;%24rhhbf;%24abt;%24pfe;%24biontech-se;%24tbio;%24sny;%24bntx;%24holx;%24diod;%24dgx;%24ebs;%24ctlt;%24rhhby;%24gsk;1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" rs=\\\"lmsid:a077000000BAh3wAAD;revsp:yahoofinance.com;lpstaid:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;pct:story\\\"\",\"site\":\"finance\",\"region\":\"US\",\"lang\":\"en-US\",\"isSupplySegment\":\"false\"},\"spaceId\":\"980771051\",\"enableC2S\":true,\"entities\":[{\"term\":\"WIKIID:Medical_test\",\"label\":\"diagnostic testing\",\"capAbtScore\":\"0.884\"},{\"term\":\"YCT:001000532\",\"score\":\"1.0\",\"label\":\"Pharmaceuticals & Drug Trials\"},{\"term\":\"YCT:001000225\",\"score\":\"0.989295\",\"label\":\"Health Care Industry\"},{\"term\":\"YCT:001000395\",\"score\":\"0.937158\",\"label\":\"Health\"},{\"term\":\"YCT:001000742\",\"score\":\"0.581633\",\"label\":\"Science\"},{\"term\":\"YCT:001000469\",\"score\":\"0.525253\",\"label\":\"Infectious Diseases\"},{\"term\":\"YCT:001000532\",\"score\":\"1.0\",\"label\":\"Pharmaceuticals & Drug Trials\"},{\"term\":\"YMEDIA:CATEGORY=FIN_WHITELISTEDPROVIDERS\",\"score\":\"1.0\",\"label\":\"\"},{\"term\":\"YMEDIA:CATEGORY=100000000\",\"score\":\"1.0\",\"label\":\"Yahoo Originals\"},{\"term\":\"YMEDIA:CATEGORY=100000002\",\"score\":\"1.0\",\"label\":\"\"},{\"term\":\"YCT:001000225\",\"score\":\"0.989295\",\"label\":\"Health Care Industry\"},{\"term\":\"YCT:001000395\",\"score\":\"0.937158\",\"label\":\"Health\"},{\"term\":\"YCT:001000742\",\"score\":\"0.581633\",\"label\":\"Science\"},{\"term\":\"YCT:001000469\",\"score\":\"0.525253\",\"label\":\"Infectious Diseases\"}],\"liveCoverageEventId\":null,\"body\":[{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EMentioned:\\u003C\\u002Fstrong\\u003E&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FGOOG\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003EAlphabet Inc&nbsp;(GOOG)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FCTLT\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003ECatalent Inc&nbsp;(CTLT)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FTBIO\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003ETranslate Bio Inc&nbsp;(TBIO)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FMRNA\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003EModerna Inc&nbsp;(MRNA)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FADPT\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003EAdaptive Biotechnologies Corp&nbsp;(ADPT)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FBNTX\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003EBioNTech SE&nbsp;(BNTX)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FTMO\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003EThermo Fisher Scientific Inc&nbsp;(TMO)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FEBS\\\"\\u003EEmergent BioSolutions Inc&nbsp;(EBS)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FINCY\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003EIncyte Corp&nbsp;(INCY)\\u003C\\u002Fa\\u003E,&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FHOLX\\\" class=\\\"mdc-link mds-link mds-link--no-underline\\\"\\u003EHologic Inc&nbsp;(HOLX)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FLH\\\"\\u003ELabCorp&nbsp;(LH)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FDGX\\\"\\u003EQuest (DGX)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FAAPL\\\"\\u003EApple (AAPL)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FREGN\\\"\\u003ERegeneron&nbsp;(REGN)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FRHHBY\\\"\\u003ERoche (RHHBY)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FSNY\\\"\\u003ESanofi&nbsp;(SNY)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FNVS\\\"\\u003ENovartis&nbsp;(NVS)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FLLY\\\"\\u003ELilly&nbsp;(LLY)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FGILD\\\"\\u003EGilead&nbsp;(GILD)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FPFE\\\"\\u003EPfizer&nbsp;(PFE)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FABT\\\"\\u003EAbbott&nbsp;(ABT)\\u003C\\u002Fa\\u003E, \\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FGSK\\\"\\u003EGlaxo&nbsp;(GSK)\\u003C\\u002Fa\\u003E\",\"length\":582,\"tagName\":\"p\"},{\"type\":\"table\",\"content\":\"\\u003Ctbody\\u003E \\u003Ctr\\u003E \\u003Ctd\\u003E\\u003Cp\\u003E\\u003Cem\\u003E\\u003Cstrong\\u003EEditor\u2019s note:&nbsp;\\u003C\\u002Fstrong\\u003EThis is the second of two updates to Morningstar's&nbsp;COVID-19 forecast. In the first part, we looked at&nbsp;\\u003C\\u002Fem\\u003E\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Frelaxing-the-lockdown-move-slowly-stay-nimble-151620574.html\\\" class=\\\"mdc-link mds-link\\\"\\u003E\\u003Cem\\u003Eplans for easing the U.S. lockdown\\u003C\\u002Fem\\u003E\\u003C\\u002Fa\\u003E\\u003Cem\\u003E.&nbsp;\\u003C\\u002Fem\\u003E\\u003Ca href=\\\"https:\\u002F\\u002Fwww.morningstar.com\\u002Fmarket-moments\\u002Fcoronavirus-economic-impact\\\" class=\\\"mdc-link mds-link\\\" rel=\\\"nofollow noopener\\\" target=\\\"_blank\\\"\\u003E\\u003Cem\\u003ERead the latest\\u003C\\u002Fem\\u003E\\u003C\\u002Fa\\u003E\\u003Cem\\u003E&nbsp;on how the coronavirus is rattling the markets and what investors can do to navigate it.\\u003C\\u002Fem\\u003E\\u003C\\u002Fp\\u003E\\u003C\\u002Ftd\\u003E \\u003C\\u002Ftr\\u003E \\u003C\\u002Ftbody\\u003E\",\"length\":282,\"tagName\":\"table\",\"attribs\":{}},{\"type\":\"text\",\"content\":\"We think widespread availability of a coronavirus vaccine or curative treatment will probably be necessary to completely remove social distancing measures. In our&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Fwww.morningstar.com\\u002Farticles\\u002F984323\\u002Frelaxing-the-lockdown-move-slowly-stay-nimble\\\" class=\\\"mdc-link mds-link\\\" rel=\\\"nofollow noopener\\\" target=\\\"_blank\\\"\\u003Ebase-case U.S. scenario\\u003C\\u002Fa\\u003E, we expect states to wait for reassurance that the COVID-19 spread has flattened before beginning to reopen businesses, and we assume a 30% reduction in visits to nonessential businesses from baseline by the end of the year. This is a significant improvement from levels at the end of March (65% reduction) and should improve further in 2021 with the availability of a coronavirus vaccine. We assume that less than 10% of the U.S. population is infected by the end of 2020, with a 0.7% death rate, as improving levels of testing help control the spread of the disease.\",\"length\":760,\"tagName\":\"p\"},{\"type\":\"list\",\"listItems\":[\"\\u003Cp\\u003ERemdesivir\u2019s recent emergency use authorization in severely ill COVID-19 patients is a turning point, but efficacy to date does not look strong enough on its own to justify relaxing lockdowns. We project $2 billion in peak sales in 2021, assuming an eventual U.S. price (after donated supplies) of around $500 per treatment.\\u003C\\u002Fp\\u003E\",\"\\u003Cp\\u003ERepurposed drugs could be the next wave of approvals. We expect IL-6 antibodies like Actemra and Kevzara could find a niche among the most severely ill patients by this summer, with data starting to read out on JAK inhibitors like Jakafi and Olumiant this summer, as well.\\u003C\\u002Fp\\u003E\",\"\\u003Cp\\u003ENovel, targeted antibodies, led by Regeneron\u2019s antibody cocktail, are likely to be effective but are behind this schedule; they could be available late this year for high-risk populations.\\u003C\\u002Fp\\u003E\",\"\\u003Cp\\u003EWhile coronavirus vaccines have yet to produce clinical data, encouraging preclinical data, strong partnerships and funding, and rapid clinical progress all seem to indicate that use in high-risk populations could be possible by the end of 2020, with tens of millions of doses potentially available by that point. If just two of these vaccines succeed, we could have enough supply to protect high-risk populations in late 2020 and for broader vaccination as we enter 2021.\\u003C\\u002Fp\\u003E\"],\"listTagType\":\"ul\"},{\"type\":\"text\",\"content\":\"Considering the utter importance of diagnostic testing to help the U.S. begin resuming economic activity in a manner that minimizes the prospect of increases in infection, we remain concerned about national testing capacity meeting necessary levels both in terms of volume and accuracy. The United States was already behind the eight ball when SARS-CoV-2 infections began to rise in February and March. Once the Food and Drug Administration began to approve COVID-19 diagnostic tests under the Emergency Use Act in March, we began to see new tests roll out and capacity for diagnostic testing rise. At the start of May, the U.S. was above 300,000 tests per day, which gets us to roughly 2.1 million tests per week.\",\"length\":714,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Nevertheless, this remains far lower than the 500,000 to more than 1 million tests per day that we see as the midrange of what epidemiologists and economists have projected is required to keep the COVID-19 infection from overwhelming our finite healthcare provider systems.\",\"length\":273,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"U.S. testing czar Adm. Brett Giroir says our testing capabilities are in the right ballpark for reopening in May and that four types of testing are needed: surveillance (testing hundreds of thousands a month to get a radar view, even among asymptomatic), symptomatic (millions of tests per month to get a nearly 10% positive rate, meaning 10% of tests coming back positive ), contact tracing (five people per confirmed case on average), and antibody testing. A 10% positive rate is the maximum recommended by the World Health Organization and a level the U.S. recently reached, based on daily data. Cumulative testing results as of May 7, with more than 8 million tests run, show an overall positive rate around 15%.\",\"length\":716,\"tagName\":\"p\"},{\"size\":{\"original\":{\"width\":1672,\"height\":1110,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FAJ3Jziu1IkT0VEFzmNd.Dw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTY3MjtoPTExMTA-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"},\"800x600\":{\"width\":800,\"height\":531,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FS2.JPK5ji8r0ePJHBKiZig--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAwO2g9NjAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"},\"800x\":{\"width\":800,\"height\":531,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F09jiduDn86KmFnDATBZLFQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"},\"1280x960\":{\"width\":1280,\"height\":850,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FWS4.nozMf3EwU3TrSLPW5A--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTI4MDtoPTk2MA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"}},\"caption\":\"Testing Improving and Positive Rate Moving in Right Direction\",\"alt\":\"Testing Improving and Positive Rate Moving in Right Direction\",\"alias\":null,\"headline\":null,\"type\":\"image\"},{\"type\":\"text\",\"content\":\"In addition, comparing U.S. testing rates to other countries gives some perspective. This comparison shows the slow start the U.S. made in ramping testing, and while there is a clear improvement over the past couple of months, the extent of the U.S. outbreak should justify even higher testing rates.\",\"length\":300,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Another way of examining this is from the perspective of positive rates--the percentage of tests coming back positive. While the U.S. is making progress on positive rates, we have just barely reached the 10% threshold as a country, and some states are well above. South Korea was at 2% (roughly 10,000 positive tests out of 600,000), and we are higher than every other developed country outside the United Kingdom, which is at 30%.\",\"length\":431,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EDiagnostic Testing and Antibody Testing Serve Two Different Strategies\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003ETo open up the economy while minimizing the spread of COVID-19, we need two general types of tests. First, we need diagnostic testing to help identify which patients are in the active phase of infection and, thus, shedding the virus to others. This is the information that is most useful for tamping down the spread of COVID-19 so that infectious patients can be quarantined. Asymptomatic patients could be tested either through surveillance (random sampling) or contact tracing (if disease detectives found the person to be in recent contact with a confirmed patient). Infected patients could be most contagious before becoming symptomatic, making quarantine based on diagnostics rather than symptoms more effective. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has estimated that 25%-50% of patients are asymptomatic. While some asymptomatic infected people go on to develop symptoms, some do not: 18% of infected patients on the Diamond Princess cruise ship in early February remained asymptomatic. In addition, at least 40% of infected patients were asymptomatic in a broad two-stage survey in the town of Vo\u2019, Italy, and in a random sample by DeCODE in Iceland.\",\"length\":1282,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Second, we also need COVID-19 antibody (serology) tests that can provide a better picture of how widely the SARS-CoV-2 virus has spread throughout the larger population, and the proportion of the population that has already cleared the virus from their systems and who may enjoy some lingering immunity to SARS-CoV-2. This test contributes information that helps us more accurately estimate prevalence and how close we might be to reaching herd immunity, generally seen with around 60% of the population.\",\"length\":504,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"We think that at this point, the diagnostic test remains the most important testing mechanism, particularly given how low the SARS-CoV-2 infection rate seems to be. We think prevalence is still probably below 5% based on antibody tests among samples in different geographic markets; two studies in California have put prevalence at 2.8% (Santa Clara County) and 4.1% (Los Angeles County), although these studies (and antibody tests in general) have been widely criticized for their potential to produce artificially high prevalence rates, or false positives. One key area of higher prevalence is New York City, which has been hit hardest by COVID-19 and where a recent analysis pegged seroprevalence at 20% (although infection rates in most of the state beyond NYC are in the low to mid-single digits). This still leaves approximately 95% of the U.S. population vulnerable to infection who will need access to diagnostic testing if they are to resume economic activity.\",\"length\":969,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Unfortunately, diagnostic testing is more labor-intensive, slower to turn around results, and reliant on trained professionals to both acquire the specimen and to run the tests in the lab. As a result, diagnostic testing is more challenging to scale up to required levels. Antibody tests are far easier to scale up because they are blood-based, easier to process, and tap into existing infrastructure and labor that can handle significantly higher throughput. Both LabCorp&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FLH\\\" class=\\\"mdc-link mds-link\\\"\\u003ELH\\u003C\\u002Fa\\u003E)&nbsp;and Quest&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FDGX\\\" class=\\\"mdc-link mds-link\\\"\\u003EDGX\\u003C\\u002Fa\\u003E)&nbsp;have extensive networks of patient service centers where specimens can be collected. These companies may even assemble mobile teams of phlebotomists to do blood draws for antibody tests on site at company locations in the second half of the year, boosting access. By the second half, we assume concerns about false positives with the initial tests will fade, particularly given that newer tests, like Roche\u2019s&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FRHHBY\\\" class=\\\"mdc-link mds-link\\\"\\u003ERHHBY\\u003C\\u002Fa\\u003E)&nbsp;serology test, have much higher specificity (99.8%) that should reduce false positives regardless of how low the true prevalence of antibodies is in the population. That said, immunity benefits from the antibody are still unclear. Lower or undetectable antibody levels in some recovered patients may not be protective, or may fade in two to three years, although memory B cells (harder to detect than antibodies) could still protect patients.\",\"length\":1383,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Antigen tests are just entering the market, and while they provide potential for higher capacity in the long run, we\u2019re concerned about test accuracy and scale (Quidel can provide 200,000 tests per week, scaling to more than 1 million a week in several weeks).\",\"length\":260,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"There is emerging research on using saliva samples for RT-PCR diagnostic testing, which suggests it is as good as, if not better than, the nasal-pharyngeal swab that currently dominates those tests. If patient data continue to bear this out, we think shifting to saliva specimens could relieve some of the factors that have slowed diagnostic testing. Experts say that the rush for coronavirus tests has led to low sensitivity, with perhaps a third of patients who are infected getting a negative test result, versus over 90% sensitivity for most PCR-based tests, but saliva-based testing could make it easier for healthcare professionals to get good samples and improve sensitivity of the test.\",\"length\":694,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Aside from the prospect of testing saliva, the current picture of capacity for RT-PCR tests, based on the largest manufacturers, looks far better in theory than in practice. We have examined U.S. capacity by the base of machines, throughput, and cycle time. Based on that, we have estimated total capacity of U.S. existing lab infrastructure can get us close to 5 million diagnostic tests per day. In other words, if we squeezed out every last bit of efficiency on our collective installed base of lab equipment--running full batches, with consecutive cycles, for 16 hours a day, seven days a week (and eliminating all other non-COVID-19 tests that might otherwise be running on that equipment).\",\"length\":695,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"In addition to the installed base, U.S. capacity to run tests is limited by the number of tests and kits available. The manufacturing of tests has accelerated but still significantly lags the capacity of the installed base to run them. Nonetheless, our estimate of the number of tests available daily gets us to more than 600,000, which could meet the numbers that public health officials have suggested would be adequate for safely reopening the economy.\",\"length\":455,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"However, these estimates reflect theoretical capacity, which is far more hopeful than de facto utilization, which gets us closer to the peak of 315,000 tests in a day. There are any number of bottlenecks and pain points that prevent us from optimizing existing capacity, and many of these inefficiencies reflect the relatively decentralized lab testing environment in the U.S.\",\"length\":376,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EKey Obstacles to Optimizing Diagnostic Testing Capacity\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EUnlike the diagnostics lab industry in other countries, including Australia and the U.K., the U.S. remains a relatively fragmented and decentralized market. Even Quest and LabCorp--the two largest independent reference labs--have only captured an estimated 22% market share. Approximately half the diagnostic market is still controlled by the smaller, hospital-based labs. Considering that most of the competitive labs operate independently and that the federal government has failed to step in with leadership, it\u2019s not surprising that we haven\u2019t seen a coordinated effort to ramp up efficient use of capacity to handle the new COVID-19 tests. This is the overarching theme, and there are additional specific factors that are causing friction in efforts to scale up. There is no magic bullet to be found. Instead, the current situation is more akin to a rowboat that has sprung multiple leaks.\",\"length\":950,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003ETests That Are Largely Proprietary to the Equipment\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EThe razor\\u002Frazor blade model is standard for diagnostic equipment makers, with the proprietary consumables offering a high-margin stream of ongoing revenue once the main machine is installed. For example, Roche\u2019s COVID-19 RT-PCR tests must be run on its cobas 6800 and 8800 high-throughput machines. This means that individual hospitals and integrated delivery networks that are collecting patient specimens with the Roche test must figure out which labs have those Roche cobas machines. This issue is somewhat mitigated if the hospital or network has contracted with LabCorp or Quest to handle some of its lab testing. According to Roche management, there are 122 cobas machines installed in 60 labs across the U.S. LabCorp and Quest are some of Roche\u2019s largest customers, and each has its own information technology systems that provide information on tests coming in and capacity throughout its network of labs. If the hospital hasn\u2019t contracted with this type of larger independent lab network, it may not have much visibility on where there\u2019s capacity to run those Roche tests it has collected, which could lead to longer turnaround times and inefficient use of the installed base.\",\"length\":1237,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"We suspect this proprietary test-to-equipment framework has been particularly cumbersome for Abbott&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FABT\\\" class=\\\"mdc-link mds-link\\\"\\u003EABT\\u003C\\u002Fa\\u003E), which introduced its COVID-19 diagnostic testing fairly early but had not seen its throughput of COVID-19 tests accelerate to the level expected. We think this is because Abbott\u2019s roughly 175 m2000 machines scattered across the U.S. are in smaller labs. The m2000 is not widely installed at Quest\u2019s network of labs, for example. Molecular diagnostic equipment at Quest is dominated by Roche and Hologic&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FHOLX\\\" class=\\\"mdc-link mds-link\\\"\\u003EHOLX\\u003C\\u002Fa\\u003E). We suspect there may be a similar situation at LabCorp. If most of Abbott\u2019s m2000 machines are not linked to a wider network, it won\u2019t benefit from information flow that can identify and match available machine capacity to incoming tests.\",\"length\":766,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003ENeed for Trained Personnel\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EThis is an issue on two fronts. First, we need trained medical professionals to obtain the specimen via nasal-pharyngeal swab. Capturing that nasal swab can be risky because it puts the medical professional close to the patient. Additionally, swabbing can make patients sneeze, which could further spread the virus if they\u2019re infectious. Second, we also need trained technicians to run the diagnostic machines. These are the people who transfer and prepare the specimens for PCR testing in the lab and monitor quality controls along the way. The dearth of trained lab professionals has been a chronic problem in the industry, even before the COVID-19 pandemic. The prospect of increasing capacity by installing more machines is likely to be constrained by the limited number of people who know how to operate them.\",\"length\":841,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003EInadequate Supplies of Personal Protective Equipment for Medical Professionals\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EThe well-documented PPE insufficiency has also hampered the ability of medical professionals to collect specimens from patients. As discussed earlier, the nasal-pharyngeal swab can result in the patient sneezing on the healthcare worker, which means the medical professionals need substantial protective gear to do their jobs safely. If the saliva-based RT-PCR test offers comparable or superior specimen capture, shifting over could relieve some of the pressure on the healthcare workers, in terms of needing less training and PPE.\",\"length\":611,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003EInadequate Reagents and Other Supplies for Tests\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EOn a preliminary basis, we have run across reports of healthcare providers running out of reagents, nasal swabs, and transport media supplies necessary to capture and preserve specimens. Test makers have suggested that they are sending out sufficient supplies with their tests. We remain skeptical that supply has matched demand. The bandwidth for producing those enzymes and primers tailored to the SARS-CoV-2 virus remains somewhat limited. These enzymes are biological molecules that are typically produced and then purified on a small scale. Increasing quantity of production will take time.\",\"length\":644,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003ERestrictive Conditions on Testing for Patients\\u003C\\u002Fem\\u003E\\u003Cbr\\u003ESevere test constraints in the early stages of the COVID-19 crisis in January and February meant that healthcare providers tried to limit the tests to symptomatic patients, those who were in contact with COVID-19 patients, and first responders. Now that more tests are available, providers can expand their guidelines for testing. However, the Centers for Disease Control and Prevention has not led the way in setting more liberal testing guidelines. Instead, it is leaving it up to the states, which has resulted in a more disjointed shift in making the tests more widely accessible.\",\"length\":631,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003ELack of Centralized IT and Logistics Capabilities\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EWe think this, perhaps, is the most significant factor in the near and mid-term that prevents us from turning our theoretical test capacity into reality. Getting the specimen from the healthcare provider to a lab with the appropriate equipment platform that has space in its overnight batches is difficult without a centralized information system. Then, take hundreds of thousands of specimens, multiplied by thousands of healthcare providers, multiplied by hundreds of labs, and by a handful of major equipment platforms. This quickly turns into a massive matching game to get each specimen to the right lab at the right time. White House coronavirus response coordinator Dr. Deborah Birx noted on April 8 that only 10% of the available 1 million Abbott tests for m2000 machines (175 in the U.S.) had been run, probably because the high-throughput machines are not always in locations where they are most needed, and staff and supplies can run short. Federal testing czar Giroir hopes to triple usage to 60% in May.\",\"length\":1066,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Both LabCorp and Quest have their own proprietary information systems that can provide insight into equipment platforms and testing capacity on a nightly basis across their own network of labs. However, roughly half the diagnostic industry in the U.S. is housed in hospital-based labs, and they are not looped into such a lab network. Same thing applies to the smaller, regional independent labs. As a result, there\u2019s a fair amount of capacity in our system that is going unused. We think addressing this shortfall will take action on the part of the federal government to centralize information flow related to the incoming tests and individual lab capacity. Based on this administration\u2019s propensity to leave diagnostic testing programs to the states, we speculate that any sort of common information system to unlock capacity in our existing lab infrastructure probably won\u2019t happen unless a different administration takes over next year.\",\"length\":941,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Significantly expanding lab infrastructure will take time. According to the Rockefeller Foundation plan, the U.S. could roughly triple current testing if we efficiently use all labs in U.S. that could do high-throughput testing. According to Rockefeller, it would take about eight months to get to 30 million tests a week, assuming an incredible ramp with strong funding. We could also make more point-of-care tests for rural areas, but building more could run into bottlenecks for China-sourced electronics or reagents. Hologic has been contacted by a range of customers, including departments of public health, hospital systems, and LabCorp and Quest, about buying more Panthers. In the near term, we expect that there will be robust placement of this kind of midsize high-throughput testing equipment. However, production of these machines is not necessarily easy to accelerate three- or four-fold to meet the current demand. Further, it is not clear to us that LabCorp and Quest, as the largest reference labs, are willing to significantly build out and maintain extra capacity that could go unused until another pandemic. Thus, the near- and mid-term expansion of capacity will likely be on the periphery of what we already have. We doubt there will be any tripling or quadrupling of the U.S. installed base of machines.\",\"length\":1325,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"In the near and mid-term, we expect most of the usable capacity to come from LabCorp and Quest more efficiently using their existing equipment. This will be enhanced by the addition of Hologic\u2019s newest COVID-19 diagnostic testing capabilities, run on its Panther machines, which are located in a range of small and midsize labs.\",\"length\":328,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EPoint-of-Care and At-Home Diagnostic Testing Unlikely to Be Short-Run Fix\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EWe may see some new innovations to address the testing challenges. Quest management said the current administration has encouraged the firm to think creatively about how to bring on more capacity in different ways. The CARES Act also contains more than $1 billion dedicated to a competition to develop new diagnostics that can get around these pain points that have slowed COVID-19 diagnostic testing so far.\",\"length\":482,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Abbott is ramping up production of its point-of-care diagnostic test, but we still see this topping out at around 2 million tests per month over the summer, translating to 67,000 tests per day. Also, the Abbott machines for POC testing are likely mainly in doctors\u2019 offices, and most of those offices are closed with the machines trapped inside. Abbott management says there are 18,000 ID Now machines in the U.S., but demand for these machines seems unmet, with the mayor of Detroit asking for just five to put in his hospitals. In other words, Abbott\u2019s machines don\u2019t appear to be translating into usable supply. Until ID Now machines are relocated to where most potential COVID-19 patients will be, we\u2019re unlikely to see POC testing significantly increase.\",\"length\":759,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"In addition, POC accuracy will probably continue to trail that of the RT-PCR tests done in the reference lab. Reported 15% rates of false negatives for the Abbott POC test should improve peripherally as medical professionals become more familiar with how to run the test and handle the specimens, but that may not be enough to close the gap with lab tests. The other leap forward for the POC tests is if they can run tests on saliva. If there\u2019s greater and more consistent concentration of the virus in saliva, that could improve accuracy. That said, each machine is severely limited in its capacity; one Abbott ID Now machine can process only 64 tests, if run continuously for 16 hours.\",\"length\":687,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"The first at-home tests are hampered by the need for a prescription and a $119 out-of-pocket payment. LabCorp expects that in a few weeks it will have enough supply of the Pixel test to branch out from the initial target of first responders, aiming for normalized production of 100,000 tests per week. We think it could be easy to remove the obstacle of needing a prescription, but LabCorp can\u2019t distribute tests without collecting money from someone to cover costs. The process of working with payers to collect the money would take time, as patients would then need to send insurance information to LabCorp for the lab to close the loop with the patient\u2019s payer, collect payment, and send out the test. LabCorp could also contract with employers directly to pay for kits in bulk, which could then be distributed to employees, but we haven\u2019t seen evidence that this is part of its strategy. Regardless, getting at-home tests in the hands of noninsured Americans seems challenging.\",\"length\":981,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EContact Tracing Offers Incremental Improvement in Fighting Outbreak\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EContact tracing can help narrow the field of testing to be more precise, but U.S. health departments don\u2019t seem well equipped using traditional methods. The Association of State and Territorial Health Officials recommends 100,000 U.S. contact tracers to get to a 1:1,000 individual\\u002Ftracer ratio, using a three-tier response of lay contact tracers, disease investigator specialists (professionals) at the state level (currently only 2,200 DIS positions), and healthcare providers or epidemiologists at the CDC (a COVID-19 corps) to support the other two tiers. In Wuhan, China, aggressive contact tracing was done by 1,800 teams of epidemiologists, with at least five members on each team. Scaling up to a level like China\u2019s would require one investigator per 1,200 individuals, or more than 300,000.\",\"length\":867,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"To control outbreaks at an R0 (reproduction number, signifying extent of contagion) of 2.5 (estimate for SARS-CoV-2), we would need to trace more than 70% of contacts of those infected, but the outbreak could be controlled with less than 50% successfully traced, if R0 is less than 1.5. We expect this could mean that if we are using additional measures beyond contact tracing to control the disease, such as social distancing or school closures, we may be able to make some headway even without perfect coverage.\",\"length\":513,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"A Boston nonprofit, Partners in Health, is hiring 1,000 people for contact tracing, and New York is launching a massive testing and contact tracing program, particularly in hard-hit, low-income communities, involving tens of thousands of tracers (the state previously had fewer than 1,000), and the state has $1.3 billion in federal funding to support the initiative. San Francisco is also boosting its 40-person contact tracer team to at least 150, or one tracer for every 5,553 residents. However, these are small-scale efforts compared with what we would need for a nationwide program.\",\"length\":588,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Technology could make this process easier and faster. Manual contact tracing (by disease detectives) may not be good enough to slow transmission, but instantaneous tracing (notifying exposed people the minute someone is diagnosed) could be, as used in South Korea and Singapore. Apps are being built to help with contact tracing, and proximity tracking could allow people to self-isolate if they get a notification that they have been near someone who is now confirmed to be infected. While apps in Asia have led to the disclosure of personal info, in the West, a system that uses Bluetooth signaling to record proximity could be less intrusive. In the U.S., many projects have been announced, like Covid Watch, CoEpi, and NextTrace, and the ability to piece all of their data together could become an issue unless we rally around one provider. Apple&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FAAPL\\\" class=\\\"mdc-link mds-link\\\"\\u003EAAPL\\u003C\\u002Fa\\u003E)&nbsp;and Google&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FGOOG\\\" class=\\\"mdc-link mds-link\\\"\\u003EGOOG\\u003C\\u002Fa\\u003E)&nbsp;announced that they are working together to facilitate contact tracing using Bluetooth functionality. To satisfy privacy concerns, rather than using GPS, their platform will focus on codes created when users are within proximity for a certain amount of time; if one is infected, the voluntary app (to be designed by healthcare agencies) could automatically warn close contacts that they may have been exposed. While they are first planning to unify their wireless protocols to allow others to build apps across platforms, we expect their own app could be more reliable than third-party apps. With any app, the idea is to limit the number of people who need to be tested in order to maintain containment of the virus. However, epidemiologists estimate that we would need to see 60% uptake of these apps for them to be effective, and so far, uptake is less than 20% for TraceTogether in Singapore and 40% for Iceland\u2019s Rakning C-19.\",\"length\":1826,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Another issue is how Americans will react to technology like contact tracing apps. President Donald Trump may be able to sway Republicans to get on board with tracing despite privacy concerns, but preserving freedom is a critical issue. GPS data could work better than Bluetooth technology, for example, as it monitors location (people and surfaces can trigger infection) but is harder to anonymize and harder to use in use in multistory situations. GPS data is helping enforce quarantine of those infected in Taiwan, as well as location-tracking wristbands in Hong Kong and texting proof of being home in Singapore. However, opinions are mixed; a recent survey by a University of Pennsylvania political scientist saw 70% of Republicans and 46% of Democrats strongly opposing the use of cellphones to enforce quarantines, but more than half of Americans back anonymized government smartphone tracking, according to a recent Harris poll.\",\"length\":936,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Even in countries that have successfully used technology for contact tracing, concerns remain. South Korea passed amendments to its Contagious Disease Control and Prevention Act following its 2015 MERS outbreak to allow override of previous privacy laws during a serious infectious disease outbreak, which allowed disclosure of a wide range of personal information to the country\u2019s federal, state, and local governments, including credit card transactions, location, transit history, and medical records. However, criticism of the level of data released to the public could lead to refinement of this strategy in the future, as significant amounts of this data were also released publicly, when aggregated data could have been enough.\",\"length\":734,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EProgress With Treatments\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EFormer FDA commissioner Scott Gottlieb sees a treatment as our best hope for returning to normal this year. We now have two regimens with emergency use authorizations, although safety issues with chloroquine (and recent studies casting more doubt on potential efficacy) put the focus squarely on Gilead\u2019s&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FGILD\\\" class=\\\"mdc-link mds-link\\\"\\u003EGILD\\u003C\\u002Fa\\u003E)&nbsp;remdesivir.\",\"length\":358,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Following strong data released April 29, Gilead received FDA emergency use authorization on May 1. While not at the same threshold as FDA approval, this allows Gilead (with the direction of state governments) to begin distributing remdesivir to severely ill patients at select hospitals in the U.S. Gilead already has 1.5 million doses of remdesivir, enough to treat roughly 300,000 patients, assuming they receive the shorter, five-day dosing regimen that proved similar to the 10-day regimen in the Simple study. Using this dose, Gilead should have enough for 1 million patients by October and 2 million patients by the end of 2020. Gilead has also announced that it plans to license remdesivir to other firms capable of manufacturing it in Europe, Asia, and the developing world through at least 2022.\",\"length\":804,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"We now assume that remdesivir can generate $2 billion in sales in 2021, but sales this year will be significantly lower (due to donations and limited supply), and we only model sales extending to 2023 (as we assume progress with a coronavirus vaccine will make stockpiling and demand less common). Our model assumes a price tag of $500 per treatment, a middle ground between the $5 per five-day course expected to help Gilead recoup manufacturing costs and the $4,500 price ceiling estimated by the Institute for Clinical and Economic Review, using a $50,000 per quality-adjusted life year threshold. We believe this will be more than enough to recoup the $1 billion in remdesivir-related development and manufacturing costs Gilead expects to incur in 2020, but not enough to significantly swing Gilead\u2019s valuation.\",\"length\":815,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Remdesivir\u2019s efficacy so far is impressive and looks likely to reduce mortality rates from COVID-19 (although mortality data so far isn\u2019t statistically significant, it shows a trend to a benefit). However, these improvements fall short of what we see as necessary for&nbsp;\\u003Ca href=\\\"https:\\u002F\\u002Fwww.morningstar.com\\u002Farticles\\u002F976107\\u002Fcoronavirus-update-long-term-economic-impact-forecast-to-be-less-than-2008-recession\\\" class=\\\"mdc-link mds-link\\\" rel=\\\"nofollow noopener\\\" target=\\\"_blank\\\"\\u003Eour former base-case scenario\\u003C\\u002Fa\\u003E, which assumed that efficacy would be strong enough to allow wider relaxing of lockdown measures on its own.\",\"length\":411,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Several other drug candidates are also moving through testing. Among anti-inflammatories, we expect IL-6 antibodies like Roche\u2019s Actemra and Regeneron&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FREGN\\\" class=\\\"mdc-link mds-link\\\"\\u003EREGN\\u003C\\u002Fa\\u003E)\\u002FSanofi\u2019s&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FSNY\\\" class=\\\"mdc-link mds-link\\\"\\u003ESNY\\u003C\\u002Fa\\u003E)&nbsp;Kevzara could find a niche among the most severely ill patients by this summer, although initial data from Kevzara was disappointing (development is now focused on critically ill patients). Data could start to read out on JAK inhibitors like Incyte&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FINCY\\\" class=\\\"mdc-link mds-link\\\"\\u003EINCY\\u003C\\u002Fa\\u003E)\\u002FNovartis\u2019&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FNVS\\\" class=\\\"mdc-link mds-link\\\"\\u003ENVS\\u003C\\u002Fa\\u003E)&nbsp;Jakafi and Incyte\\u002FLilly\u2019s&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FLLY\\\" class=\\\"mdc-link mds-link\\\"\\u003ELLY\\u003C\\u002Fa\\u003E)&nbsp;Olumiant this summer, as well, although we have limited view on their potential efficacy. Targeted antibodies, led by Regeneron\u2019s antibody cocktail, are among the most likely to succeed but are behind this schedule, and we don\u2019t expect them to be available until late this year for high-risk populations. While convalescent serum and hyperimmune globulins from plasma firms could also be quite effective, scale is severely constrained; according to Adaptive Biotechnologies&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FADPT\\\" class=\\\"mdc-link mds-link\\\"\\u003EADPT\\u003C\\u002Fa\\u003E), convalescent antibodies can treat only one or two patients for every donation from a recovered patient, and quality can vary.\",\"length\":1129,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Future trials will be more likely to focus on combinations with remdesivir, and a trial adding Olumiant to remdesivir (to enroll 1,000 patients) began May 8. Pfizer\u2019s&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FPFE\\\" class=\\\"mdc-link mds-link\\\"\\u003EPFE\\u003C\\u002Fa\\u003E)&nbsp;protease inhibitor is also entering studies this summer and could be a good candidate for combination therapy with remdesivir.\",\"length\":309,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003ECoronavirus Vaccine Advancement Even Faster Than Accelerated Timelines\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EVaccine development typically takes years--28 years for varicella and FluMist, and 15 years for HPV and rotavirus. We\u2019ve been waiting decades for an effective HIV vaccine, without success. Preparing manufacturing plants to make a new vaccine can cost anywhere from $50 million to $700 million, according to a 2017 paper in the medical journal Vaccine, and the investments are typically made in a stepwise fashion at different scales, based on the available data and probability of eventual approval. However, if a firm is willing to take financial risks, the process can be accelerated.\",\"length\":657,\"tagName\":\"p\"},{\"size\":{\"original\":{\"width\":1672,\"height\":900,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F9iDYgfOUW3bKg74jPAfemA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTY3MjtoPTkwMA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"},\"800x600\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F5oIlxNtwiWmLsXGvFoxUlg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAwO2g9NjAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"},\"800x\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FjeeRzgX_TiFWzuxXoCMBng--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"},\"1280x960\":{\"width\":1280,\"height\":689,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FiwOzCLyyqT5GHc4Vrd.nnQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTI4MDtoPTk2MA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"}},\"caption\":\"The Standard Paradigm for Vaccine Development is Lengthy...\",\"alt\":\"The Standard Paradigm for Vaccine Development is Lengthy...\",\"alias\":null,\"headline\":null,\"type\":\"image\"},{\"size\":{\"original\":{\"width\":1672,\"height\":900,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FMO7y6ga4RSO9Us1sygS0IQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTY3MjtoPTkwMA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"},\"800x600\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FkFCylpNqaAmtzhpkOM2.aA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAwO2g9NjAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"},\"800x\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FWm2eWaxHqJy39umPmcY8RQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"},\"1280x960\":{\"width\":1280,\"height\":689,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FAPXTt8EIS8DFjpAav8LNRQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTI4MDtoPTk2MA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"}},\"caption\":\"...But It Can Be Accelerated in a Pandemic\",\"alt\":\"...But It Can Be Accelerated in a Pandemic\",\"alias\":null,\"headline\":null,\"type\":\"image\"},{\"type\":\"text\",\"content\":\"For example, rather than waiting for confirmation of efficacy, a firm can move to large-scale production while efficacy is being tested. Groups like the Bill &amp; Melinda Gates Foundation are taking on some of this risk by offering to pay for manufacturing capacity for a handful of promising vaccines. Government entities (the U.S. Biomedical Advanced Research Development Authority) and public-private alliances (Coalition for Epidemic Preparedness Innovations) are also rapidly offering funding.\",\"length\":499,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Also, rather than building manufacturing capacity, the accelerated process requires partnering with contract manufacturers or large pharma firms to buy extra capacity. This still requires tech transfer for the partner to be able to manufacture the new coronavirus vaccine, but if done early enough, it allows large-scale production to ramp during the second phase of trials. In addition, capital expense is significantly lower for cell-free manufacturing (less than $200 million for nucleic acid vaccines like Moderna\u2019s&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FMRNA\\\" class=\\\"mdc-link mds-link\\\"\\u003EMRNA\\u003C\\u002Fa\\u003E)&nbsp;versus up to $1 billion for more traditional vaccines), which requires smaller reactors and purification tools than recombinant protein vaccines and can be more flexible in switching from one vaccine to another, lowering the risk from investing in manufacturing of any one vaccine in its portfolio. Several of the most advanced programs are nucleic acid (RNA or DNA) vaccines.\",\"length\":913,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Finally, the approval would come in two stages. Broad approval would still be reserved for when a larger phase 3 trial is completed, but the FDA could grant an early, accelerated approval (or emergency use authorization) based on phase 1 and phase 2 safety and efficacy data.\",\"length\":275,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EFDA Likely to Accelerate Coronavirus Vaccine Approval if Pandemic Continues This Fall\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EThe FDA\u2019s perspective on approval of a coronavirus vaccine will probably vary depending on how extensively the pandemic is still spreading in the U.S. by the time we have phase 2 data, which will likely be late this summer. With some circulating virus, firms should be able to conduct larger, controlled phase 2\\u002Fphase 3 studies that can confirm whether antibodies generated in response to a vaccine actually protect individuals from infection. The FDA can also look at antibody levels generated by the vaccine and try to determine whether this could be a biomarker for protection. The second is what Moderna has referred to as looking at \u201cserological correlates\u201d of protection. This can be done by comparing to preclinical models of the vaccine offering protection, or to antibody levels in convalescent serum (from patients who have recovered from infection). If the virus is widespread--and need for the vaccine is most urgent--then Fauci and FDA officials have noted that an emergency use authorization could be made based on phase 1 and animal model safety data as well as efficacy data from phase 2. Such a decision would need to weigh the safety risks; while data through phase 2 should clarify such risks as viral enhancement, it will not be able to isolate any ultrarare risks, which can only be found by testing several thousand volunteers.\",\"length\":1435,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"If there are a limited number of outbreaks by late this summer, when larger phase 3 studies might be starting (a good problem to have), there are also creative ways of potentially accelerating development to stay ahead of a second wave. The most ethically controversial is challenge studies, which offer a faster option than traditional phase 3 studies by deliberately exposing volunteers to the virus to test a vaccine\u2019s efficacy. For example, 1 Day Sooner is working to qualify healthy, low-risk volunteers for a potential challenge study, with more than 14,000 volunteers listed on the website as of May 8. However, there are serious ethical questions about deliberately infecting patients in such studies, even with their permission. Another way to accelerate development and reduce the number of placebo volunteers is to test multiple vaccines in one trial with one shared control arm; normally, drugmakers avoid this sort of trial, as it forces head-to-head comparisons, but this situation may be exceptional.\",\"length\":1015,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"We expect initial approval could be reserved for a high-risk population, including the elderly, those with pre-existing conditions, and essential workers (including healthcare workers). We expect that children--who rarely suffer serious consequences from infection and would have the most to lose from theoretical severe but very rare side effects of vaccination--would not be vaccinated until longer-term studies are completed. Vaccination could also be focused on areas with the largest outbreaks if supply is limited.\",\"length\":520,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EProbability of Approval Looks Quite High, at Least for a Handful of Coronavirus Vaccines\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003ERecent analysis examining the probability of success of different types of therapeutics, using data from a variety of small- and large-cap drug firms from 2000 to 2015, indicated that vaccines have the highest overall probability of sales, 42% from phase 2 start to approval, and this now stands at 45.8%, using the traditional slow and steady development pathway. In addition, researchers are already familiar with coronaviruses, and particularly familiar with designing vaccines for other serious coronaviruses like SARS and MERS. Key parts of the virus are conserved in SARS-CoV-2 (overall, the viruses are 80% identical), so many vaccines target the spike protein or a portion of it. Researchers see this as unlikely to mutate rapidly, as well, as it is critical for viruses to be able to enter the cell. We think this increases the likelihood of approval. Also, given the sheer number of coronavirus vaccines and the diverse nature of their designs, we would expect some attrition, but some success. Bill Gates recently noted that of the 115 vaccine candidates in the pipeline, 8-10 look \u201cparticularly promising,\u201d noting that 60% efficacy would be able to produce herd immunity if we eventually vaccinate roughly 7 billion people, or most of the world\u2019s population. This estimate is likely based on SARS-CoV-2\u2019s reproduction number of 2.5, which means that if 60% are immune and only 40% are vulnerable, the effective transmission rate would decline to 1, meaning flat levels of transmission.\",\"length\":1586,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Even if trials complete, plenty of skeptics point to the fact that manufacturing validation typically takes several months, not to mention the manufacturing ramp. However, we think there have been enough partnerships announced to expand manufacturing capacity, as well as parallel programs at several firms, that the capacity should be there if the vaccines are safe and effective, and we assume the FDA would approve the manufacturing facilities at a breakthrough pace. As long as more than one coronavirus vaccine makes it to emergency authorization, that would also relieve some of the pressure on manufacturing to surpass the 1 billion mark. Newer technologies mean much easier scale-up--mRNA vaccines are easier to produce than antigen-based vaccines and require very small doses. DNA and RNA platforms have the most potential for rapid development, followed by recombinant-subunit vaccines.\",\"length\":896,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EVirus Enhancement a Key Safety Risk\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EUntil we see evidence that vaccinated patients have been challenged with the virus, we won\u2019t know whether the antibodies created in response to the vaccine paradoxically reduce a patient\u2019s ability to fight a virus. Immune enhancement can be due to antibody-dependent enhancement (antibodies help infection spread) or cell-based enhancement (allergic, type 2 helper T-cell-based inflammation). Allergic inflammation was an issue for at least one SARS vaccine in older mice when they were challenged with the virus. With Sanofi\u2019s Dengvaxia, a vaccine against one of dengue fever\u2019s four serotypes, later infection with a different serotype led to much more severe illness than in those who had not received the vaccine. An RSV vaccine tested in the 1960s caused infections to become much more lethal due to allergic inflammation. Fauci has noted that the key concern in phase 1 is enhancement of the virus, and studies are now in progress for several vaccines.\",\"length\":993,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003ELeading Coronavirus Vaccine Programs Could Offer Significant Capacity by Year-End\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EWhile vaccines have yet to produce clinical data, encouraging preclinical data, strong partnerships and funding, and rapid progress into large phase 1\\u002Fphase 2 studies all seem to indicate that use in high-risk populations could be possible by the end of the year, with tens or even hundreds of millions of doses available. While we doubt that all vaccines will see strong enough safety and efficacy to reach approval from the FDA, several stand out with a head start and aggressive plans for supplying the market. If just two or three of these vaccines succeed, we could have enough supply to protect high-risk populations in late 2020 (allowing further relaxing of distancing measures) and for broader vaccination as we enter 2021.\",\"length\":814,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003EModerna\u2019s mRNA-1273\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EModerna\u2019s mRNA-based vaccine is a single antigen vaccine targeting the full-length spike protein. Although the firm has no approved therapies, it has data from more than 1,500 patients studied in various vaccine clinical trials attesting to its safety, and patients have developed neutralizing antibodies to virus antigens for all eight of the viruses that Moderna has vaccinated against in trials. We expect rapid acceleration of manufacturing and development timelines (enabled by at-risk manufacturing expansion, government funding, partnerships, and parallel clinical trials) to allow emergency use by late 2020 and approval for wider distribution in 2021.\",\"length\":680,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Moderna shipped the first vaccine to the National Institute of Allergy and Infectious Diseases 42 days after sequence selection, a record for vaccines, with the first patient dosed as of March 16. This phase 1 trial involves a two-shot series in healthy volunteers, first in 45 adults age 18-55 at three different doses (now fully enrolled), and then at these three doses for 30 older adults (56-70) and 30 elderly adults (71 and older). Phase 1 data is still expected in the second quarter. Moderna received FDA clearance on May 6 to begin a phase 2 immunogenicity study in 600 patients, with 300 adults age 18-55 and 300 age 55 and up receiving two doses of either placebo, 50 ug, or 250 ug doses, so this study will run in parallel with phase 1. Phase 3 timelines have moved up aggressively, and the first phase 3 trial is now expected to begin in early summer, with design still being finalized (although this NIH-partnered study will likely be conducted in the U.S. and will compare natural infection rates and symptoms with patients who have been vaccinated with mRNA-1273 or placebo). We think this coronavirus vaccine could be available for emergency use (healthcare workers) in fall 2020 based on phase 1 and phase 2 data (comparing immunogenicity to what is seen in the plasma of recovered patients), and for broader commercial use in 2021 (based on a potential interim look at phase 3 data in late 2020 and full data in 2021). The Biomedical Advanced Research and Development Authority has agreed to commit up to $483 million to push the vaccine forward to approval, through development and manufacturing support (moving to 24\\u002F7 manufacturing).\",\"length\":1655,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Moderna is ramping up internal manufacturing to allow millions of doses per month in 2020 and tens of millions per month in 2021, and management\u2019s belief that the 50 ug dose could be selected would help expand the reach of Moderna\u2019s vaccine to more patients (the firm\u2019s Norwood, Massachusetts, facility could supply up to 100 million doses a year at this dosage). An April 30 partnership with Lonza boosts capacity by 10 times, with the goal of producing 1 billion doses a year at the 50 ug expected dose (manufacturing at Lonza suites in the U.S. and Switzerland to begin in July).\",\"length\":582,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003EJohnson &amp; Johnson\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EJohnson &amp; Johnson&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FJNJ\\\" class=\\\"mdc-link mds-link\\\"\\u003EJNJ\\u003C\\u002Fa\\u003E)&nbsp;selected an Ad26 vector candidate expressing the SARS-CoV-2 spike protein as of March 30. The firm has steadily accelerated development plans, most recently moving up its estimated phase 1 start from early November to September at the latest, with data available December 2020 and potential launch in emergency use in the first quarter of 2021. J&amp;J has also accelerated supply estimates, from an initial estimate of 300 million doses a year in 8-12 months and ready for emergency use by early 2021 to annual production of 600 million-900 million coronavirus vaccines likely by early 2021 and full supply of 1 billion doses by late 2021. Emergent BioSolutions&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FEBS\\\" class=\\\"mdc-link mds-link\\\"\\u003EEBS\\u003C\\u002Fa\\u003E)&nbsp;will act as one contract development and manufacturing organization beginning in 2021. Catalent&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FCTLT\\\" class=\\\"mdc-link mds-link\\\"\\u003ECTLT\\u003C\\u002Fa\\u003E)&nbsp;will supply large-scale manufacturing capacity as well, ready for 24\\u002F7 manufacturing by January 2021. J&amp;J is aiming for a not-for-profit price around $10.\",\"length\":1010,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003EUniversity of Oxford\\u002FVaccitech\\u002FMerck KGaA\\u002FAstraZeneca\u2019s ChAdOx1 nCoV-19\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EThis chimp AAV vaccine for the spike protein started a large (1,100 volunteers) phase 1 COV001 study in April 2020, with data expected in May for the first group of volunteers (age 18-55), followed by 55-70 and 70-plus cohorts. This is part of a partnership between Merck KGaA and the Jenner Institute (part of a joint venture with University of Oxford and Pirbright Institute). Oxford now has a 10-liter scale process for the adenovirus vector vaccine. They expect data by autumn 2020 from the phase 2\\u002Fphase 3 portion of the study (5,000 volunteers expected to start enrolling in May), which could allow emergency approval in September, when the first few million doses could be available. Data from a rhesus macaque study was positive in April (six challenged monkeys stayed healthy). AstraZeneca&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FAZN\\\" class=\\\"mdc-link mds-link\\\"\\u003EAZN\\u003C\\u002Fa\\u003E)&nbsp;joined as global development and manufacturing lead on April 30, with a cited goal of 100 million doses by the end of 2020. The collaboration is not-for-profit during the pandemic.\",\"length\":1067,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003ESanofi\\u002FGlaxo\\u003C\\u002Fem\\u003E\\u003Cbr\\u003ESanofi is working with BARDA on a coronavirus vaccine, using proven influenza FluBlok technology (with Glaxo\u2019s adjuvant booster). Sanofi partnered this program with Glaxo&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FGSK\\\" class=\\\"mdc-link mds-link\\\"\\u003EGSK\\u003C\\u002Fa\\u003E)&nbsp;on April 14 and plans to move a coronavirus vaccine to development in the fourth quarter of 2020, with earliest approval in the second half of 2021. They expect to be able to manufacture a billion doses by April 2021 by sharing their technology (Sanofi\u2019s S-protein antigen using recombinant DNA technology and Glaxo\u2019s adjuvant technology, which can lower the required dose). Sanofi also entered a collaboration with Translate Bio&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FTBIO\\\" class=\\\"mdc-link mds-link\\\"\\u003ETBIO\\u003C\\u002Fa\\u003E)&nbsp;for its mRNA vaccine, which, like the more traditional Sanofi\\u002FGlaxo vaccine, could be in a clinical trial by the end of 2020 and be approved by the end of 2021. Translate\u2019s vaccine has been manufactured at a 100-gram scale, and CMO manufacturing of two 250-gram batches per month could add to supply; at Moderna\u2019s midlevel dose, this could vaccinate 3 million people per month initially, but hundreds of millions by the end of 2021 with Sanofi\u2019s help (at kilogram-size batches). Sanofi expects 90 million-360 million doses by the first quarter of 2021.\",\"length\":1199,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003ECureVac\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EWorking with CEPI, CureVac has two mRNA candidates that do not target the spike protein poised to enter trials by summer. CureVac\u2019s mRNA is self-amplifying, which reduces the amount of vaccine needed for manufacturing. While the three approved manufacturing suites could make 10 million doses per campaign, a fourth suite would push this north of a billion per production run. CureVac received funding from the European Commission in March.\",\"length\":448,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cem\\u003EPfizer\\u002FBioNTech\\u003C\\u002Fem\\u003E\\u003Cbr\\u003EBioNTech&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FBNTX\\\" class=\\\"mdc-link mds-link\\\"\\u003EBNTX\\u003C\\u002Fa\\u003E)&nbsp;started a trial in Germany, with the first cohort of 12 volunteers in Germany dosed by April 29, and a U.S. trial (a phase 1\\u002Fphase 2 trial to enroll 360 adults and elderly volunteers) kicked off on May 5. Fosun has China rights, and BioNTech signed a letter of intent March 17 with Pfizer elsewhere (expanding their flu vaccine partnership to coronavirus). As of early April, Pfizer said it could have tens of millions of doses by the end of 2020 and hundreds of millions in 2021. The first BNT162 study in Germany will test doses between 1ug and 100 ug in 200 volunteers (ages 18-55) for four vaccines (modified mRNA, uRNA, and self-amplifying RNA). SaRNA could have a big dosing advantage, potentially requiring just one dose (others could require prime and boost) and 60 times lower dose versus uRNA vaccine (and perhaps against Moderna\u2019s mRNA vaccine). Pfizer plans to choose the one or two most promising to move forward by June, with the help of data from primates and plasma of vaccinated humans due by late May\\u002Fearly June. Pfizer is aiming for an EUA or accelerated approval in October (with human study and surrogate endpoint), at the start of flu season and a time when the next wave could be building. Pfizer\u2019s Mikael Dolsten said on a call with Stat news that it could focus on the high-risk population, which could be 30%-40% of the broader population.\",\"length\":1407,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EFading Antibody Levels and Mutation Rates Unlikely to Derail Near-Term Pipelines\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EWith a new virus, it\u2019s difficult to say how long immunity will last after infection or after treatment with targeted antibodies or a vaccine. We don\u2019t know what antibody level is sufficient to protect a patient, although research on convalescent serum (from recovered patients) is ongoing. For older coronaviruses that trigger common colds, reinfection can occur. However, even if protection is incomplete, experts say antibodies are likely to at least lead to milder infections, and recent research seems to indicate that almost all infected patients produce antibodies. We will very likely need to continue to make new versions of antibodies or vaccines if the virus recurs. However, we think it\u2019s very likely that coronavirus vaccines in development today, if effective in trials, will provide enough immunity to get us through the pandemic.\",\"length\":925,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"While SARS-CoV-2 could mutate to become resistant to vaccines currently in development (targeting the spike protein), we think the evidence so far indicates that this is unlikely. RNA viruses--which include viruses like HIV, influenza, and coronaviruses--generally have the highest mutation rates among microorganisms, creating concerns about how long a potential treatment or vaccine could be effective before SARS-CoV-2 is able to mutate around it. HIV vaccines have been in development for decades without positive results because HIV\u2019s surface molecules (envelope glycoproteins) mutate so rapidly, even within one patient, that they can learn to evade treatment and vaccines, and we now have multiple versions of the virus circulating in society. For influenza, we have vaccines, but these are only at best 60% effective in preventing the flu. This is because there are multiple strains of flu with different surface markers, or antigens, and with so many different strains circulating, it is difficult to predict which one will become most dangerous in a given season (and only so many can be selected for the vaccine). In addition, the flu can mutate, creating new versions that would require new vaccines. Flu vaccine effectiveness can be as low as 20%-30% if vaccine manufacturers do not select the viral strain that ends up being most common that season.\",\"length\":1363,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"While most RNA viruses have an RNA polymerase that operates without proofreading capabilities--meaning that the viral genetic material mutates rapidly--coronaviruses have such large genomes that they do have proofreading, so their mutation rate is significantly lower. In addition, typically, the most crucial parts of the virus--for example, the spike protein (which allows the virus to infect a cell and is the target of vaccines and antibodies), the polymerase (that copies coronavirus genes, targeted by Gilead\u2019s remdesivir), and the protease (that cut peptides to help form key viral enzymes, targeted by Pfizer\u2019s antiviral)--are not subject to as much variation because of their essential nature. While antivirals like remdesivir could pressure the virus and trigger mutations in the viral polymerase that allow higher mutation rates, changing a viruses\u2019 established mutation rate is more likely to destabilize it and weaken it. A recent hypothesis regarding SARS-CoV-2 mutations and increased transmissibility of a new mutant version (Spike D614G) has been released (a preprint article, not a peer-reviewed publication), but Moderna doesn\u2019t expect mutations seen so far to interfere with the efficacy of its vaccine. In addition, if Moderna validates its technology with an initial vaccine, time to availability would be quite short for a new vaccine, with manufacturing capacity already expanded and a much-abbreviated development timeline (like annual flu vaccine changes).\",\"length\":1482,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Finally, drug developers are working on ways to make their products less vulnerable to mutations. Antibody developers like Regeneron are also working on potential cocktails of antibodies to make sure that a potential point mutation doesn\u2019t erode efficacy, and Regeneron says that its cocktails work on all of the spike protein variants it\u2019s tested in vitro (Amgen&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FAMGN\\\" class=\\\"mdc-link mds-link\\\"\\u003EAMGN\\u003C\\u002Fa\\u003E)&nbsp;and Adaptive are hoping for two or three in their cocktail, as well). By the time such point mutations develop (if they do), we should have well-developed infrastructure for producing novel vaccines, allowing for a much faster response. In addition, current antivirals could offer some protection despite mutations that lower coronavirus vaccine efficacy.\",\"length\":736,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EIn Our Pharma and Biotech Coverage, Roche, Pfizer, and Sanofi Undervalued\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EGilead\u2019s remdesivir received emergency use authorization from the FDA on May 1 based on strong data from two clinical studies. Although the initial supply will be donated, we expect a $500 U.S. price tag to allow for $2 billion in sales in 2021. The arrival of coronavirus vaccines is likely to make any profits short term, limiting the upside to Gilead\u2019s valuation, and the shares look fairly valued.\",\"length\":475,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Roche is a leading supplier of SARS-CoV-2 diagnostics and antibody tests, which provides some counterbalance to the decline in routine diagnostic tests due to the pandemic. Immunology drug Actemra could also prove helpful in severely ill patients (data should be available this month). While Roche shares have performed strongly during the downturn, they remain slightly undervalued.\",\"length\":383,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Regeneron and Amgen are both racing to bring targeted antibodies to market, which could serve as treatments or prophylaxis for COVID-19. We think Regeneron is a few months ahead, and greater visibility gives us confidence to include $2 billion in potential sales in our model in 2021, similar to the sales potential of remdesivir. However, without clinical data or guidance on pricing, it\u2019s difficult for this to move the meter substantially on our Regeneron valuation, and the shares look slightly overvalued. Amgen\u2019s partnership with Adaptive is encouraging, but we\u2019re awaiting more details before including this in our model, and Amgen shares look fairly valued.\",\"length\":665,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Big Pharma firms like J&amp;J, Sanofi, Glaxo, Astra, and Pfizer are all rapidly accelerating development and manufacturing timelines to bring a coronavirus vaccine to market. Shares for all these firms have held up well during the pandemic, but we think the shares of Pfizer and Sanofi still look slightly undervalued, and Pfizer\u2019s partnership with BioNTech offers several shots on goal. That said, pandemic sales for most of these coronavirus vaccines will likely be not-for-profit.\",\"length\":483,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EMost Diagnostics Names Appear Fairly Valued or Overvalued\\u003C\\u002Fstrong\\u003E\\u003Cbr\\u003EWe modestly lowered our fair value estimates for LabCorp and Quest to reflect loss of revenue from non-COVID-19 tests, which will only be partially offset by COVID-19 tests. If the normal volume of surgeries and elective procedures returns sooner than expected, this could offer upside to our valuations. We think LabCorp\u2019s higher proportion of esoteric tests (hit less severely than routine tests) could allow it to fare marginally better, and shares look slightly undervalued.\",\"length\":536,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Abbott remains overvalued, from our perspective, after we incorporated declines in medical devices to reflect procedures crowded out by COVID-19 through the second and third quarters, as well as softness in nutritionals thanks to global recessionary conditions. Traditional and point-of-care COVID-19 tests support strong molecular diagnostics growth but don\u2019t significantly sway our valuation.\",\"length\":394,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"Hologic shares are fairly valued, in our opinion, after incorporating weakness in the women\u2019s health and surgical segments, which is partially offset by COVID-19-driven growth in molecular diagnostics. Considering Hologic\u2019s extensive installed base of Panthers in the U.S. and their presence in the largest reference labs, increased production of SARS-CoV-2 tests could add upside to our valuation.\",\"length\":398,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"While Thermo Fisher&nbsp;(\\u003Ca href=\\\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fquote\\u002FTMO\\\" class=\\\"mdc-link mds-link\\\"\\u003ETMO\\u003C\\u002Fa\\u003E)&nbsp;stands to benefit from COVID-19 as one of the developers of diagnostic testing with scale, a pullback in capital spending will modestly affect its instrumentation business. However, Thermo Fisher\u2019s business is less exposed to higher-ticket purchases than many of its analytical instrument peers (and relative to its own business during the last economic pullback), and its strong consumable revenue stream should help the company weather this cycle rather unscathed. The market seems to agree, with the shares trading above prepandemic levels and ahead of our valuation.\",\"length\":606,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EThis article was written by Karen Anderson, CFA\u00a9 and Healthcare Strategist at Morningstar, a research partner for&nbsp;Yahoo Finance Premium.\\u003C\\u002Fstrong\\u003E\",\"length\":141,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EKaren and Preston Caldwell, Equity Analyst at Morningstar, will discuss the long-term economic impact of the global shutdown in a special Yahoo Finance Premium webinar on Tuesday, May 19 at 12pm ET.&nbsp;\\u003C\\u002Fstrong\\u003E\\u003Ca href=\\\"https:\\u002F\\u002Fgo.morningstar.com\\u002FLong-Term-Impact\\\" rel=\\\"nofollow noopener\\\" target=\\\"_blank\\\"\\u003E\\u003Cstrong\\u003ERegister for free today.\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fa\\u003E\",\"length\":228,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EKaren Andersen has a position in the following security mentioned above: DGX. Find out about Morningstar\u2019s&nbsp;\\u003C\\u002Fstrong\\u003E\\u003Ca href=\\\"https:\\u002F\\u002Fwww.morningstar.com\\u002Feditorial-policy\\\" class=\\\"mdc-link mds-link\\\" rel=\\\"nofollow noopener\\\" target=\\\"_blank\\\"\\u003E\\u003Cstrong\\u003Eeditorial policies\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fa\\u003E\\u003Cstrong\\u003E.\\u003C\\u002Fstrong\\u003E\",\"length\":131,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Cstrong\\u003EAdditional Morningstar research is available in Yahoo Finance Premium.&nbsp;\\u003C\\u002Fstrong\\u003E\\u003Ca href=\\\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Fpremium-marketing?ncid=editoriald_yhm5ec0oo8o\\\"\\u003E\\u003Cstrong\\u003EStart your free trial today.*\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fa\\u003E\",\"length\":105,\"tagName\":\"p\"},{\"type\":\"text\",\"content\":\"\\u003Ca href=\\\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Fpremium-marketing?ncid=editoriald_yhm5ec0oo8o\\\"\\u003E  \\u003C\\u002Fa\\u003E\",\"length\":0,\"tagName\":\"p\"},{\"size\":{\"original\":{\"width\":720,\"height\":177,\"ratio\":4.067796610169491,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FiUajoTdoIOKpImXTWIey6g--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9NzIwO2g9MTc3\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-04\\u002F81f62ba0-7424-11ea-a97b-dc69225e0d0c\"}},\"alt\":\"Try Yahoo Finance Premium for free today.\",\"alias\":null,\"headline\":null,\"type\":\"image\",\"link\":{\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Fpremium-marketing?ncid=editoriald_yhm5ec0oo8o\",\"isExternal\":false}}],\"verticalVideo\":null,\"summary\":\"Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.\",\"tagsInfo\":{\"id\":\"$sanofi\",\"name\":\"$sanofi\"},\"site\":\"finance\",\"searchNoIndex\":\"false\",\"blogSite\":\"finance\",\"author\":{\"name\":\"Joanna Kong\",\"title\":\"Yahoo Finance Premium\",\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002F\"},\"thumbnail\":{\"width\":\"1672\",\"height\":\"1110\",\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FyfmPmOmwuoMa7svbTToA.g--~B\\u002FaD0xMTEwO3c9MTY3MjtzbT0xO2FwcGlkPXl0YWNoeW9u\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\",\"tag\":\"size=original\"},\"payoffs\":{},\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"alias\":\"ymedia-alias:story=coronavirus-vaccine-progress-accelerates-155109303\",\"provider\":null,\"ibsImages\":null,\"sortComments\":false,\"videoMicrodata\":null,\"contentType\":\"story\",\"publishDateStr\":\"May 14, 2020\",\"hideComments\":false,\"vibePost\":null,\"pending\":false,\"title\":\"Coronavirus Vaccine Progress Accelerates\",\"tags\":[\"$sanofi\",\"$incy\",\"$quest-diagnostics-incorporated\",\"$nvs\",\"$aapl\",\"$rhhvf\",\"$goog\",\"$nvsef\",\"$roche-holding-ag\",\"$lly\",\"$gild\",\"$lh\",\"$regn\",\"$glaxf\",\"$googl\",\"$tmo\",\"$mrna\",\"$adpt\",\"$laboratory-corporation-of-america-holdings\",\"yfipremium\",\"$snynf\",\"$rhhbf\",\"$abt\",\"$pfe\",\"$biontech-se\",\"$tbio\",\"$sny\",\"$bntx\",\"$holx\",\"$diod\",\"$dgx\",\"$ebs\",\"$ctlt\",\"$rhhby\",\"$gsk\"],\"bodyImages\":[{\"size\":{\"original\":{\"width\":1672,\"height\":1110,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FAJ3Jziu1IkT0VEFzmNd.Dw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTY3MjtoPTExMTA-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"},\"800x600\":{\"width\":800,\"height\":531,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FS2.JPK5ji8r0ePJHBKiZig--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAwO2g9NjAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"},\"800x\":{\"width\":800,\"height\":531,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F09jiduDn86KmFnDATBZLFQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"},\"1280x960\":{\"width\":1280,\"height\":850,\"ratio\":1.5063063063063062,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FWS4.nozMf3EwU3TrSLPW5A--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTI4MDtoPTk2MA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F7e7a2c40-95fa-11ea-afff-79b6b59e34b6\"}},\"caption\":\"Testing Improving and Positive Rate Moving in Right Direction\",\"alt\":\"Testing Improving and Positive Rate Moving in Right Direction\",\"alias\":null,\"headline\":null,\"type\":\"image\"},{\"size\":{\"original\":{\"width\":1672,\"height\":900,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F9iDYgfOUW3bKg74jPAfemA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTY3MjtoPTkwMA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"},\"800x600\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F5oIlxNtwiWmLsXGvFoxUlg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAwO2g9NjAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"},\"800x\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FjeeRzgX_TiFWzuxXoCMBng--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"},\"1280x960\":{\"width\":1280,\"height\":689,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FiwOzCLyyqT5GHc4Vrd.nnQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTI4MDtoPTk2MA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F4415e670-95fa-11ea-bdf9-f2bd25ff3f99\"}},\"caption\":\"The Standard Paradigm for Vaccine Development is Lengthy...\",\"alt\":\"The Standard Paradigm for Vaccine Development is Lengthy...\",\"alias\":null,\"headline\":null,\"type\":\"image\"},{\"size\":{\"original\":{\"width\":1672,\"height\":900,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FMO7y6ga4RSO9Us1sygS0IQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTY3MjtoPTkwMA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"},\"800x600\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FkFCylpNqaAmtzhpkOM2.aA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAwO2g9NjAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"},\"800x\":{\"width\":800,\"height\":431,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FWm2eWaxHqJy39umPmcY8RQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODAw\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"},\"1280x960\":{\"width\":1280,\"height\":689,\"ratio\":1.8577777777777778,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FAPXTt8EIS8DFjpAav8LNRQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9MTI4MDtoPTk2MA--\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F5dff3370-95fa-11ea-bebf-39dd74820101\"}},\"caption\":\"...But It Can Be Accelerated in a Pandemic\",\"alt\":\"...But It Can Be Accelerated in a Pandemic\",\"alias\":null,\"headline\":null,\"type\":\"image\"},{\"size\":{\"original\":{\"width\":720,\"height\":177,\"ratio\":4.067796610169491,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FiUajoTdoIOKpImXTWIey6g--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9NzIwO2g9MTc3\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-uploaded-images\\u002F2020-04\\u002F81f62ba0-7424-11ea-a97b-dc69225e0d0c\"}},\"alt\":\"Try Yahoo Finance Premium for free today.\",\"alias\":null,\"headline\":null,\"type\":\"image\",\"link\":{\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Fpremium-marketing?ncid=editoriald_yhm5ec0oo8o\",\"isExternal\":false}}],\"type\":\"story\",\"hrefLangs\":[{\"rel\":\"alternate\",\"hrefLang\":\"x-default\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-CA\",\"href\":\"https:\\u002F\\u002Fca.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-US\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-GB\",\"href\":\"https:\\u002F\\u002Fuk.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-IN\",\"href\":\"https:\\u002F\\u002Fin.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-NZ\",\"href\":\"https:\\u002F\\u002Fnz.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-IE\",\"href\":\"https:\\u002F\\u002Fie.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-AU\",\"href\":\"https:\\u002F\\u002Fau.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"},{\"rel\":\"alternate\",\"hrefLang\":\"en-SG\",\"href\":\"https:\\u002F\\u002Fsg.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\"}],\"uuid\":\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\",\"canonicalUrl\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-vaccine-progress-accelerates-155109303.html\",\"seoTitle\":\"Coronavirus Vaccine Progress Accelerates\",\"rapid\":{},\"tumblr\":null,\"snippet\":false,\"publishDate\":\"Thu, 14 May 2020 15:51:09 GMT\",\"attribution\":{\"author\":{\"name\":\"Joanna Kong\",\"title\":\"Yahoo Finance Premium\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fjoanna-kong\",\"alias\":\"joanna-kong\"},\"provider\":{\"name\":\"Yahoo Finance\",\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"logo\":{\"size\":{\"original\":{\"ratio\":0,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FrreDgBV94x1h_KZYC6i1gg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0x\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-uploaded-images\\u002F2020-01\\u002F4cb0aab0-42e2-11ea-bc79-5bef33ee891c\"},\"40x40\":{\"width\":40,\"height\":40,\"ratio\":0,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FnS35MysnuXJyidkB0Opscg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9NDA7aD00MA--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-uploaded-images\\u002F2020-01\\u002F4cb0aab0-42e2-11ea-bc79-5bef33ee891c\"},\"84x84\":{\"width\":84,\"height\":84,\"ratio\":0,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FxN76WXOX_mffi8EAWYz2pw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtzbT0xO3c9ODQ7aD04NA--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-uploaded-images\\u002F2020-01\\u002F4cb0aab0-42e2-11ea-bc79-5bef33ee891c\"}}},\"provider_object_ref\":\"c9a91351-e63e-381c-8c4f-1ba10f39b666\"}}}},\"_viewedContentIds\":{\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\":true},\"_slotCompositeReady\":{\"Lead-0-CommonSlotComposite\":true,\"Side-1-CommonSlotComposite\":true},\"_currentPlaylistId\":null},\"CompositeStore\":{\"_instances\":{\"Hero-0-FinanceHeader\":{\"status\":\"initialized\"},\"Col2-1-RecentQuotes\":{\"status\":\"initialized\"},\"Lead-0-CommonSlotComposite\":{\"status\":\"initialized\"},\"Side-1-CommonSlotComposite\":{\"status\":\"initialized\"},\"Col2-5-HeightContainer\":{\"status\":\"initialized\"},\"UH-0-UH\":{\"status\":\"initialized\"},\"UH-1-DesktopNav\":{\"status\":\"initialized\"},\"Hero-1-FeatureBar\":{\"status\":\"initialized\"},\"Hero-5-HeadComponentVideo\":{\"status\":\"initialized\"},\"UH-0-UH-0-Header\":{\"status\":\"initialized\"},\"UH-1-DesktopNav-acct-switch-0-AccountSwitch\":{\"status\":\"initialized\"},\"account-switch-uh-0-AccountSwitch\":{\"status\":\"initialized\"}}},\"StreamStore\":{\"pageUuid\":\"ee6c0f80-61d5-3bba-8101-bb8bd4d538c3\",\"articleCategory\":{\"term\":\"YCT:001000532\",\"label\":\"Pharmaceuticals & Drug Trials\"},\"pageCategory\":\"YPROP:FINANCE\",\"fallbackCategory\":\"YPROP:FINANCE\",\"parentCategory\":\"\",\"pageSubsite\":\"\",\"streams\":{\"SIDEKICK:TOPSTORIES.sidekick\":{\"bpos\":1,\"data\":{\"stream_items\":[{\"i13n\":{\"bpos\":1,\"cpos\":1,\"cposy\":1},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fsix-positive-tests-coronavirus-premier-league-clubs-154903031--sow.html\",\"title\":\"Burnley's Woan among six positive COVID-19 tests at Premier League clubs\",\"images\":{\"original\":{\"height\":511,\"width\":768,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FLiU4S51BhwfWSADmf67XoA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FN6sY2RZdEHtTfPop68vpyw--~B\\u002FaD01MTE7dz03Njg7YXBwaWQ9eXRhY2h5b24-\\u002Fhttp:\\u002F\\u002Fmedia.zenfs.com\\u002Fen_us\\u002FNews\\u002Fafp.com\\u002Fd915f50e11a5f6fd6833266d4bb4907388f7b895.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FSXuXhvzdMw9L0GtRM3nIHA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FLiU4S51BhwfWSADmf67XoA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FN6sY2RZdEHtTfPop68vpyw--~B\\u002FaD01MTE7dz03Njg7YXBwaWQ9eXRhY2h5b24-\\u002Fhttp:\\u002F\\u002Fmedia.zenfs.com\\u002Fen_us\\u002FNews\\u002Fafp.com\\u002Fd915f50e11a5f6fd6833266d4bb4907388f7b895.jpg\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fsix-positive-tests-coronavirus-premier-league-clubs-154903031--sow.html\",\"id\":\"b51a11f2-cebe-33a1-9009-9bf7df538c83\",\"publisher\":\"AFP\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":2,\"cposy\":2},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fburnley-assistant-manager-ian-woan-195813582.html\",\"title\":\"Burnley assistant manager Ian Woan tests positive for coronavirus\",\"images\":{\"original\":{\"height\":1562,\"width\":2499,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FqLwtGu.ZNKpLmQThtOGkmw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FvC6Ojrz_FBdVlYwRMVnttw--~B\\u002FaD0xNTYyO3c9MjQ5OTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-GB\\u002Fthe_telegraph_818\\u002F41453ebd77899a3bab51d74828e2a88e\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FJ7PDKlb4OTdOBrPPJyUNZg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FqLwtGu.ZNKpLmQThtOGkmw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FvC6Ojrz_FBdVlYwRMVnttw--~B\\u002FaD0xNTYyO3c9MjQ5OTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-GB\\u002Fthe_telegraph_818\\u002F41453ebd77899a3bab51d74828e2a88e\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fburnley-assistant-manager-ian-woan-195813582.html\",\"id\":\"a3a321a1-8279-3086-beb9-9471e651e60a\",\"publisher\":\"The Telegraph\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":3,\"cposy\":3},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fpremier-league-confirms-six-positive-173225730.html\",\"title\":\"Premier League confirms six positive COVID-19 cases after testing\",\"images\":{\"original\":{\"height\":508,\"width\":800,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F1q7MXuiEwvCI8REqIaDXAw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fu6P1v2y3Mp.F.yoMn57vEg--~B\\u002FaD01MDg7dz04MDA7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-US\\u002Freuters.com\\u002F8815090ce898708e1294b944b784cd2d\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F1cWdpP.qS2Sbw_RFu9zzdg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F1q7MXuiEwvCI8REqIaDXAw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fu6P1v2y3Mp.F.yoMn57vEg--~B\\u002FaD01MDg7dz04MDA7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-US\\u002Freuters.com\\u002F8815090ce898708e1294b944b784cd2d\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fpremier-league-confirms-six-positive-173225730.html\",\"id\":\"63ab6da3-f4af-31a5-82dd-9b8c12544713\",\"publisher\":\"Reuters\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":4,\"cposy\":4},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Fwww.wsj.com\\u002Farticles\\u002Fa-political-assault-on-antibody-tests-11589908458?mod=itp_wsj&yptr=yahoo\",\"title\":\"A Political Assault on Antibody Tests\",\"images\":{\"original\":{\"height\":369,\"width\":553,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FL3FSlkIvMoWL3Gd3aygchA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FH_pCXLAh4G58cFYeQlCMcQ--~B\\u002FaD0zNjk7dz01NTM7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-us\\u002Fwsj.com\\u002Fdb8c8359b18753110e5e0f223133fc2f\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FMqXYc9RHUzE252roUFR8hw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FL3FSlkIvMoWL3Gd3aygchA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FH_pCXLAh4G58cFYeQlCMcQ--~B\\u002FaD0zNjk7dz01NTM7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-us\\u002Fwsj.com\\u002Fdb8c8359b18753110e5e0f223133fc2f\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Fm\\u002F8b688be8-2f23-3204-b24b-82424c0a20bd\\u002Fa-political-assault-on.html\",\"id\":\"8b688be8-2f23-3204-b24b-82424c0a20bd\",\"publisher\":\"The Wall Street Journal\",\"off_network\":true},{\"i13n\":{\"bpos\":1,\"cpos\":5,\"cposy\":5},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-covid-19-daily-roundup-225500817.html\",\"title\":\"Coronavirus (COVID-19) Update: Daily Roundup\",\"images\":{\"original\":{\"height\":94,\"width\":400,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F5g7e7EJaa0B4yERObaZLdQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FhmNduLI1xnjP4NIBiHxT4w--~B\\u002FaD05NDt3PTQwMDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen\\u002Fusnewswire.com\\u002Fc2dda8e27e5f933c46e1a6b84da4057a\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F4TBgZyMzlP_Z6NTfO7uGqA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F5g7e7EJaa0B4yERObaZLdQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FhmNduLI1xnjP4NIBiHxT4w--~B\\u002FaD05NDt3PTQwMDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen\\u002Fusnewswire.com\\u002Fc2dda8e27e5f933c46e1a6b84da4057a\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcoronavirus-covid-19-daily-roundup-225500817.html\",\"id\":\"3e23f702-e7a2-338a-99bc-209d642c0935\",\"publisher\":\"PR Newswire\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":6,\"cposy\":6},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fover-4-million-will-contract-coronavirus-as-states-reopen-wharton-model-172015472.html\",\"title\":\"Over 4 million in US will contract coronavirus if states fully reopen: Wharton model\",\"images\":{\"original\":{\"height\":2600,\"width\":3900,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F6DzPvDU12cFoTykDF3XDqw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-05\\u002F6527ef00-99f3-11ea-ac7f-1c379e02683a\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FIhwrnyEmRBEOgIdxRvMyGw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F6DzPvDU12cFoTykDF3XDqw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-05\\u002F6527ef00-99f3-11ea-ac7f-1c379e02683a\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fover-4-million-will-contract-coronavirus-as-states-reopen-wharton-model-172015472.html\",\"id\":\"a3995013-ce7a-3f00-b41f-b845242268e3\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":7,\"cposy\":7},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Ftesla-raise-full-self-driving-220933356.html\",\"title\":\"Tesla to raise 'full self-driving' option price to $8k \",\"images\":{\"original\":{\"height\":4321,\"width\":7691,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F_E89ILYev5uULaqVFI6FWQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FnpulMz9I82Yc6sddJPOS_w--~B\\u002Fdz03NjkxO2g9NDMyMTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec4591e6ca6be051a981d10\\u002F5ec4591e6ca6be051a981d11_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FAfnohJtu1d64hngRBYtPMA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F_E89ILYev5uULaqVFI6FWQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FnpulMz9I82Yc6sddJPOS_w--~B\\u002Fdz03NjkxO2g9NDMyMTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec4591e6ca6be051a981d10\\u002F5ec4591e6ca6be051a981d11_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Ftesla-raise-full-self-driving-220933356.html\",\"id\":\"b63a7b59-e31d-30cd-9799-06f102bfb905\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":8,\"cposy\":8},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fdemocrats-president-trump-coronavirus-163824935.html\",\"title\":\"Democrats slam President Trump for 'lazy, four-page copy and paste project' on coronavirus\",\"images\":{\"original\":{\"height\":3272,\"width\":4888,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FMX3dOsE1w.b0gDVtinh5bA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-05\\u002F59046d70-99ee-11ea-bf7a-ab7390ed652d\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FqwE8bpBe6Wqt3pDG_KFOUw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FMX3dOsE1w.b0gDVtinh5bA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-05\\u002F59046d70-99ee-11ea-bf7a-ab7390ed652d\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fdemocrats-president-trump-coronavirus-163824935.html\",\"id\":\"6402721a-7d49-361e-939e-a77a2593ff8e\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":9,\"cposy\":9},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Ffomc-minutes-lowes-target-report-earnings-what-to-know-in-markets-wednesday-222436084.html\",\"title\":\"FOMC minutes, plus Lowe's and Target report earnings: What to know in markets Wednesday\",\"images\":{\"original\":{\"height\":4128,\"width\":6192,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F49i.CQuZUXlAJDCdfdRJiw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002F4522ae50-99e6-11ea-aff1-ae5f8f285b7a\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FQajlWA2PbX0WdlemsQ2upA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F49i.CQuZUXlAJDCdfdRJiw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002F4522ae50-99e6-11ea-aff1-ae5f8f285b7a\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Ffomc-minutes-lowes-target-report-earnings-what-to-know-in-markets-wednesday-222436084.html\",\"id\":\"de74030f-df88-3628-94f6-31a11d19a111\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":10,\"cposy\":10},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Finside-michael-jordans-14-800-215937324.html\",\"title\":\"Inside Michael Jordan's $14,800,000 Chicago-area estate\",\"images\":{\"original\":{\"height\":1080,\"width\":1920,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FtmPFrPuBYONfxy_902TnWA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F.prWYPDYsYwessgDU3rieA--~B\\u002Fdz0xOTIwO2g9MTA4MDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec456ceb43fec69be44026c\\u002F5ec456ceb43fec69be44026d_o_U_v2.png\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FCo8_a4gdxvZ_fhh_ksUaLQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FtmPFrPuBYONfxy_902TnWA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F.prWYPDYsYwessgDU3rieA--~B\\u002Fdz0xOTIwO2g9MTA4MDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec456ceb43fec69be44026c\\u002F5ec456ceb43fec69be44026d_o_U_v2.png\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Finside-michael-jordans-14-800-215937324.html\",\"id\":\"a75cfd5d-b7eb-3fcb-a04d-90b61f4e1c36\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":11,\"cposy\":11},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fmoderna-stock-volatile-amid-coronavirus-021933804.html\",\"title\":\"Moderna Stock Volatile Amid Work on Coronavirus Vaccine\",\"images\":{\"original\":{\"height\":267,\"width\":400,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FxTc6wna1TALjfcfTsddAUw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F4wve76Fjr17sUZGlQCJCvg--~B\\u002FaD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-us\\u002Finsidermonkey.com\\u002F229af667ee872155899465db4c5b62bb\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FL9MSWrpffVzCEVpRvHLO_w--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FxTc6wna1TALjfcfTsddAUw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F4wve76Fjr17sUZGlQCJCvg--~B\\u002FaD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-us\\u002Finsidermonkey.com\\u002F229af667ee872155899465db4c5b62bb\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fmoderna-stock-volatile-amid-coronavirus-021933804.html\",\"id\":\"f86a6a51-9a80-30ab-83b4-78c9b281a11c\",\"publisher\":\"Insider Monkey\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":12,\"cposy\":12},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fnasa-head-human-spaceflight-bows-225246383.html\",\"title\":\"Days before landmark launch, NASA\u2019s head of human spaceflight quits due to \u2018mistake\u2019\",\"images\":{\"original\":{\"height\":422,\"width\":630,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FSdi328B8IUIkYAHvUV4U9w--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-US\\u002Fgeekwire_312\\u002F940126ab26fe83c13d2920445001f085\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FHynScfXg4_z.WT9QN4HWfw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FSdi328B8IUIkYAHvUV4U9w--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen-US\\u002Fgeekwire_312\\u002F940126ab26fe83c13d2920445001f085\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fnasa-head-human-spaceflight-bows-225246383.html\",\"id\":\"46199ea7-a532-3e58-9977-a47061744f34\",\"publisher\":\"GeekWire\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":13,\"cposy\":13},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fnvidia-unveils-ai-fight-coronavirus-172414034.html\",\"title\":\"Nvidia unveils new AI to fight coronavirus\",\"images\":{\"original\":{\"height\":3005,\"width\":5340,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fp1djcEFxezwOCQI5z9FYSw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F14\\u002F5ebd7ec190a80d675a63bfe9\\u002F5ebd7ec190a80d675a63bfea_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002Ffm3tpayguiLfqGAUg0a7Jw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fp1djcEFxezwOCQI5z9FYSw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F14\\u002F5ebd7ec190a80d675a63bfe9\\u002F5ebd7ec190a80d675a63bfea_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fnvidia-unveils-ai-fight-coronavirus-172414034.html\",\"id\":\"6dec3bf1-6774-3e2b-bb4f-79a9faf5d2a1\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":14,\"cposy\":14},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fmost-volume-trading-around-rate-142737826.html\",\"title\":\"The 'most volume of trading has been around the rate sector' amid COVID-19 crisis: Tradeweb CEO\",\"images\":{\"original\":{\"height\":4500,\"width\":8000,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F_aSwMmyHFNsSMTYl.BO_aQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F08\\u002F5eb56c5a5f6f656335c2c0cd\\u002F5eb5856384a08c74cced1681_o_U_v4.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FEeYaH.xG_RjzMCFFlx3k5A--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F_aSwMmyHFNsSMTYl.BO_aQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F08\\u002F5eb56c5a5f6f656335c2c0cd\\u002F5eb5856384a08c74cced1681_o_U_v4.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fmost-volume-trading-around-rate-142737826.html\",\"id\":\"c44cb875-c224-33a8-93ca-c99e0fc3205c\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":15,\"cposy\":15},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fstock-market-news-live-may-20-2020-221852318.html\",\"title\":\"Stock market news live updates: Stock futures fall, extending declines\",\"images\":{\"original\":{\"height\":3456,\"width\":5184,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FmVaWKQnw_KguzbibptoKKw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002Fbebd1710-9a17-11ea-bfdf-32ef011721b1\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FO.Dj.OoPJUcyQTCouqCMxA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FmVaWKQnw_KguzbibptoKKw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002Fbebd1710-9a17-11ea-bfdf-32ef011721b1\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fstock-market-news-live-may-20-2020-221852318.html\",\"id\":\"14c1181e-51fd-3fc2-9ddc-6498fa4fcf42\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":16,\"cposy\":16},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fjacqueline-novogratz-talks-her-book-213240384.html\",\"title\":\"Jacqueline Novogratz talks her new book 'Manifesto for a Moral Revolution'\",\"images\":{\"original\":{\"height\":414,\"width\":736,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FU76ZKLDX7Qc8jhqabSXhhg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FZKT_30nT6M_MeiWluuvVyQ--~B\\u002Fdz03MzY7aD00MTQ7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec4507a84a08c74cced3df2\\u002F5ec4507a84a08c74cced3df3_o_U_v2.png\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FaHphuBvYiBr.H4ZRk7HllA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FU76ZKLDX7Qc8jhqabSXhhg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FZKT_30nT6M_MeiWluuvVyQ--~B\\u002Fdz03MzY7aD00MTQ7YXBwaWQ9eXRhY2h5b24-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec4507a84a08c74cced3df2\\u002F5ec4507a84a08c74cced3df3_o_U_v2.png\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fjacqueline-novogratz-talks-her-book-213240384.html\",\"id\":\"9167244a-362b-3ff6-9d34-aee8b9ace65d\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":17,\"cposy\":17},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Feurope-slowly-exits-lockdown-sweden-hunkers-down-long-021756299.html\",\"title\":\"As Europe slowly exits lockdown, Sweden hunkers down for long haul\",\"images\":{\"original\":{\"height\":512,\"width\":768,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FOPDLMkkg5._n9UcI_YS_Yg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FZu44EF6PwBpOWycwOj9FxA--~B\\u002FaD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-\\u002Fhttp:\\u002F\\u002Fmedia.zenfs.com\\u002Fen_us\\u002FNews\\u002Fafp.com\\u002F066faa7db98d63c7ebf819da8a71e09c259d3cfc.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FgwmyTin6.BJcffM0B6xR.A--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FOPDLMkkg5._n9UcI_YS_Yg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FZu44EF6PwBpOWycwOj9FxA--~B\\u002FaD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-\\u002Fhttp:\\u002F\\u002Fmedia.zenfs.com\\u002Fen_us\\u002FNews\\u002Fafp.com\\u002F066faa7db98d63c7ebf819da8a71e09c259d3cfc.jpg\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Feurope-slowly-exits-lockdown-sweden-hunkers-down-long-021756299.html\",\"id\":\"508eb8fe-5cb3-3e5e-8a1a-1184556359b2\",\"publisher\":\"AFP\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":18,\"cposy\":18},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Ftrump-u-pass-10m-testing-205427089.html\",\"title\":\"Trump: U.S. will pass 10M testing conducted this week\",\"images\":{\"original\":{\"height\":3186,\"width\":5667,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fl1F0FRFh4MXsxdPTMTmyuQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F11\\u002F5eb9bb909bb2c071712dc3e8\\u002F5eb9bb909bb2c071712dc3e9_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FylNGaDu_LIFV9E9x4FzxZA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fl1F0FRFh4MXsxdPTMTmyuQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F11\\u002F5eb9bb909bb2c071712dc3e8\\u002F5eb9bb909bb2c071712dc3e9_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Ftrump-u-pass-10m-testing-205427089.html\",\"id\":\"b0a5211d-36ef-3b90-a799-e8984402ecc3\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":19,\"cposy\":19},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Funemployment-pay-drama-rages-residents-192734345.html\",\"title\":\"Some renters are set to face evictions amid coronavirus crisis\",\"images\":{\"original\":{\"height\":2518,\"width\":4482,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FVVwBotKyBuYbSLoGZkU3WA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F12\\u002F5ebaf8a790a80d675a63b88f\\u002F5ebb157b9bb2c071712dc884_o_U_v5.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F6TTt34DeWExUdmCHCdKRTA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FVVwBotKyBuYbSLoGZkU3WA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F12\\u002F5ebaf8a790a80d675a63b88f\\u002F5ebb157b9bb2c071712dc884_o_U_v5.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Funemployment-pay-drama-rages-residents-192734345.html\",\"id\":\"82bb8c4a-56b5-3be1-a4d2-94a0a37b115c\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":20,\"cposy\":20},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fstock-market-news-live-may-6-2020-222531890.html\",\"title\":\"Stock market news live updates: Wall Street ends mixed, weighing grim data against states reopening\",\"images\":{\"original\":{\"height\":2800,\"width\":4200,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FDdFM9KtVvWqSAymfruHSsQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-05\\u002F7ff19b80-8f1f-11ea-adff-c55fa4077628\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FTAWONlivEV6QlX7VVYoKCQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FDdFM9KtVvWqSAymfruHSsQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-05\\u002F7ff19b80-8f1f-11ea-adff-c55fa4077628\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fstock-market-news-live-may-6-2020-222531890.html\",\"id\":\"c483277d-b11c-3041-8699-701d03ea5904\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":21,\"cposy\":21},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fstock-market-news-live-may-19-2020-221634424.html\",\"title\":\"Stock market news live updates: Wall St. ends lower, snap 3 day rally as investors pause for breath\",\"images\":{\"original\":{\"height\":4160,\"width\":6240,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FQli0aPFupqgrfkJaPoaYIQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002F5c8ee540-9955-11ea-bfe5-f210f064c7dc\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FUy8hnuOlBPDqlopQITn7Fw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FQli0aPFupqgrfkJaPoaYIQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002F5c8ee540-9955-11ea-bfe5-f210f064c7dc\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fstock-market-news-live-may-19-2020-221634424.html\",\"id\":\"058d1e59-c43d-38c9-9d85-cb73c11ba7fe\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":22,\"cposy\":22},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Frestaurateur-nick-kokonas-covid-19-210553528.html\",\"title\":\"Restaurateur Nick Kokonas on COVID-19 impact\",\"images\":{\"original\":{\"height\":3559,\"width\":6315,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FxZHg07e2Ugg5vWvTstDI5Q--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FTA4rD.vGBrh60ttNjXVoWg--~B\\u002Fdz02MzE1O2g9MzU1OTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec44a3290fe357a07b58f9b\\u002F5ec44a3290fe357a07b58f9c_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FAYPpTxeh_asd4KhR79CEEQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FxZHg07e2Ugg5vWvTstDI5Q--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FTA4rD.vGBrh60ttNjXVoWg--~B\\u002Fdz02MzE1O2g9MzU1OTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec44a3290fe357a07b58f9b\\u002F5ec44a3290fe357a07b58f9c_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Frestaurateur-nick-kokonas-covid-19-210553528.html\",\"id\":\"17e9e71a-ab77-34d7-9b17-509c8589d32e\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":23,\"cposy\":23},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fmexico-city-virus-deaths-could-020408995.html\",\"title\":\"Mexico City virus deaths could be more than triple official toll\",\"images\":{\"original\":{\"height\":3240,\"width\":5760,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fhj_UVbfkTPQYEW0.47.lvQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F_.QO.9_aak_VuB67hW4naw--~B\\u002FaD0zMjQwO3c9NTc2MDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen\\u002Fpa_viral_news_704\\u002F0391383035e88337e4c063b3e00731a3\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FbShplGtC6dz9hAb0f7w03w--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fhj_UVbfkTPQYEW0.47.lvQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F_.QO.9_aak_VuB67hW4naw--~B\\u002FaD0zMjQwO3c9NTc2MDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen\\u002Fpa_viral_news_704\\u002F0391383035e88337e4c063b3e00731a3\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fmexico-city-virus-deaths-could-020408995.html\",\"id\":\"76f54cbf-7cb9-31f5-a869-361b366342a5\",\"publisher\":\"PA Media: World News\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":24,\"cposy\":24},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fmore-consumers-show-interest-traveling-172024841.html\",\"title\":\"More consumers show interest in traveling on cruises in the near term: Analyst\",\"images\":{\"original\":{\"height\":2395,\"width\":4256,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fzmj_1NnMMb1UAHjR734Qtw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F14\\u002F5ebd7dd992fc2805e470c674\\u002F5ebd80195f6f656335c2d6d2_o_U_v3.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FUhv_RynGNRYaQfcoEaClyQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Fzmj_1NnMMb1UAHjR734Qtw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F14\\u002F5ebd7dd992fc2805e470c674\\u002F5ebd80195f6f656335c2d6d2_o_U_v3.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fmore-consumers-show-interest-traveling-172024841.html\",\"id\":\"aff621c4-69a3-3260-b847-09484200d92d\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":25,\"cposy\":25},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fstocks-fall-powell-pledges-full-140928993.html\",\"title\":\"Stocks fall after Powell pledges full Fed support\",\"images\":{\"original\":{\"height\":3056,\"width\":5439,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FO.L9dA8oAHqGgnUM_iJVOQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F13\\u002F5ebbff9e90fe357a07b57985\\u002F5ebbff9e90fe357a07b57986_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002F97FEwvka1cAlOTpbOp7i7Q--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FO.L9dA8oAHqGgnUM_iJVOQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F13\\u002F5ebbff9e90fe357a07b57985\\u002F5ebbff9e90fe357a07b57986_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fstocks-fall-powell-pledges-full-140928993.html\",\"id\":\"c3df2de1-d980-37e2-bd3d-d70c84c0b030\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":26,\"cposy\":26},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fhome-depot-sales-soar-housing-141155942.html\",\"title\":\"Home Depot sales soar, Housing starts plunge 30% in April\",\"images\":{\"original\":{\"height\":2250,\"width\":4000,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FrXQuARcUaxZYO0jcT4DzbA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec3e92c90fe357a07b58e37\\u002F5ec3e92c90fe357a07b58e38_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FqH6hBXCcUiW0tT6mcvjoMg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FrXQuARcUaxZYO0jcT4DzbA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec3e92c90fe357a07b58e37\\u002F5ec3e92c90fe357a07b58e38_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fhome-depot-sales-soar-housing-141155942.html\",\"id\":\"00a38e4c-bdbe-3896-bd5f-8ef682f6af74\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":27,\"cposy\":27},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcarson-block-shorts-chinese-k-12-company-gsx-fraud-201001809.html\",\"title\":\"Short seller Carson Block: This Chinese K-12 company is 'a near-total fraud'\",\"images\":{\"original\":{\"height\":2742,\"width\":4078,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FNkBQk0xnOdISVfjTNgFqBQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002Fb1eb1f60-9949-11ea-bda7-a31b4643b142\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FVK_.ceKy6.M3XhF9CRzDaw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FNkBQk0xnOdISVfjTNgFqBQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-images\\u002F2020-05\\u002Fb1eb1f60-9949-11ea-bda7-a31b4643b142\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcarson-block-shorts-chinese-k-12-company-gsx-fraud-201001809.html\",\"id\":\"84747b3f-58d9-3a4e-a66b-e92abb268490\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":28,\"cposy\":28},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fcant-wrong-midstream-oil-gas-205046626.html\",\"title\":\"You can't go wrong with midstream oil, gas stocks: Annandale Capital CEO\",\"images\":{\"original\":{\"height\":3210,\"width\":5695,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FdwvZkhNgslbwPENQRnMPtg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FlgWQNFdTCeM_qjlxG5UOBQ--~B\\u002Fdz01Njk1O2g9MzIxMDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec446a690fe357a07b58f82\\u002F5ec446a690fe357a07b58f83_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FqfsyTRNPKqHU0ItyYP_yCg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FdwvZkhNgslbwPENQRnMPtg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FlgWQNFdTCeM_qjlxG5UOBQ--~B\\u002Fdz01Njk1O2g9MzIxMDthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec446a690fe357a07b58f82\\u002F5ec446a690fe357a07b58f83_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fcant-wrong-midstream-oil-gas-205046626.html\",\"id\":\"d7afaa92-588c-32f8-bab1-281f0bbe7f50\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":29,\"cposy\":29},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fputins-russia-bungled-coronavirus-053003286.html\",\"title\":\"How Putin's Russia Bungled the Pandemic\",\"images\":{\"original\":{\"height\":784,\"width\":1296,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Ff.imYthSE6i41YYihzPPVQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FthBM3Z1k62lpB1StkJ5mgQ--~B\\u002FaD03ODQ7dz0xMjk2O2FwcGlkPXl0YWNoeW9u\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen\\u002Fbloomberg_opinion_268\\u002F5d65ccf8372b4d492ce7934512817e14\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FBXvpFq_F7gyrpE_R5VgDsw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002Ff.imYthSE6i41YYihzPPVQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FthBM3Z1k62lpB1StkJ5mgQ--~B\\u002FaD03ODQ7dz0xMjk2O2FwcGlkPXl0YWNoeW9u\\u002Fhttps:\\u002F\\u002Fmedia.zenfs.com\\u002Fen\\u002Fbloomberg_opinion_268\\u002F5d65ccf8372b4d492ce7934512817e14\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fputins-russia-bungled-coronavirus-053003286.html\",\"id\":\"680157b5-f6d8-33b8-8a13-85c7c200e823\",\"publisher\":\"Bloomberg\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":30,\"cposy\":30},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fcuraleaf-ceo-company-earnings-cannabis-180232242.html\",\"title\":\"Curaleaf CEO: cannabis is one of the best-performing industries in the country right now\",\"images\":{\"original\":{\"height\":1502,\"width\":2671,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FrYilMQDZ9ELi915wItIBgg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec41f3a90a80d675a63d16e\\u002F5ec447fc92fc2805e470d801_o_U_v5.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FSl9IN4SL5xdWbd3GsUGRvQ--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FrYilMQDZ9ELi915wItIBgg--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec41f3a90a80d675a63d16e\\u002F5ec447fc92fc2805e470d801_o_U_v5.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fcuraleaf-ceo-company-earnings-cannabis-180232242.html\",\"id\":\"85158304-ec82-343d-95db-570b68c5afe9\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":31,\"cposy\":31},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Ftrump-administration-looks-punish-china-132827976.html\",\"title\":\"Trump administration looks to punish China over virus: RPT\",\"images\":{\"original\":{\"height\":3301,\"width\":5876,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F.Ey6JoBKmg_oxCaTR3vNpw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F01\\u002F5eac23fd6ca6be051a97dc7c\\u002F5eac23fd6ca6be051a97dc7d_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FOeWFPZx2Mo4wTSHirw8Pfw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002F.Ey6JoBKmg_oxCaTR3vNpw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F01\\u002F5eac23fd6ca6be051a97dc7c\\u002F5eac23fd6ca6be051a97dc7d_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Ftrump-administration-looks-punish-china-132827976.html\",\"id\":\"e04fe739-843e-30ca-8380-1fd57c20b08b\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":32,\"cposy\":32},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fpompeo-says-evidence-ties-covid-172129983.html\",\"title\":\"Pompeo says evidence ties COVID-19 to China lab\",\"images\":{\"original\":{\"height\":3324,\"width\":5917,\"url\":\"http:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FGf_XfTOFbzvfbH7RdICnWw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F04\\u002F5eb04f1c9bb2c071712daa34\\u002F5eb04f1c9bb2c071712daa35_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FbwLhZtczs8TVa8t4IqynEg--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FGf_XfTOFbzvfbH7RdICnWw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F04\\u002F5eb04f1c9bb2c071712daa34\\u002F5eb04f1c9bb2c071712daa35_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fpompeo-says-evidence-ties-covid-172129983.html\",\"id\":\"66ff36ff-fa18-3baa-b183-dfdd9143001a\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":33,\"cposy\":33},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcomplex-networks-launches-the-natural-evolution-of-the-sneaker-market-194508339.html\",\"title\":\"Complex Networks launches Sole Collector app\",\"images\":{\"original\":{\"height\":568,\"width\":778,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FMSnIl46vy6AqnMa5JH0OTQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F1b514590-9a00-11ea-bfdd-9f1171c9cf53\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FjF_SJ2VRJi5HatKciMQItw--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FMSnIl46vy6AqnMa5JH0OTQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fos\\u002Fcreatr-uploaded-images\\u002F2020-05\\u002F1b514590-9a00-11ea-bfdd-9f1171c9cf53\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fcomplex-networks-launches-the-natural-evolution-of-the-sneaker-market-194508339.html\",\"id\":\"ad62f9a2-b7c4-3b88-a75f-28ca985d14ad\",\"publisher\":\"Yahoo Finance\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":34,\"cposy\":34},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fmarkets-dow-sinks-390-points-205018583.html\",\"title\":\"MARKETS: Dow sinks 390 points into the close \u2014 YF Premium is bullish on Electronic Arts\",\"images\":{\"original\":{\"height\":2809,\"width\":5000,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FGTpgzbBuKuHYwyDxEE_OwQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FQRDTYqeM75OoXKUNgs2Iyw--~B\\u002Fdz01MDAwO2g9MjgwOTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec4468c84a08c74cced3db2\\u002F5ec4468c84a08c74cced3db3_o_U_v2.jpg\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FMdC.CvZ7FSsuoLhi3vc60Q--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FGTpgzbBuKuHYwyDxEE_OwQ--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FQRDTYqeM75OoXKUNgs2Iyw--~B\\u002Fdz01MDAwO2g9MjgwOTthcHBpZD15dGFjaHlvbg--\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F19\\u002F5ec4468c84a08c74cced3db2\\u002F5ec4468c84a08c74cced3db3_o_U_v2.jpg\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fmarkets-dow-sinks-390-points-205018583.html\",\"id\":\"cbad3af2-b67d-3292-8077-4923f9de107b\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":35,\"cposy\":35},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fyahoo-finance-presents-arnold-donald-134802948.html\",\"title\":\"Yahoo Finance Presents: Arnold Donald\",\"images\":{\"original\":{\"height\":1080,\"width\":1920,\"url\":\"http:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FDrtxQST3yhk0yX3YCIIISw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F01\\u002F5eac289290a80d675a639286\\u002F5eac289290a80d675a639287_o_U_v2.png\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FPz9xLG66R0Wg4GYHd5mZ1Q--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl2.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FDrtxQST3yhk0yX3YCIIISw--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fs.yimg.com\\u002Fhd\\u002Fcp-video-transcode\\u002Fprod\\u002F2020-05\\u002F01\\u002F5eac289290a80d675a639286\\u002F5eac289290a80d675a639287_o_U_v2.png\",\"height\":312,\"width\":600}},\"type\":\"video\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideo\\u002Fyahoo-finance-presents-arnold-donald-134802948.html\",\"id\":\"b2d6132f-0b68-3582-8f1c-af41bc315014\",\"publisher\":\"Yahoo Finance Video\",\"off_network\":false},{\"i13n\":{\"bpos\":1,\"cpos\":36,\"cposy\":36},\"is_eligible\":true,\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fbarbara-corcoran-rising-mortgage-applications-are-a-ray-of-hope-135346729.html\",\"title\":\"Barbara Corcoran: Rising mortgage applications are a \u2018ray of hope\u2019\",\"images\":{\"original\":{\"height\":2398,\"width\":3000,\"url\":\"http:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FLsm1wr2sfj7lzBPJa9NJSA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-04\\u002F3df149c0-8000-11ea-bacb-316bc2f95aa5\"},\"img:320x?\":{\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fny\\u002Fapi\\u002Fres\\u002F1.2\\u002FySEzNVIVJZZsz3avStJAFA--~A\\u002FYXBwaWQ9aGlnaGxhbmRlcjtoPTMxMjt3PTYwMDtxPTc1O2ZpPXN0cmlt\\u002Fhttp:\\u002F\\u002Fl1.yimg.com\\u002Fuu\\u002Fapi\\u002Fres\\u002F1.2\\u002FLsm1wr2sfj7lzBPJa9NJSA--\\u002FYXBwaWQ9eXRhY2h5b247cT03NTs-\\u002Fhttps:\\u002F\\u002Fmedia-mbst-pub-ue1.s3.amazonaws.com\\u002Fcreatr-images\\u002F2020-04\\u002F3df149c0-8000-11ea-bacb-316bc2f95aa5\",\"height\":312,\"width\":600}},\"type\":\"article\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002Fbarbara-corcoran-rising-mortgage-applications-are-a-ray-of-hope-135346729.html\",\"id\":\"1b801101-7b9c-334e-8ee4-8265ef33a39b\",\"publisher\":\"Yahoo Finance\",\"off_network\":false}],\"more_items\":[],\"more\":0,\"category\":\"SIDEKICK:TOPSTORIES\",\"view\":\"sidekick\",\"comscore\":\"pageview_candidate\",\"components\":[{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"},{\"bundleName\":\"tdv2-applet-stream\",\"name\":\"Featured\"}]},\"ts\":1589941876.417,\"cposy\":37}}},\"HeightContainerStore\":{\"_childCompositeReady\":{\"Col2-5-HeightContainer\":true}},\"UserStore\":{\"guid\":\"\",\"login\":\"\",\"alias\":\"\",\"firstName\":\"\",\"comscoreC14\":-1,\"isSignedIn\":false,\"isRecognized\":false,\"isLoaded\":true},\"ProfileStore\":{\"err\":{},\"guid\":\"\",\"profileUrl\":\"\",\"userProfile\":{\"nickName\":\"\",\"imageUrl\":\"\"},\"_isLoaded\":false,\"_isRecognized\":false,\"_isSignedIn\":false},\"ComponentConfigStore\":{\"configs\":{\"Col1-3-CanvassComments\":{\"enableCommentsOffnet\":true,\"ui\":{\"containerExtraClasses\":\"BdT Bdtc(#222) Bdtw(2px) T(20px)\",\"showContextDisplayText\":false},\"enable\":false},\"SideTop-1-HeadComponentAttribution\":{\"attribution\":{\"aliasAuthorUrlFormat\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002F{alias}\",\"authorClasses\":\"Lh(18px) Td(n) Fw(b) Fz(12px) C(#000)\",\"dateClasses\":\"Fz(11px) Mb(4px)\",\"dateDotClasses\":\"\",\"defaultLogoDim\":\"84x84\",\"enable\":false,\"enableAliasAuthorUrl\":false,\"enableAuthorSocial\":true,\"enableCompositeComponent\":false,\"enableNewAttribution\":true,\"enablePublishTimestamp\":false,\"enableShareButtons\":false,\"enableSwapAuthProvPosByProp\":false,\"forceEnableProvider\":true,\"labelClasses\":\"Mstart(6px) B(6px) Fw(b)\",\"providerLinkClasses\":\"\",\"providerNameClasses\":\"\",\"providerWrapperClasses\":\"\",\"renderInlineAttribution\":false,\"shareButtons\":{\"buttons\":[\"tumblr\",\"facebook\",\"twitter\",\"pinterest\",\"mail\"],\"enableCommentsButton\":false,\"enableCommentsButtonOffnet\":false,\"enableLikeButton\":false,\"enableRoundShareButtons\":true,\"enableSticky\":false,\"isTouchDevice\":false,\"lcpButtons\":[\"tumblr\",\"facebook\",\"twitter\",\"pinterest\",\"mail\"]},\"enableCanvassComments\":true,\"enableCommentsButtonOffnet\":true},\"shareButtons\":{\"buttons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enableShareModal\":false,\"lcpButtons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"isTouchDevice\":false,\"styles\":{\"buttonWidth\":\"\",\"commentsClasses\":\"Ta(c) W(40px) H(28px) Mb(12px) Lh(20px)\",\"commentsIconClasses\":\"H(20px)\",\"commentsLabelClasses\":\"Pos(a)! End(2px) D(n)--modalFloatingCloseBtn\",\"iconRendererClasses\":\"\",\"likeClasses\":\"canvas-modal-like-button W(40px) H(28px) Ta(c) D(ib) lightweight_D(n)\",\"likeButtonClasses\":\"O(n)\",\"likeIconClasses\":\"\",\"outerContainerClasses\":\"\",\"tooltipClasses\":\"C(#000) C($c-fuji-blue-1-a)!:h Lh(1.3em) Fz(12px) Whs(n) Pos(a) Start(36px) W(100%) T(2px)! O(n)! Ta(start) D(n)--modalFloatingCloseBtn\",\"transparentBgc\":true,\"shareButtonTooltipClasses\":\"Fz(12px)! C($c-fuji-blue-1-a)!:h\"}},\"i13n\":{\"sec\":\"hl-viewer\"}},\"Side-0-CanvasShareButtons\":{\"shareButtons\":{\"buttons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enableShareModal\":false,\"lcpButtons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"isTouchDevice\":false,\"styles\":{\"buttonWidth\":\"\",\"commentsClasses\":\"Ta(c) W(40px) H(28px) Mb(4px) Lh(20px)\",\"commentsIconClasses\":\"H(20px)\",\"commentsLabelClasses\":\"Pos(a)! End(2px) D(n)--modalFloatingCloseBtn\",\"iconRendererClasses\":\"\",\"likeClasses\":\"canvas-modal-like-button W(40px) H(28px) Ta(c) Pt(8px) D(ib) lightweight_D(n)\",\"likeButtonClasses\":\"O(n)\",\"likeIconClasses\":\"\",\"outerContainerClasses\":\"\",\"tooltipClasses\":\"C(#000) C($c-fuji-blue-1-a)!:h Lh(1.3em) Fz(12px) Whs(n) Pos(a) Start(36px) W(100%) T(2px)! O(n)! Ta(start) D(n)--modalFloatingCloseBtn\",\"transparentBgc\":true,\"shareButtonTooltipClasses\":\"Fz(12px)! C($c-fuji-blue-1-a)!:h\"},\"enableCanvassComments\":true},\"i13n\":{\"sec\":\"hl-viewer\"}},\"Col1-0-ContentCanvas\":{\"ads\":{\"adchoices_url\":\"https:\\u002F\\u002Fwww.verizonmedia.com\\u002Fpolicies\\u002Fus\\u002Fen\\u002Fverizonmedia\\u002Fprivacy\\u002Fadinfo\\u002Findex.html\",\"enableCacheableAd\":false,\"enableCinemaGraph\":false,\"enableCinemaGraphBeacon\":false,\"enableGeminiFeedback\":false,\"enableInterstitialAd\":false,\"frequency\":0,\"interstitialAdInterval\":7,\"interstitialAdStart\":2,\"inlineSlideshowAdRefresh\":[\"LREC\"],\"lightboxAdPositions\":[\"LREC-2\",\"LREC2-2\"],\"limit\":0,\"photosetAd\":{\"enable\":false},\"sponsored_url\":\"http:\\u002F\\u002Fhelp.yahoo.com\\u002Fkb\\u002Findex?page=content&y=PROD_FRONT&locale=en_US&id=SLN14553\",\"start\":2000},\"attribution\":{\"aliasAuthorUrlFormat\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002F{alias}\",\"authorClasses\":\"Lh(18px) Td(n) Fw(b) Fz(12px) C(#000)\",\"dateClasses\":\"Fz(11px) Mb(4px)\",\"dateDotClasses\":\"\",\"defaultLogoDim\":\"84x84\",\"enable\":false,\"enableAliasAuthorUrl\":false,\"enableAuthorSocial\":true,\"enableCompositeComponent\":false,\"enableNewAttribution\":true,\"enablePublishTimestamp\":false,\"enableShareButtons\":false,\"enableSwapAuthProvPosByProp\":false,\"forceEnableProvider\":true,\"labelClasses\":\"Mstart(6px) B(6px) Fw(b)\",\"providerLinkClasses\":\"\",\"providerNameClasses\":\"\",\"providerWrapperClasses\":\"\",\"renderInlineAttribution\":false,\"shareButtons\":{\"buttons\":[\"tumblr\",\"facebook\",\"twitter\",\"pinterest\",\"mail\"],\"enableCommentsButton\":false,\"enableCommentsButtonOffnet\":false,\"enableLikeButton\":false,\"enableRoundShareButtons\":true,\"enableSticky\":false,\"isTouchDevice\":false,\"lcpButtons\":[\"tumblr\",\"facebook\",\"twitter\",\"pinterest\",\"mail\"]}},\"bodyAdsSlot\":{\"enabled\":false,\"position\":3,\"pos\":\"LREC\",\"style\":{\"marginTop\":\"10px\",\"marginBottom\":\"10px\",\"marginLeft\":\"-10px\",\"marginRight\":\"-10px\",\"textAlign\":\"center\"}},\"bodySlot\":{\"enabled\":false,\"position\":4},\"canvasTag\":{\"enable\":false,\"enableCommentsLink\":false,\"enableBottomBorder\":false,\"tagFollowLink\":false},\"caasDelay\":100,\"dockFirstIframe\":false,\"dockFirstIframeDomains\":[],\"doubleIframe\":{\"host\":\"https:\\u002F\\u002Fs.yimg.com\",\"path\":\"\\u002Faaq\\u002Fyc\\u002Fhtml\\u002Fembed-iframe-min.2d7457d4.html\"},\"enableCollapsibleBody\":true,\"enableExpandableComments\":true,\"enableGraphiq\":true,\"enableInstagram\":true,\"enableLeadContent\":false,\"enableLightboxLooping\":true,\"enableLiveCoverage\":true,\"enableMutingBodyVideos\":true,\"enableMutingLeadVideo\":true,\"enableNoBorderReadMore\":false,\"enableReadMore\":true,\"enableRelatedTags\":false,\"enableSlideshow\":true,\"enableStructuredMicrodata\":true,\"enableSlideshowNumbering\":true,\"enableTextWrap\":true,\"enableTitle\":false,\"enableTouch\":false,\"enableTumblrActionButtons\":false,\"enableVerticalSlideshow\":false,\"enableVerticalVideo\":false,\"enableVideoAutoPlay\":true,\"enableVideoCameraBanner\":false,\"enableVideoDocking\":false,\"enableVideoEarlyInit\":false,\"enableVideoLazyLoad\":false,\"enableVideoMicrodata\":true,\"enableVideoOnly\":false,\"enableVideosContinuousPlay\":true,\"forceVideoAutoplayOff\":false,\"homepageUrl\":\"https:\\u002F\\u002Fwww.yahoo.com\",\"i13n\":{\"sec\":\"hl-viewer\"},\"imageCharCount\":1000,\"imageDimensions\":[\"800x\"],\"imageScrollMargin\":0,\"includeIBImageInSlideshow\":false,\"includeBodyImageInSlideshow\":false,\"inlineSlideshowDimension\":[\"800x600\"],\"lazyLoadFirstIframe\":false,\"leadVideoIframe\":{\"enabled\":false,\"params\":[]},\"lightboxImageDimensions\":[\"1280x960\"],\"logoOverlay\":\"bottomRight\",\"minImageWidthToBeInSlideshow\":200,\"minImageHeightToBeInSlideshow\":200,\"minImgCountToShowSlideshow\":2,\"openLightboxForImages\":false,\"openNewPageForPreviewReadMore\":false,\"readMoreCharLimit\":4250,\"shareButtons\":{\"buttons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enableShareModal\":false,\"lcpButtons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"isTouchDevice\":false,\"styles\":{\"buttonWidth\":\"\",\"commentsClasses\":\"Ta(c) W(40px) H(28px) Mb(12px) Lh(20px)\",\"commentsIconClasses\":\"H(20px)\",\"commentsLabelClasses\":\"Pos(a)! End(2px) D(n)--modalFloatingCloseBtn\",\"iconRendererClasses\":\"\",\"likeClasses\":\"canvas-modal-like-button W(40px) H(28px) Ta(c) D(ib) lightweight_D(n)\",\"likeButtonClasses\":\"O(n)\",\"likeIconClasses\":\"\",\"outerContainerClasses\":\"\",\"tooltipClasses\":\"C(#000) C($c-fuji-blue-1-a)!:h Lh(1.3em) Fz(12px) Whs(n) Pos(a) Start(36px) W(100%) T(2px)! O(n)! Ta(start) D(n)--modalFloatingCloseBtn\",\"transparentBgc\":true,\"shareButtonTooltipClasses\":\"Fz(12px)! C($c-fuji-blue-1-a)!:h\"}},\"shortBodyLimit\":1000,\"showCoverItem\":true,\"showLeadVideo\":true,\"showSynthesizedSlideshow\":false,\"skimlinks\":{\"enable\":false},\"ui\":{\"bodyClasses\":\"Fz(15px) Lh(1.6) C($c-fuji-grey-l) Ff($ff-secondary)\"},\"videoExpName\":\"y20\",\"videoGeminiSectionId\":null,\"videoNativePlaylist\":true,\"yahooVideoIframe\":{\"enabled\":false},\"enableCanvassComments\":true,\"enableVideoManager\":true,\"structuredData\":{\"publisher\":{\"@type\":\"Organization\",\"name\":\"Yahoo Finance\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\",\"logo\":{\"@type\":\"ImageObject\",\"width\":354,\"height\":50,\"url\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fp\\u002Fyahoo_finance_en-US_h_p_finance_2.png\"}}}},\"Col1-2-CanvasShareButtons\":{\"shareButtons\":{\"buttons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enableShareModal\":false,\"lcpButtons\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"isTouchDevice\":false,\"styles\":{\"buttonWidth\":\"\",\"commentsClasses\":\"Ta(c) W(40px) H(28px) Mb(4px) Lh(20px)\",\"commentsIconClasses\":\"H(20px)\",\"commentsLabelClasses\":\"Pos(a)! End(2px) D(n)--modalFloatingCloseBtn\",\"iconRendererClasses\":\"\",\"likeClasses\":\"canvas-modal-like-button W(40px) H(28px) Ta(c) Pt(8px) D(ib) lightweight_D(n)\",\"likeButtonClasses\":\"O(n)\",\"likeIconClasses\":\"\",\"outerContainerClasses\":\"\",\"tooltipClasses\":\"C(#000) C($c-fuji-blue-1-a)!:h Lh(1.3em) Fz(12px) Whs(n) Pos(a) Start(36px) W(100%) T(2px)! O(n)! Ta(start) D(n)--modalFloatingCloseBtn\",\"transparentBgc\":true,\"shareButtonTooltipClasses\":\"Fz(12px)! C($c-fuji-blue-1-a)!:h\"},\"enableCanvassComments\":true},\"i13n\":{\"sec\":\"hl-viewer\"}},\"Col2Ext-0-Stream\":{\"ads\":{\"ad_polices\":true,\"adchoices_url\":\"https:\\u002F\\u002Fwww.verizonmedia.com\\u002Fpolicies\\u002Fus\\u002Fen\\u002Fverizonmedia\\u002Fprivacy\\u002Fadinfo\\u002Findex.html\",\"advertiseWithUsUrl\":\"https:\\u002F\\u002Fwww.ad.com\\u002F?utm_source=yahoo-news&utm_medium=referral&utm_campaign=ad-feedback\",\"cluster\":false,\"contentType\":\"\",\"count\":25,\"enableFlashSale\":false,\"enableGeminiAdFeedback\":true,\"enableGeminiDealsWithoutBackground\":false,\"enableVideoManagerGemini\":true,\"fallback\":false,\"force_thumbnail_size\":false,\"frequency\":3,\"geminiPromotionsEnabled\":false,\"generic_viewability\":true,\"inline_video\":false,\"letterbox_thumb\":true,\"sponsored_label_support\":true,\"partial_viewability\":true,\"pu\":\"www.yahoo.com\",\"related_ct_ads_count\":3,\"related_ct_se\":\"5454650\",\"related_start_index\":3,\"se\":4250754,\"showCTA\":false,\"showCTAThumbnail\":false,\"spaceid\":2023538075,\"sponsored_url\":\"http:\\u002F\\u002Fhelp.yahoo.com\\u002Fkb\\u002Findex?page=content&y=PROD_FRONT&locale=en_US&id=SLN14553\",\"start_index\":2,\"timeout\":0,\"type\":\"STRM,STRM_CONTENT\",\"useHqImg\":true,\"useOrigImg\":false,\"useResizedImages\":true,\"videoAdCCOnMute\":false,\"videoExpName\":\"gemini\",\"vpaidTimeout\":5,\"ctx_signals_enabled\":true},\"batches\":{\"pagination\":false,\"size\":32,\"timeout\":500,\"total\":170,\"start_index\":16,\"end_index\":18},\"cache_ads\":false,\"cache_ttl\":0,\"category\":\"SIDEKICK:TOPSTORIES\",\"clear_on_navigate\":false,\"embedComponents\":[],\"enableAuthorBio\":true,\"flyout_enabled\":false,\"forceJpg\":true,\"i13n\":{\"sec\":\"sdkick\"},\"imageResizer\":null,\"login\":{\"src\":\"fpctx\"},\"max_dedupe_ADID_size\":50,\"max_dedupe_UUID_size\":250,\"max_exclude\":10,\"min_count\":3,\"min_count_error\":false,\"pageload_image_count\":3,\"pageload_item_count\":-1,\"perf_beacon\":false,\"perf_label\":\"\",\"offnet\":{\"include_lcp\":true,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"]},\"use_preview\":true,\"url_scheme\":\"domain\"},\"redisCompress\":false,\"releasesParams\":{\"limit\":20,\"offset\":0},\"sentiment_comments_enabled\":false,\"service\":{\"specRetry\":{\"enabled\":false}},\"sidekick_sectionid_enabled\":false,\"store\":{\"ls_delay\":1000,\"ls_ttl\":86400},\"ui\":{\"ad_image_fit\":false,\"attribution_pos\":\"bottom\",\"comments\":false,\"comments_count\":2,\"comments_offnet\":false,\"container_classnames\":\"\",\"dispatch_content_store\":true,\"editorial_content_count\":0,\"editorial_featured_count\":1,\"enable_lead_fallback_image\":false,\"exclude_types\":\"\",\"image_quality_override\":true,\"inline_video\":false,\"item_classnames\":\"\",\"lead_fallback_image\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fdh\\u002Fap\\u002Fmy\\u002Fthemes\\u002Fdark_1366x854_01_prog.jpg\",\"link_params\":false,\"link_out_allowed\":true,\"magazine_featured\":true,\"magazine_icon\":false,\"max_width\":900,\"mega_image_height\":\"\",\"needtoknow_roundup_only\":false,\"needtoknow_template\":\"\",\"ntk_bypassA3c\":true,\"property_colors\":true,\"pubtime_maxage\":-1,\"related_count\":5,\"related_enabled\":false,\"related_item_width\":\"\",\"related_min\":3,\"relative_links\":true,\"render_video_featured\":false,\"require_resized_image\":false,\"roundup\":false,\"scrollbuffer\":900,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enable\":false},\"show_comment_count\":false,\"show_error\":true,\"show_publisher_color\":true,\"show_read\":true,\"show_summary\":true,\"show_type_icon\":true,\"smart_crop\":true,\"sponsored_label\":false,\"sponsored_label_pos\":\"bottom\",\"storyline_count\":2,\"storyline_enabled\":false,\"storyline_min\":2,\"summary\":false,\"tiles\":{\"allowPartialRows\":true,\"doubleTallStart\":0,\"featured_label\":false,\"gradient\":false,\"height\":175,\"resizeImages\":false,\"textOnly\":[{\"backgroundColor\":\"#fff\",\"foregroundColor\":\"#000\"}],\"width_max\":300,\"width_min\":200},\"titleInnerClassName\":\"Lh(15px) Fw(b) LineClamp(3,45px)\",\"thumbnail\":true,\"thumbnail_align\":\"right\",\"thumbnail_size\":100,\"title_pos\":\"bottom\",\"touch_device\":false,\"user_intent\":false,\"view\":\"sidekick\",\"featured_summary\":false,\"follow_content\":false,\"inline_filters_max\":0,\"title\":\"disabled\"},\"use_article_category\":false,\"use_content_id\":false,\"use_content_site\":false,\"use_page_category\":false,\"use_prefetch\":false,\"use_yct_wikiids\":true,\"video\":{\"disable_buffer_on_pause\":true,\"disable_title_on_hover\":true,\"enable_ads\":false,\"enable_cc_on_mute\":false,\"energy_saver_mode\":false,\"enable_custom_controls\":false,\"enable_detached_video\":false,\"enable_docking\":false,\"enable_expand_on_unmute\":false,\"enable_video_enrichment\":false,\"use_inline_video\":false},\"blending_enabled\":true,\"extended_sidekick\":true},\"Col2Ext-2-Stream\":{\"ads\":{\"ad_polices\":true,\"adchoices_url\":\"https:\\u002F\\u002Fwww.verizonmedia.com\\u002Fpolicies\\u002Fus\\u002Fen\\u002Fverizonmedia\\u002Fprivacy\\u002Fadinfo\\u002Findex.html\",\"advertiseWithUsUrl\":\"https:\\u002F\\u002Fwww.ad.com\\u002F?utm_source=yahoo-news&utm_medium=referral&utm_campaign=ad-feedback\",\"cluster\":false,\"contentType\":\"\",\"count\":25,\"enableFlashSale\":false,\"enableGeminiAdFeedback\":true,\"enableGeminiDealsWithoutBackground\":false,\"enableVideoManagerGemini\":true,\"fallback\":false,\"force_thumbnail_size\":false,\"frequency\":3,\"geminiPromotionsEnabled\":false,\"generic_viewability\":true,\"inline_video\":false,\"letterbox_thumb\":true,\"sponsored_label_support\":true,\"partial_viewability\":true,\"pu\":\"www.yahoo.com\",\"related_ct_ads_count\":3,\"related_ct_se\":\"5454650\",\"related_start_index\":3,\"se\":4250754,\"showCTA\":false,\"showCTAThumbnail\":false,\"spaceid\":2023538075,\"sponsored_url\":\"http:\\u002F\\u002Fhelp.yahoo.com\\u002Fkb\\u002Findex?page=content&y=PROD_FRONT&locale=en_US&id=SLN14553\",\"start_index\":2,\"timeout\":0,\"type\":\"STRM,STRM_CONTENT\",\"useHqImg\":true,\"useOrigImg\":false,\"useResizedImages\":true,\"videoAdCCOnMute\":false,\"videoExpName\":\"gemini\",\"vpaidTimeout\":5,\"ctx_signals_enabled\":true},\"batches\":{\"pagination\":false,\"size\":32,\"timeout\":500,\"total\":170,\"start_index\":19,\"end_index\":31},\"cache_ads\":false,\"cache_ttl\":0,\"category\":\"SIDEKICK:TOPSTORIES\",\"clear_on_navigate\":false,\"embedComponents\":[],\"enableAuthorBio\":true,\"flyout_enabled\":false,\"forceJpg\":true,\"i13n\":{\"sec\":\"sdkick\"},\"imageResizer\":null,\"login\":{\"src\":\"fpctx\"},\"max_dedupe_ADID_size\":50,\"max_dedupe_UUID_size\":250,\"max_exclude\":10,\"min_count\":3,\"min_count_error\":false,\"pageload_image_count\":3,\"pageload_item_count\":-1,\"perf_beacon\":false,\"perf_label\":\"\",\"offnet\":{\"include_lcp\":true,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"]},\"use_preview\":true,\"url_scheme\":\"domain\"},\"redisCompress\":false,\"releasesParams\":{\"limit\":20,\"offset\":0},\"sentiment_comments_enabled\":false,\"service\":{\"specRetry\":{\"enabled\":false}},\"sidekick_sectionid_enabled\":false,\"store\":{\"ls_delay\":1000,\"ls_ttl\":86400},\"ui\":{\"ad_image_fit\":false,\"attribution_pos\":\"bottom\",\"comments\":false,\"comments_count\":2,\"comments_offnet\":false,\"container_classnames\":\"\",\"dispatch_content_store\":true,\"editorial_content_count\":0,\"editorial_featured_count\":1,\"enable_lead_fallback_image\":false,\"exclude_types\":\"\",\"image_quality_override\":true,\"inline_video\":false,\"item_classnames\":\"\",\"lead_fallback_image\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fdh\\u002Fap\\u002Fmy\\u002Fthemes\\u002Fdark_1366x854_01_prog.jpg\",\"link_params\":false,\"link_out_allowed\":true,\"magazine_featured\":true,\"magazine_icon\":false,\"max_width\":900,\"mega_image_height\":\"\",\"needtoknow_roundup_only\":false,\"needtoknow_template\":\"\",\"ntk_bypassA3c\":true,\"property_colors\":true,\"pubtime_maxage\":-1,\"related_count\":5,\"related_enabled\":false,\"related_item_width\":\"\",\"related_min\":3,\"relative_links\":true,\"render_video_featured\":false,\"require_resized_image\":false,\"roundup\":false,\"scrollbuffer\":900,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enable\":false},\"show_comment_count\":false,\"show_error\":true,\"show_publisher_color\":true,\"show_read\":true,\"show_summary\":true,\"show_type_icon\":true,\"smart_crop\":true,\"sponsored_label\":false,\"sponsored_label_pos\":\"bottom\",\"storyline_count\":2,\"storyline_enabled\":false,\"storyline_min\":2,\"summary\":false,\"tiles\":{\"allowPartialRows\":true,\"doubleTallStart\":0,\"featured_label\":false,\"gradient\":false,\"height\":175,\"resizeImages\":false,\"textOnly\":[{\"backgroundColor\":\"#fff\",\"foregroundColor\":\"#000\"}],\"width_max\":300,\"width_min\":200},\"titleInnerClassName\":\"Lh(15px) Fw(b) LineClamp(3,45px)\",\"thumbnail\":true,\"thumbnail_align\":\"right\",\"thumbnail_size\":100,\"title_pos\":\"bottom\",\"touch_device\":false,\"user_intent\":false,\"view\":\"sidekick\",\"featured_summary\":false,\"follow_content\":false,\"inline_filters_max\":0,\"title\":\"disabled\"},\"use_article_category\":false,\"use_content_id\":false,\"use_content_site\":false,\"use_page_category\":false,\"use_prefetch\":false,\"use_yct_wikiids\":true,\"video\":{\"disable_buffer_on_pause\":true,\"disable_title_on_hover\":true,\"enable_ads\":false,\"enable_cc_on_mute\":false,\"energy_saver_mode\":false,\"enable_custom_controls\":false,\"enable_detached_video\":false,\"enable_docking\":false,\"enable_expand_on_unmute\":false,\"enable_video_enrichment\":false,\"use_inline_video\":false},\"blending_enabled\":true,\"extended_sidekick\":true},\"UH-0-UH\":{\"bundleName\":\"tdv2-applet-uh\",\"name\":\"Header\",\"mrt\":{\"cache\":true,\"skipAlertOnChecksumMismatch\":true},\"compositeConfig\":{\"mrt\":{\"flush\":false,\"cache\":true,\"skipAlertOnChecksumMismatch\":true,\"prioritize\":false},\"uh\":{\"search\":{\"queries\":{\"fr\":\"uh3_finance_vert\"},\"placeholderText\":\"FINANCE_UH_SEARCH_WEB\",\"instantSearch\":false,\"autofocus\":false,\"action\":\"\\u002Fquote\\u002F\",\"enableFuzzyQuery\":false,\"newsCount\":4,\"quotesCount\":6,\"listCount\":4,\"quotesQueryId\":\"tss_match_phrase_query\",\"multiQuoteQueryId\":\"multi_quote_single_token_query\",\"newsQueryId\":\"news_ss_symbols\",\"enableCb\":true,\"enableNavLinks\":true,\"feedback\":{\"enabled\":false,\"href\":\"https:\\u002F\\u002Fyahoo.uservoice.com\\u002Fforums\\u002F439018\"},\"style\":{\"container\":{\"wrapper\":\"Mend(375px) Mstart(194px) Maw(595px) H(35px) Trstf(eo) Trsde(0s) Trsdu(0.14s) Trsp(a) ie-7_H(100%)\"},\"input\":{\"content\":\"Bdrs(2px)! ie-7_Lh(18px) ie-8_Lh(18px) ie-7_W(88%) ie-7_Mt(2px) ie-7_H(100%)\"},\"search_button\":{\"content_1\":\"C(white) Fz(16px) two-btn_Fz(s) H(35px) ie-7_Lh(18px) ie-8_Lh(18px) ie-7_W(140px) ie-7_H(41px) Mend(0)! ie-8_W(140px) Mstart(5px) W(140px)\"}}},\"ui\":{\"back\":false,\"follow\":false,\"mail\":true,\"notifications\":false,\"profile\":true,\"search\":true,\"share\":false,\"topbar\":true,\"skip_nav\":true},\"skip_nav\":{\"data\":{\"items\":{\"item_1\":{\"name\":\"Skip to Navigation\",\"link\":\"#Navigation\",\"order\":1},\"item_2\":{\"name\":\"Skip to Market Summary\",\"link\":\"#market-summary\",\"order\":2},\"item_3\":{\"name\":\"Skip to Main Content\",\"link\":\"#Main\",\"order\":3},\"item_4\":{\"name\":\"Skip to Related Content\",\"link\":\"#Aside\",\"order\":4}}}},\"useTopicTitle\":false,\"style\":{\"container\":{\"wrapper\":\"Miw(980px) UH Z(10) Py(14px) Pos(r)\"}},\"profile\":{\"mode\":\"server\"}}},\"enableRichSearch\":true,\"disablePortfolioNavUpdate\":false,\"pfUrlType\":\"portfolio\",\"urlPrefix\":\"https:\\u002F\\u002Ffinance.yahoo.com\"},\"UH-1-DesktopNav\":{\"closeBtn\":false,\"renderMobileOnServer\":false,\"renderSecondaryNav\":true,\"i13n\":{\"sec\":\"navrail\"},\"i13n_follow\":{\"sec\":\"social-flw\",\"elm\":\"follow\",\"outcm\":\"follow\",\"itc\":0,\"mpos\":\"\"},\"ui\":{\"bgColor\":\"Bgc(#f9f9f9)\",\"darkTheme\":false,\"displayGroupTitle\":false,\"headerTitle\":null,\"highlightPropertyHome\":false,\"isNavLink\":false,\"mailBadgeClass\":\"Bgc($c-fuji-red-1-a) Bdrs(11px) Bdc(#fff) Bdw(2px)Bds(s) W(8px) H(8px) Pos(a) T(8px) Start(26px)\",\"makeSticky\":false,\"navCache\":true,\"navSections\":\"property\",\"relativeLinks\":false,\"remoteAdapter\":true,\"renderLogoNav\":false,\"renderPropertyNav\":true,\"sections\":[\"property\"],\"showMailCount\":false,\"showPropertyHome\":true,\"disableFollowPopouts\":true,\"enableCCPAFooter\":true},\"theme\":{\"daaPrivacyRightsIcon\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fcv\\u002Fapiv2\\u002Fdefault\\u002F20200109\\u002FPrivacy_Rights_icon.png\",\"daaPrivacyRightsIconClasses\":\"Mstart(1px) Va(m) W(20px) H(20px)\",\"mobileIconHeight\":60,\"mobileIconWidth\":150,\"mobileSectionBorder\":{}},\"account_switch\":{\"isEnabled\":true},\"featureSwitches\":{\"useSubnavTitleSlk\":true},\"profile\":{\"mode\":\"client\",\"avatarSize\":\"36px\",\"loginBaseUrl\":\"https:\\u002F\\u002Flogin.yahoo.com\\u002Fconfig\\u002Flogin\",\"settingUrl\":\"https:\\u002F\\u002Fedit.yahoo.com\\u002Fconfig\\u002Feval_profile\",\"urls\":{\"signed_in\":{\"protocol\":\"https\",\"hostname\":\"login.yahoo.com\",\"pathname\":\"\\u002Fconfig\\u002Flogin\",\"query\":{}},\"signed_out\":{\"protocol\":\"https\",\"hostname\":\"login.yahoo.com\",\"pathname\":\"\\u002Fconfig\\u002Flogin\",\"query\":{\".direct\":2,\"logout\":1}},\"signed_out_as\":{\"protocol\":\"https\",\"hostname\":\"login.yahoo.com\",\"pathname\":\"\\u002Fconfig\\u002Flogin\",\"query\":{\".direct\":1,\"logout_all\":1}},\"account_info\":{\"protocol\":\"https\",\"hostname\":\"edit.yahoo.com\",\"pathname\":\"\\u002Fconfig\\u002Feval_profile\",\"query\":{}}}},\"mobileSectionMeta\":{\"property\":{},\"yahooSites\":{\"listMeta\":{}},\"services\":{},\"apps\":{\"listMeta\":{}},\"tools\":{\"listMeta\":{}}},\"components\":{\"propertyHome\":{\"title\":\"PROPERTY_HOME\",\"dragonFlyKey\":\"PROPERTY_HOME\"},\"finance\":{\"title\":\"Finance\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\",\"collapse\":true,\"type\":\"finance\",\"linkWidth\":250,\"i13n\":{},\"links\":true,\"propertyColor\":\"#efefef\"}},\"linkMeta\":{\"finance\":{\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\"},\"sports_myteams\":{\"bundles\":{\"props\":{\"urlPrefix\":\"https:\\u002F\\u002Fsports.yahoo.com\"}}}},\"renderVersion\":\"rc5\"},\"Hero-1-FeatureBar\":{\"contentSite\":\"\",\"convertContentUrl\":true,\"imageSize\":{\"width\":272,\"height\":144},\"scoobyCompat\":false,\"ui\":{\"container_classnames\":\"Miw(1007px) Maw(1260px) Bxz(bb) Bdstartc(#fff) Bdstartw(20px) Bdendc(#fff) Bdends(s) Bdendw(20px) Bdstarts(s) Mx(a) My(10px)\",\"strictViewMatch\":false},\"useNCP\":true,\"linkRenderTarget\":\"default\",\"mrt\":{\"cache\":true,\"skipAlertOnChecksumMismatch\":true},\"site\":\"finance\"},\"Hero-4-HeroSlideshow\":{\"animate\":false,\"buffer\":2,\"enableCacheableAd\":false,\"enableInterstitialAd\":true,\"enableTouch\":false,\"followLinkOnNav\":false,\"imageDimensions\":[\"1280x960\"],\"isSmartphone\":false,\"interstitialAdStart\":3,\"interstitialAdInterval\":7,\"loadMoreBuffer\":6,\"loadMoreCount\":25,\"looping\":true,\"layoutStyle\":\"default\",\"nativeAdDimension\":[\"1280x960\"],\"theme\":\"dark\",\"updateInPrerender\":false,\"useFixedHeight\":false},\"Hero-5-HeadComponentVideo\":{\"enableVerticalVideo\":false,\"enableVideoCameraBanner\":false,\"enableVideoDocking\":false,\"enableVideoEarlyInit\":false,\"enableVideoOnly\":false,\"enableVideosContinuousPlay\":true,\"enableVideoMicrodata\":true,\"forceVideoAutoplayOff\":false,\"leadVideoIframe\":{\"enabled\":false,\"params\":[]},\"logoOverlay\":\"bottomRight\",\"videoExpName\":\"y20\",\"videoGeminiSectionId\":null,\"videoNativePlaylist\":true,\"i13n\":{\"sec\":\"hl-viewer\"},\"enableServerSideVRM\":false,\"enableVRMMetrics\":true,\"videoFallbackChannel\":\"finance-videotron\"},\"YDC-Stream\":{\"ads\":{\"ad_polices\":true,\"adchoices_url\":\"https:\\u002F\\u002Fwww.verizonmedia.com\\u002Fpolicies\\u002Fus\\u002Fen\\u002Fverizonmedia\\u002Fprivacy\\u002Fadinfo\\u002Findex.html\",\"advertiseWithUsUrl\":\"https:\\u002F\\u002Fwww.ad.com\\u002F?utm_source=yahoo-news&utm_medium=referral&utm_campaign=ad-feedback\",\"cluster\":false,\"contentType\":\"\",\"count\":25,\"enableFlashSale\":false,\"enableGeminiAdFeedback\":false,\"enableGeminiDealsWithoutBackground\":false,\"enableVideoManagerGemini\":true,\"fallback\":false,\"force_thumbnail_size\":false,\"frequency\":3,\"geminiPromotionsEnabled\":false,\"generic_viewability\":true,\"inline_video\":false,\"letterbox_thumb\":true,\"sponsored_label_support\":true,\"partial_viewability\":true,\"pu\":\"www.yahoo.com\",\"related_ct_ads_count\":3,\"related_ct_se\":\"5454650\",\"related_start_index\":3,\"se\":4492794,\"showCTA\":false,\"showCTAThumbnail\":false,\"spaceid\":2023538075,\"sponsored_url\":\"http:\\u002F\\u002Fhelp.yahoo.com\\u002Fkb\\u002Findex?page=content&y=PROD_FRONT&locale=en_US&id=SLN14553\",\"start_index\":2,\"timeout\":0,\"type\":\"STRM,STRM_CONTENT\",\"useHqImg\":true,\"useOrigImg\":false,\"useResizedImages\":true,\"videoAdCCOnMute\":false,\"videoExpName\":\"gemini\",\"vpaidTimeout\":5},\"batches\":{\"pagination\":false,\"size\":25,\"timeout\":500,\"total\":25},\"cache_ads\":false,\"cache_ttl\":300,\"category\":\"YPROP:FINANCE\",\"clear_on_navigate\":false,\"embedComponents\":[],\"enableAuthorBio\":true,\"flyout_enabled\":false,\"forceJpg\":true,\"i13n\":{\"sec\":\"strm\"},\"imageResizer\":null,\"login\":{\"src\":\"fpctx\"},\"max_dedupe_ADID_size\":50,\"max_dedupe_UUID_size\":250,\"max_exclude\":0,\"min_count\":3,\"min_count_error\":false,\"pageload_image_count\":60,\"pageload_item_count\":60,\"perf_beacon\":false,\"perf_label\":\"\",\"offnet\":{\"include_lcp\":true,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"]},\"use_preview\":true,\"url_scheme\":\"domain\"},\"redisCompress\":false,\"releasesParams\":{\"limit\":20,\"offset\":0},\"sentiment_comments_enabled\":false,\"service\":{\"specRetry\":{\"enabled\":true,\"triggerDelayPct\":50,\"throttleRate\":300}},\"sidekick_sectionid_enabled\":false,\"store\":{\"ls_delay\":1000,\"ls_ttl\":86400},\"ui\":{\"ad_image_fit\":false,\"attribution_pos\":\"inline-bottom\",\"comments\":false,\"comments_count\":2,\"comments_offnet\":true,\"container_classnames\":\"\",\"dispatch_content_store\":true,\"editorial_content_count\":0,\"editorial_featured_count\":1,\"enable_lead_fallback_image\":false,\"exclude_types\":\"\",\"image_quality_override\":true,\"inline_video\":false,\"item_classnames\":\"\",\"lead_fallback_image\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fdh\\u002Fap\\u002Fmy\\u002Fthemes\\u002Fdark_1366x854_01_prog.jpg\",\"link_params\":false,\"link_out_allowed\":true,\"magazine_featured\":true,\"magazine_icon\":false,\"max_width\":900,\"mega_image_height\":\"\",\"needtoknow_roundup_only\":false,\"needtoknow_template\":\"\",\"ntk_bypassA3c\":true,\"property_colors\":true,\"pubtime_maxage\":-1,\"related_count\":5,\"related_enabled\":true,\"related_item_width\":\"\",\"related_min\":3,\"relative_links\":false,\"render_video_featured\":false,\"require_resized_image\":false,\"roundup\":false,\"scrollbuffer\":900,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enable\":false},\"show_comment_count\":false,\"show_error\":true,\"show_publisher_color\":true,\"show_read\":true,\"show_summary\":true,\"show_type_icon\":true,\"smart_crop\":true,\"sponsored_label\":false,\"sponsored_label_pos\":\"bottom\",\"storyline_count\":2,\"storyline_enabled\":false,\"storyline_min\":2,\"summary\":true,\"tiles\":{\"allowPartialRows\":true,\"doubleTallStart\":0,\"featured_label\":false,\"gradient\":false,\"height\":175,\"resizeImages\":true,\"textOnly\":[{\"backgroundColor\":\"#fff\",\"foregroundColor\":\"#000\"}],\"width_max\":300,\"width_min\":200},\"titleInnerClassName\":\"Lh(15px) Fw(b) LineClamp(3,45px)\",\"thumbnail\":true,\"thumbnail_align\":\"right\",\"thumbnail_size\":100,\"title_pos\":\"bottom\",\"touch_device\":false,\"user_intent\":false,\"view\":\"mega\",\"enable_canvass_comments\":true,\"follow_content\":false,\"inline_filters_max\":0,\"tumblr_reblog\":false,\"breaking_news\":false,\"button_pos\":\"right\",\"image_classes\":\"W(26.5%) Maw(220px)\",\"show_label\":true,\"featured_count\":1,\"follow_cluster\":false},\"use_article_category\":false,\"use_content_id\":true,\"use_content_site\":true,\"use_page_category\":true,\"use_prefetch\":false,\"use_yct_wikiids\":true,\"video\":{\"disable_buffer_on_pause\":true,\"disable_title_on_hover\":true,\"enable_ads\":false,\"enable_cc_on_mute\":false,\"energy_saver_mode\":false,\"enable_custom_controls\":false,\"enable_detached_video\":false,\"enable_docking\":false,\"enable_expand_on_unmute\":false,\"enable_video_enrichment\":true,\"use_inline_video\":false},\"components\":{\"StreamHeroCarousel\":{\"ui\":{\"follow_content\":false}},\"WideHero\":{\"ui\":{\"follow_content\":false}}},\"persist_category\":true,\"use_mags_nydc\":true,\"ss_endpoint\":\"ga-hr.slingstone.yahoo.com@score\\u002Fv9\\u002Ffinance\\u002Fen-US\\u002Funified\\u002Fmega\",\"ss_timeout\":400},\"Col2Ext-5-Footer\":{\"copyright\":{},\"enableLegalAttribution\":true,\"isCCPAEnabled\":true,\"legalAttribution\":\"ATTRIBUTION_YAHOO\",\"links\":[\"disclaimer\",\"help\",\"suggestions\",\"sitemap\"],\"linkMeta\":{\"about_our_ads\":{\"title\":\"ABOUT_OUR_ADS\",\"href\":\"https:\\u002F\\u002Fwww.verizonmedia.com\\u002Fpolicies\\u002Fus\\u002Fen\\u002Fverizonmedia\\u002Fprivacy\\u002Fadinfo\\u002Findex.html\"},\"advertise\":{\"title\":\"ADVERTISE\",\"href\":\"https:\\u002F\\u002Fadvertising.yahoo.com\"},\"careers\":{\"title\":\"CAREERS\",\"href\":\"https:\\u002F\\u002Fcareers.yahoo.com\\u002Fus\"},\"feedback\":{\"title\":\"FEEDBACK\",\"href\":\"https:\\u002F\\u002Fyahoo.uservoice.com\\u002Fforums\\u002F341361-yahoo-home\"},\"help\":{\"title\":\"HELP\",\"href\":\"https:\\u002F\\u002Fhelp.yahoo.com\\u002Fl\\u002Fus\\u002Fyahoo\\u002Ffinance\\u002F\"},\"privacy\":{\"title\":\"PRIVACYUPDATED\",\"href\":\"https:\\u002F\\u002Fpolicies.yahoo.com\\u002Fus\\u002Fen\\u002Fyahoo\\u002Fprivacy\\u002Findex.htm\"},\"suggestions\":{\"title\":\"SUGGESTIONS\",\"href\":\"https:\\u002F\\u002Fyahoo.uservoice.com\\u002Fforums\\u002F382977\"},\"terms\":{\"title\":\"TERMSUPDATED\",\"href\":\"https:\\u002F\\u002Fpolicies.yahoo.com\\u002Fus\\u002Fen\\u002Fyahoo\\u002Fterms\\u002Futos\\u002Findex.htm\"},\"disclaimer\":{\"title\":\"DISCLAIMER\",\"href\":\"https:\\u002F\\u002Fhelp.yahoo.com\\u002Fkb\\u002Ffinance\\u002FSLN2310.html?impressions=true\"},\"sitemap\":{\"title\":\"SITEMAP\",\"href\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsitemap\\u002F\"}},\"wrapperClassName\":\"yvpDocked_Mt(260px)\",\"enableCCPAFooter\":true},\"Col2-5-HeightContainer-0-Stream\":{\"ads\":{\"ad_polices\":true,\"adchoices_url\":\"https:\\u002F\\u002Fwww.verizonmedia.com\\u002Fpolicies\\u002Fus\\u002Fen\\u002Fverizonmedia\\u002Fprivacy\\u002Fadinfo\\u002Findex.html\",\"advertiseWithUsUrl\":\"https:\\u002F\\u002Fwww.ad.com\\u002F?utm_source=yahoo-news&utm_medium=referral&utm_campaign=ad-feedback\",\"cluster\":false,\"contentType\":\"\",\"count\":25,\"enableFlashSale\":false,\"enableGeminiAdFeedback\":true,\"enableGeminiDealsWithoutBackground\":false,\"enableVideoManagerGemini\":true,\"fallback\":false,\"force_thumbnail_size\":false,\"frequency\":3,\"geminiPromotionsEnabled\":false,\"generic_viewability\":true,\"inline_video\":false,\"letterbox_thumb\":true,\"sponsored_label_support\":true,\"partial_viewability\":true,\"pu\":\"www.yahoo.com\",\"related_ct_ads_count\":3,\"related_ct_se\":\"5454650\",\"related_start_index\":3,\"se\":4250754,\"showCTA\":false,\"showCTAThumbnail\":false,\"spaceid\":2023538075,\"sponsored_url\":\"http:\\u002F\\u002Fhelp.yahoo.com\\u002Fkb\\u002Findex?page=content&y=PROD_FRONT&locale=en_US&id=SLN14553\",\"start_index\":2,\"timeout\":0,\"type\":\"STRM,STRM_CONTENT\",\"useHqImg\":true,\"useOrigImg\":false,\"useResizedImages\":true,\"videoAdCCOnMute\":false,\"videoExpName\":\"gemini\",\"vpaidTimeout\":5,\"ctx_signals_enabled\":true},\"batches\":{\"pagination\":false,\"size\":32,\"timeout\":500,\"total\":170,\"start_index\":0,\"end_index\":15},\"cache_ads\":false,\"cache_ttl\":0,\"category\":\"SIDEKICK:TOPSTORIES\",\"clear_on_navigate\":false,\"embedComponents\":[],\"enableAuthorBio\":true,\"flyout_enabled\":false,\"forceJpg\":true,\"i13n\":{\"sec\":\"sdkick\"},\"imageResizer\":null,\"login\":{\"src\":\"fpctx\"},\"max_dedupe_ADID_size\":50,\"max_dedupe_UUID_size\":250,\"max_exclude\":10,\"min_count\":3,\"min_count_error\":false,\"pageload_image_count\":3,\"pageload_item_count\":-1,\"perf_beacon\":false,\"perf_label\":\"\",\"offnet\":{\"include_lcp\":true,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"]},\"use_preview\":true,\"url_scheme\":\"domain\"},\"redisCompress\":false,\"releasesParams\":{\"limit\":20,\"offset\":0},\"sentiment_comments_enabled\":false,\"service\":{\"specRetry\":{\"enabled\":false}},\"sidekick_sectionid_enabled\":false,\"store\":{\"ls_delay\":1000,\"ls_ttl\":86400},\"ui\":{\"ad_image_fit\":false,\"attribution_pos\":\"bottom\",\"comments\":false,\"comments_count\":2,\"comments_offnet\":false,\"container_classnames\":\"\",\"dispatch_content_store\":true,\"editorial_content_count\":0,\"editorial_featured_count\":1,\"enable_lead_fallback_image\":false,\"exclude_types\":\"\",\"image_quality_override\":true,\"inline_video\":false,\"item_classnames\":\"\",\"lead_fallback_image\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fdh\\u002Fap\\u002Fmy\\u002Fthemes\\u002Fdark_1366x854_01_prog.jpg\",\"link_params\":false,\"link_out_allowed\":true,\"magazine_featured\":true,\"magazine_icon\":false,\"max_width\":900,\"mega_image_height\":\"\",\"needtoknow_roundup_only\":false,\"needtoknow_template\":\"\",\"ntk_bypassA3c\":true,\"property_colors\":true,\"pubtime_maxage\":-1,\"related_count\":5,\"related_enabled\":false,\"related_item_width\":\"\",\"related_min\":3,\"relative_links\":false,\"render_video_featured\":false,\"require_resized_image\":false,\"roundup\":false,\"scrollbuffer\":900,\"share_buttons\":{\"buttons_to_show\":[\"tumblr\",\"facebook\",\"twitter\",\"mail\"],\"enable\":false},\"show_comment_count\":false,\"show_error\":true,\"show_publisher_color\":true,\"show_read\":true,\"show_summary\":true,\"show_type_icon\":true,\"smart_crop\":true,\"sponsored_label\":false,\"sponsored_label_pos\":\"bottom\",\"storyline_count\":2,\"storyline_enabled\":false,\"storyline_min\":2,\"summary\":false,\"tiles\":{\"allowPartialRows\":true,\"doubleTallStart\":0,\"featured_label\":false,\"gradient\":false,\"height\":175,\"resizeImages\":false,\"textOnly\":[{\"backgroundColor\":\"#fff\",\"foregroundColor\":\"#000\"}],\"width_max\":300,\"width_min\":200},\"titleInnerClassName\":\"Lh(15px) Fw(b) LineClamp(3,45px)\",\"thumbnail\":true,\"thumbnail_align\":\"right\",\"thumbnail_size\":100,\"title_pos\":\"bottom\",\"touch_device\":false,\"user_intent\":false,\"view\":\"sidekick\",\"featured_summary\":false,\"follow_content\":false,\"inline_filters_max\":0,\"smush_images\":true},\"use_article_category\":false,\"use_content_id\":true,\"use_content_site\":false,\"use_page_category\":false,\"use_prefetch\":false,\"use_yct_wikiids\":true,\"video\":{\"disable_buffer_on_pause\":true,\"disable_title_on_hover\":true,\"enable_ads\":false,\"enable_cc_on_mute\":false,\"energy_saver_mode\":false,\"enable_custom_controls\":false,\"enable_detached_video\":false,\"enable_docking\":false,\"enable_expand_on_unmute\":false,\"enable_video_enrichment\":false,\"use_inline_video\":false},\"blending_enabled\":true},\"UH-0-UH-0-Header\":{\"uh\":{\"featureSwitches\":{\"navrailCollapse\":true},\"style\":{\"container\":{\"wrapper\":\"Miw(980px) UH Z(10) Py(14px) Pos(r)\"}},\"backgroundColor\":\"Bgc(#f9f9f9)\",\"theme\":{\"topbarBackground\":\"Bgc(#2d1152)\",\"topbarIcon\":\"#1d1da3\",\"profileBackground\":\"Bgc($c-fuji-purple-1-c):h C($c-fuji-purple-1-c) Bdc($c-fuji-purple-1-c)\",\"profileIcon\":\"#400090\",\"mailBackground\":\"Bgc($c-fuji-purple-1-c)\",\"mailNotificationBackground\":\"Bgc($c-fuji-red-1-a)\",\"mailNotificationBorderColor\":\"Bdc(#fff)\"},\"help\":{\"style\":{\"container\":{\"wrapper\":\"D(ib) Mstart(16px) Va(t) Mt(3px)\"},\"separator\":{\"content\":\"Bgc(#e2e2e6) H(1px)\"},\"icon\":{\"settings\":{\"content\":\"D(n) Lh(2.6) Mstart(4px)\",\"asset\":{\"name\":\"CoreSettings\",\"height\":32,\"width\":32,\"path\":\"M12.57 3.98c-.08.022-.16.05-.238.075-.022.004-.044.01-.07.014l-.006.008c-.907.288-1.785.685-2.62 1.188h-.004c-.698.322-1.288-.052-1.44-.164l-.515-.396c-.42-.414-1.094-.408-1.51.012L4.61 6.302c-.414.42-.41 1.096.012 1.51l.57.928c.09.22.205.652.007 1.114-.06.104-.12.207-.176.314-.036.062-.07.126-.1.19-.054.105-.106.212-.158.317-.036.078-.076.155-.11.232-.044.093-.083.188-.12.283-.044.092-.084.188-.122.283l-.09.24c-.042.112-.082.224-.123.338-.018.067-.04.132-.06.198-.04.127-.083.255-.12.387-.016.052-.026.105-.04.16-.032.122-.066.246-.094.37-.222.466-.628.657-.89.734l-.768.1c-.592.005-1.065.488-1.06 1.076l.018 2.223c.004.57.46 1.027 1.02 1.05l-.005.005s1.47.216 1.83 1c.024.087.048.176.075.264l.034.102c.046.145.094.29.145.434l.05.13c.05.133.102.265.155.396l.06.152c.055.123.11.243.168.364.026.055.053.112.076.167.06.12.122.237.185.352.062.124.13.244.2.365.048.085.096.17.147.255l.08.13c.192.486.06.907-.078 1.167l-.653.85c-.412.42-.408 1.094.01 1.507l1.584 1.56c.42.414 1.095.41 1.51-.01l1.18-.724c.267-.114.647-.19 1.073-.016.123.064.242.124.364.184v.01c.062.03.124.058.188.087.192.094.385.183.583.263.008.004.014.008.022.01.148.06.3.118.452.174.02.006.038.014.06.02.14.05.28.098.425.143.03.01.06.02.093.028.132.042.265.08.398.115.303.173.49.426.576.58l.34 1.462c-.007.59.463 1.075 1.05 1.084l.253.003c.08.02.167.032.256.03l.86-.013.852.015c.09.002.172-.012.253-.03l.257-.004c.586-.01 1.057-.494 1.05-1.083l.337-1.46c.087-.157.274-.41.576-.582.135-.034.267-.073.4-.115.032-.01.06-.02.09-.028.143-.045.285-.092.43-.144.017-.005.036-.013.056-.02.15-.055.3-.113.45-.173.007-.002.016-.006.02-.01.198-.08.39-.168.585-.262.063-.028.126-.056.187-.088v-.01c.12-.06.242-.12.363-.183.427-.174.808-.098 1.074.016l1.18.724c.414.42 1.09.424 1.51.01l1.58-1.56c.42-.412.427-1.09.013-1.507l-.65-.85c-.14-.26-.27-.68-.082-1.167.027-.042.056-.085.083-.13.05-.083.097-.17.148-.254.067-.122.135-.242.2-.365.063-.117.124-.235.182-.353.027-.055.052-.11.077-.167.057-.122.113-.242.165-.364.02-.052.042-.1.064-.152.053-.132.105-.263.156-.396.016-.044.03-.087.047-.13.05-.144.1-.29.148-.434.008-.035.02-.07.03-.103.026-.088.052-.176.076-.265.363-.784 1.83-1 1.83-1l-.005-.004c.564-.023 1.013-.482 1.017-1.05l.02-2.224c.004-.588-.468-1.07-1.06-1.076l-.77-.1c-.258-.078-.663-.27-.888-.734-.03-.125-.06-.25-.092-.372-.02-.054-.028-.107-.045-.16-.035-.13-.076-.26-.116-.386l-.06-.197c-.04-.113-.083-.225-.125-.338-.028-.078-.055-.16-.09-.24-.038-.094-.076-.19-.12-.282-.037-.094-.078-.19-.12-.283-.035-.077-.075-.154-.11-.232-.053-.106-.103-.212-.155-.317l-.104-.19c-.055-.106-.114-.21-.173-.314-.2-.46-.084-.892.005-1.114l.572-.93c.42-.412.426-1.088.013-1.508l-1.56-1.584c-.413-.42-1.09-.426-1.508-.012L23.7 5.1c-.15.112-.744.486-1.442.165h-.005c-.832-.503-1.71-.9-2.616-1.188l-.007-.01c-.026-.003-.228-.065-.31-.088l-.18-.09c-.355-.216-.53-.55-.6-.713l-.33-1.332c0-.588-.475-1.067-1.065-1.067H14.75c-.59 0-1.072.48-1.072 1.068l-.327 1.332s-.21.724-.78.802zm3.377 18.717c-3.763 0-6.81-3.05-6.81-6.808s3.046-6.81 6.81-6.81c3.76 0 6.805 3.05 6.805 6.81s-3.046 6.807-6.805 6.807z\"},\"name\":\"CoreSettings\",\"size\":28,\"wrapper\":\"D(ib)\"}},\"link\":{\"content\":\"Td(n) Td(u):h D(b) C(#000)\",\"wrapper\":\"Py(8px) Px(10px)\"},\"panel\":{\"content\":\"Mx(-10px) Pos(r) My(0) P(0) C(#000)!\",\"wrapper\":\"Bdrs(4px) Bgc(menuBgc) Bxsh(customShadowFlyoutMenu) D(b) End(0) Pos(a) Px(10px) T(40px) Ta(start)\"},\"button\":{\"wrapper\":\"Cur(p) Bgc(#3775dd) Pt(0) Pend(3px) Fz(13px) Bdw(1px) Bds(s) Mt(2px) Mstart(3px) Whs(nw) Ta(c) C(#fff) Bdc(#182e5c)\"},\"menulist\":{\"wrapper\":\"Fz(13px)\"}},\"data\":{\"items\":{\"account_info\":{\"order\":1,\"title\":\"Account Info\",\"url\":{\"protocol\":\"https\",\"hostname\":\"login.yahoo.com\",\"pathname\":\"\\u002Faccount\\u002Fpersonalinfo\\u002F\",\"query\":{}}},\"help\":{\"order\":2,\"title\":\"Help\",\"url\":{\"protocol\":\"https\",\"hostname\":\"help.yahoo.com\",\"pathname\":\"kb\\u002Fhelpcentral\\u002F\"}},\"separator\":{\"order\":3},\"suggestions\":{\"order\":4,\"title\":\"Suggestions\",\"url\":{\"protocol\":\"https\",\"hostname\":\"yahoo.uservoice.com\"}}}}},\"logo\":{\"style\":{\"cobrand\":{\"partner\":{},\"yahoo\":{}},\"container\":{\"inline\":{}},\"country_property\":{},\"property\":{},\"yahoo\":{}},\"isCobrand\":false,\"logoBgSize\":\"Bgz(250px)\",\"backgroundColor\":null,\"backgroundPosX\":\"Bgpx(0)\",\"backgroundPosY\":\"Bgpy(0)\",\"height\":74,\"width\":125,\"defaultRetinaImage\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fd\\u002Fyahoo_frontpage_en-US_s_f_pw_bestfit_frontpage_2x.png\",\"defaultNonRetinaImage\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fd\\u002Fyahoo_frontpage_en-US_s_f_pw_bestfit_frontpage.png\",\"image\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fl\\u002Fyahoo_en-US_f_pw_125x32_2x.png\",\"nonRetinaImage\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fl\\u002Fyahoo_en-US_f_pw_125x32.png\",\"link\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002F\"},\"mail\":{\"useCors\":true,\"style\":{\"button\":{\"inline\":{}},\"mailcount\":{}},\"data\":{\"icon\":{\"mail\":{\"asset\":{\"name\":\"NavMail\",\"height\":512,\"width\":512,\"path\":\"M460.586 91.31H51.504c-10.738 0-19.46 8.72-19.46 19.477v40.088l224 104.03 224-104.03v-40.088c0-10.757-8.702-19.478-19.458-19.478M32.046 193.426V402.96c0 10.758 8.72 19.48 19.458 19.48h409.082c10.756 0 19.46-8.722 19.46-19.48V193.428l-224 102.327-224-102.327z\"},\"name\":\"NavMail\",\"height\":35,\"width\":30}},\"mode\":\"client\"},\"urls\":{\"mail\":{\"protocol\":\"https\",\"hostname\":\"mail.yahoo.com\",\"pathname\":\"\\u002F\",\"query\":{}}},\"compose\":{\"url\":\"https:\\u002F\\u002Fmrd.mail.yahoo.com\\u002Fcompose\"},\"api\":{\"protocol\":\"https\",\"host\":\"apis.mail.yahoo.com\",\"path\":\"\\u002Fws\\u002Fv3\\u002Fbatch\",\"query\":{\"appId\":\"UniversalHeader\"}},\"count\":{\"api\":{\"protocol\":\"https\",\"host\":\"yqlmailapps.query.yahoo.com\",\"path\":\"\\u002Fv1\\u002Fconsole\\u002Fyql\",\"query\":{\"appid\":\"UnivHeader\",\"crumb\":\"{crumb}\",\"format\":\"json\",\"q\":\"SELECT decos.counts.unseen FROM ymail.decos WHERE mailboxes.id IN (SELECT mailboxes.id FROM ymail.mailboxes WHERE mailboxes.isPrimary=\\\"true\\\" AND ymreqid=\\\"{ymreqid}\\\") AND decos.id=\\\"FTI\\\" AND decos.counts.accountId=1 AND ymreqid=\\\"{ymreqid}\\\"\"}},\"jsonp\":{\"timeout\":3000,\"prefix\":\"__uhmc__\"},\"body\":{\"requests\":[{\"id\":\"GetMailboxId\",\"uri\":\"\\u002Fws\\u002Fv3\\u002Fmailboxes\\u002F\",\"method\":\"GET\",\"filters\":{\"iterator\":\"$..mailboxes[?(@.isPrimary==true)]\",\"select\":{\"mailboxId\":\"$..id\"}},\"suppressResponse\":true,\"requests\":[{\"id\":\"ListDecos\",\"uri\":\"\\u002Fws\\u002Fv3\\u002Fmailboxes\\u002F@.id==$(mailboxId)\\u002Fdecos\",\"method\":\"GET\"}]}],\"responseType\":\"json\"},\"timeout\":3000,\"maxCountDisplay\":99,\"pollingDuration\":10,\"pollingInterval\":2,\"pollingWindow\":110000},\"mailservices\":{\"api\":{\"host\":\"mail.yahoo.com\",\"path\":\"\\u002F\",\"protocol\":\"https\",\"query\":{\".src\":\"ym\"}}},\"preview\":{\"api\":{\"protocol\":\"https\",\"host\":\"yqlmailapps.query.yahoo.com\",\"path\":\"\\u002Fv1\\u002Fconsole\\u002Fyql\",\"query\":{\"format\":\"json\",\"q\":\"SELECT messages.id, messages.headers.date, messages.headers.subject, messages.headers.from.name, messages.headers.from.email, messages.flags.read FROM ymail.messages WHERE ymreqid=\\\"{ymreqid}\\\" AND mailboxes.id IN (SELECT mailboxes.id FROM ymail.mailboxes WHERE ymreqid=\\\"{ymreqid}\\\" AND mailboxes.isSelected=\\\"true\\\") limit 6\",\"crumb\":\"{crumb}\"}},\"fetchInterval\":5000,\"jsonp\":{\"timeout\":3000,\"prefix\":\"__uhmp__\"},\"body\":{\"requests\":[{\"id\":\"GetMailboxId\",\"uri\":\"\\u002Fws\\u002Fv3\\u002Fmailboxes\\u002F\",\"method\":\"GET\",\"filters\":{\"select\":{\"mailboxId\":\"$..mailboxes[?(@.isSelected==true)].id\"}},\"suppressResponse\":true,\"requests\":[{\"id\":\"ListMessages\",\"uri\":\"\\u002Fws\\u002Fv3\\u002Fmailboxes\\u002F@.id==$(mailboxId)\\u002Fmessages\\u002F@.select==q?q=count%3A6+offset%3A0+folderType%3AINBOX+-sort%3Adate&appid=UniversalHeader\",\"method\":\"GET\"}]}],\"responseType\":\"json\"},\"timeout\":3000,\"urls\":{\"message\":\"https:\\u002F\\u002Fmrd.mail.yahoo.com\\u002Fmsg?fid=Inbox&src=hp&mid=\"}},\"url\":\"https:\\u002F\\u002Fmail.yahoo.com\\u002F\",\"signedInUrl\":\"https:\\u002F\\u002Fmail.yahoo.com\\u002F\"},\"notifications\":{\"autoInitSubscription\":false,\"data\":{\"icon\":{\"asset\":{\"name\":\"nav-bell\",\"height\":512,\"width\":512,\"path\":\"M294.2 428.05h-74.4c0 20.543 16.656 37.2 37.2 37.2 20.535 0 37.2-12.47 37.2-37.2zM136.1 195.55c0 62.284-53.51 94.162-55.728 95.452L71 296.352v94.498h372v-94.498l-9.373-5.35c-.562-.318-55.727-32.573-55.727-95.452 0-63.88-12.533-148.8-120.9-148.8-108.368 0-120.9 84.92-120.9 148.8z\"},\"name\":\"nav-bell\",\"size\":28}},\"hasNotificationCenterLink\":false,\"notificationClient\":{\"badge\":{\"hideClass\":\"D(n)\"},\"enabled\":false,\"historyServicePath\":\"\\u002F_td\\u002Fapi\\u002Fresource\\u002FNotificationHistory.getHistory\",\"panel\":{\"maxCount\":6,\"notificationCenterPath\":\"\\u002Fnotifications\"},\"promos\":{\"enableNotifOnboard\":false}},\"notifPromoBackoffDuration\":604800,\"polling\":true,\"pollingInterval\":300,\"promoId\":\"promo\",\"style\":{\"button\":{},\"notificationsCount\":{}},\"subscriptionHelper\":{\"enabled\":false,\"enableChurnCheck\":false,\"enableSubsResyncIfError\":false,\"churnCheckBackoff\":604800,\"confirmationNotification\":{\"enabled\":true,\"icon\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fuh\\u002Fnotifications\\u002Fdefault-notif-img.png\",\"body\":\"We will send you notifications about latest breaking news.\",\"title\":\"Welcome!\"},\"overlay\":{\"default\":{\"imageHeight\":227,\"imageUrl\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fuh\\u002Fnotifications\\u002Finst-push-perm-6.png\",\"imageWidth\":541,\"overlayId\":\"permission-instructions\",\"xOffset\":335,\"yOffset\":83},\"denied\":{\"imageHeight\":326,\"imageUrl\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fuh\\u002Fnotifications\\u002Finst-unblock-push-perm.png\",\"imageWidth\":490,\"overlayId\":\"unblock-instructions\",\"xOffset\":100,\"yOffset\":2}},\"resubscribeOnChurn\":false,\"serviceWorkerUrl\":\"\\u002Fservice-worker.js\",\"spaceId\":null,\"subscriptionService\":{\"context\":null,\"host\":null,\"path\":\"\\u002F_td\\u002Fapi\\u002Fresource\",\"protocol\":null},\"subscriptionPayload\":{\"topic\":\"gondor_homerun_news\"},\"supportedBrowsers\":{\"chrome\":{\"maxVersion\":0,\"minVersion\":54,\"os\":[\"win\",\"mac\"],\"useServiceWorker\":true}}}},\"account_switch\":{\"isEnabled\":true,\"styles\":{\"avatar\":{},\"secondary_accounts\":{}}},\"placeHolder\":{\"width\":\"\"},\"profile\":{\"style\":{\"account_info\":{},\"avatar\":{},\"container\":{},\"panel\":{},\"button\":{\"inline\":{}},\"signed_out\":{}},\"data\":{\"icon\":{\"profile\":{\"asset\":{\"name\":\"profile\",\"height\":48,\"width\":48,\"path\":\"M4.095 33.61c1.092 2.7 2.607 4.937 4.562 6.696 1.94 1.766 4.23 3.072 6.847 3.922 2.632.846 5.472 1.27 8.53 1.27 3.012 0 5.837-.425 8.458-1.27 1.053-.342 2.046-.754 2.986-1.244 1.41-.732 2.705-1.617 3.87-2.678 1.948-1.76 3.472-3.996 4.558-6.697 1.092-2.7 1.636-5.903 1.636-9.614 0-3.702-.544-6.904-1.636-9.61-1.086-2.703-2.608-4.934-4.56-6.694-1.944-1.767-4.23-3.07-6.854-3.922-2.62-.847-5.445-1.27-8.457-1.27-3.06 0-5.9.423-8.53 1.27-.847.277-1.662.607-2.443.98-1.623.777-3.1 1.753-4.404 2.942-1.956 1.76-3.47 3.992-4.562 6.694-1.09 2.706-1.636 5.908-1.636 9.61-.002 3.71.545 6.914 1.635 9.613zM35.838 34.758l-23.674.002v-2.21s.017-1.425 3.123-2.716c1.538-.633 3.35-1.854 6.6-2.24-.997-.705-1.44-2.154-2.29-4.17-.02-.032-.03-.068-.043-.1-.193.032-.393.032-.537-.046-.398-.232-.636-1.48-.642-2.092-.01-.906.48-.824.48-.824s.017 0 .042-.004c-.006-.07-.01-.142-.01-.213 0-.86-.174-2.24.053-2.988.353-1.176.78-2.46 1.72-2.464.874 0 .28-1.006 1.348-1.345 1.102-.348 2.912.262 3.283.262.53 0 1.863.378 2.78 1.284.646.64.572 1.08.93 2.25.23.777.057 2.167.057 3 0 .07-.007.14-.014.213.018.007.03.007.03.007s.487-.082.478.824c-.004.612-.248 1.86-.635 2.092-.146.078-.34.078-.53.052-.01.026-.023.058-.033.09-.85 1.996-1.308 3.457-2.305 4.162 3.283.38 5.107 1.61 6.654 2.25 3.128 1.287 3.14 2.533 3.14 2.533l-.002 2.39z\"},\"name\":\"profile\",\"size\":34}}},\"mode\":\"server\",\"authStateCheck\":false,\"avatarSize\":\"36px\",\"loginBaseUrl\":\"https:\\u002F\\u002Flogin.yahoo.com\\u002Fconfig\\u002Flogin\",\"settingUrl\":\"https:\\u002F\\u002Fedit.yahoo.com\\u002Fconfig\\u002Feval_profile\",\"signoutUrl\":\"https:\\u002F\\u002Flogin.yahoo.com\\u002Faccount\\u002Flogout?logout=1&.direct=2&.done=https:\\u002F\\u002Fwww.yahoo.com\",\"urls\":{\"signed_in\":{\"protocol\":\"https\",\"hostname\":\"login.yahoo.com\",\"pathname\":\"\\u002Fconfig\\u002Flogin\",\"query\":{}},\"signed_out\":{\"protocol\":\"https\",\"hostname\":\"login.yahoo.com\",\"pathname\":\"\\u002Faccount\\u002Flogout\",\"query\":{\".direct\":2,\"logout\":1}},\"account_info\":{\"protocol\":\"https\",\"hostname\":\"edit.yahoo.com\",\"pathname\":\"\\u002Fconfig\\u002Feval_profile\",\"query\":{}}}},\"search\":{\"style\":{\"cancel_button\":{},\"table\":{},\"container\":{\"wrapper\":\"Mend(375px) Mstart(194px) Maw(595px) H(35px) Trstf(eo) Trsde(0s) Trsdu(0.14s) Trsp(a) ie-7_H(100%)\"},\"input\":{\"content\":\"Bdrs(2px)! ie-7_Lh(18px) ie-8_Lh(18px) ie-7_W(88%) ie-7_Mt(2px) ie-7_H(100%)\"},\"search_button\":{\"inline_1\":{},\"inline_2\":{},\"content_1\":\"C(white) Fz(16px) two-btn_Fz(s) H(35px) ie-7_Lh(18px) ie-8_Lh(18px) ie-7_W(140px) ie-7_H(41px) Mend(0)! ie-8_W(140px) Mstart(5px) W(140px)\"},\"magnifying_glass\":{}},\"verticalSearchEnabled\":false,\"verticalSearchButtonText\":null,\"webSearchButtonText\":\"SEARCH_WEB\",\"verticalSearchAction\":null,\"autofocus\":false,\"assistYlc\":\";_ylc=X3oDMTFiaHBhMnJmBF9TAzIwMjM1MzgwNzUEaXRjAzEEc2VjA3NyY2hfcWEEc2xrA3NyY2hhc3Q-\",\"ylc\":\";_ylc=X3oDMTFiN25laTRvBF9TAzIwMjM1MzgwNzUEaXRjAzEEc2VjA3NyY2hfcWEEc2xrA3NyY2h3ZWI-\",\"buttonText\":\"SEARCH\",\"glowEnabled\":false,\"placeholderIcon\":false,\"placeholderText\":\"FINANCE_UH_SEARCH_WEB\",\"autocomplete\":{},\"icon\":{},\"instantSearch\":false,\"searchHint\":false,\"cancelBtn\":false,\"clearBtn\":false,\"termCompleteBtn\":false,\"magnifyingGlass\":false,\"useIcon\":false,\"queries\":{\"fr\":\"uh3_finance_vert\"},\"showSubPartnerLogo\":false,\"enableCancelButton\":false,\"action\":\"\\u002Fquote\\u002F\",\"enableFuzzyQuery\":false,\"newsCount\":4,\"quotesCount\":6,\"listCount\":4,\"quotesQueryId\":\"tss_match_phrase_query\",\"multiQuoteQueryId\":\"multi_quote_single_token_query\",\"newsQueryId\":\"news_ss_symbols\",\"enableCb\":true,\"enableNavLinks\":true,\"feedback\":{\"enabled\":false,\"href\":\"https:\\u002F\\u002Fyahoo.uservoice.com\\u002Fforums\\u002F439018\"}},\"searchOrigin\":{\"fr\":\"uh3_finance_web\",\"fr2\":\"p:finvsrp,m:{FRSOURCE}\"},\"skip_nav\":{\"style\":{\"container\":{\"wrapper\":\"Pos(a)\"},\"link\":{\"content\":\"W(0) D(ib) Whs(nw) Pos(a) Bg(#500095) C(#fff) Op(0) W(a):f Op(1):f P(5px):f\"}},\"data\":{\"items\":{\"item_1\":{\"name\":\"Skip to Navigation\",\"link\":\"#Navigation\",\"order\":1},\"item_2\":{\"name\":\"Skip to Market Summary\",\"link\":\"#market-summary\",\"order\":2},\"item_3\":{\"name\":\"Skip to Main Content\",\"link\":\"#Main\",\"order\":3},\"item_4\":{\"name\":\"Skip to Related Content\",\"link\":\"#Aside\",\"order\":4}}}},\"topbar\":{\"style\":{\"nav_home\":{\"inline\":{},\"link\":{}},\"nav_main\":{\"link\":{},\"link_home\":{\"icon\":{\"down_arrow\":{\"inline\":{}},\"home\":{\"inline\":{}}}},\"link_more\":{\"icon\":{\"down_arrow\":{\"inline\":{}}}}},\"nav_more\":{\"inline\":{},\"link\":{}}},\"data\":{\"force_absolute\":{\"answers\":false,\"finance\":false,\"games\":false,\"groups\":false,\"home\":false,\"mail\":false,\"mobile\":false,\"screen\":false,\"search\":false,\"shopping\":false,\"sports\":false,\"weather\":false},\"force_absolute_all\":true,\"homeSwitcher\":{\"enabled\":false},\"more\":11,\"more_item\":{\"link\":\"https:\\u002F\\u002Feverything.yahoo.com\",\"title\":\"More\"},\"icon\":{\"home\":{\"asset\":{\"name\":\"home\",\"height\":32,\"width\":32,\"path\":\"M16.153 3.224L0 16.962h4.314v11.814h9.87v-8.003h3.934v8.003h9.84V16.962H32\"},\"name\":\"home\",\"size\":16},\"down_arrow\":{\"asset\":{\"name\":\"CoreArrowDown\",\"height\":512,\"width\":512,\"path\":\"M500.77 131.432L477.53 108.18c-14.45-14.55-40.11-14.55-54.51 0L255.845 275.363 88.582 108.124c-15.015-14.874-39.363-14.874-54.42.108L10.94 131.486c-14.58 14.44-14.58 40.11-.033 54.442l217.77 217.845c15.004 14.82 39.33 14.874 54.42-.108L500.88 185.82c14.818-14.982 14.87-39.298-.11-54.388z\"},\"name\":\"CoreArrowDown\",\"size\":8}}},\"promo\":{\"icon\":\"\",\"iconAlt\":\"\",\"link\":\"\",\"text\":\"\"}},\"data\":{\"action\":{\"load_nav\":{\"cache\":{\"enabled\":true}},\"load_theme\":{\"cache\":{\"enabled\":true},\"client\":{\"enabled\":true}}}},\"navTitle\":\"\",\"ui\":{\"alphatar\":true,\"back\":false,\"darkTheme\":false,\"help\":false,\"logo\":true,\"mail\":true,\"mailcount\":true,\"mailpreview\":true,\"menuBtn\":true,\"notifications\":false,\"openSearchBtn\":false,\"profile\":true,\"profileCardOpen\":false,\"profileCardAvatar\":false,\"profileCardName\":false,\"profileCardEmail\":false,\"profileCardSignout\":false,\"profileCardAcctInfo\":false,\"search\":true,\"share\":false,\"skip_nav\":true,\"theme\":\"default\",\"topbar\":true,\"topbarFFPromo\":false,\"topbarSticky\":true,\"topbarPromo\":false,\"partnerTheme\":false,\"follow\":false},\"useNavTitle\":false,\"useTopicTitle\":false},\"i13n\":{\"sec\":\"uh\"},\"mrt\":{\"flush\":false,\"cache\":true,\"skipAlertOnChecksumMismatch\":true,\"prioritize\":false}},\"UH-1-DesktopNav-acct-switch-0-AccountSwitch\":{\"isEnabled\":true,\"clientRender\":true,\"accountListLength\":3,\"enableAlphatar\":true,\"host\":\"login.yahoo.com\",\"urlReplacements\":{\"CRUMB\":{\".crumb\":\"{crumb}\"},\"DONE\":{\".done\":\"{doneUrl}\"},\"DONE_YAHOO\":{\".done\":\"{doneUrlYahoo}\"}},\"urls\":{\"accountInfo\":{\"protocol\":\"https\",\"path\":\"\\u002Faccount\\u002Fpersonalinfo\\u002F\",\"query\":[\"DONE\",{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\".src\":\"{site}\"}]},\"switchUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Fd\",\"query\":[\"CRUMB\",{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\".src\":\"{site}\"},{\"login\":\"{alias}\"},{\"as\":\"1\"},\"DONE\"]},\"manageUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Fmanage_account\",\"query\":[\"CRUMB\",{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\".src\":\"{site}\"},\"DONE\"]},\"logoutUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Faccount\\u002Flogout\",\"query\":[\"CRUMB\",{\".src\":\"{site}\"},{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\"logout_all\":\"1\"},{\".direct\":\"1\"},\"DONE_YAHOO\"]},\"requestUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Fw\\u002Fdevice_users\",\"query\":[\"CRUMB\"]}},\"styles\":{\"account_switch_main\":{\"wrapper\":\"Py(16px)\",\"account_info\":\"C($c-fuji-grey-l) C(asLinkHoverColor):h Td(n) Td(n):h D(ib) Mstart(asIconWidth) Pend(asEndPadding) Whs(nw)\"},\"signed_out\":{\"wrapper\":\"Py(14px) Ta(c) Bdt(asMenuBorder)\",\"content\":\"C($c-fuji-grey-l) C(asLinkHoverColor):h  Td(n) Td(n):h\"},\"add_accounts\":{\"icon_wrapper\":\"W(asIconWidth) D(ib) Va(t) Ta(c)\",\"icon_content\":\"C($c-fuji-grey-l) Fz(30px) Fw(200) Lh(1.5)\",\"text\":\"Pt(16px) D(ib) C($c-fuji-grey-l) Zoom Fz(15px)\",\"wrapper\":\"Bdt(asMenuBorder) Td(n) Td(n):h D(b) Whs(nw) Bgc(asMenuHoverBgc):h H(50px) Pend(asEndPadding)\"},\"avatar\":{\"size\":40,\"color\":\"#400090\",\"content\":\"Bdrs(100px) Bgz(cv) D(ib)\",\"panel_content\":\"D(ib) Va(m) Bgz(cv) Bdrs(100px)\",\"name\":\"D(n) Lh(2.6) Mstart(4px)\",\"wrapper\":\"Zoom Va(t) Ta(c) Fl(start) W(asIconWidth)\"},\"main_account\":{\"alias\":\"C(asLightTextColor) Ell Pt(2px)\",\"alias_wrapper\":\"Ell C(#000) Fz(13px)\",\"content\":\"C($c-fuji-grey-l) D(ib) Fz(13px) Pt(10px)\",\"name\":\"C($c-fuji-grey-l) Ell Fz(15px)\",\"name_wrapper\":\"Fz(15px) Ell\",\"user_info_wrapper\":\"W(2\\u002F3) D(ib) Zoom Lts(n) Tren(a) Va(t)\",\"wrapper\":\"Cf\"},\"secondary_accounts\":{\"list\":\"Pos(r) M(0) P(0) List(n)\",\"list_item\":\"Bdt(asMenuBorder)\",\"anchor\":\"Td(n) Td(n):h Py(16px) D(b) Cf C(#000) Bgc(asMenuHoverBgc):h\"}}},\"account-switch-uh-0-AccountSwitch\":{\"isEnabled\":true,\"clientRender\":true,\"accountListLength\":3,\"enableAlphatar\":true,\"host\":\"login.yahoo.com\",\"urlReplacements\":{\"CRUMB\":{\".crumb\":\"{crumb}\"},\"DONE\":{\".done\":\"{doneUrl}\"},\"DONE_YAHOO\":{\".done\":\"{doneUrlYahoo}\"}},\"urls\":{\"accountInfo\":{\"protocol\":\"https\",\"path\":\"\\u002Faccount\\u002Fpersonalinfo\\u002F\",\"query\":[\"DONE\",{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\".src\":\"{site}\"}]},\"switchUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Fd\",\"query\":[\"CRUMB\",{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\".src\":\"{site}\"},{\"login\":\"{alias}\"},{\"as\":\"1\"},\"DONE\"]},\"manageUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Fmanage_account\",\"query\":[\"CRUMB\",{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\".src\":\"{site}\"},\"DONE\"]},\"logoutUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Faccount\\u002Flogout\",\"query\":[\"CRUMB\",{\".src\":\"{site}\"},{\".intl\":\"{intl}\"},{\".lang\":\"{lang}\"},{\".partner\":\"{partner}\"},{\"logout_all\":\"1\"},{\".direct\":\"1\"},\"DONE_YAHOO\"]},\"requestUrl\":{\"protocol\":\"https\",\"path\":\"\\u002Fw\\u002Fdevice_users\",\"query\":[\"CRUMB\"]}},\"styles\":{\"account_switch_main\":{\"wrapper\":\"Py(16px)\",\"account_info\":\"C($c-fuji-grey-l) C(asLinkHoverColor):h Td(n) Td(n):h D(ib) Mstart(asIconWidth) Pend(asEndPadding) Whs(nw)\"},\"signed_out\":{\"wrapper\":\"Py(14px) Ta(c) Bdt(asMenuBorder)\",\"content\":\"C($c-fuji-grey-l) C(asLinkHoverColor):h  Td(n) Td(n):h\"},\"add_accounts\":{\"icon_wrapper\":\"W(asIconWidth) D(ib) Va(t) Ta(c)\",\"icon_content\":\"C($c-fuji-grey-l) Fz(30px) Fw(200) Lh(1.5)\",\"text\":\"Pt(16px) D(ib) C($c-fuji-grey-l) Zoom Fz(15px)\",\"wrapper\":\"Bdt(asMenuBorder) Td(n) Td(n):h D(b) Whs(nw) Bgc(asMenuHoverBgc):h H(50px) Pend(asEndPadding)\"},\"avatar\":{\"size\":40,\"color\":\"#400090\",\"content\":\"Bdrs(100px) Bgz(cv) D(ib)\",\"panel_content\":\"D(ib) Va(m) Bgz(cv) Bdrs(100px)\",\"name\":\"D(n) Lh(2.6) Mstart(4px)\",\"wrapper\":\"Zoom Va(t) Ta(c) Fl(start) W(asIconWidth)\"},\"main_account\":{\"alias\":\"C(asLightTextColor) Ell Pt(2px)\",\"alias_wrapper\":\"Ell C(#000) Fz(13px)\",\"content\":\"C($c-fuji-grey-l) D(ib) Fz(13px) Pt(10px)\",\"name\":\"C($c-fuji-grey-l) Ell Fz(15px)\",\"name_wrapper\":\"Fz(15px) Ell\",\"user_info_wrapper\":\"W(2\\u002F3) D(ib) Zoom Lts(n) Tren(a) Va(t)\",\"wrapper\":\"Cf\"},\"secondary_accounts\":{\"list\":\"Pos(r) M(0) P(0) List(n)\",\"list_item\":\"Bdt(asMenuBorder)\",\"anchor\":\"Td(n) Td(n):h Py(16px) D(b) Cf C(#000) Bgc(asMenuHoverBgc):h\"}}}}},\"RecentQuotesStore\":{\"recentquotes\":{},\"errorList\":[{\"statusCode\":404,\"message\":\"user has no recent quotes on their PRF cookie\"}]},\"NavServiceStore\":{\"nav\":{},\"finance\":{\"sections\":[\"property\"],\"nav\":[{\"statusCode\":200,\"message\":\"ok\",\"data\":{\"items\":[{\"name\":\"Coronavirus\",\"url\":\"https:\\u002F\\u002Fnews.yahoo.com\\u002Fcoronavirus\",\"children\":[],\"id\":\"root_1\"},{\"name\":\"Watchlists\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fwatchlists\",\"children\":[],\"id\":\"root_2\"},{\"name\":\"My Portfolio\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fportfolios\",\"children\":[],\"id\":\"root_3\"},{\"name\":\"Screeners\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fscreener\",\"children\":[{\"name\":\"Saved Screeners\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fscreener\",\"children\":[],\"id\":\"root_4_1\"},{\"name\":\"Equity Screener\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fscreener\\u002Fnew\",\"children\":[],\"id\":\"root_4_2\"},{\"name\":\"Mutual Fund Screener\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fscreener\\u002Fmutualfund\\u002Fnew\",\"children\":[],\"id\":\"root_4_3\"},{\"name\":\"ETF Screener\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fscreener\\u002Fetf\\u002Fnew\",\"children\":[],\"id\":\"root_4_4\"},{\"name\":\"Future Screener\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fscreener\\u002Ffuture\\u002Fnew\",\"id\":\"root_4_5\"},{\"name\":\"Index Screener\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fscreener\\u002Findex\\u002Fnew\",\"id\":\"root_4_6\"}],\"id\":\"root_4\"},{\"name\":\"Premium\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fpremium?ncid=navbarprem_fqbo1nu0ks0\",\"children\":[{\"name\":\"Dashboard\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fpremium?ncid=navbarprem_tnvxpbqj4ro\",\"id\":\"root_5_1\"},{\"name\":\"Research Reports\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fresearch?ncid=researchna_lyj1jlz33ia\",\"id\":\"root_5_2\"},{\"name\":\"Investment Ideas\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fresearch\\u002Ftrade-ideas?ncid=navbarprem_esdiq3t5kkc\",\"id\":\"root_5_3\"},{\"name\":\"Blog\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftopic\\u002Fpremium\",\"id\":\"root_5_4\"}],\"id\":\"root_5\"},{\"name\":\"Markets\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fcalendar\",\"children\":[{\"name\":\"Cryptocurrencies\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fcryptocurrencies\",\"children\":[],\"id\":\"root_6_1\"},{\"name\":\"Calendars\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fcalendar\",\"children\":[],\"id\":\"root_6_2\"},{\"name\":\"Trending Tickers\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftrending-tickers\",\"children\":[],\"id\":\"root_6_3\"},{\"name\":\"Stocks: Most Actives\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fmost-active\",\"children\":[],\"id\":\"root_6_4\"},{\"name\":\"Stocks: Gainers\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fgainers\",\"children\":[],\"id\":\"root_6_5\"},{\"name\":\"Stocks: Losers\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Flosers\",\"children\":[],\"id\":\"root_6_6\"},{\"name\":\"Top ETFs\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fetfs\",\"children\":[],\"id\":\"root_6_7\"},{\"name\":\"Futures\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fcommodities\",\"id\":\"root_6_8\"},{\"name\":\"World Indices\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fworld-indices\",\"children\":[],\"id\":\"root_6_9\"},{\"name\":\"Currencies\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fcurrencies\",\"children\":[],\"id\":\"root_6_10\"},{\"name\":\"Top Mutual Funds\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fmutualfunds\",\"children\":[],\"id\":\"root_6_11\"},{\"name\":\"Options: Highest Open Interest\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Foptions\\u002Fhighest-open-interest\",\"children\":[],\"id\":\"root_6_12\"},{\"name\":\"Options: Highest Implied Volatility\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Foptions\\u002Fhighest-implied-volatility\",\"children\":[],\"id\":\"root_6_13\"},{\"name\":\"US Treasury Bonds Rates\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fbonds\",\"children\":[],\"id\":\"root_6_14\"},{\"name\":\"Currency Converter\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fcurrency-converter\",\"id\":\"root_6_15\"}],\"id\":\"root_6\"},{\"name\":\"News\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\\u002F\",\"children\":[{\"name\":\"Latest News\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fnews\",\"id\":\"root_7_1\"},{\"name\":\"Stock Market News\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftopic\\u002Fstock-market-news\",\"id\":\"root_7_2\"},{\"name\":\"Morning Brief\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftopic\\u002Fmorning-brief\",\"id\":\"root_7_3\"},{\"name\":\"Trumponomics\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftrumponomics\",\"id\":\"root_7_4\"},{\"name\":\"Aarthi Swaminathan\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Faarthi-swaminathan\",\"id\":\"root_7_5\"},{\"name\":\"Adam Shapiro\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fadam-shapiro\",\"id\":\"root_7_6\"},{\"name\":\"Adriana Belmonte\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fadriana-belmonte\",\"id\":\"root_7_7\"},{\"name\":\"Akiko Fujita\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fakiko-fujita\",\"id\":\"root_7_8\"},{\"name\":\"Alexis Christoforous\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Falexis-christoforous\",\"id\":\"root_7_9\"},{\"name\":\"Alexis Keenan\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Falexis-keenan\",\"id\":\"root_7_10\"},{\"name\":\"Amanda Fung\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Famanda-fung\",\"id\":\"root_7_11\"},{\"name\":\"Andy Serwer\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fandy-serwer\",\"id\":\"root_7_12\"},{\"name\":\"Anjalee Khemlani\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fanjalee-khemlani\",\"id\":\"root_7_13\"},{\"name\":\"Ben Werschkul\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fben-werschkul\",\"id\":\"root_7_14\"},{\"name\":\"Brian Cheung\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fbrian-cheung\",\"id\":\"root_7_15\"},{\"name\":\"Brian Sozzi\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fbrian-sozzi\",\"id\":\"root_7_16\"},{\"name\":\"Daniel Howley\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fdaniel-howley\",\"id\":\"root_7_17\"},{\"name\":\"Daniel Roberts\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fdaniel-roberts\",\"id\":\"root_7_18\"},{\"name\":\"Emily McCormick\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Femily-mccormick\",\"id\":\"root_7_19\"},{\"name\":\"Erin Fuchs\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Ferin-fuchs\",\"id\":\"root_7_20\"},{\"name\":\"Ethan Wolff-Mann\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fethan-wolff-mann\",\"id\":\"root_7_21\"},{\"name\":\"Heidi Chung\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fheidi-chung\",\"id\":\"root_7_22\"},{\"name\":\"Javier E. David\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fjavier-e-david\",\"id\":\"root_7_23\"},{\"name\":\"Jen Rogers\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fjen-rogers\",\"id\":\"root_7_24\"},{\"name\":\"Jessica Smith\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fjessica-smith\",\"id\":\"root_7_25\"},{\"name\":\"Julia La Roche\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fjulia-la-roche\",\"id\":\"root_7_26\"},{\"name\":\"Julie Hyman\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fjulie-hyman\",\"id\":\"root_7_27\"},{\"name\":\"Kristin Myers\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fkristin-myers-115\",\"id\":\"root_7_28\"},{\"name\":\"Lisa Scherzer\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Flisa-scherzer\",\"id\":\"root_7_29\"},{\"name\":\"Lulu Chiang\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Flulu-chiang\",\"id\":\"root_7_30\"},{\"name\":\"Max Zahn\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fmax-zahn\",\"id\":\"root_7_31\"},{\"name\":\"Melody Hahm\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fmelody-hahm\",\"id\":\"root_7_32\"},{\"name\":\"Michael Kelley\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fmichael-b-kelley\\u002F\",\"id\":\"root_7_33\"},{\"name\":\"Myles Udland\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fmyles-udland\",\"id\":\"root_7_34\"},{\"name\":\"Nishant Mohan\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fnishant-mohan\",\"id\":\"root_7_35\"},{\"name\":\"Pras Subramanian\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fpras-subramanian\",\"id\":\"root_7_36\"},{\"name\":\"Reggie Wade\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Freggie-wade\",\"id\":\"root_7_37\"},{\"name\":\"Rick Newman\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Frick-newman\",\"id\":\"root_7_38\"},{\"name\":\"Sam Ro\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fsam-ro\",\"id\":\"root_7_39\"},{\"name\":\"Seana Smith\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fseana-smith\",\"id\":\"root_7_40\"},{\"name\":\"Sheila Bair\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fsheila-bair\",\"id\":\"root_7_41\"},{\"name\":\"Sibile Marcellus\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fsibile-marcellus\",\"id\":\"root_7_42\"},{\"name\":\"Zack Guzman\",\"url\":\"https:\\u002F\\u002Fwww.yahoo.com\\u002Fauthor\\u002Fzack-guzman\",\"id\":\"root_7_43\"}],\"id\":\"root_7\"},{\"name\":\"Personal Finance\",\"url\":\"https:\\u002F\\u002Fmoney.yahoo.com\",\"openInNewTab\":true,\"children\":[{\"name\":\"Home\",\"url\":\"https:\\u002F\\u002Fmoney.yahoo.com\",\"openInNewTab\":true,\"id\":\"root_8_1\"},{\"name\":\"Retirement\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftopic\\u002Fretirement\",\"id\":\"root_8_2\"},{\"name\":\"Taxes\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftopic\\u002Ftaxes\",\"id\":\"root_8_3\"},{\"name\":\"Articles & Tutorials\",\"url\":\"https:\\u002F\\u002Fwww.cashay.com\\u002F\",\"openInNewTab\":true,\"id\":\"root_8_4\"},{\"name\":\"Rates\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Frates\",\"children\":[],\"id\":\"root_8_5\"}],\"id\":\"root_8\"},{\"name\":\"Videos\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideos\\u002F\",\"children\":[{\"name\":\"All Videos\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fvideos\",\"id\":\"root_9_1\"},{\"name\":\"The First Trade\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fshow\\u002Ffirsttrade\",\"id\":\"root_9_2\"},{\"name\":\"On the Move\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fshow\\u002Fonthemove\",\"id\":\"root_9_3\"},{\"name\":\"YFi PM\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fshow\\u002Fyfi-pm\",\"id\":\"root_9_4\"},{\"name\":\"The Ticker\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fshow\\u002Ftheticker\",\"id\":\"root_9_5\"},{\"name\":\"The Final Round\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fshow\\u002Ffinalround\",\"id\":\"root_9_6\"},{\"name\":\"Influencers with Andy Serwer\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Flive\\u002Finfluencers\\u002F\",\"id\":\"root_9_7\"},{\"name\":\"Yahoo Finance Presents\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Flive\\u002Fyahoo-finance-presents\\u002F\",\"id\":\"root_9_8\"},{\"name\":\"ETF Report\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftopic\\u002Fetf-report\",\"id\":\"root_9_9\"},{\"name\":\"Davos\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Flive\\u002Fdavos\",\"id\":\"root_9_10\"},{\"name\":\"Berkshire Hathaway\",\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Fbrklivestream\",\"id\":\"root_9_11\"},{\"name\":\"Yahoo Finance All Markets Summit\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Flive\\u002Fallmarketssummit\",\"id\":\"root_9_12\"},{\"name\":\"Breakouts\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Flive\\u002Fbreakouts\",\"id\":\"root_9_13\"},{\"name\":\"My Three Cents\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Flive\\u002Fmy-three-cents\",\"id\":\"root_9_14\"},{\"name\":\"Events\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fshow\\u002Fevents\",\"id\":\"root_9_15\"},{\"name\":\"Women and Money\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftopic\\u002Fwomenandmoney\",\"id\":\"root_9_16\"}],\"id\":\"root_9\"},{\"name\":\"Industries\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Findustries\",\"children\":[{\"name\":\"Basic Materials\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_basic_materials\",\"id\":\"root_10_1\"},{\"name\":\"Communication Services\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_communication_services\",\"id\":\"root_10_2\"},{\"name\":\"Consumer Cyclical\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_consumer_cyclical\",\"id\":\"root_10_3\"},{\"name\":\"Consumer Defensive\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_consumer_defensive\",\"id\":\"root_10_4\"},{\"name\":\"Energy\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_energy\",\"id\":\"root_10_5\"},{\"name\":\"Financial Services\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_financial_services\",\"id\":\"root_10_6\"},{\"name\":\"Healthcare\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_healthcare\",\"id\":\"root_10_7\"},{\"name\":\"Industrials\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_industrials\",\"id\":\"root_10_8\"},{\"name\":\"Real Estate\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_real_estate\",\"id\":\"root_10_9\"},{\"name\":\"Technology\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_technology\",\"id\":\"root_10_10\"},{\"name\":\"Utilities\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Fsector\\u002Fms_utilities\",\"id\":\"root_10_11\"}],\"id\":\"root_10\"},{\"name\":\"Tech\",\"url\":\"https:\\u002F\\u002Ffinance.yahoo.com\\u002Ftech\",\"children\":[{\"name\":\"Reviews\",\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Ftech\\u002Freviews\",\"children\":[],\"id\":\"root_11_1\"},{\"name\":\"How To\",\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Ftech\\u002Fhow-to\",\"children\":[],\"id\":\"root_11_2\"},{\"name\":\"Games\",\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Ftech\\u002Fgames\",\"children\":[],\"id\":\"root_11_3\"},{\"name\":\"Video\",\"url\":\"http:\\u002F\\u002Ffinance.yahoo.com\\u002Ftech\\u002Fvideo\",\"children\":[],\"id\":\"root_11_4\"}],\"id\":\"root_11\"}]}},{\"warning\":\"Invalid namespace or brand, using default\",\"url\":\"https:\\u002F\\u002Fguce.yahoo.com\\u002Fmanage-selling-my-info?locale=en-US\",\"label\":\"Do not sell my info\",\"showDAAPrivacyRightsIcon\":true}]}},\"MarketTimeStore\":{\"data\":{\"mins\":null,\"hrs\":null,\"message\":\"U.S. Markets closed\"},\"metadata\":{\"status\":\"YFT_MARKET_CLOSED\",\"time\":\"2020-05-20T02:31:16Z\"}},\"ThemeStore\":{\"last_accessed_cache_key\":\"-1022282874\",\"data\":{\"-1022282874\":{\"uh\":{\"style\":{\"container\":{\"right_list\":\"End(20px) List(n) Pos(a) T(14px)\",\"wrapper_1\":\"Bdbs(s) Bdw(1px) Miw(1024px) End(0) Start(0) UH Z(10)\",\"wrapper_2\":\"Bdc($c-divider) Py(14px)\",\"wrapper_3\":\"T(0)\",\"wrapper_4\":\"T(22px)\",\"wrapper_5\":\"Pos(f)\",\"wrapper_6\":\"Pos(r)\",\"wrapper_7\":\"Bgc($bg-header)\",\"wrapper_8\":\"Panel-open_Bxsh(shadowOn)\"}},\"help\":{\"style\":{\"icon\":{\"settings\":{\"color\":\"#400090\",\"content\":\"D(n) Lh(2.6) Mstart(4px)\",\"wrapper\":\"D(ib)\"}}}},\"logo\":{\"style\":{\"cobrand\":{\"partner\":{},\"yahoo\":{},\"wrapper_1\":\"Bgr(nr) D(b) Fl(start) Mstart(10px)\"},\"container\":{\"inline\":{\"backgroundColor\":\"transparent\"},\"wrapper_1\":\"Fl(start) Fz(0) M(0) P(0)\",\"wrapper_2\":\"ie-7_W(190px) Miw(190px) UHMR1D_Py(0)\"},\"country_property\":{\"content_1\":\"Bgpx(0) Bgr(nr) Cur(p) D(b) H(35px)\",\"content_2\":\"Bgz(702px) Mx(a)! W(155px)\"},\"property\":{\"content_1\":\"Bgpx(0) Bgr(nr) Cur(p) D(b) H(35px)\",\"content_2\":\"Bgz(702px) Mx(a)! W(92px)\",\"image_1x\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fd\\u002Fyahoo_finance_en-US_s_f_pw_351x40_finance.png\",\"image_2x\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fd\\u002Fyahoo_finance_en-US_s_f_pw_351x40_finance_2x.png\"},\"yahoo\":{\"content_1\":\"Bgpx(0) Bgr(nr) Cur(p) D(b) H(35px) Mstart(20px)\",\"content_2\":\"Bgz(284px) Mx(a)! W(140px)\",\"image_1x\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fd\\u002Fyahoo_frontpage_en-US_s_f_pw_bestfit_frontpage.png\",\"image_2x\":\"https:\\u002F\\u002Fs.yimg.com\\u002Frz\\u002Fd\\u002Fyahoo_frontpage_en-US_s_f_pw_bestfit_frontpage_2x.png\"},\"template\":\"property\"}},\"mail\":{\"style\":{\"button\":{\"inline\":{},\"content_1\":\"Pos(r) D(ib) Ta(s) Td(n):h\",\"content_2\":\"\",\"icon_1\":\"#400090\",\"icon_2\":\"#400090\",\"text_1\":\"Lh(userNavTextLh) D(ib) C($c-fuji-purple-1-c) Fz(14px) Fw(b) Va(t) Mstart(6px)\",\"text_2\":\"Lh(userNavTextLh) D(ib) C($c-fuji-purple-1-c) Fz(14px) Fw(b) Va(t) Mstart(6px)\",\"wrapper\":\"D(ib) Mstart(14px) Mt(-1px) ua-ie8_Pb(10px) ua-ie9_Pb(10px)\"},\"mailcount\":{\"wrapper_1\":\"Bgc($c-fuji-red-1-a) Bdrs(11px) C(#fff) Start(18px) Fz(11px) Fw(b) Pos(a) Py(4px) Ta(c) T(-8px) W(22px)\"}}},\"notifications\":{\"style\":{\"button\":{\"icon\":\"#400090\",\"wrapper\":\"D(ib) Mstart(14px) Mt(-1px) ua-ie8_Pb(10px) ua-ie9_Pb(10px)\"},\"notificationsCount\":{\"wrapper_1\":\"Bgc($c-fuji-red-1-a) Bdrs(11px) C(#fff) Start(22px) Fz(11px) Fw(b) Pos(a) Lh(2) Ta(c) T(-10px) W(22px)\"}}},\"profile\":{\"style\":{\"account_info\":{\"alias\":\"C(textColor) Ell Maw(160px)\",\"content\":\"C(#0078ff) C(#0078ff):h C(#0078ff):v D(ib) Fz(13px) My(2px)\",\"name\":\"C(textColor) Ell Fw(b) Fz(13px) Maw(160px)\",\"wrapper\":\"P(16px)\"},\"avatar\":{\"content\":\"Lh(userNavTextLh) Bdrs(45%) Mt(-2px) Bgz(cv) C(signInBtn) Cur(p) D(ib) Fz(34px) H(34px) W(34px) ua-ie7_D(n)\",\"color\":\"#400090\",\"name\":\"Whs(nw) D(ib) Maw(100px) Ov(h) Mt(-1px) Tov(e) Lh(userNavTextLh) C($c-fuji-purple-1-c) Pstart(8px) Fz(14px) Fw(b) Va(t) ua-ie7_D(n)\",\"wrapper\":\"P(0) Bd(0) Pos(r) ua-ie8_Pb(10px) ua-ie9_Pb(10px)\",\"size\":34},\"container\":{\"wrapper\":\"Fl(start) H(34px) Mx(8px)\"},\"panel\":{\"wrapper\":\"Bdrs(4px) Bgc(menuBgc) Bxsh(customShadowFlyoutMenu) D(n) End(0) Pos(a) T(40px) Ta(start) uh-menu-open_D(b) W(280px)\"},\"button\":{\"inline\":{},\"content_1\":\"Bdrs(5px) Bds(s) Bdw(2px) C(#fff):h D(ib) Ell Fz(14px) Fw(b) Py(2px) Mt(3px) Ta(c) Td(n):h Miw(78px) H(18px)\",\"content_2\":\"Bdc(signInBtn) Bgc(signInBtn):h C(signInBtn)\",\"wrapper\":\"Fl(start) Mx(4px) Mend(9px)\"},\"signed_out\":{\"content\":\"C(textColor)\",\"wrapper\":\"Bdtc(#e1e1e5) Bdts(s) Bdtw(1px) Mx(16px) Py(16px) Ta(c)\"}}},\"search\":{\"style\":{\"cancel_button\":{\"content\":\"D(n)\"},\"container\":{\"content\":\"M(0) P(0) Whs(nw)\",\"wrapper\":\"D(ib) uh-max_Py(50px)\"},\"table\":{\"wrapper\":\"Bdsp(0) Bdcl(c) Maw(searchMaxWidth) Miw(searchMinWidth) W(searchWidth) ie-8_W(searchMinWidthLightWeight) ie-7_W(searchMinWidthLightWeight) ie-7_Miw(searchMinWidthLightWeight) ie-8_Miw(searchMinWidthLightWeight)\"},\"input\":{\"content\":\"Va(t)\"},\"search_button\":{\"inline_1\":{\"filter\":\"chroma(color=#000)\"},\"inline_2\":{},\"content_1\":\"Bdrs(4px) Bdtw(0) Bdw(1px) Bgr(rx) Mstart(5px) Bxz(cb) C(#fff) Ff(ss)! Fz(15px) two-btn_Fz(13px) Lh(32px)! Mend(0)! My(0)! Miw(92px) Px(14px) Py(0) Ta(c) Td(n) Va(t) Zoom\",\"content_2\":\"Bg(searchBtnBg) Bxsh(customShadowSearchButton)\"},\"magnifying_glass\":{\"color\":\"#000\"}}},\"topbar\":{\"style\":{\"nav_home\":{\"inline\":{\"boxShadow\":\"0 4px 7px rgba(0,0,0,.2)\",\"border\":\"0px 1px 1px 1px\",\"borderColor\":\"1px solid #d9d9d9\"},\"link\":{\"content\":\"C(#1d1da3)! D(b) Py(3px) Td(n) Td(u):h\"},\"content\":\"Bgc(#fff) C(#eee) List(n) My(.55em) Pos(r) Px(10px)!\",\"wrapper\":\"Bd(1px solid #d9d9d9) Bgc(#fff) D(b) Pos(a) Start(0) T(100%)\"},\"nav_main\":{\"link\":{\"content\":\"C(#fff) Td(n) Td(u):h\",\"wrapper\":\"D(ib) Lh(1.7) Mend(18px) Pstart(14px) Va(t) Zoom\"},\"link_home\":{\"icon\":{\"down_arrow\":{\"inline\":{\"cursor\":\"pointer\",\"marginLeft\":\"5px\",\"verticalAlign\":\"middle\"},\"color_1\":\"#fff\",\"color_2\":\"#1d1da3\"},\"home\":{\"inline\":{\"cursor\":\"pointer\",\"marginRight\":\"6px\",\"marginTop\":\"1px\",\"verticalAlign\":\"top\"},\"color_1\":\"#fff\",\"color_2\":\"#1d1da3\"}},\"content_1\":\"C(#fff) Td(n) Pos(r) Z(1) rapidnofollow\",\"content_2\":\"C(#1d1da3)!\",\"text\":\"Fw(400) Mstart(-1px) Td(u):h\",\"wrapper_1\":\"D(ib) Lh(1.7) Mend(18px) Pstart(10px) Va(t) Zoom\",\"wrapper_2\":\"Bgc(#fff)!\"},\"link_more\":{\"icon\":{\"down_arrow\":{\"inline\":{\"cursor\":\"pointer\",\"marginLeft\":\"5px\",\"verticalAlign\":\"middle\"},\"color_1\":\"#fff\",\"color_2\":\"#1d1da3\"}},\"content_1\":\"C(#fff) Pos(r) Td(n) Z(1) yucs-leavable rapidnofollow\",\"content_2\":\"C(#1d1da3)!\",\"text\":\"Td(u):h\",\"wrapper_1\":\"D(ib) Lh(1.7) Pend(6px) Pos(r) Pstart(10px) Va(t) Z(4) Zoom\",\"wrapper_2\":\"Bgc(#fff)!\"},\"content_1\":\"H(22px) Lh(1.7) M(0) NavLinks P(0) Whs(nw) Z(11)\",\"content_2\":\"Bgc(#2d1152)\",\"content_3\":\"Pos(a) Start(0) End(0)\",\"wrapper_1\":\"C(#fff) Fz(13px)\",\"wrapper_2\":\"H(22px)\"},\"nav_more\":{\"inline\":{\"boxShadow\":\"0 4px 7px rgba(0,0,0,.2)\",\"border\":\"0px 1px 1px 1px\",\"borderColor\":\"1px solid #d9d9d9\"},\"link\":{\"content\":\"C(#1d1da3)! D(b) Py(3px) Td(n) Td(u):h\"},\"content\":\"Bgc(#fff) C(#eee) Pos(r) Px(10px)! List(n) My(.55em)\",\"wrapper\":\"Bgc(#fff) Bd(1px solid #d9d9d9) D(b) Pos(a) Start(0) T(100%)\"}}}}}}},\"UHAccountSwitchStore\":{\"site\":\"finance\",\"crumb\":\"30wdiPOI.Es\",\"sendRequest\":false,\"isEnabled\":true},\"NavStore\":{\"data\":{\"items\":[]}},\"MarketSummaryStore\":{\"data\":[{\"symbol\":\"ES=F\",\"name\":\"S&P Futures\"},{\"symbol\":\"YM=F\",\"name\":\"Dow Futures\"},{\"symbol\":\"NQ=F\",\"name\":\"Nasdaq Futures\"},{\"symbol\":\"RTY=F\",\"name\":\"Russell 2000 Futures\"},{\"symbol\":\"CL=F\",\"name\":\"Crude Oil\"},{\"symbol\":\"GC=F\",\"name\":\"Gold\"},{\"symbol\":\"SI=F\",\"name\":\"Silver\"},{\"symbol\":\"EURUSD=X\",\"name\":\"EUR\\u002FUSD\"},{\"symbol\":\"^TNX\",\"name\":\"10-Yr Bond\"},{\"symbol\":\"^VIX\",\"name\":\"Vix\"},{\"symbol\":\"GBPUSD=X\",\"name\":\"GBP\\u002FUSD\"},{\"symbol\":\"BTC-USD\"},{\"symbol\":\"^CMC200\",\"name\":\"CMC Crypto 200\"},{\"symbol\":\"^FTSE\",\"name\":\"FTSE 100\"},{\"symbol\":\"^N225\",\"name\":\"Nikkei 225\"}]},\"StreamDataStore\":{\"quoteData\":{\"^TNX\":{\"sourceInterval\":30,\"exchange\":\"NYB\",\"regularMarketTime\":{\"raw\":1589914794,\"fmt\":\"2:59PM EDT\"},\"shortName\":\"10-Yr Bond\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":-0.032999992,\"fmt\":\"-0.0330\"},\"regularMarketPreviousClose\":{\"raw\":0.744,\"fmt\":\"0.7440\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":30,\"priceHint\":4,\"regularMarketPrice\":{\"raw\":0.711,\"fmt\":\"0.7110\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"INDEX\",\"symbol\":\"^TNX\",\"language\":\"en-US\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":-4.4354825,\"fmt\":\"-4.44%\"},\"fullExchangeName\":\"NYBOT\",\"tradeable\":false},\"RTY=F\":{\"sourceInterval\":10,\"exchange\":\"CME\",\"regularMarketTime\":{\"raw\":1589941273,\"fmt\":\"10:21PM EDT\"},\"shortName\":\"Russell 2000 Futures\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":14.300049,\"fmt\":\"14.30\"},\"regularMarketPreviousClose\":{\"raw\":1307.5,\"fmt\":\"1,307.50\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":10,\"regularMarketPrice\":{\"raw\":1321.8,\"fmt\":\"1,321.80\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"FUTURE\",\"symbol\":\"RTY=F\",\"language\":\"en-US\",\"headSymbolAsString\":\"RTY=F\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":1.093694,\"fmt\":\"1.09%\"},\"fullExchangeName\":\"CME\",\"tradeable\":false},\"^N225\":{\"sourceInterval\":20,\"exchange\":\"OSA\",\"regularMarketTime\":{\"raw\":1589940670,\"fmt\":\"11:11AM JST\"},\"shortName\":\"Nikkei 225\",\"exchangeTimezoneName\":\"Asia\\u002FTokyo\",\"regularMarketChange\":{\"raw\":166.56055,\"fmt\":\"166.56\"},\"regularMarketPreviousClose\":{\"raw\":20433.45,\"fmt\":\"20,433.45\"},\"exchangeTimezoneShortName\":\"JST\",\"exchangeDataDelayedBy\":0,\"priceHint\":2,\"regularMarketPrice\":{\"raw\":20600.01,\"fmt\":\"20,600.01\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":32400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"INDEX\",\"symbol\":\"^N225\",\"language\":\"en-US\",\"market\":\"jp_market\",\"regularMarketChangePercent\":{\"raw\":0.81513673,\"fmt\":\"0.82%\"},\"fullExchangeName\":\"Osaka\",\"tradeable\":false},\"GC=F\":{\"sourceInterval\":15,\"exchange\":\"CMX\",\"regularMarketTime\":{\"raw\":1589941273,\"fmt\":\"10:21PM EDT\"},\"shortName\":\"Gold\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":8.599976,\"fmt\":\"8.60\"},\"regularMarketPreviousClose\":{\"raw\":1745.6,\"fmt\":\"1,745.60\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":30,\"regularMarketPrice\":{\"raw\":1754.2,\"fmt\":\"1,754.20\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"FUTURE\",\"symbol\":\"GC=F\",\"language\":\"en-US\",\"headSymbolAsString\":\"GC=F\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":0.4926659,\"fmt\":\"0.49%\"},\"fullExchangeName\":\"COMEX\",\"tradeable\":false},\"^VIX\":{\"sourceInterval\":15,\"exchange\":\"WCB\",\"regularMarketTime\":{\"raw\":1589919292,\"fmt\":\"4:14PM EDT\"},\"shortName\":\"Vix\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":1.2300014,\"fmt\":\"1.23\"},\"regularMarketPreviousClose\":{\"raw\":29.3,\"fmt\":\"29.30\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":20,\"priceHint\":2,\"regularMarketPrice\":{\"raw\":30.53,\"fmt\":\"30.53\"},\"triggerable\":true,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"POSTPOST\",\"quoteType\":\"INDEX\",\"symbol\":\"^VIX\",\"language\":\"en-US\",\"market\":\"us_market\",\"regularMarketChangePercent\":{\"raw\":4.197957,\"fmt\":\"4.20%\"},\"fullExchangeName\":\"Chicago Options\",\"tradeable\":false},\"BTC-USD\":{\"sourceInterval\":15,\"quoteSourceName\":\"CryptoCurrency\",\"exchange\":\"CCC\",\"regularMarketTime\":{\"raw\":1589941770,\"fmt\":\"3:29AM BST\"},\"exchangeTimezoneName\":\"Europe\\u002FLondon\",\"regularMarketChange\":{\"raw\":12.62207,\"fmt\":\"12.62\"},\"regularMarketPreviousClose\":{\"raw\":9722.794,\"fmt\":\"9,722.79\"},\"exchangeTimezoneShortName\":\"BST\",\"exchangeDataDelayedBy\":0,\"regularMarketPrice\":{\"raw\":9735.416,\"fmt\":\"9,735.42\"},\"triggerable\":true,\"gmtOffSetMilliseconds\":3600000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"CRYPTOCURRENCY\",\"symbol\":\"BTC-USD\",\"language\":\"en-US\",\"market\":\"ccc_market\",\"regularMarketChangePercent\":{\"raw\":0.12981936,\"fmt\":\"0.13%\"},\"fullExchangeName\":\"CCC\",\"tradeable\":false},\"NQ=F\":{\"sourceInterval\":10,\"exchange\":\"CME\",\"regularMarketTime\":{\"raw\":1589941273,\"fmt\":\"10:21PM EDT\"},\"shortName\":\"Nasdaq Futures\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":45,\"fmt\":\"45.00\"},\"regularMarketPreviousClose\":{\"raw\":9300.75,\"fmt\":\"9,300.75\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":10,\"regularMarketPrice\":{\"raw\":9345.75,\"fmt\":\"9,345.75\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"FUTURE\",\"symbol\":\"NQ=F\",\"language\":\"en-US\",\"headSymbolAsString\":\"NQ=F\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":0.48383194,\"fmt\":\"0.48%\"},\"fullExchangeName\":\"CME\",\"tradeable\":false},\"GBPUSD=X\":{\"sourceInterval\":15,\"exchange\":\"CCY\",\"regularMarketTime\":{\"raw\":1589941865,\"fmt\":\"3:31AM BST\"},\"shortName\":\"GBP\\u002FUSD\",\"exchangeTimezoneName\":\"Europe\\u002FLondon\",\"regularMarketChange\":{\"raw\":0.0016368628,\"fmt\":\"0.0016\"},\"regularMarketPreviousClose\":{\"raw\":1.2246197,\"fmt\":\"1.2246\"},\"exchangeTimezoneShortName\":\"BST\",\"exchangeDataDelayedBy\":0,\"priceHint\":4,\"currency\":\"USD\",\"regularMarketPrice\":{\"raw\":1.2262566,\"fmt\":\"1.2263\"},\"triggerable\":true,\"gmtOffSetMilliseconds\":3600000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"CURRENCY\",\"symbol\":\"GBPUSD=X\",\"language\":\"en-US\",\"market\":\"ccy_market\",\"regularMarketChangePercent\":{\"raw\":0.13366078,\"fmt\":\"0.1337%\"},\"fullExchangeName\":\"CCY\",\"tradeable\":false},\"CL=F\":{\"sourceInterval\":30,\"exchange\":\"NYM\",\"regularMarketTime\":{\"raw\":1589912995,\"fmt\":\"2:29PM EDT\"},\"shortName\":\"Crude Oil\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":-0.13999939,\"fmt\":\"-0.14\"},\"regularMarketPreviousClose\":{\"raw\":32.5,\"fmt\":\"32.50\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":30,\"regularMarketPrice\":{\"raw\":32.36,\"fmt\":\"32.36\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"FUTURE\",\"symbol\":\"CL=F\",\"language\":\"en-US\",\"headSymbolAsString\":\"CL=F\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":-0.43076736,\"fmt\":\"-0.43%\"},\"fullExchangeName\":\"NY Mercantile\",\"tradeable\":false},\"ES=F\":{\"sourceInterval\":10,\"exchange\":\"CME\",\"regularMarketTime\":{\"raw\":1589941273,\"fmt\":\"10:21PM EDT\"},\"shortName\":\"S&P Futures\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":16.75,\"fmt\":\"16.75\"},\"regularMarketPreviousClose\":{\"raw\":2918.75,\"fmt\":\"2,918.75\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":10,\"regularMarketPrice\":{\"raw\":2935.5,\"fmt\":\"2,935.50\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"FUTURE\",\"symbol\":\"ES=F\",\"language\":\"en-US\",\"headSymbolAsString\":\"ES=F\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":0.5738758,\"fmt\":\"0.57%\"},\"fullExchangeName\":\"CME\",\"tradeable\":false},\"^CMC200\":{\"sourceInterval\":15,\"exchange\":\"NIM\",\"regularMarketTime\":{\"raw\":1589941849,\"fmt\":\"10:30PM EDT\"},\"shortName\":\"CMC Crypto 200\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":3.3750916,\"fmt\":\"3.38\"},\"regularMarketPreviousClose\":{\"raw\":191.147,\"fmt\":\"191.15\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":0,\"priceHint\":2,\"regularMarketPrice\":{\"raw\":194.5221,\"fmt\":\"194.52\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"POSTPOST\",\"quoteType\":\"INDEX\",\"symbol\":\"^CMC200\",\"language\":\"en-US\",\"market\":\"us_market\",\"regularMarketChangePercent\":{\"raw\":1.7657046,\"fmt\":\"1.77%\"},\"fullExchangeName\":\"Nasdaq GIDS\",\"tradeable\":false},\"YM=F\":{\"sourceInterval\":10,\"exchange\":\"CBT\",\"regularMarketTime\":{\"raw\":1589941273,\"fmt\":\"10:21PM EDT\"},\"shortName\":\"Dow Futures\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":161,\"fmt\":\"161.00\"},\"regularMarketPreviousClose\":{\"raw\":24158,\"fmt\":\"24,158.00\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":10,\"regularMarketPrice\":{\"raw\":24319,\"fmt\":\"24,319.00\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"FUTURE\",\"symbol\":\"YM=F\",\"language\":\"en-US\",\"headSymbolAsString\":\"YM=F\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":0.6664459,\"fmt\":\"0.67%\"},\"fullExchangeName\":\"CBOT\",\"tradeable\":false},\"^FTSE\":{\"sourceInterval\":15,\"exchange\":\"FGI\",\"regularMarketTime\":{\"raw\":1589902530,\"fmt\":\"4:35PM BST\"},\"shortName\":\"FTSE 100\",\"exchangeTimezoneName\":\"Europe\\u002FLondon\",\"regularMarketChange\":{\"raw\":-46.359863,\"fmt\":\"-46.36\"},\"regularMarketPreviousClose\":{\"raw\":6048.59,\"fmt\":\"6,048.59\"},\"exchangeTimezoneShortName\":\"BST\",\"exchangeDataDelayedBy\":15,\"priceHint\":2,\"regularMarketPrice\":{\"raw\":6002.23,\"fmt\":\"6,002.23\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":3600000,\"region\":\"US\",\"marketState\":\"PREPRE\",\"quoteType\":\"INDEX\",\"symbol\":\"^FTSE\",\"language\":\"en-US\",\"market\":\"gb_market\",\"regularMarketChangePercent\":{\"raw\":-0.7664574,\"fmt\":\"-0.77%\"},\"fullExchangeName\":\"FTSE Index\",\"tradeable\":false},\"SI=F\":{\"sourceInterval\":15,\"exchange\":\"CMX\",\"regularMarketTime\":{\"raw\":1589941257,\"fmt\":\"10:20PM EDT\"},\"shortName\":\"Silver\",\"exchangeTimezoneName\":\"America\\u002FNew_York\",\"regularMarketChange\":{\"raw\":0.16900063,\"fmt\":\"0.17\"},\"regularMarketPreviousClose\":{\"raw\":17.901,\"fmt\":\"17.90\"},\"exchangeTimezoneShortName\":\"EDT\",\"exchangeDataDelayedBy\":30,\"regularMarketPrice\":{\"raw\":18.07,\"fmt\":\"18.07\"},\"triggerable\":false,\"gmtOffSetMilliseconds\":-14400000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"FUTURE\",\"symbol\":\"SI=F\",\"language\":\"en-US\",\"headSymbolAsString\":\"SI=F\",\"market\":\"us24_market\",\"regularMarketChangePercent\":{\"raw\":0.9440849,\"fmt\":\"0.94%\"},\"fullExchangeName\":\"COMEX\",\"tradeable\":false},\"EURUSD=X\":{\"sourceInterval\":15,\"exchange\":\"CCY\",\"regularMarketTime\":{\"raw\":1589941865,\"fmt\":\"3:31AM BST\"},\"shortName\":\"EUR\\u002FUSD\",\"exchangeTimezoneName\":\"Europe\\u002FLondon\",\"regularMarketChange\":{\"raw\":0.0015538931,\"fmt\":\"0.0016\"},\"regularMarketPreviousClose\":{\"raw\":1.092538,\"fmt\":\"1.0925\"},\"exchangeTimezoneShortName\":\"BST\",\"exchangeDataDelayedBy\":0,\"priceHint\":4,\"currency\":\"USD\",\"regularMarketPrice\":{\"raw\":1.0940919,\"fmt\":\"1.0941\"},\"triggerable\":true,\"gmtOffSetMilliseconds\":3600000,\"region\":\"US\",\"marketState\":\"REGULAR\",\"quoteType\":\"CURRENCY\",\"symbol\":\"EURUSD=X\",\"language\":\"en-US\",\"market\":\"ccy_market\",\"regularMarketChangePercent\":{\"raw\":0.142236,\"fmt\":\"0.1422%\"},\"fullExchangeName\":\"CCY\",\"tradeable\":false}},\"mktmData\":{}},\"MobileHeaderStore\":{\"navTitle\":\"finance\",\"useNavTitle\":false}}},\"options\":{\"optimizePromiseCallback\":true},\"plugins\":{\"BeaconPlugin\":{\"appName\":\"td-app-yahoo\",\"appVersion\":\"2.0.26426025\"},\"BundlePlugin\":{\"loadedBundles\":[\"yahoodotcom-layout.RC5TwoColumnLayout\",\"react-finance.y20\",\"tdv2-applet-navrail\",\"react-lightbox\",\"tdv2-applet-featurebar\",\"td-ads\",\"tdv2-applet-slideshow\",\"tdv2-applet-content-canvas\",\"tdv2-applet-canvass\",\"tdv2-service-profile\",\"tdv2-applet-livecoverage\",\"tdv2-applet-video-modal\",\"react-share-buttons\",\"tdv2-applet-swisschamp\",\"tdv2-applet-stream\",\"tdv2-applet-userintent\",\"tdv2-applet-footer\",\"tdv2-service-ccpa\",\"tdv2-applet-uh\",\"tdv2-applet-account-switch\",\"tdv2-applet-search-input\",\"td-app-yahoo\"],\"meta\":{\"react-sports.nav\":{\"langBundle\":\"react-sports\"},\"react-sports.y20\":{\"langBundle\":\"react-sports\"},\"react-weather.simple\":{\"langBundle\":\"react-weather\"},\"tdv2-applet-abu-news.abunews\":{\"langBundle\":\"tdv2-applet-abu-news\"},\"tdv2-applet-abu-news.y20\":{\"langBundle\":\"tdv2-applet-abu-news\"},\"tdv2-applet-account-switch\":{\"dependencies\":[\"tdv2-applet-userintent\",\"tdv2-service-profile\"]},\"tdv2-applet-canvass\":{\"dependencies\":[\"tdv2-service-profile\"]},\"tdv2-applet-content-canvas.CanvasStickyShareButtons\":{\"dependencies\":[\"tdv2-applet-canvass\",\"tdv2-applet-follow\",\"react-share-buttons\"],\"langBundle\":\"tdv2-applet-content-canvas\"},\"tdv2-applet-content-canvas.CommunityBar\":{\"dependencies\":[\"tdv2-applet-canvass\",\"tdv2-applet-swisschamp.FunctionButtons\"],\"langBundle\":\"tdv2-applet-content-canvas\"},\"tdv2-applet-content-canvas\":{\"dependencies\":[\"tdv2-applet-canvass\",\"tdv2-applet-livecoverage\",\"tdv2-applet-slideshow\",\"tdv2-applet-video-modal\",\"react-share-buttons\"],\"langBundle\":\"tdv2-applet-content-canvas\"},\"tdv2-applet-content-canvas.vibe\":{\"dependencies\":[\"tdv2-applet-canvass\",\"react-share-buttons\"],\"langBundle\":\"tdv2-applet-content-canvas\"},\"tdv2-applet-footer\":{\"dependencies\":[\"tdv2-service-ccpa\"]},\"tdv2-applet-header\":{\"langBundle\":\"tdv2-applet-header\"},\"tdv2-applet-header.news\":{\"langBundle\":\"tdv2-applet-header\"},\"tdv2-applet-header.sports\":{\"langBundle\":\"tdv2-applet-header\"},\"tdv2-applet-sponsored-moments.streamSponsoredMoments\":{\"langBundle\":\"tdv2-applet-sponsored-moments\"},\"tdv2-applet-sports-media\":{\"dependencies\":[\"tdv2-applet-footer\"]},\"tdv2-applet-sports-scores.y20\":{\"langBundle\":\"tdv2-applet-sports-scores\"},\"tdv2-applet-stream\":{\"dependencies\":[\"react-share-buttons\",\"tdv2-applet-userintent\",\"tdv2-applet-video-modal\"]},\"tdv2-applet-stream.tiles\":{\"dependencies\":[\"react-tumblr-tile\"],\"langBundle\":\"tdv2-applet-stream\"},\"tdv2-applet-stream-hero.carousel\":{\"dependencies\":[\"td-ads\",\"tdv2-applet-video-modal\"],\"langBundle\":\"tdv2-applet-stream-hero\"},\"tdv2-applet-stream-hero\":{\"dependencies\":[\"td-ads\",\"tdv2-applet-video-modal\"]},\"tdv2-applet-stream-hero.featuredhero\":{\"dependencies\":[\"td-ads\",\"tdv2-applet-video-modal\"],\"langBundle\":\"tdv2-applet-stream-hero\"},\"tdv2-applet-stream-hero.widehero\":{\"dependencies\":[\"td-ads\",\"tdv2-applet-video-modal\"],\"langBundle\":\"tdv2-applet-stream-hero\"},\"tdv2-applet-swisschamp.SidekickWrapper\":{\"dependencies\":[\"react-adblock-promo\"]},\"tdv2-applet-uh\":{\"dependencies\":[\"tdv2-applet-account-switch\",\"tdv2-applet-search-input\",\"tdv2-service-profile\"]},\"tdv2-applet-uh.smartphone\":{\"dependencies\":[\"tdv2-applet-account-switch\",\"tdv2-applet-search-input\",\"tdv2-service-profile\"]},\"tdv2-applet-uh.tablet\":{\"dependencies\":[\"tdv2-applet-account-switch\",\"tdv2-applet-search-input\",\"tdv2-service-profile\"]},\"tdv2-wafer-header\":{\"dependencies\":[\"tdv2-service-profile\"]},\"tdv2-wafer-header.finance\":{\"dependencies\":[\"tdv2-service-profile\"]}},\"reqContext\":{\"authed\":\"0\",\"ynet\":\"0\",\"ssl\":\"1\",\"spdy\":\"0\",\"ytee\":\"0\",\"mode\":\"normal\",\"site\":\"finance\",\"region\":\"US\",\"lang\":\"en-US\",\"bucket\":\"finance-US-en-US-def\",\"colo\":\"gq1\",\"device\":\"featurephone\",\"bot\":\"1\",\"ecma\":\"default\",\"environment\":\"prod\",\"intl\":\"us\",\"partner\":\"none\",\"tz\":\"America\\u002FLos_Angeles\",\"feature\":[\"enableCMP\",\"enableConsentData\",\"enableCCPAFooter\",\"enableGDPRFooter\",\"enableGuceJs\",\"enableGuceJsOverlay\",\"videoDocking\",\"newContentAttribution\",\"newLogo\",\"livecoverage\"],\"nps\":{}},\"loadChildBundles\":true,\"loadStaticBundles\":true,\"loadedBundlesByParentInstanceId\":{\"UH-0-UH\":{\"react-finance.y20\":true,\"tdv2-applet-uh\":true,\"tdv2-applet-account-switch\":true},\"UH-1-DesktopNav\":{\"tdv2-applet-navrail\":true,\"tdv2-applet-account-switch\":true},\"Overlay-0-Lightbox\":{\"react-lightbox\":true},\"Hero-0-FinanceHeader\":{\"react-finance.y20\":true},\"Hero-1-FeatureBar\":{\"tdv2-applet-featurebar\":true},\"Hero-2-Ad\":{\"td-ads\":true},\"Hero-3-Ad\":{\"td-ads\":true},\"Hero-4-HeroSlideshow\":{\"tdv2-applet-slideshow\":true},\"Hero-5-HeadComponentVideo\":{\"tdv2-applet-content-canvas\":true},\"Lead-0-CommonSlotComposite\":{\"tdv2-applet-content-canvas\":true},\"SideTop-0-HeadComponentTitle\":{\"tdv2-applet-content-canvas\":true},\"SideTop-1-HeadComponentAttribution\":{\"tdv2-applet-content-canvas\":true},\"Side-0-CanvasShareButtons\":{\"tdv2-applet-content-canvas\":true},\"Side-1-CommonSlotComposite\":{\"tdv2-applet-content-canvas\":true},\"Side-2-Empty\":{\"tdv2-applet-swisschamp\":true},\"Col1-0-ContentCanvas\":{\"tdv2-applet-content-canvas\":true},\"Col1-1-ContentIFrame\":{\"react-finance.y20\":true},\"Col1-2-CanvasShareButtons\":{\"tdv2-applet-content-canvas\":true},\"Col1-3-CanvassComments\":{\"tdv2-applet-content-canvas\":true},\"Col1-4-Ad\":{\"td-ads\":true},\"Col1-5-Ad\":{\"td-ads\":true},\"Col2-0-SymbolLookup\":{\"react-finance.y20\":true},\"Col2-1-RecentQuotes\":{\"react-finance.y20\":true},\"Col2-2-Ad\":{\"td-ads\":true},\"Col2-3-Ad\":{\"td-ads\":true},\"Col2-4-CommonSlotComposite\":{\"tdv2-applet-content-canvas\":true},\"Col2-5-HeightContainer\":{\"tdv2-applet-swisschamp\":true,\"tdv2-applet-stream\":true},\"Col2-6-Ad\":{\"td-ads\":true},\"Bottom-0-Ad\":{\"td-ads\":true},\"YDC-Stream\":{\"tdv2-applet-stream\":true},\"Col2Ext-0-Stream\":{\"tdv2-applet-stream\":true},\"Col2Ext-1-Ad\":{\"td-ads\":true},\"Col2Ext-2-Stream\":{\"tdv2-applet-stream\":true},\"Col2Ext-3-Ad\":{\"td-ads\":true},\"Col2Ext-4-Ad\":{\"td-ads\":true},\"Col2Ext-5-Footer\":{\"tdv2-applet-footer\":true},\"Col2-5-HeightContainer-0-Stream\":{\"tdv2-applet-stream\":true}}},\"DaggrPlugin\":{\"daggr\":{\"requests\":{\"StreamService:ab0439a645b9a6d3849326e9578b0201\":{\"resource\":\"StreamService\",\"id\":\"StreamService:ab0439a645b9a6d3849326e9578b0201\",\"error\":null,\"requesters\":[{\"id\":\"Col2Ext-0-Stream\",\"dataKey\":\"streamItems\"},{\"id\":\"Col2Ext-2-Stream\",\"dataKey\":\"streamItems\"}]},\"StreamService:55999f1b114b8f513321aa9d9e89de0b\":{\"resource\":\"StreamService\",\"id\":\"StreamService:55999f1b114b8f513321aa9d9e89de0b\",\"error\":null,\"requesters\":[{\"id\":\"Col2-5-HeightContainer-0-Stream\",\"dataKey\":\"streamItems\"}]}}}},\"DevToolsPlugin\":{\"actionHistory\":[],\"enableDebug\":false},\"FetchrPlugin\":{\"xhrContext\":{\"feature\":\"enableCMP,enableConsentData,enableCCPAFooter,enableGDPRFooter,enableGuceJs,enableGuceJsOverlay,videoDocking,newContentAttribution,newLogo,livecoverage\",\"bkt\":\"finance-US-en-US-def\",\"crumb\":\"jZvJfIOZpXE\",\"device\":\"featurephone\",\"intl\":\"us\",\"lang\":\"en-US\",\"partner\":\"none\",\"prid\":\"d1fpqmlfc95jj\",\"region\":\"US\",\"site\":\"finance\",\"tz\":\"America\\u002FLos_Angeles\",\"ver\":\"2.0.26426025\",\"ecma\":\"default\"},\"xhrPath\":\"\\u002F_td\\u002Fapi\\u002Fresource\",\"xhrTimeout\":3000,\"corsPath\":null},\"LoggerPlugin\":{\"logLevel\":3},\"RouterPlugin\":{\"appLevelEnable\":true},\"SessionPlugin\":{\"bucketLogString\":\"finance-US-en-US-def\",\"bucketMetaData\":{},\"dabState\":\"\",\"dimensions\":{\"authed\":\"0\",\"ynet\":\"0\",\"ssl\":\"1\",\"spdy\":\"0\",\"ytee\":\"0\",\"mode\":\"normal\",\"site\":\"finance\",\"region\":\"US\",\"lang\":\"en-US\",\"bucket\":\"finance-US-en-US-def\",\"colo\":\"gq1\",\"device\":\"featurephone\",\"bot\":\"1\",\"ecma\":\"default\",\"environment\":\"prod\",\"intl\":\"us\",\"partner\":\"none\",\"tz\":\"America\\u002FLos_Angeles\",\"feature\":[\"enableCMP\",\"enableConsentData\",\"enableCCPAFooter\",\"enableGDPRFooter\",\"enableGuceJs\",\"enableGuceJsOverlay\",\"videoDocking\",\"newContentAttribution\",\"newLogo\",\"livecoverage\"],\"nps\":{}},\"enableSpdyAssetUrls\":true,\"enableSpdyAssetUrlsFlag\":true,\"experimentIds\":{},\"host\":\"finance.yahoo.com\",\"isBot\":true,\"isCorpUser\":false,\"isDevInfo\":false,\"isYnet\":false,\"pathPrefix\":\"\\u002F_td\",\"protocol\":\"https\",\"query\":{\"m_mode\":\"multipart\",\"_cachedInstances\":\"UH-0-UH\",\"_appName\":\"td-app-yahoo\",\"_appVer\":\"2.0.26426025\",\"_esiAuthed\":\"0\",\"_esiBucket\":\"finance-US-en-US-def\",\"_esiInclude\":\"1\",\"_esiRid\":\"d1fpqmlfc95jj\"},\"rid\":\"d1fpqmlfc95jj\",\"woe\":{\"woeid_country\":\"23424977\",\"country\":\"US\",\"confidence_country\":\"100\",\"woeid_state\":\"2347563\",\"state\":\"CA\",\"confidence_state\":\"100\",\"zip_woeid\":\"12797284\"},\"sampleIds\":{},\"spdyPathPrefix\":\"https:\\u002F\\u002Fmbp.yimg.com\\u002Fsy\",\"userAgent\":{\"browserName\":\"\",\"browserVersion\":\"\",\"osName\":\"\",\"osVersion\":\"\"}},\"GucePlugin\":{\"ccpaData\":{\"warning\":\"Invalid locale, using default\",\"url\":\"https:\\u002F\\u002Fguce.yahoo.com\\u002Fmanage-selling-my-info?locale=en-US\",\"label\":\"Do not sell my info\",\"showDAAPrivacyRightsIcon\":true,\"daaPrivacyRightsIconUrl\":\"https:\\u002F\\u002Fs.yimg.com\\u002Fcv\\u002Fapiv2\\u002Fdefault\\u002F20200109\\u002FPrivacy_Rights_icon.png\"}},\"UserPlugin\":{\"user\":{\"crumb\":\"jZvJfIOZpXE\",\"firstName\":null}}}},\"plugins\":{\"BundlePlugin\":{\"mainBundle\":\"td-app-yahoo\"},\"ResourcePlugin\":{\"registry\":{\"configs\":{\"td-app-yahoo\":{\"ads\":1,\"app\":1,\"assets\":1,\"dimensions\":1,\"feature\":1,\"feedback\":1,\"i13n\":1,\"moduleBlacklist\":1,\"prefetch\":1,\"rss\":1,\"sections\":1},\"react-avatar\":{\"defaultColors\":1},\"react-finance\":{\"app\":1,\"atomize\":1,\"componentFooter\":1,\"componentNavHelper\":1,\"componentNotificationAlert\":1,\"componentSignInBtn\":1,\"componentUH\":1,\"cookies\":1,\"defaultViews\":1,\"i13n\":1,\"industries\":1,\"listConfig\":1,\"styles\\u002Fbtn\":1,\"styles\\u002Fcommon\":1,\"styles\\u002Fdropbox\":1,\"styles\\u002Finput\":1,\"styles\\u002FreactAutoCompleteResults\":1,\"styles\\u002Ftable\":1},\"react-sports\":{\"atomic-classsets\":1,\"boxscoreLeagues\":1,\"componentAdBlockPromo\":1,\"componentBigBoard\":1,\"componentBoxscore\":1,\"componentCDSPromoImage\":1,\"componentDraft\":1,\"componentDraftProspects\":1,\"componentDraftResults\":1,\"componentEventStatus\":1,\"componentFantasy\":1,\"componentFreeAgency\":1,\"componentGolfTours\":1,\"componentGraphStats\":1,\"componentInterstitial\":1,\"componentIntlLogin\":1,\"componentLeaderboard\":1,\"componentLeagueCompetitors\":1,\"componentLeagueInjuriesTransactions\":1,\"componentLeaguePlayers\":1,\"componentLeagueSchedule\":1,\"componentLeagueStandings\":1,\"componentLeagueTeams\":1,\"componentLeagueTracks\":1,\"componentMatchHeader\":1,\"componentMobileNavSports\":1,\"componentMotorsportsSchedule\":1,\"componentNavrailTeams\":1,\"componentOdds\":1,\"componentPlayer\":1,\"componentPromo\":1,\"componentRaceLeaderboard\":1,\"componentSalaryManagerTables\":1,\"componentScoreboard\":1,\"componentSeatgeekTickets\":1,\"componentSportsUH\":1,\"componentSportsbookPromo\":1,\"componentStats\":1,\"componentTeam\":1,\"componentTennisBoxscore\":1,\"componentTennisSchedule\":1,\"componentTennisTournaments\":1,\"graphStats\":1,\"injuryStatusMapping\":1,\"intlFormats\":1,\"onThisDay\":1,\"positionGroups\":1,\"pushNotifications\":1,\"seasonStatLeaders\":1,\"soccerFormations\":1,\"sortableStatsConfig\":1,\"sportsSearchConfig\":1,\"sportsbookConfig\":1},\"react-sports-utils\":{\"placeholderImages\":1},\"react-tile\":{\"config\":1},\"react-video\":{\"ve-module\":1,\"video-reel\":1},\"react-weather\":{\"componentWeather\":1,\"componentWeatherAppPromote\":1,\"componentWeatherChannelPromote\":1,\"componentWeatherStaticList\":1},\"td-service-canvas\":{\"config\":1},\"td-service-canvass\":{\"api\":1},\"td-service-location\":{\"config\":1},\"td-stores-location\":{\"config\":1},\"td-stores-sports\":{\"resources\":1,\"statcloud\\u002Fnormalize-schema-statcloud\":1,\"statcloud\\u002Fstatcloud\":1,\"sierra\\u002Fnormalize-schema-sierra\":1,\"sierra\\u002Fsierra\":1,\"olympics\\u002Folympics\":1,\"graphite\\u002Fgraphite\":1,\"fantasy\\u002Ffantasy\":1,\"dailyfantasy\\u002Fdailyfantasy\":1,\"dailyfantasy\\u002Fnormalize-schema-dailyfantasy\":1},\"tdv2-applet-abu-chatbox\":{\"common\":1,\"componentChatBox\":1,\"componentCheckIn\":1,\"componentEndorseBanner\":1},\"tdv2-applet-abu-footer\":{\"FooterEnum\":1},\"tdv2-applet-abu-news\":{\"componentAbuBreakingNews\":1,\"componentAbuFirebaseFCM\":1,\"componentAbuUhTags\":1,\"componentAuthorContentList\":1,\"componentBanner\":1,\"componentBlogAuthorProfile\":1,\"componentHeadlines\":1,\"componentHeadlinesStream\":1,\"componentHero\":1,\"componentMagazine\":1,\"componentMostPopular\":1,\"componentRelatedContent\":1,\"componentSpecialColumn\":1,\"componentStreamAds\":1,\"componentTags\":1,\"componentViewAlsoView\":1,\"constants\":1,\"pages\":1,\"routes\":1,\"timezone\":1},\"tdv2-applet-abu-search\":{\"componentSearch\":1},\"tdv2-applet-account-switch\":{\"componentAccountSwitch\":1,\"i13n\":1},\"tdv2-applet-apac-membership\":{\"componentChallengesList\":1,\"componentSeasons\":1},\"tdv2-applet-apac-web-components\":{\"componentSeasons\":1},\"tdv2-applet-bubble\":{\"componentBubble\":1,\"componentTextPromo\":1},\"tdv2-applet-canvass\":{\"app\":1,\"atomize\":1,\"componentComments\":1},\"tdv2-applet-cardstrip\":{\"componentMoviesCardStrip\":1,\"config\":1},\"tdv2-applet-channels\":{\"componentChannels\":1,\"thumbnails\":1},\"tdv2-applet-content-caas\":{\"componentContentCaas\":1},\"tdv2-applet-content-canvas\":{\"attributionStyles\":1,\"componentCanvasCommunityBar\":1,\"componentCardView\":1,\"componentContentCanvas\":1,\"componentOneIdButtons\":1,\"componentStickyShareButtons\":1,\"componentStorylineItem\":1,\"componentStorylines\":1,\"pages\":1,\"routes\":1,\"siteCategory\":1},\"tdv2-applet-discussion\":{\"componentDiscussionCarousel\":1,\"componentDiscussionList\":1},\"tdv2-applet-drop\":{\"componentDropList\":1},\"tdv2-applet-everything\":{\"configEverything\":1,\"configWorldSites\":1},\"tdv2-applet-featurebar\":{\"componentFeatureBar\":1,\"componentFeatureBarSmartphone\":1},\"tdv2-applet-follow\":{\"componentFollow\":1,\"regal\":1},\"tdv2-applet-followauthor\":{\"componentFollowAuthor\":1,\"componentFollowHeadlines\":1},\"tdv2-applet-footer\":{\"componentFooter\":1},\"tdv2-applet-header\":{\"componentHeader\":1,\"componentUtilityHeader\":1,\"componentWeather\":1},\"tdv2-applet-horoscope\":{\"componentHoroscope\":1,\"config\":1},\"tdv2-applet-livecoverage\":{\"componentLiveCoverage\":1},\"tdv2-applet-native-ads\":{\"componentGeminiDeals\":1,\"componentPencilAd\":1,\"componentSponsoredAd\":1},\"tdv2-applet-navrail\":{\"componentNavLite\":1,\"nav\\u002Fdesktop\":1,\"nav\\u002Findex\":1,\"nav\\u002Fmaster\":1,\"nav\\u002Fsmartphone\":1,\"nav\\u002Ftablet\":1,\"nav\\u002Fsite\\u002Fautos\":1,\"nav\\u002Fsite\\u002Fbeauty\":1,\"nav\\u002Fsite\\u002Fcelebrity\":1,\"nav\\u002Fsite\\u002Fcricket\":1,\"nav\\u002Fsite\\u002Fentertainment\":1,\"nav\\u002Fsite\\u002Ffinance\":1,\"nav\\u002Fsite\\u002Ffood\":1,\"nav\\u002Fsite\\u002Ffp\":1,\"nav\\u002Fsite\\u002Fgma\":1,\"nav\\u002Fsite\\u002Fhkstylemen\":1,\"nav\\u002Fsite\\u002Fhktravelnow\":1,\"nav\\u002Fsite\\u002Findex\":1,\"nav\\u002Fsite\\u002Fivy\":1,\"nav\\u002Fsite\\u002Fkatiecouric\":1,\"nav\\u002Fsite\\u002Flifestyle\":1,\"nav\\u002Fsite\\u002Fm6info\":1,\"nav\\u002Fsite\\u002Fmovies\":1,\"nav\\u002Fsite\\u002Fmusic\":1,\"nav\\u002Fsite\\u002Fnews\":1,\"nav\\u002Fsite\\u002Fsaludbucal\":1,\"nav\\u002Fsite\\u002Fsaudebucal\":1,\"nav\\u002Fsite\\u002Fsports\":1,\"nav\\u002Fsite\\u002Fstyle\":1,\"nav\\u002Fsite\\u002Ftech\":1,\"nav\\u002Fsite\\u002Ftravel\":1,\"nav\\u002Fsite\\u002Ftv\":1,\"nav\\u002Fsite\\u002Fweather\":1,\"nav\\u002Fsite\\u002Fyourfinancialjourney\":1,\"nav\\u002Fpartner\\u002Findex\":1,\"nav\\u002Flang\\u002Findex\":1,\"nav\\u002Fdevice\\u002Findex\":1},\"tdv2-applet-pk\":{\"PKServiceConfig\":1,\"componentPK\":1,\"componentPKMobile\":1,\"componentPKRightRail\":1,\"componentSeasons\":1,\"constant\":1},\"tdv2-applet-poll\":{\"componentModal\":1,\"componentSmartContent\":1,\"componentSmartContentDetailPage\":1,\"componentSmartContentDetailResult\":1,\"componentSmartContentRightRail\":1,\"constant\":1},\"tdv2-applet-profile-dashboard\":{\"componentProfileDashboardEntry\":1},\"tdv2-applet-rawads\":{\"componentRawAds\":1},\"tdv2-applet-rmp\":{\"componentRmp\":1,\"redis\":1},\"tdv2-applet-search-input\":{\"searchassist\":1},\"tdv2-applet-showtimes\":{\"componentShowtimes\":1},\"tdv2-applet-slideshow\":{\"componentHeroSlideshow\":1,\"layoutStyles\":1,\"theme\":1},\"tdv2-applet-sponsored-moments\":{\"componentDesktopMomentsAd\":1,\"componentSponsoredMomentsAd\":1,\"componentSponsoredMomentsAdWafer\":1,\"componentSponsoredMomentsCaas\":1,\"wafer\":1},\"tdv2-wafer-utils\":{\"componentGtmPixel\":1,\"wafer\":1,\"styles\\u002Ftabs\":1},\"tdv2-applet-sports-bracket\":{\"componentBracket\":1,\"componentBracketPromo\":1},\"tdv2-applet-sports-header\":{\"componentMobileHeader\":1,\"componentNavRail\":1,\"wafer\":1},\"tdv2-applet-sports-media\":{\"componentBreakingNews\":1,\"componentDescriptionBanner\":1,\"componentExperts\":1,\"componentHubVideo\":1},\"tdv2-applet-sports-promos\":{\"componentPromos\":1,\"wafer\":1},\"tdv2-applet-sports-scores\":{\"componentMyTeams\":1,\"componentMyTeamsGames\":1,\"componentScoreStrip\":1},\"tdv2-applet-stream\":{\"componentStream\":1},\"tdv2-applet-stream-hero\":{\"componentFeaturedHero\":1,\"componentStreamHero\":1,\"componentStreamHeroCarousel\":1,\"componentWideHero\":1},\"tdv2-applet-style\":{\"componentStyleCover\":1,\"config\":1},\"tdv2-applet-uh\":{\"componentHeader\":1,\"searchOrigins\":1,\"components\\u002Findex\":1,\"components\\u002Fmaster\":1,\"components\\u002Fsite\\u002Findex\":1,\"components\\u002Fpartner\\u002Findex\":1,\"components\\u002Flang\\u002Findex\":1,\"components\\u002Fenvironment\\u002Findex\":1,\"components\\u002Fdevice\\u002Findex\":1},\"tdv2-applet-userintent\":{\"componentUserintent\":1},\"tdv2-applet-video-lightbox\":{\"componentContentLightboxVideo\":1,\"componentVideoLightbox\":1},\"tdv2-applet-video-modal\":{\"componentVideoModal\":1,\"keyboard-shortcuts\":1,\"modalShareButtons\":1,\"thumbnails-cover\":1,\"thumbnails\":1,\"videoModalExamples\":1},\"tdv2-applet-videolist\":{\"componentVideoRightRail\":1},\"tdv2-service-ads\":{\"config\":1},\"tdv2-service-caas\":{\"content\":1,\"dimensions\":1,\"sidekick\":1},\"tdv2-service-subscriptions\":{\"config\":1},\"tdv2-wafer-adfeedback\":{\"app\":1,\"wafer\":1},\"tdv2-wafer-gtmpixel\":{\"componentGTMPixel\":1},\"tdv2-wafer-header\":{\"aol-channels\":1,\"app\":1,\"componentHeader\":1,\"componentHeaderDesktop\":1,\"componentHeaderIntl\":1,\"componentHeaderTablet\":1,\"componentHeaderYBar\":1,\"componentMailCount\":1,\"componentMailPreview\":1,\"componentMailPreviewOptIn\":1,\"wafer\":1,\"utils\\u002FgetAtomicClassNames\":1,\"styles\\u002FAccordionPanelItem\":1,\"styles\\u002FAds\":1,\"styles\\u002FBackButton\":1,\"styles\\u002FBackButtonNew\":1,\"styles\\u002FDialogue\":1,\"styles\\u002FGetApp\":1,\"styles\\u002FHandwrite\":1,\"styles\\u002FHeader\":1,\"styles\\u002FHeaderDesktop\":1,\"styles\\u002FHeaderTablet\":1,\"styles\\u002FLogo\":1,\"styles\\u002FLogoNew\":1,\"styles\\u002FMailCount\":1,\"styles\\u002FMailMenu\":1,\"styles\\u002FMailPreview\":1,\"styles\\u002FMailPreviewOptIn\":1,\"styles\\u002FNavigationBar\":1,\"styles\\u002FNotificationMenu\":1,\"styles\\u002FProfileButton\":1,\"styles\\u002FProfileMenu\":1,\"styles\\u002FProfilePanel\":1,\"styles\\u002FSearchAssist\":1,\"styles\\u002FSearchBox\":1,\"styles\\u002FSearchButton\":1,\"styles\\u002FSearchKeyword\":1,\"styles\\u002FSimplePanelItem\":1,\"styles\\u002FSkipLinks\":1,\"styles\\u002FTooltip\":1,\"styles\\u002FTopBar\":1,\"styles\\u002FWeatherMenu\":1,\"styles\\u002Findex\":1,\"headerDesktop\\u002Far-JO\":1,\"headerDesktop\\u002Fde-DE\":1,\"headerDesktop\\u002Fel-GR\":1,\"headerDesktop\\u002Fen-AE\":1,\"headerDesktop\\u002Fen-AU\":1,\"headerDesktop\\u002Fen-GB\":1,\"headerDesktop\\u002Fen-IE\":1,\"headerDesktop\\u002Fen-IN\":1,\"headerDesktop\\u002Fen-MY\":1,\"headerDesktop\\u002Fen-NZ\":1,\"headerDesktop\\u002Fen-PH\":1,\"headerDesktop\\u002Fen-SG\":1,\"headerDesktop\\u002Fen-ZA\":1,\"headerDesktop\\u002Fes-ES\":1,\"headerDesktop\\u002Fes-US\":1,\"headerDesktop\\u002Ffr-BE\":1,\"headerDesktop\\u002Ffr-FR\":1,\"headerDesktop\\u002Fid-ID\":1,\"headerDesktop\\u002Findex\":1,\"headerDesktop\\u002Fit-IT\":1,\"headerDesktop\\u002Fnl-BE\":1,\"headerDesktop\\u002Fpt-BR\":1,\"headerDesktop\\u002Fro-RO\":1,\"headerDesktop\\u002Fsv-SE\":1,\"headerDesktop\\u002Fvi-VN\":1,\"assets\\u002FAssistJs-v1\":1,\"assets\\u002FAssistJs\":1,\"assets\\u002FLogo\":1,\"assets\\u002FNavigationScrollHandler\":1,\"assets\\u002FNotificationClient\":1,\"assets\\u002FPanelItems\":1,\"assets\\u002FfinanceSearch\":1},\"tdv2-wafer-hpsetpromo\":{\"app\":1,\"componentHpSetBannerPromo\":1,\"componentHpSetPromo\":1,\"wafer\":1,\"assets\\u002FHpSetButtonHandler\":1,\"assets\\u002FHpSetPromoHandler\":1},\"tdv2-wafer-promo\":{\"app\":1,\"componentBanner\":1,\"componentCustomBanner\":1,\"componentEditorial\":1,\"componentFullScreenBanner\":1,\"componentLoginBanner\":1,\"componentTourney\":1,\"wafer\":1},\"tdv2-wafer-sitemap\":{\"componentSiteMapContent\":1,\"componentSiteMapIndex\":1},\"tdv2-wafer-topicmanagement\":{\"app\":1,\"componentOnboarding\":1,\"componentTopicManagement\":1,\"wafer\":1},\"tdv2-wafer-tv\":{\"app\":1,\"componentTVDesktop\":1,\"componentTVLive\":1,\"componentTVProgram\":1,\"componentTVSchedule\":1,\"componentTVStream\":1,\"vpConfig\":1,\"wafer\":1},\"vertical-video-util\":{\"category\":1},\"video-service\":{\"channel_service_config\":1}},\"lang\":{\"td-app-yahoo\":{\"strings\":1},\"nebula.chart\":{\"strings\":1},\"nebula.i18n\":{\"strings\":1},\"react-finance\":{\"strings\":1},\"react-location-widget\":{\"strings\":1},\"react-showtimes\":{\"strings\":1},\"react-sports\":{\"strings\":1},\"react-tumblr-tile\":{\"strings\":1},\"react-weather\":{\"strings\":1},\"td-ads\":{\"strings\":1},\"tdv2-applet-abu-chatbox\":{\"strings\":1},\"tdv2-applet-abu-footer\":{\"strings\":1},\"tdv2-applet-abu-news\":{\"strings\":1},\"tdv2-applet-abu-search\":{\"strings\":1},\"tdv2-applet-account-switch\":{\"strings\":1},\"tdv2-applet-apac-membership\":{\"strings\":1},\"tdv2-applet-apac-web-components\":{\"strings\":1},\"tdv2-applet-bubble\":{\"strings\":1},\"tdv2-applet-canvass\":{\"strings\":1},\"tdv2-applet-cardstrip\":{\"strings\":1},\"tdv2-applet-channels\":{\"strings\":1},\"tdv2-applet-content-caas\":{\"strings\":1},\"tdv2-applet-content-canvas\":{\"strings\":1},\"tdv2-applet-discussion\":{\"strings\":1},\"tdv2-applet-everything\":{\"strings\":1},\"tdv2-applet-featurebar\":{\"strings\":1},\"tdv2-applet-follow\":{\"strings\":1},\"tdv2-applet-followauthor\":{\"strings\":1},\"tdv2-applet-footer\":{\"strings\":1},\"tdv2-applet-header\":{\"strings\":1},\"tdv2-applet-horoscope\":{\"strings\":1},\"tdv2-applet-livecoverage\":{\"strings\":1},\"tdv2-applet-native-ads\":{\"strings\":1},\"tdv2-applet-navrail\":{\"strings\":1},\"tdv2-applet-pk\":{\"strings\":1},\"tdv2-applet-poll\":{\"strings\":1},\"tdv2-applet-profile-dashboard\":{\"strings\":1},\"tdv2-applet-rawads\":{\"strings\":1},\"tdv2-applet-search-input\":{\"strings\":1},\"tdv2-applet-showtimes\":{\"strings\":1},\"tdv2-applet-slideshow\":{\"strings\":1},\"tdv2-applet-sponsored-moments\":{\"strings\":1},\"tdv2-wafer-utils\":{\"strings\":1},\"tdv2-applet-sports-bracket\":{\"strings\":1},\"tdv2-applet-sports-header\":{\"strings\":1},\"tdv2-applet-sports-media\":{\"strings\":1},\"tdv2-applet-sports-promos\":{\"strings\":1},\"tdv2-applet-sports-scores\":{\"strings\":1},\"tdv2-applet-stream\":{\"strings\":1},\"tdv2-applet-stream-hero\":{\"strings\":1},\"tdv2-applet-style\":{\"strings\":1},\"tdv2-applet-swisschamp\":{\"strings\":1},\"tdv2-applet-uh\":{\"strings\":1},\"tdv2-applet-userintent\":{\"strings\":1},\"tdv2-applet-video-lightbox\":{\"strings\":1},\"tdv2-applet-video-modal\":{\"strings\":1},\"tdv2-service-subscriptions\":{\"strings\":1},\"tdv2-wafer-adfeedback\":{\"strings\":1},\"tdv2-wafer-header\":{\"strings\":1},\"tdv2-wafer-hpsetpromo\":{\"strings\":1},\"tdv2-wafer-promo\":{\"strings\":1},\"tdv2-wafer-sitemap\":{\"strings\":1},\"tdv2-wafer-topicmanagement\":{\"strings\":1},\"tdv2-wafer-tv\":{\"strings\":1},\"yahoodotcom-layout\":{\"strings\":1}}},\"options\":{\"defaultBundle\":\"td-app-yahoo\"}}}};\n}(this));\n</script>\r\n<div><script type=\"text/javascript\">window._loadEvt = false; \nwindow._adPerfData = []; \nwindow._adPosMsg = []; \nwindow._perfMark = function _perfMark (name) {if (window.performance && window.performance.mark){try {if (window.performance.getEntriesByName(\"NAVIGATE_START\") && window.performance.getEntriesByName(\"NAVIGATE_START\")[0]) { name = \"CL_\" + name ;}window.performance.mark(name);} catch (e) {console.warn(name + ' could not be marked:',e);}};};\nwindow._perfMeasure = function _perfMeasure (name, start, end) {if (window.performance && window.performance.measure){try {if (window.performance.getEntriesByName(\"NAVIGATE_START\") && window.performance.getEntriesByName(\"NAVIGATE_START\")[0]) { start = \"CL_\" + start ;end = \"CL_\" + end ;name = \"CL_\" + name ;}window.performance.measure(name, start, end);} catch (e) {console.warn(name + ' could not be added:',e);}};};\nwindow._pushAdPerfMetric = function _pushAdPerfMetric(key) {if (window.performance && window.performance.now) {_adPerfData.push([key, Math.round(window.performance.now())]);}};\nwindow._fireAdPerfBeacon = function _fireAdPerfBeacon(eventName) {try {if (window && window.rapidInstance && window.performance) {var navClickMark = window.performance.getEntriesByName('NAVIGATE_START') &&window.performance.getEntriesByName('NAVIGATE_START').pop();var navClickTime = navClickMark && navClickMark.startTime || 0;var userTime = {};window.performance.getEntries().forEach(function forEachPerfTime (item) {if (item.name.search('DARLA_') > -1) {if (item.entryType === \"mark\") {userTime[item.name] = Math.round(item.startTime) - navClickTime;window.performance.clearMarks(item.name);} else if (item.entryType === \"measure\") {userTime[item.name] = Math.round(item.duration);window.performance.clearMeasures(item.name);}}});var perfData = {perf_usertime: {utm: userTime}};\nwindow.rapidInstance.beaconPerformanceData(perfData);}} catch (e) {console.warn('Could not send the beacon:',e);}};\nwindow.DARLA_CONFIG = {\"autoRotation\":10000,\"darlaAssetFetch\":false,\"cacheDarlaAsset\":false,\"events\":{\"AUTO\":{\"name\":\"AUTO\",\"autoStart\":1,\"autoMax\":25,\"autoRT\":10000,\"autoIV\":1,\"autoDDG\":1,\"ps\":{\"BTNA\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTNB\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTNC\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"BTND\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB2-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LDRB2-2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC2-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-5\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-6\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-7\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-8\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC2-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC3\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC3-4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-5\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-6\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-7\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-8\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"LREC3-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"10000\"},\"LREC4\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"MAST\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"MAST-9\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"MON-1\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"35000\"},\"SPL\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"SPL-2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"SPL2\":{\"autoIV\":1,\"autoMax\":25,\"autoRT\":\"60000\"},\"WIDGET\":{\"autoIV\":0,\"autoMax\":0,\"autoRT\":3600000}},\"sa\":\"ticker=\\\"DGX;GOOG;GOOGL;CTLT;TBIO;MRNA;ADPT;BNTX;TMO;EBS;INCY;HOLX;LH;AAPL;REGN;RHHBF;RHHBY;RHHVF;SNY;SNYNF;NVS;NVSEF;LLY;DIOD;GILD;PFE;ABT;GLAXF;GSK\\\" wiki_topics=\\\"Medical_test;COVID-19_vaccine;Health_care_provider;LabCorp;Emergency_Use_Authorization;Contact_tracing;Vaccine;United_States\\\" ctopid=\\\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" hashtag=\\\"%24sanofi;%24incy;%24quest-diagnostics-incorporated;%24nvs;%24aapl;%24rhhvf;%24goog;%24nvsef;%24roche-holding-ag;%24lly;%24gild;%24lh;%24regn;%24glaxf;%24googl;%24tmo;%24mrna;%24adpt;%24laboratory-corporation-of-america-holdings;yfipremium;%24snynf;%24rhhbf;%24abt;%24pfe;%24biontech-se;%24tbio;%24sny;%24bntx;%24holx;%24diod;%24dgx;%24ebs;%24ctlt;%24rhhby;%24gsk;1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" megamodal=true rs=\\\"lmsid:a077000000BAh3wAAD;revsp:yahoofinance.com;lpstaid:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;pct:story;pt:content;site:finance;ver:y20;pd:non_modal\\\" Y-BUCKET=\\\"finance-US-en-US-def\\\"\",\"ssl\":1,\"secure\":1,\"ult\":{\"pg\":{\"property\":\"finance_en-US\",\"test\":\"finance-US-en-US-def\"}}},\"DEFAULT\":{\"clw\":{\"LREC\":{\"blocked_by\":\"MON-1\"},\"MON-1\":{\"blocked_by\":\"LREC\"},\"MAST-9\":{\"blocked_by\":\"SPL,LDRB-9\"},\"MAST\":{\"blocked_by\":\"SPL,LDRB\"},\"LDRB\":{\"blocked_by\":\"MAST,SPL\"},\"LDRB-9\":{\"blocked_by\":\"MAST-9,SPL\"},\"SPL\":{\"blocked_by\":\"MAST,LDRB\"}},\"sp\":\"980771051\",\"ssl\":1,\"secure\":1,\"ult\":{\"pg\":{\"property\":\"finance_en-US\",\"test\":\"finance-US-en-US-def\"}}},\"adFetch\":{\"ps\":\"BTNA,BTNB,BTNC,BTND,MAST,LDRB,SPL,LREC,LREC2,LREC3,LREC4,FOOT,FSRVY\",\"sp\":\"980771051\",\"sa\":\"ticker=\\\"DGX;GOOG;GOOGL;CTLT;TBIO;MRNA;ADPT;BNTX;TMO;EBS;INCY;HOLX;LH;AAPL;REGN;RHHBF;RHHBY;RHHVF;SNY;SNYNF;NVS;NVSEF;LLY;DIOD;GILD;PFE;ABT;GLAXF;GSK\\\" wiki_topics=\\\"Medical_test;COVID-19_vaccine;Health_care_provider;LabCorp;Emergency_Use_Authorization;Contact_tracing;Vaccine;United_States\\\" ctopid=\\\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" hashtag=\\\"%24sanofi;%24incy;%24quest-diagnostics-incorporated;%24nvs;%24aapl;%24rhhvf;%24goog;%24nvsef;%24roche-holding-ag;%24lly;%24gild;%24lh;%24regn;%24glaxf;%24googl;%24tmo;%24mrna;%24adpt;%24laboratory-corporation-of-america-holdings;yfipremium;%24snynf;%24rhhbf;%24abt;%24pfe;%24biontech-se;%24tbio;%24sny;%24bntx;%24holx;%24diod;%24dgx;%24ebs;%24ctlt;%24rhhby;%24gsk;1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" megamodal=true rs=\\\"lmsid:a077000000BAh3wAAD;revsp:yahoofinance.com;lpstaid:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;pct:story;pt:content;site:finance;ver:y20;pd:non_modal\\\" Y-BUCKET=\\\"finance-US-en-US-def\\\"\",\"optionalps\":\"\",\"launchViewportAdPos\":\"\",\"site\":\"finance\",\"ssl\":1,\"secure\":1,\"ult\":{\"pg\":{\"property\":\"finance_en-US\",\"test\":\"finance-US-en-US-def\"}}},\"TD_AUTO\":{\"ps\":\"DEFAULT,BTNA,BTNB,BTNC,BTND,FOOT,FOOT9,FSRVY,LREC,LREC-1,LREC-2,LREC-9,LREC2-1,LREC2-2,LREC2-4,LREC2-5,LREC2-6,LREC2-7,LREC2-8,LREC2-9,LREC2,LREC3,LREC3-1,LREC3-4,LREC3-5,LREC3-6,LREC3-7,LREC3-8,LREC3-9,LREC4,LDRB,LDRB-1,LDRB-9,LDRB2-1,LDRB2-2,LDRP,MAST,MAST-9,MFPAD,MON,MON-1,MON2,MON-9,MOMENTS,NE1,SCREC,SPL,SPL-2,SPL2,SPRZ,SPON,TXTL,WFPAD,UBALDRB,UBALDRB-9,UBALDRB2-1,UBALDRB2-2,UBALREC,UBALREC-1,UBALREC-9,UBALREC2-9,UBALREC2,UBALREC3,UBALREC3-9,UBALREC4,INARTICLE,AS6,WIDGET\",\"ssl\":1,\"secure\":1,\"ult\":{\"pg\":{\"property\":\"finance_en-US\",\"test\":\"finance-US-en-US-def\"}}}},\"positions\":{\"DEFAULT\":{\"meta\":{\"stack\":\"ydc\",\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"},\"clean\":\"defaultcleanDEFAULT\",\"dest\":\"defaultdestDEFAULT\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"DEFAULT\",\"staticLayout\":false},\"BTNA\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"defaultcleanBTNA\",\"dest\":\"defaultdestBTNA\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTNA\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"BTNB\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"defaultcleanBTNB\",\"dest\":\"defaultdestBTNB\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTNB\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"BTNC\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"defaultcleanBTNC\",\"dest\":\"defaultdestBTNC\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTNC\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"BTND\":{\"w\":120,\"h\":60,\"autoFetch\":false,\"failed\":true,\"clean\":\"defaultcleanBTND\",\"dest\":\"defaultdestBTND\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"id\":\"BTND\",\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"FOOT\":{\"id\":\"FOOT\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1},\"failed\":true,\"clean\":\"defaultcleanFOOT\",\"dest\":\"defaultdestFOOT\",\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"FOOT9\":{\"id\":\"FOOT9\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1},\"clean\":\"defaultcleanFOOT9\",\"dest\":\"defaultdestFOOT9\",\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"FSRVY\":{\"id\":\"FSRVY\",\"enable\":true,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"lyr\":1},\"failed\":true,\"clean\":\"defaultcleanFSRVY\",\"dest\":\"defaultdestFSRVY\",\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC\":{\"id\":\"LREC\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanLREC\",\"dest\":\"defaultdestLREC\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC-1\":{\"id\":\"LREC-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC-1\",\"dest\":\"defaultdestLREC-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC-2\":{\"id\":\"LREC-2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC-2\",\"dest\":\"defaultdestLREC-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC-9\":{\"id\":\"LREC-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC-9\",\"dest\":\"defaultdestLREC-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-1\":{\"id\":\"LREC2-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-1\",\"dest\":\"defaultdestLREC2-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-2\":{\"id\":\"LREC2-2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-2\",\"dest\":\"defaultdestLREC2-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-4\":{\"id\":\"LREC2-4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-4\",\"dest\":\"defaultdestLREC2-4\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-5\":{\"id\":\"LREC2-5\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-5\",\"dest\":\"defaultdestLREC2-5\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-6\":{\"id\":\"LREC2-6\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-6\",\"dest\":\"defaultdestLREC2-6\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-7\":{\"id\":\"LREC2-7\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-7\",\"dest\":\"defaultdestLREC2-7\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-8\":{\"id\":\"LREC2-8\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-8\",\"dest\":\"defaultdestLREC2-8\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2-9\":{\"id\":\"LREC2-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC2-9\",\"dest\":\"defaultdestLREC2-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC2\":{\"id\":\"LREC2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"failed\":true,\"clean\":\"defaultcleanLREC2\",\"dest\":\"defaultdestLREC2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3\":{\"id\":\"LREC3\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"failed\":true,\"clean\":\"defaultcleanLREC3\",\"dest\":\"defaultdestLREC3\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-1\":{\"id\":\"LREC3-1\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC3-1\",\"dest\":\"defaultdestLREC3-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-4\":{\"id\":\"LREC3-4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC3-4\",\"dest\":\"defaultdestLREC3-4\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-5\":{\"id\":\"LREC3-5\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC3-5\",\"dest\":\"defaultdestLREC3-5\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-6\":{\"id\":\"LREC3-6\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC3-6\",\"dest\":\"defaultdestLREC3-6\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-7\":{\"id\":\"LREC3-7\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC3-7\",\"dest\":\"defaultdestLREC3-7\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-8\":{\"id\":\"LREC3-8\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC3-8\",\"dest\":\"defaultdestLREC3-8\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC3-9\":{\"id\":\"LREC3-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanLREC3-9\",\"dest\":\"defaultdestLREC3-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LREC4\":{\"id\":\"LREC4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"metaSize\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"failed\":true,\"clean\":\"defaultcleanLREC4\",\"dest\":\"defaultdestLREC4\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB\":{\"id\":\"LDRB\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"failed\":true,\"clean\":\"defaultcleanLDRB\",\"dest\":\"defaultdestLDRB\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB-1\":{\"id\":\"LDRB-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanLDRB-1\",\"dest\":\"defaultdestLDRB-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB-9\":{\"id\":\"LDRB-9\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanLDRB-9\",\"dest\":\"defaultdestLDRB-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB2-1\":{\"id\":\"LDRB2-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanLDRB2-1\",\"dest\":\"defaultdestLDRB2-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRB2-2\":{\"id\":\"LDRB2-2\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanLDRB2-2\",\"dest\":\"defaultdestLDRB2-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"LDRP\":{\"id\":\"LDRP\",\"w\":320,\"h\":50,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1},\"enable\":true,\"metaSize\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanLDRP\",\"dest\":\"defaultdestLDRP\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MAST\":{\"id\":\"MAST\",\"w\":970,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"closeBtn\":{\"adc\":0,\"mode\":2,\"useShow\":1},\"metaSize\":true,\"failed\":true,\"clean\":\"defaultcleanMAST\",\"dest\":\"defaultdestMAST\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MAST-9\":{\"id\":\"MAST-9\",\"w\":970,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"closeBtn\":{\"adc\":0,\"mode\":2,\"useShow\":1},\"metaSize\":true,\"clean\":\"defaultcleanMAST-9\",\"dest\":\"defaultdestMAST-9\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MFPAD\":{\"id\":\"MFPAD\",\"w\":720,\"h\":90,\"autoFetch\":false,\"enable\":true,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"metaSize\":true,\"staticLayout\":false,\"fdb\":false,\"clean\":\"defaultcleanMFPAD\",\"dest\":\"defaultdestMFPAD\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON\":{\"id\":\"MON\",\"w\":300,\"h\":600,\"dest\":\"defaultdestMON\",\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanMON\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON-1\":{\"id\":\"MON-1\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanMON-1\",\"dest\":\"defaultdestMON-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON2\":{\"id\":\"MON2\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanMON2\",\"dest\":\"defaultdestMON2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MON-9\":{\"id\":\"MON-9\",\"w\":300,\"h\":600,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"resize-to\":1,\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanMON-9\",\"dest\":\"defaultdestMON-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"MOMENTS\":{\"id\":\"MOMENTS\",\"w\":375,\"h\":667,\"flex\":{\"ratio\":\"1x1.78\",\"w\":{\"min\":320},\"h\":{\"min\":568}},\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"resize-to\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanMOMENTS\",\"dest\":\"defaultdestMOMENTS\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"NE1\":{\"id\":\"NE1\",\"w\":970,\"h\":60,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1},\"enable\":true,\"staticLayout\":true,\"metaSize\":true,\"z\":2000,\"clean\":\"defaultcleanNE1\",\"dest\":\"defaultdestNE1\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"SCREC\":{\"id\":\"SCREC\",\"w\":300,\"h\":65,\"pos\":\"SCREC\",\"autoFetch\":false,\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanSCREC\",\"dest\":\"defaultdestSCREC\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"SPL\":{\"id\":\"SPL\",\"flex\":\"both\",\"enable\":true,\"autoFetch\":false,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"type\":\"stream\",\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\",\"failed\":true,\"clean\":\"defaultcleanSPL\",\"dest\":\"defaultdestSPL\",\"fallback\":null,\"metaSize\":false},\"SPL-2\":{\"id\":\"SPL-2\",\"flex\":\"both\",\"enable\":true,\"autoFetch\":false,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"type\":\"stream\",\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\",\"clean\":\"defaultcleanSPL-2\",\"dest\":\"defaultdestSPL-2\",\"fallback\":null,\"metaSize\":false},\"SPL2\":{\"id\":\"SPL2\",\"autoFetch\":false,\"flex\":\"both\",\"enable\":true,\"staticLayout\":false,\"fclose\":2,\"fdb\":{\"on\":1,\"where\":\"inside\"},\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"meta\":{\"stack\":\"ydc\",\"type\":\"stream\",\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"},\"css\":\".Mags-FontA{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:300}.Mags-FontA.Size1{font-size:13px}.Mags-FontA.Size2{font-size:16px}.Mags-FontA.Size3{font-size:20px}.Mags-FontA.Size4{font-size:22px}.Mags-FontA.Size5{font-size:33px}.Mags-FontA.Size6{font-size:35px}.Mags-FontA.Size7{font-size:58px}.Mags-FontA.Size8{font-size:70px}.Mags-FontA.Size9{font-size:100px}.Mags-FontB{font-family:Georgia,Times,serif;font-weight:400}.Mags-FontB.Size1{font-size:18px}.Mags-FontC{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-weight:400}.Mags-FontC.Size1{font-size:11px}.Mags-FontC.Size2{font-size:14px}.Mags-FontC.Size3{font-size:16px}.Mags-FontC.Size4{font-size:20px}.Mags-FontC.Size5{font-size:30px}.Mags-FontC.Size6{font-size:32px}.Mags-FontC.Size7{font-size:52px}\",\"clean\":\"defaultcleanSPL2\",\"dest\":\"defaultdestSPL2\",\"fallback\":null,\"metaSize\":false},\"SPRZ\":{\"id\":\"SPRZ\",\"autoFetch\":false,\"flex\":\"both\",\"enable\":true,\"staticLayout\":false,\"fdb\":false,\"supports\":{\"cmsg\":1},\"uhslot\":\".YDC-UH\",\"clean\":\"defaultcleanSPRZ\",\"dest\":\"defaultdestSPRZ\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"SPON\":{\"pos\":\"SPON\",\"h\":1,\"id\":\"SPON\",\"w\":1,\"autoFetch\":false,\"clean\":\"defaultcleanSPON\",\"dest\":\"defaultdestSPON\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"TXTL\":{\"id\":\"TXTL\",\"w\":120,\"h\":170,\"css\":\".ad-tl2b{overflow:hidden;text-align:left}p{margin:0}a{color:#020e65}a:hover{color:#0078ff}.y-fp-pg-controls{margin-top:5px;margin-bottom:5px}#tl1_slug{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-size:11px;color:#999}#fc_align a{font-family:'Helvetica Neue',Helvetica,Arial,sans-serif;font-size:11px}a:link{text-decoration:none}\",\"autoFetch\":false,\"clean\":\"defaultcleanTXTL\",\"dest\":\"defaultdestTXTL\",\"enable\":true,\"fallback\":null,\"metaSize\":false,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"WFPAD\":{\"id\":\"WFPAD\",\"w\":320,\"h\":50,\"autoFetch\":false,\"enable\":true,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1,\"lyr\":1,\"resize-to\":1},\"metaSize\":true,\"staticLayout\":false,\"fdb\":false,\"clean\":\"defaultcleanWFPAD\",\"dest\":\"defaultdestWFPAD\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB\":{\"id\":\"UBALDRB\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanUBALDRB\",\"dest\":\"defaultdestUBALDRB\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB-9\":{\"id\":\"UBALDRB-9\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanUBALDRB-9\",\"dest\":\"defaultdestUBALDRB-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB2-1\":{\"id\":\"UBALDRB2-1\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanUBALDRB2-1\",\"dest\":\"defaultdestUBALDRB2-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALDRB2-2\":{\"id\":\"UBALDRB2-2\",\"w\":728,\"h\":90,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"clean\":\"defaultcleanUBALDRB2-2\",\"dest\":\"defaultdestUBALDRB2-2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC\":{\"id\":\"UBALREC\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanUBALREC\",\"dest\":\"defaultdestUBALREC\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC-1\":{\"id\":\"UBALREC-1\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanUBALREC-1\",\"dest\":\"defaultdestUBALREC-1\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC-9\":{\"id\":\"UBALREC-9\",\"w\":300,\"h\":250,\"fr\":\"expIfr_exp\",\"autoFetch\":false,\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":3,\"clean\":\"defaultcleanUBALREC-9\",\"dest\":\"defaultdestUBALREC-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC2-9\":{\"id\":\"UBALREC2-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanUBALREC2-9\",\"dest\":\"defaultdestUBALREC2-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC2\":{\"id\":\"UBALREC2\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanUBALREC2\",\"dest\":\"defaultdestUBALREC2\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC3\":{\"id\":\"UBALREC3\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanUBALREC3\",\"dest\":\"defaultdestUBALREC3\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC3-9\":{\"id\":\"UBALREC3-9\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanUBALREC3-9\",\"dest\":\"defaultdestUBALREC3-9\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"UBALREC4\":{\"id\":\"UBALREC4\",\"w\":300,\"h\":250,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"fdb\":true,\"z\":9,\"clean\":\"defaultcleanUBALREC4\",\"dest\":\"defaultdestUBALREC4\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"INARTICLE\":{\"id\":\"INARTICLE\",\"w\":375,\"h\":211,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"flex\":{\"ratio\":\"1.78x1\",\"w\":{\"min\":10},\"h\":{\"min\":5}},\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":true,\"z\":9,\"clean\":\"defaultcleanINARTICLE\",\"dest\":\"defaultdestINARTICLE\",\"fallback\":null,\"metaSize\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"AS6\":{\"id\":\"AS6\",\"w\":850,\"h\":173,\"autoFetch\":false,\"fr\":\"expIfr_exp\",\"supports\":{\"exp-ovr\":1,\"exp-push\":1},\"enable\":true,\"staticLayout\":false,\"metaSize\":false,\"z\":9,\"clean\":\"defaultcleanAS6\",\"dest\":\"defaultdestAS6\",\"fallback\":null,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}},\"WIDGET\":{\"id\":\"WIDGET\",\"clean\":\"defaultcleanWIDGET\",\"dest\":\"defaultdestWIDGET\",\"metaSize\":false,\"w\":600,\"h\":635,\"flex\":{\"w\":{\"min\":600,\"max\":800}},\"enable\":true,\"fallback\":null,\"staticLayout\":false,\"meta\":{\"hostURL\":\"https://finance.yahoo.com/news/coronavirus-vaccine-progress-accelerates-155109303.html\"}}},\"rotationTimingDisabled\":true,\"contentTypeAdPosModifier\":{\"slideshow\":[\"-LREC\",\"LREC-2\",\"LREC2\"],\"inlineSlideshow\":[]},\"useYAC\":0,\"usePE\":1,\"servicePath\":\"\",\"xservicePath\":\"\",\"beaconPath\":\"\",\"renderPath\":\"\",\"allowFiF\":false,\"srenderPath\":\"https://s.yimg.com/rq/darla/3-25-1/html/r-sf.html\",\"renderFile\":\"https://s.yimg.com/rq/darla/3-25-1/html/r-sf.html\",\"sfbrenderPath\":\"https://s.yimg.com/rq/darla/3-25-1/html/r-sf.html\",\"msgPath\":\"https://fc.yahoo.com/unsupported-1946.html\",\"cscPath\":\"https://s.yimg.com/rq/darla/3-25-1/html/r-csc.html\",\"root\":\"sdarla\",\"edgeRoot\":\"https://s.yimg.com/rq/darla/3-25-1\",\"sedgeRoot\":\"https://s.yimg.com/rq/darla/3-25-1\",\"version\":\"3-25-1\",\"tpbURI\":\"\",\"hostFile\":\"https://s.yimg.com/rq/darla/3-25-1/js/g-r-min.js\",\"beaconsDisabled\":true,\"fdb_locale\":\"What don't you like about this ad?|It's offensive|Something else|Thank you for helping us improve your Yahoo experience|It's not relevant|It's distracting|I don't like this ad|Send|Done|Why do I see ads?|Learn more about your feedback.|Want an ad-free inbox? Upgrade to Yahoo Mail Pro!|Upgrade Now\",\"property\":\"\",\"lang\":\"en-US\",\"debug\":false,\"auto_render\":true}\nwindow.DARLA_CONFIG.servicePath = window.location.protocol + \"//fc.yahoo.com/sdarla/php/fc.php\";window.DARLA_CONFIG.dm = 1;window.DARLA_CONFIG.onStartRequest = function() {window._perfMark('DARLA_REQSTART');};\nwindow.DARLA_CONFIG.onFinishRequest = function() {window._perfMark('DARLA_REQEND');};\nwindow.DARLA_CONFIG.onStartParse = function() {window._perfMark('DARLA_PSTART');};\nwindow.DARLA_CONFIG.onSuccess = function(eventName) {if (eventName === 'AUTO') {return;}if (window._DarlaEvents) {window._DarlaEvents.emit(\"success\", {eventName: eventName});}window._perfMark('DARLA_DONE_' + eventName);window._darlaSuccessEvt = eventName;if (window._loadEvt) {window._fireAdPerfBeacon(eventName);}};\nwindow.DARLA_CONFIG.onStartPosRender = function(posItem) {var posId = posItem && posItem.pos;window._perfMark('DARLA_ADSTART_' + posId);if (window._pushAdPerfMetric) {window._pushAdPerfMetric(\"DARLA_ADSTART_\" + posId);}};\nwindow.DARLA_CONFIG.onFinishPosRender = function(posId, reqList, posItem) {var ltime;window._perfMark('DARLA_ADEND_' + posId);window._perfMeasure('DARLA_RENDERTIME_' + posId, 'DARLA_ADSTART_'+posId, 'DARLA_ADEND_'+posId);if(window._DarlaEvents) {window._DarlaEvents.emit(\"finishrender\", {pos:posId, list:reqList, item:posItem});}var aboveFoldPositions = [\"MAST\",\"LDRB\",\"SPRZ\",\"SPL\",\"SPL-2\",\"LREC\",\"MON-1\"];if (window._pushAdPerfMetric) {if (window.performance && window.performance.now) {ltime = window.performance.now();}window._pushAdPerfMetric(\"ADEND_\"+posId);var adModDiv = posItem.conf.dest.replace(\"dest\", \"\") + \"-sizer\";setTimeout(function () {if (window.performance && window.YAFT !== undefined &&window.YAFT.isInitialized() && -1 !== aboveFoldPositions.indexOf(posId)) {window.YAFT.triggerCustomTiming(adModDiv, \"\", ltime);}}, 300);}};\nwindow.DARLA_CONFIG.onBeforePosMsg = function(msg, posId) {var maxWidth = 970, maxHeight = 600;var newWidth, newHeight, pos;if (window._DarlaEvents && msg === \"exp-push\" && posId && 0 === posId.indexOf(\"LREC\")) {window._DarlaEvents.emit(\"exp-push\", arguments);}if (\"MAST\" !== posId) {return;}if (msg === \"resize-to\") {newWidth = arguments[2];newHeight = arguments[3];} else if (msg === \"exp-push\" || msg === \"exp-ovr\") {pos = $sf.host.get(\"MAST\");newWidth = pos.conf.w + arguments[6] + arguments[7];newHeight = pos.conf.h + arguments[5] + arguments[8];}if (newWidth > maxWidth || newHeight > maxHeight) {return true;}};\nwindow.DARLA_CONFIG.onFinishParse = function(eventName, response) {try {window._perfMark('DARLA_PEND');if (eventName === \"prefetch\") {window._DarlaPrefetchResponse = response;}if (window._DarlaEvents) {window._DarlaEvents.emit(\"finishparse\", {response: response,eventName: eventName});}} catch (e) {console.error(e);throw e;}if (eventName === \"AUTO\") {var adPositionList = response.ps();var groupAdsList = [];for (var i = 0; i < groupAdsList.length; i++) {if (adPositionList.indexOf(groupAdsList[i]) >= 0) {var adPosItem = response.item(groupAdsList[i]);if (!adPosItem.hasErr && adPosItem.size + \"\" !== \"1x1\" && (adPosItem.meta && adPosItem.meta.y && adPosItem.meta.y.size && adPosItem.meta.y.size + \"\" !== \"1x1\")) {var adNode = document.getElementById(\"default\" + groupAdsList[i] + \"-sizer\");if (adNode && adNode.classList) {adNode.classList.remove(\"D(n)\");adNode.classList.remove(\"D-n\");}}}}}\n};\nwindow.DARLA_CONFIG.onStartPrefetchRequest = function(eventName) {window._perfMark('DARLA_PFSTART');};\nwindow.DARLA_CONFIG.onFinishPrefetchRequest = function(eventName, status) {window._perfMark('DARLA_PFEND');try {window._DarlaEvents.emit('finishprefetch', {status: status,eventName: eventName});} catch (e) {console.error(e);throw e;}\n};\nwindow.DARLA_CONFIG.onPosMsg = function(cmd, pos, msg) {try {if (window._DarlaEvents && cmd === \"cmsg\") {var posmsg = {pos: pos,msg: msg};window._DarlaEvents.emit(\"splashmsg\", posmsg);if (window._adPosMsg) {window._adPosMsg[window._adPosMsg.length] = posmsg;}}if (window._DarlaEvents && (cmd === \"ui-fclose-show\" || cmd === \"ui-fclose-close\")) {setTimeout(function _emitAdResize(){window._DarlaEvents.emit(\"adresize\", {pos: pos})}, 0);}} catch (e) {console.error(e);throw e;}\n};\n(function () {var _onloadEvt = function _onloadEvtHandler() {window._loadEvt = true;if (window._darlaSuccessEvt) {window._fireAdPerfBeacon(window._darlaSuccessEvt);}};if (window.addEventListener) {window.addEventListener(\"load\", _onloadEvt);} else if (window.attachEvent) {window.attachEvent(\"onload\", _onloadEvt);}function _onDarlaError (type) {return function _darlaErrHandler(evName) {try {if (window._DarlaEvents) {window._DarlaEvents.emit(\"darlaerror\" + evName);window._DarlaEvents.emit(\"darlaerror\", {type: type,eventName: evName,error: true});}} catch (e) {console.error(e);throw e;}};};window.DARLA_CONFIG.onRequestTimeout = _onDarlaError(\"requestTimeout\");window.DARLA_CONFIG.onRenderTimeout = _onDarlaError(\"renderTimeout\");window.DARLA_CONFIG.onFailure = _onDarlaError(\"failure\");window.DARLA_CONFIG.onIdle = function onDarlaIdle () {    try {        window._DarlaEvents && window._DarlaEvents.emit(\"onIdle\");    } catch (e) {        console.error(e);        throw e;    }};})();\nwindow.$sf = window.sf = {};\nwindow.$sf.host = {onReady: function (autorender, deferrender, firstRenderPos, deferRenderDelay) {window._perfMark('DARLA_ONREADY');window._perfMeasure('DARLA_ONREADY');window.sfready = true;if (window._DarlaEvents && !autorender) {window._DarlaEvents.emit(\"darlaboot\");} else if (autorender){window._perfMark('DARLA_RSTART');if (typeof DARLA !== \"undefined\" && DARLA) {if (deferrender && firstRenderPos) {var firstBatchPos = [];var prefetchedPos = DARLA.prefetched();if (prefetchedPos.length <= 0) {return;}var firstRender = firstRenderPos.split(',');if (firstRender && firstRender.length > 0) {for (var i = 0; i < firstRender.length; i++) {var position = firstRender[i];var index = prefetchedPos.indexOf(position);if (index >= 0) {firstBatchPos = firstBatchPos.concat(prefetchedPos.splice(index, 1));}};}if (firstBatchPos.length > 0) {var renderWithRetry = function(pos) {if (DARLA.inProgress()) {var waittime = 600, maxwait = 100, deferRetry = 0, interval;interval = setInterval(function() {deferRetry ++;if (!DARLA.inProgress()){clearInterval(interval);DARLA.render(pos);}if (deferRetry > maxwait){clearInterval(interval);}}, waittime);} else {DARLA.render(pos);}};renderWithRetry(firstBatchPos);setTimeout(renderWithRetry, deferRenderDelay, prefetchedPos);} else {DARLA.render();}} else {DARLA.render();}}}}\n};\nwindow.sf_host = window.$sf.host;\ndocument.onreadystatechange = function () {if (document.readyState == \"interactive\") {window._perfMark('DOM_INTERACTIVE');}};</script>\n<script type=\"text/x-safeframe\" id=\"fc\" _ver=\"3-25-1\">{\"positions\":[{\"id\":\"BTNA\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"BTNA\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"BTNB\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"BTNB\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"BTNC\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"BTNC\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"BTND\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"BTND\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"MAST\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"MAST\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"LDRB\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"LDRB\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"SPL\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"SPL\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"LREC\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"LREC\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"LREC2\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"LREC2\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"LREC3\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"LREC3\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"LREC4\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"LREC4\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"FOOT\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"FOOT\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}},{\"id\":\"FSRVY\",\"html\":\"<!-- SpaceID=0 robot -->\\n\",\"lowHTML\":\"\",\"meta\":{\"y\":{\"pos\":\"FSRVY\",\"cscHTML\":false,\"cscURI\":\"\",\"behavior\":\"non_exp\",\"adID\":\"#19\",\"matchID\":\"#19\",\"bookID\":false,\"slotID\":false,\"serveType\":false,\"ttl\":-1,\"err\":\"robot\",\"hasExternal\":false,\"supp_ugc\":false,\"placementID\":-1,\"fdb\":null,\"serveTime\":-1,\"impID\":\"\",\"creativeID\":-1,\"adc\":\"{\\\"label\\\":\\\"AdChoices\\\",\\\"url\\\":\\\"https:\\\\\\/\\\\\\/info.yahoo.com\\\\\\/privacy\\\\\\/us\\\\\\/yahoo\\\\\\/relevantads.html\\\",\\\"close\\\":\\\"Close\\\",\\\"closeAd\\\":\\\"Close Ad\\\",\\\"showAd\\\":\\\"Show ad\\\",\\\"collapse\\\":\\\"Collapse\\\",\\\"fdb\\\":\\\"I don't like this ad\\\",\\\"code\\\":\\\"en-us\\\"}\",\"is3rd\":1,\"facStatus\":{},\"userProvidedData\":{},\"facRotation\":{},\"slotData\":{}}}}],\"conf\":{\"useYAC\":0,\"usePE\":1,\"servicePath\":\"\",\"xservicePath\":\"\",\"beaconPath\":\"\",\"renderPath\":\"\",\"allowFiF\":false,\"srenderPath\":\"https:\\/\\/s.yimg.com\\/rq\\/darla\\/3-25-1\\/html\\/r-sf.html\",\"renderFile\":\"https:\\/\\/s.yimg.com\\/rq\\/darla\\/3-25-1\\/html\\/r-sf.html\",\"sfbrenderPath\":\"https:\\/\\/s.yimg.com\\/rq\\/darla\\/3-25-1\\/html\\/r-sf.html\",\"msgPath\":\"https:\\/\\/fc.yahoo.com\\/unsupported-1946.html\",\"cscPath\":\"https:\\/\\/s.yimg.com\\/rq\\/darla\\/3-25-1\\/html\\/r-csc.html\",\"root\":\"sdarla\",\"edgeRoot\":\"https:\\/\\/s.yimg.com\\/rq\\/darla\\/3-25-1\",\"sedgeRoot\":\"https:\\/\\/s.yimg.com\\/rq\\/darla\\/3-25-1\",\"version\":\"3-25-1\",\"tpbURI\":\"\",\"hostFile\":\"https:\\/\\/s.yimg.com\\/rq\\/darla\\/3-25-1\\/js\\/g-r-min.js\",\"property\":\"finance_en-US\",\"fdb_locale\":\"What don't you like about this ad?|It's offensive|Something else|Thank you for helping us improve your Yahoo experience|It's not relevant|It's distracting|I don't like this ad|Send|Done|Why do I see ads?|Learn more about your feedback.|Want an ad-free inbox? Upgrade to Yahoo Mail Pro!|Upgrade Now\",\"positions\":{\"BTNA\":{\"dest\":\"destBTNA\",\"asz\":\"120x60\",\"id\":\"BTNA\",\"w\":\"120\",\"h\":\"60\"},\"BTNB\":{\"dest\":\"destBTNB\",\"asz\":\"120x60\",\"id\":\"BTNB\",\"w\":\"120\",\"h\":\"60\"},\"BTNC\":{\"dest\":\"destBTNC\",\"asz\":\"120x60\",\"id\":\"BTNC\",\"w\":\"120\",\"h\":\"60\"},\"BTND\":{\"dest\":\"destBTND\",\"asz\":\"120x60\",\"id\":\"BTND\",\"w\":\"120\",\"h\":\"60\"},\"MAST\":{\"dest\":\"destMAST\",\"asz\":\"970x250\",\"id\":\"MAST\",\"w\":\"970\",\"h\":\"250\"},\"LDRB\":{\"dest\":\"destLDRB\",\"asz\":\"728x90\",\"id\":\"LDRB\",\"w\":\"728\",\"h\":\"90\"},\"SPL\":{\"dest\":\"destSPL\",\"id\":\"SPL\"},\"LREC\":{\"dest\":\"destLREC\",\"asz\":\"300x250\",\"id\":\"LREC\",\"w\":\"300\",\"h\":\"250\"},\"LREC2\":{\"dest\":\"destLREC2\",\"asz\":\"300x250\",\"id\":\"LREC2\",\"w\":\"300\",\"h\":\"250\"},\"LREC3\":{\"dest\":\"destLREC3\",\"asz\":\"300x250\",\"id\":\"LREC3\",\"w\":\"300\",\"h\":\"250\"},\"LREC4\":{\"dest\":\"destLREC4\",\"asz\":\"300x250\",\"id\":\"LREC4\",\"w\":\"300\",\"h\":\"250\"},\"FOOT\":{\"dest\":\"destFOOT\",\"id\":\"FOOT\"},\"FSRVY\":{\"dest\":\"destFSRVY\",\"id\":\"FSRVY\"}},\"events\":{\"DEFAULT\":{\"ult\":{\"pg\":{\"property\":\"finance_en-US\",\"test\":\"finance-US-en-US-def\"}},\"clw\":{\"LREC\":{\"blocked_by\":\"MON-1\"},\"MON-1\":{\"blocked_by\":\"LREC\"},\"MAST\":{\"blocked_by\":\"SPL,LDRB\"},\"LDRB\":{\"blocked_by\":\"MAST,SPL\"},\"SPL\":{\"blocked_by\":\"MAST,LDRB\"}}}},\"lang\":\"en-US\",\"spaceID\":\"980771051\",\"debug\":false,\"asString\":\"{\\\"useYAC\\\":0,\\\"usePE\\\":1,\\\"servicePath\\\":\\\"\\\",\\\"xservicePath\\\":\\\"\\\",\\\"beaconPath\\\":\\\"\\\",\\\"renderPath\\\":\\\"\\\",\\\"allowFiF\\\":false,\\\"srenderPath\\\":\\\"https:\\\\\\/\\\\\\/s.yimg.com\\\\\\/rq\\\\\\/darla\\\\\\/3-25-1\\\\\\/html\\\\\\/r-sf.html\\\",\\\"renderFile\\\":\\\"https:\\\\\\/\\\\\\/s.yimg.com\\\\\\/rq\\\\\\/darla\\\\\\/3-25-1\\\\\\/html\\\\\\/r-sf.html\\\",\\\"sfbrenderPath\\\":\\\"https:\\\\\\/\\\\\\/s.yimg.com\\\\\\/rq\\\\\\/darla\\\\\\/3-25-1\\\\\\/html\\\\\\/r-sf.html\\\",\\\"msgPath\\\":\\\"https:\\\\\\/\\\\\\/fc.yahoo.com\\\\\\/unsupported-1946.html\\\",\\\"cscPath\\\":\\\"https:\\\\\\/\\\\\\/s.yimg.com\\\\\\/rq\\\\\\/darla\\\\\\/3-25-1\\\\\\/html\\\\\\/r-csc.html\\\",\\\"root\\\":\\\"sdarla\\\",\\\"edgeRoot\\\":\\\"https:\\\\\\/\\\\\\/s.yimg.com\\\\\\/rq\\\\\\/darla\\\\\\/3-25-1\\\",\\\"sedgeRoot\\\":\\\"https:\\\\\\/\\\\\\/s.yimg.com\\\\\\/rq\\\\\\/darla\\\\\\/3-25-1\\\",\\\"version\\\":\\\"3-25-1\\\",\\\"tpbURI\\\":\\\"\\\",\\\"hostFile\\\":\\\"https:\\\\\\/\\\\\\/s.yimg.com\\\\\\/rq\\\\\\/darla\\\\\\/3-25-1\\\\\\/js\\\\\\/g-r-min.js\\\",\\\"property\\\":\\\"finance_en-US\\\",\\\"fdb_locale\\\":\\\"What don't you like about this ad?|It's offensive|Something else|Thank you for helping us improve your Yahoo experience|It's not relevant|It's distracting|I don't like this ad|Send|Done|Why do I see ads?|Learn more about your feedback.|Want an ad-free inbox? Upgrade to Yahoo Mail Pro!|Upgrade Now\\\",\\\"positions\\\":{\\\"BTNA\\\":{\\\"dest\\\":\\\"destBTNA\\\",\\\"asz\\\":\\\"120x60\\\",\\\"id\\\":\\\"BTNA\\\",\\\"w\\\":\\\"120\\\",\\\"h\\\":\\\"60\\\"},\\\"BTNB\\\":{\\\"dest\\\":\\\"destBTNB\\\",\\\"asz\\\":\\\"120x60\\\",\\\"id\\\":\\\"BTNB\\\",\\\"w\\\":\\\"120\\\",\\\"h\\\":\\\"60\\\"},\\\"BTNC\\\":{\\\"dest\\\":\\\"destBTNC\\\",\\\"asz\\\":\\\"120x60\\\",\\\"id\\\":\\\"BTNC\\\",\\\"w\\\":\\\"120\\\",\\\"h\\\":\\\"60\\\"},\\\"BTND\\\":{\\\"dest\\\":\\\"destBTND\\\",\\\"asz\\\":\\\"120x60\\\",\\\"id\\\":\\\"BTND\\\",\\\"w\\\":\\\"120\\\",\\\"h\\\":\\\"60\\\"},\\\"MAST\\\":{\\\"dest\\\":\\\"destMAST\\\",\\\"asz\\\":\\\"970x250\\\",\\\"id\\\":\\\"MAST\\\",\\\"w\\\":\\\"970\\\",\\\"h\\\":\\\"250\\\"},\\\"LDRB\\\":{\\\"dest\\\":\\\"destLDRB\\\",\\\"asz\\\":\\\"728x90\\\",\\\"id\\\":\\\"LDRB\\\",\\\"w\\\":\\\"728\\\",\\\"h\\\":\\\"90\\\"},\\\"SPL\\\":{\\\"dest\\\":\\\"destSPL\\\",\\\"id\\\":\\\"SPL\\\"},\\\"LREC\\\":{\\\"dest\\\":\\\"destLREC\\\",\\\"asz\\\":\\\"300x250\\\",\\\"id\\\":\\\"LREC\\\",\\\"w\\\":\\\"300\\\",\\\"h\\\":\\\"250\\\"},\\\"LREC2\\\":{\\\"dest\\\":\\\"destLREC2\\\",\\\"asz\\\":\\\"300x250\\\",\\\"id\\\":\\\"LREC2\\\",\\\"w\\\":\\\"300\\\",\\\"h\\\":\\\"250\\\"},\\\"LREC3\\\":{\\\"dest\\\":\\\"destLREC3\\\",\\\"asz\\\":\\\"300x250\\\",\\\"id\\\":\\\"LREC3\\\",\\\"w\\\":\\\"300\\\",\\\"h\\\":\\\"250\\\"},\\\"LREC4\\\":{\\\"dest\\\":\\\"destLREC4\\\",\\\"asz\\\":\\\"300x250\\\",\\\"id\\\":\\\"LREC4\\\",\\\"w\\\":\\\"300\\\",\\\"h\\\":\\\"250\\\"},\\\"FOOT\\\":{\\\"dest\\\":\\\"destFOOT\\\",\\\"id\\\":\\\"FOOT\\\"},\\\"FSRVY\\\":{\\\"dest\\\":\\\"destFSRVY\\\",\\\"id\\\":\\\"FSRVY\\\"}},\\\"events\\\":{\\\"DEFAULT\\\":{\\\"ult\\\":{\\\"pg\\\":{\\\"property\\\":\\\"finance_en-US\\\",\\\"test\\\":\\\"finance-US-en-US-def\\\"}},\\\"clw\\\":{\\\"LREC\\\":{\\\"blocked_by\\\":\\\"MON-1\\\"},\\\"MON-1\\\":{\\\"blocked_by\\\":\\\"LREC\\\"},\\\"MAST\\\":{\\\"blocked_by\\\":\\\"SPL,LDRB\\\"},\\\"LDRB\\\":{\\\"blocked_by\\\":\\\"MAST,SPL\\\"},\\\"SPL\\\":{\\\"blocked_by\\\":\\\"MAST,LDRB\\\"}}}},\\\"lang\\\":\\\"en-US\\\",\\\"spaceID\\\":\\\"980771051\\\",\\\"debug\\\":false}\"},\"meta\":{\"y\":{\"pageEndHTML\":false,\"pos_list\":[\"BTNA\",\"BTNB\",\"BTNC\",\"BTND\",\"MAST\",\"LDRB\",\"SPL\",\"LREC\",\"LREC2\",\"LREC3\",\"LREC4\",\"FOOT\",\"FSRVY\"],\"transID\":\"darla_prefetch_1589941876296_1582969484_3\",\"k2_uri\":\"\",\"fac_rt\":-1,\"ttl\":-1,\"spaceID\":\"980771051\",\"lookupTime\":2,\"procTime\":4,\"npv\":0,\"pvid\":\"2MvU2Dk4LjFiDVI8kkV8ugF9NzEuMgAAAAAwv7bx\",\"serveTime\":-1,\"ep\":{\"site-attribute\":\"ticker=\\\"DGX;GOOG;GOOGL;CTLT;TBIO;MRNA;ADPT;BNTX;TMO;EBS;INCY;HOLX;LH;AAPL;REGN;RHHBF;RHHBY;RHHVF;SNY;SNYNF;NVS;NVSEF;LLY;DIOD;GILD;PFE;ABT;GLAXF;GSK\\\" wiki_topics=\\\"Medical_test;COVID-19_vaccine;Health_care_provider;LabCorp;Emergency_Use_Authorization;Contact_tracing;Vaccine;United_States\\\" ctopid=\\\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" hashtag=\\\"%24sanofi;%24incy;%24quest-diagnostics-incorporated;%24nvs;%24aapl;%24rhhvf;%24goog;%24nvsef;%24roche-holding-ag;%24lly;%24gild;%24lh;%24regn;%24glaxf;%24googl;%24tmo;%24mrna;%24adpt;%24laboratory-corporation-of-america-holdings;yfipremium;%24snynf;%24rhhbf;%24abt;%24pfe;%24biontech-se;%24tbio;%24sny;%24bntx;%24holx;%24diod;%24dgx;%24ebs;%24ctlt;%24rhhby;%24gsk;1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\\\" megamodal=true rs=\\\"lmsid:a077000000BAh3wAAD;revsp:yahoofinance.com;lpstaid:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;pct:story;pt:content;site:finance;ver:y20;pd:non_modal\\\" Y-BUCKET=\\\"finance-US-en-US-def\\\"\",\"tgt\":\"_blank\",\"secure\":true,\"ref\":\"https:\\/\\/finance.yahoo.com\\/news\\/coronavirus-vaccine-progress-accelerates-155109303.html\",\"ult\":{\"pg\":{\"property\":\"finance_en-US\",\"test\":\"finance-US-en-US-def\"}},\"clw\":{\"LREC\":{\"blocked_by\":\"MON-1\"},\"MON-1\":{\"blocked_by\":\"LREC\"},\"MAST\":{\"blocked_by\":\"SPL,LDRB\"},\"LDRB\":{\"blocked_by\":\"MAST,SPL\"},\"SPL\":{\"blocked_by\":\"MAST,LDRB\"}},\"lang\":\"en-US\",\"filter\":\"no_expandable;exp_iframe_expandable;\",\"darlaID\":\"darla_instance_1589941876296_386194549_2\"},\"pym\":{\".\":\"v0.0.9;;-;\"},\"host\":\"\",\"filtered\":[],\"pe\":\"\"}}}</script><meta itemprop=\"metadata/x-safeframe\" content=\"{"positions":[{"id":"BTNA","lowHTML":"","meta":{"y":{"pos":"BTNA","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"BTNB","lowHTML":"","meta":{"y":{"pos":"BTNB","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"BTNC","lowHTML":"","meta":{"y":{"pos":"BTNC","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"BTND","lowHTML":"","meta":{"y":{"pos":"BTND","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"MAST","lowHTML":"","meta":{"y":{"pos":"MAST","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"LDRB","lowHTML":"","meta":{"y":{"pos":"LDRB","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"SPL","lowHTML":"","meta":{"y":{"pos":"SPL","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"LREC","lowHTML":"","meta":{"y":{"pos":"LREC","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"LREC2","lowHTML":"","meta":{"y":{"pos":"LREC2","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"LREC3","lowHTML":"","meta":{"y":{"pos":"LREC3","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"LREC4","lowHTML":"","meta":{"y":{"pos":"LREC4","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"FOOT","lowHTML":"","meta":{"y":{"pos":"FOOT","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}},{"id":"FSRVY","lowHTML":"","meta":{"y":{"pos":"FSRVY","behavior":"non_exp","adID":"#19","matchID":"#19","bookID":false,"slotID":false,"serveType":false,"ttl":-1,"err":"robot","hasExternal":false,"supp_ugc":"","placementID":-1,"fdb":null,"serveTime":-1,"impID":"","creativeID":-1,"adc":"{\"label\":\"AdChoices\",\"url\":\"https:\\\/\\\/info.yahoo.com\\\/privacy\\\/us\\\/yahoo\\\/relevantads.html\",\"close\":\"Close\",\"closeAd\":\"Close Ad\",\"showAd\":\"Show ad\",\"collapse\":\"Collapse\",\"fdb\":\"I don't like this ad\",\"code\":\"en-us\"}","is3rd":1,"facStatus":{},"userProvidedData":{},"facRotation":{},"slotData":{}}}}],"conf":null,"meta":{"y":{"pos_list":["BTNA","BTNB","BTNC","BTND","MAST","LDRB","SPL","LREC","LREC2","LREC3","LREC4","FOOT","FSRVY"],"transID":"darla_prefetch_1589941876296_1582969484_3","k2_uri":"","fac_rt":-1,"ttl":-1,"spaceID":"980771051","lookupTime":2,"procTime":4,"npv":0,"pvid":"2MvU2Dk4LjFiDVI8kkV8ugF9NzEuMgAAAAAwv7bx","serveTime":-1,"ep":{"site-attribute":"ticker=\"DGX;GOOG;GOOGL;CTLT;TBIO;MRNA;ADPT;BNTX;TMO;EBS;INCY;HOLX;LH;AAPL;REGN;RHHBF;RHHBY;RHHVF;SNY;SNYNF;NVS;NVSEF;LLY;DIOD;GILD;PFE;ABT;GLAXF;GSK\" wiki_topics=\"Medical_test;COVID-19_vaccine;Health_care_provider;LabCorp;Emergency_Use_Authorization;Contact_tracing;Vaccine;United_States\" ctopid=\"1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\" hashtag=\"%24sanofi;%24incy;%24quest-diagnostics-incorporated;%24nvs;%24aapl;%24rhhvf;%24goog;%24nvsef;%24roche-holding-ag;%24lly;%24gild;%24lh;%24regn;%24glaxf;%24googl;%24tmo;%24mrna;%24adpt;%24laboratory-corporation-of-america-holdings;yfipremium;%24snynf;%24rhhbf;%24abt;%24pfe;%24biontech-se;%24tbio;%24sny;%24bntx;%24holx;%24diod;%24dgx;%24ebs;%24ctlt;%24rhhby;%24gsk;1542500;1480989;1483489;1577000;12716000;1638500;1675500;1714500\" megamodal=true rs=\"lmsid:a077000000BAh3wAAD;revsp:yahoofinance.com;lpstaid:ee6c0f80-61d5-3bba-8101-bb8bd4d538c3;pct:story;pt:content;site:finance;ver:y20;pd:non_modal\" Y-BUCKET=\"finance-US-en-US-def\"","tgt":"_blank","secure":true,"ref":"https:\/\/finance.yahoo.com\/news\/coronavirus-vaccine-progress-accelerates-155109303.html","ult":{"pg":{"property":"finance_en-US","test":"finance-US-en-US-def"}},"clw":{"LREC":{"blocked_by":"MON-1"},"MON-1":{"blocked_by":"LREC"},"MAST":{"blocked_by":"SPL,LDRB"},"LDRB":{"blocked_by":"MAST,SPL"},"SPL":{"blocked_by":"MAST,LDRB"}},"lang":"en-US","filter":"no_expandable;exp_iframe_expandable;","darlaID":"darla_instance_1589941876296_386194549_2"},"pym":{".":"v0.0.9;;-;"},"host":"","filtered":[]}}}\">\n\n<!-- gq1-sdarlaws-012.adx.gq1.yahoo.com Wed May 20 02:31:16 UTC 2020 -->\n<script type=\"text/javascript\">if (typeof DARLA !== \"undefined\" && DARLA) {DARLA.config(window.DARLA_CONFIG);window.sf_host.onReady(true,true,'BTNA,BTNB,BTNC,BTND,LREC',3000);}</script>\n<style>\n.hide-lrec-ad .darla-lrec-ad {display: none;}.hide-non-lrec34 .darla-nonlrec34-ad {display: none;}.hide-non-lrec34 .sticky-outer-wrapper .tdv2-applet-stream .js-stream-content .controller,.hide-non-lrec34 .YDC-Height-Container .tdv2-applet-stream .js-stream-content .controller {display: none;}.hide-non-lrec34ldrb .darla-nonlrec34ldrb-ad {display: none;}.hide-non-lrec34ldrb .sticky-outer-wrapper .tdv2-applet-stream .js-stream-content .controller,.hide-non-lrec34ldrb .YDC-Height-Container .tdv2-applet-stream .js-stream-content .controller {display: none;}.hide-lrec-groups-lrec12 .darla-nonlrec34ldrb-ad,.hide-lrec-groups-lrec34 .darla-lrec34-ad,.hide-all-lrecs .darla-lrec-ad {display: none;}</style>\n</div>\r\n<script>window.daggr=window.daggr||{};window.daggr.results={};window.daggr.results['StreamService:Col2Ext-0-Stream_Col2Ext-2-Stream']=null\r\n;window.daggr.results['StreamService:Col2-5-HeightContainer-0-Stream']=null\r\n;window.daggr.fallbackData=[{requesters: [{id:\"Col2Ext-0-Stream\", dataKey:\"streamItems\"},{id:\"Col2Ext-2-Stream\", dataKey:\"streamItems\"}], result: window.daggr.results['StreamService:Col2Ext-0-Stream_Col2Ext-2-Stream']},{requesters: [{id:\"Col2-5-HeightContainer-0-Stream\", dataKey:\"streamItems\"}], result: window.daggr.results['StreamService:Col2-5-HeightContainer-0-Stream']}];</script><script src=\"https://s.yimg.com/os/yaft/yaft-0.3.22.min.js\" defer></script>\n<script src=\"https://s.yimg.com/os/yaft/yaft-plugin-aftnoad-0.1.3.min.js\" defer></script>\n<script src=\"https://s.yimg.com/aaq/yc/js/main.3e415e39e0b242f225a0.min.js\" defer></script>\n<script>window.webpackPublicPath='https://s.yimg.com/aaq/yc/js/';</script></body></html>"}